id	sid	tid	token	lemma	pos
ajmri-3088	1	1	pa	pa	PROPN
ajmri-3088	1	2	ge	ge	PROPN
ajmri-3088	1	3	1	1	NUM
ajmri-3088	1	4	pa	pa	PROPN
ajmri-3088	1	5	ge	ge	PROPN
ajmri-3088	1	6	50	50	NUM
ajmri-3088	1	7	american	american	ADJ
ajmri-3088	1	8	journal	journal	NOUN
ajmri-3088	1	9	of	of	ADP
ajmri-3088	1	10	multidisciplinary	multidisciplinary	ADJ
ajmri-3088	1	11	research	research	NOUN
ajmri-3088	1	12	and	and	CCONJ
ajmri-3088	1	13	innovation	innovation	NOUN
ajmri-3088	1	14	(	(	PUNCT
ajmri-3088	1	15	ajmri	ajmri	NOUN
ajmri-3088	1	16	)	)	PUNCT
ajmri-3088	1	17	discovering	discover	VERB
ajmri-3088	1	18	variability	variability	NOUN
ajmri-3088	1	19	in	in	ADP
ajmri-3088	1	20	population	population	NOUN
ajmri-3088	1	21	of	of	ADP
ajmri-3088	1	22	t	t	PROPN
ajmri-3088	1	23	-	-	PUNCT
ajmri-3088	1	24	lymphocyte	lymphocyte	ADJ
ajmri-3088	1	25	subsets	subset	NOUN
ajmri-3088	1	26	present	present	ADJ
ajmri-3088	1	27	in	in	ADP
ajmri-3088	1	28	peripheral	peripheral	ADJ
ajmri-3088	1	29	blood	blood	NOUN
ajmri-3088	1	30	of	of	ADP
ajmri-3088	1	31	patients	patient	NOUN
ajmri-3088	1	32	co	co	VERB
ajmri-3088	1	33	-	-	VERB
ajmri-3088	1	34	infected	infect	VERB
ajmri-3088	1	35	by	by	ADP
ajmri-3088	1	36	hiv	hiv	PROPN
ajmri-3088	1	37	and	and	CCONJ
ajmri-3088	1	38	hbv	hbv	NOUN
ajmri-3088	1	39	through	through	ADP
ajmri-3088	1	40	laboratory	laboratory	NOUN
ajmri-3088	1	41	medicine	medicine	PROPN
ajmri-3088	1	42	suzan	suzan	PROPN
ajmri-3088	1	43	eid	eid	PROPN
ajmri-3088	1	44	elshishtawy	elshishtawy	PROPN
ajmri-3088	1	45	ibrahim1	ibrahim1	NOUN
ajmri-3088	1	46	*	*	PUNCT
ajmri-3088	1	47	volume	volume	NOUN
ajmri-3088	1	48	3	3	NUM
ajmri-3088	1	49	issue	issue	NOUN
ajmri-3088	1	50	5	5	NUM
ajmri-3088	1	51	,	,	PUNCT
ajmri-3088	1	52	year	year	NOUN
ajmri-3088	1	53	2024	2024	NUM
ajmri-3088	1	54	issn	issn	X
ajmri-3088	1	55	:	:	PUNCT
ajmri-3088	1	56	2158	2158	NUM
ajmri-3088	1	57	-	-	SYM
ajmri-3088	1	58	8155	8155	NUM
ajmri-3088	1	59	(	(	PUNCT
ajmri-3088	1	60	online	online	NOUN
ajmri-3088	1	61	)	)	PUNCT
ajmri-3088	1	62	,	,	PUNCT
ajmri-3088	1	63	2832	2832	NUM
ajmri-3088	1	64	-	-	SYM
ajmri-3088	1	65	4854	4854	NUM
ajmri-3088	1	66	(	(	PUNCT
ajmri-3088	1	67	print	print	NOUN
ajmri-3088	1	68	)	)	PUNCT
ajmri-3088	1	69	doi	doi	NOUN
ajmri-3088	1	70	:	:	PUNCT
ajmri-3088	1	71	https://doi.org/10.54536/ajmri.v3i5.3088	https://doi.org/10.54536/ajmri.v3i5.3088	PROPN
ajmri-3088	2	1	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	ADJ
ajmri-3088	2	2	article	article	NOUN
ajmri-3088	2	3	information	information	NOUN
ajmri-3088	2	4	abstract	abstract	ADV
ajmri-3088	2	5	received	receive	VERB
ajmri-3088	2	6	:	:	PUNCT
ajmri-3088	2	7	august	august	PROPN
ajmri-3088	2	8	18	18	NUM
ajmri-3088	2	9	,	,	PUNCT
ajmri-3088	2	10	2024	2024	NUM
ajmri-3088	2	11	accepted	accept	VERB
ajmri-3088	2	12	:	:	PUNCT
ajmri-3088	2	13	september	september	PROPN
ajmri-3088	2	14	20	20	NUM
ajmri-3088	2	15	,	,	PUNCT
ajmri-3088	2	16	2024	2024	NUM
ajmri-3088	2	17	published	publish	VERB
ajmri-3088	2	18	:	:	PUNCT
ajmri-3088	2	19	september	september	PROPN
ajmri-3088	2	20	24	24	NUM
ajmri-3088	2	21	,	,	PUNCT
ajmri-3088	2	22	2024	2024	NUM
ajmri-3088	2	23	an	an	DET
ajmri-3088	2	24	alarming	alarming	ADJ
ajmri-3088	2	25	number	number	NOUN
ajmri-3088	2	26	of	of	ADP
ajmri-3088	2	27	296	296	NUM
ajmri-3088	2	28	million	million	NUM
ajmri-3088	2	29	individuals	individual	NOUN
ajmri-3088	2	30	in	in	ADP
ajmri-3088	2	31	egypt	egypt	PROPN
ajmri-3088	2	32	have	have	AUX
ajmri-3088	2	33	recently	recently	ADV
ajmri-3088	2	34	been	be	AUX
ajmri-3088	2	35	diagnosed	diagnose	VERB
ajmri-3088	2	36	as	as	ADP
ajmri-3088	2	37	hbv	hbv	NOUN
ajmri-3088	2	38	positive	positive	ADJ
ajmri-3088	2	39	;	;	PUNCT
ajmri-3088	2	40	because	because	SCONJ
ajmri-3088	2	41	these	these	DET
ajmri-3088	2	42	two	two	NUM
ajmri-3088	2	43	viruses	virus	NOUN
ajmri-3088	2	44	share	share	VERB
ajmri-3088	2	45	similar	similar	ADJ
ajmri-3088	2	46	routes	route	NOUN
ajmri-3088	2	47	of	of	ADP
ajmri-3088	2	48	transmission	transmission	NOUN
ajmri-3088	2	49	,	,	PUNCT
ajmri-3088	2	50	about	about	ADV
ajmri-3088	2	51	10	10	NUM
ajmri-3088	2	52	%	%	NOUN
ajmri-3088	2	53	of	of	ADP
ajmri-3088	2	54	this	this	DET
ajmri-3088	2	55	population	population	NOUN
ajmri-3088	2	56	is	be	AUX
ajmri-3088	2	57	also	also	ADV
ajmri-3088	2	58	thought	think	VERB
ajmri-3088	2	59	to	to	PART
ajmri-3088	2	60	be	be	AUX
ajmri-3088	2	61	hiv	hiv	PROPN
ajmri-3088	2	62	positive	positive	ADJ
ajmri-3088	2	63	.	.	PUNCT
ajmri-3088	3	1	it	it	PRON
ajmri-3088	3	2	is	be	AUX
ajmri-3088	3	3	widely	widely	ADV
ajmri-3088	3	4	acknowledged	acknowledge	VERB
ajmri-3088	3	5	that	that	SCONJ
ajmri-3088	3	6	coinfection	coinfection	NOUN
ajmri-3088	3	7	with	with	ADP
ajmri-3088	3	8	hiv	hiv	PROPN
ajmri-3088	3	9	and	and	CCONJ
ajmri-3088	3	10	hbv	hbv	PROPN
ajmri-3088	3	11	has	have	VERB
ajmri-3088	3	12	a	a	DET
ajmri-3088	3	13	significant	significant	ADJ
ajmri-3088	3	14	negative	negative	ADJ
ajmri-3088	3	15	effect	effect	NOUN
ajmri-3088	3	16	on	on	ADP
ajmri-3088	3	17	the	the	DET
ajmri-3088	3	18	immune	immune	ADJ
ajmri-3088	3	19	system	system	NOUN
ajmri-3088	3	20	and	and	CCONJ
ajmri-3088	3	21	accelerates	accelerate	VERB
ajmri-3088	3	22	the	the	DET
ajmri-3088	3	23	loss	loss	NOUN
ajmri-3088	3	24	of	of	ADP
ajmri-3088	3	25	t	t	PROPN
ajmri-3088	3	26	-	-	PUNCT
ajmri-3088	3	27	lymphocyte	lymphocyte	NOUN
ajmri-3088	3	28	subpopulations	subpopulation	NOUN
ajmri-3088	3	29	,	,	PUNCT
ajmri-3088	3	30	which	which	PRON
ajmri-3088	3	31	are	be	AUX
ajmri-3088	3	32	essential	essential	ADJ
ajmri-3088	3	33	for	for	ADP
ajmri-3088	3	34	immunological	immunological	ADJ
ajmri-3088	3	35	defense	defense	NOUN
ajmri-3088	3	36	.	.	PUNCT
ajmri-3088	4	1	this	this	DET
ajmri-3088	4	2	enlightening	enlightening	ADJ
ajmri-3088	4	3	study	study	NOUN
ajmri-3088	4	4	,	,	PUNCT
ajmri-3088	4	5	carried	carry	VERB
ajmri-3088	4	6	out	out	ADP
ajmri-3088	4	7	in	in	ADP
ajmri-3088	4	8	cairo	cairo	PROPN
ajmri-3088	4	9	,	,	PUNCT
ajmri-3088	4	10	egypt	egypt	PROPN
ajmri-3088	4	11	,	,	PUNCT
ajmri-3088	4	12	explores	explore	VERB
ajmri-3088	4	13	the	the	DET
ajmri-3088	4	14	complicated	complicated	ADJ
ajmri-3088	4	15	dynamics	dynamic	NOUN
ajmri-3088	4	16	of	of	ADP
ajmri-3088	4	17	t	t	NOUN
ajmri-3088	4	18	-	-	PUNCT
ajmri-3088	4	19	cell	cell	NOUN
ajmri-3088	4	20	subsets	subset	NOUN
ajmri-3088	4	21	and	and	CCONJ
ajmri-3088	4	22	carefully	carefully	ADV
ajmri-3088	4	23	looks	look	VERB
ajmri-3088	4	24	at	at	ADP
ajmri-3088	4	25	the	the	DET
ajmri-3088	4	26	immunological	immunological	ADJ
ajmri-3088	4	27	effects	effect	NOUN
ajmri-3088	4	28	and	and	CCONJ
ajmri-3088	4	29	frequency	frequency	NOUN
ajmri-3088	4	30	of	of	ADP
ajmri-3088	4	31	coinfection	coinfection	NOUN
ajmri-3088	4	32	between	between	ADP
ajmri-3088	4	33	hiv	hiv	PROPN
ajmri-3088	4	34	and	and	CCONJ
ajmri-3088	4	35	hbv	hbv	NOUN
ajmri-3088	4	36	.	.	PUNCT
ajmri-3088	5	1	naturally	naturally	ADV
ajmri-3088	5	2	,	,	PUNCT
ajmri-3088	5	3	of	of	ADP
ajmri-3088	5	4	the	the	DET
ajmri-3088	5	5	35	35	NUM
ajmri-3088	5	6	patients	patient	NOUN
ajmri-3088	5	7	in	in	ADP
ajmri-3088	5	8	the	the	DET
ajmri-3088	5	9	cohort	cohort	NOUN
ajmri-3088	5	10	under	under	ADP
ajmri-3088	5	11	examination	examination	NOUN
ajmri-3088	5	12	,	,	PUNCT
ajmri-3088	5	13	an	an	DET
ajmri-3088	5	14	impressive	impressive	ADJ
ajmri-3088	5	15	8.4	8.4	NUM
ajmri-3088	5	16	%	%	NOUN
ajmri-3088	5	17	had	have	VERB
ajmri-3088	5	18	coinfections	coinfection	NOUN
ajmri-3088	5	19	with	with	ADP
ajmri-3088	5	20	hbv	hbv	NOUN
ajmri-3088	5	21	and	and	CCONJ
ajmri-3088	5	22	hiv	hiv	PROPN
ajmri-3088	5	23	.	.	PUNCT
ajmri-3088	6	1	systematic	systematic	ADJ
ajmri-3088	6	2	immunophenotyping	immunophenotyping	NOUN
ajmri-3088	6	3	of	of	ADP
ajmri-3088	6	4	several	several	ADJ
ajmri-3088	6	5	t	t	NOUN
ajmri-3088	6	6	-	-	PUNCT
ajmri-3088	6	7	cell	cell	NOUN
ajmri-3088	6	8	subsets	subset	NOUN
ajmri-3088	6	9	,	,	PUNCT
ajmri-3088	6	10	such	such	ADJ
ajmri-3088	6	11	as	as	ADP
ajmri-3088	6	12	cd4	cd4	PROPN
ajmri-3088	6	13	+	+	PROPN
ajmri-3088	6	14	,	,	PUNCT
ajmri-3088	6	15	cd8	cd8	PROPN
ajmri-3088	6	16	+	+	PROPN
ajmri-3088	6	17	,	,	PUNCT
ajmri-3088	6	18	cd45ro	cd45ro	NOUN
ajmri-3088	6	19	,	,	PUNCT
ajmri-3088	6	20	cd16	cd16	PROPN
ajmri-3088	6	21	+	+	PROPN
ajmri-3088	6	22	56	56	NUM
ajmri-3088	6	23	,	,	PUNCT
ajmri-3088	6	24	and	and	CCONJ
ajmri-3088	6	25	cd45ra	cd45ra	PROPN
ajmri-3088	6	26	,	,	PUNCT
ajmri-3088	6	27	was	be	AUX
ajmri-3088	6	28	used	use	VERB
ajmri-3088	6	29	in	in	ADP
ajmri-3088	6	30	the	the	DET
ajmri-3088	6	31	study	study	NOUN
ajmri-3088	6	32	,	,	PUNCT
ajmri-3088	6	33	and	and	CCONJ
ajmri-3088	6	34	the	the	DET
ajmri-3088	6	35	results	result	NOUN
ajmri-3088	6	36	showed	show	VERB
ajmri-3088	6	37	clear	clear	ADJ
ajmri-3088	6	38	differences	difference	NOUN
ajmri-3088	6	39	between	between	ADP
ajmri-3088	6	40	coinfected	coinfecte	VERB
ajmri-3088	6	41	and	and	CCONJ
ajmri-3088	6	42	mono	mono	NOUN
ajmri-3088	6	43	-	-	PUNCT
ajmri-3088	6	44	infected	infect	VERB
ajmri-3088	6	45	peopleusing	peopleuse	VERB
ajmri-3088	6	46	trustworthy	trustworthy	ADJ
ajmri-3088	6	47	methods	method	NOUN
ajmri-3088	6	48	like	like	ADP
ajmri-3088	6	49	microfluid	microfluid	VERB
ajmri-3088	6	50	inertial	inertial	ADJ
ajmri-3088	6	51	separation	separation	NOUN
ajmri-3088	6	52	and	and	CCONJ
ajmri-3088	6	53	flow	flow	NOUN
ajmri-3088	6	54	cytometry	cytometry	NOUN
ajmri-3088	6	55	has	have	AUX
ajmri-3088	6	56	given	give	VERB
ajmri-3088	6	57	researchers	researcher	NOUN
ajmri-3088	6	58	significant	significant	ADJ
ajmri-3088	6	59	insights	insight	NOUN
ajmri-3088	6	60	into	into	ADP
ajmri-3088	6	61	the	the	DET
ajmri-3088	6	62	complex	complex	ADJ
ajmri-3088	6	63	immunological	immunological	ADJ
ajmri-3088	6	64	circumstances	circumstance	NOUN
ajmri-3088	6	65	connected	connect	VERB
ajmri-3088	6	66	to	to	ADP
ajmri-3088	6	67	hiv	hiv	PROPN
ajmri-3088	6	68	/	/	SYM
ajmri-3088	6	69	hbv	hbv	PROPN
ajmri-3088	6	70	coinfection	coinfection	NOUN
ajmri-3088	6	71	.	.	PUNCT
ajmri-3088	7	1	interestingly	interestingly	ADV
ajmri-3088	7	2	,	,	PUNCT
ajmri-3088	7	3	a	a	DET
ajmri-3088	7	4	significant	significant	ADJ
ajmri-3088	7	5	decrease	decrease	NOUN
ajmri-3088	7	6	in	in	ADP
ajmri-3088	7	7	cd4	cd4	PROPN
ajmri-3088	7	8	+	+	PROPN
ajmri-3088	7	9	cells	cell	NOUN
ajmri-3088	7	10	—	—	PUNCT
ajmri-3088	7	11	a	a	DET
ajmri-3088	7	12	crucial	crucial	ADJ
ajmri-3088	7	13	marker	marker	NOUN
ajmri-3088	7	14	of	of	ADP
ajmri-3088	7	15	hiv	hiv	PROPN
ajmri-3088	7	16	progression	progression	NOUN
ajmri-3088	7	17	—	—	PUNCT
ajmri-3088	7	18	was	be	AUX
ajmri-3088	7	19	observed	observe	VERB
ajmri-3088	7	20	in	in	ADP
ajmri-3088	7	21	over	over	ADP
ajmri-3088	7	22	50	50	NUM
ajmri-3088	7	23	%	%	NOUN
ajmri-3088	7	24	of	of	ADP
ajmri-3088	7	25	the	the	DET
ajmri-3088	7	26	coinfected	coinfecte	VERB
ajmri-3088	7	27	patients	patient	NOUN
ajmri-3088	7	28	,	,	PUNCT
ajmri-3088	7	29	suggesting	suggest	VERB
ajmri-3088	7	30	an	an	DET
ajmri-3088	7	31	accelerated	accelerated	ADJ
ajmri-3088	7	32	course	course	NOUN
ajmri-3088	7	33	of	of	ADP
ajmri-3088	7	34	the	the	DET
ajmri-3088	7	35	illness	illness	NOUN
ajmri-3088	7	36	in	in	ADP
ajmri-3088	7	37	these	these	DET
ajmri-3088	7	38	individuals	individual	NOUN
ajmri-3088	7	39	.	.	PUNCT
ajmri-3088	8	1	moreover	moreover	ADV
ajmri-3088	8	2	,	,	PUNCT
ajmri-3088	8	3	the	the	DET
ajmri-3088	8	4	study	study	NOUN
ajmri-3088	8	5	establishes	establish	VERB
ajmri-3088	8	6	the	the	DET
ajmri-3088	8	7	foundation	foundation	NOUN
ajmri-3088	8	8	for	for	ADP
ajmri-3088	8	9	particular	particular	ADJ
ajmri-3088	8	10	treatment	treatment	NOUN
ajmri-3088	8	11	strategies	strategy	NOUN
ajmri-3088	8	12	and	and	CCONJ
ajmri-3088	8	13	adds	add	VERB
ajmri-3088	8	14	to	to	ADP
ajmri-3088	8	15	our	our	PRON
ajmri-3088	8	16	scientific	scientific	ADJ
ajmri-3088	8	17	understanding	understand	VERB
ajmri-3088	8	18	coinfection	coinfection	NOUN
ajmri-3088	8	19	dynamics	dynamic	NOUN
ajmri-3088	8	20	.	.	PUNCT
ajmri-3088	9	1	these	these	DET
ajmri-3088	9	2	therapies	therapy	NOUN
ajmri-3088	9	3	,	,	PUNCT
ajmri-3088	9	4	based	base	VERB
ajmri-3088	9	5	on	on	ADP
ajmri-3088	9	6	the	the	DET
ajmri-3088	9	7	study	study	NOUN
ajmri-3088	9	8	’s	’s	PART
ajmri-3088	9	9	detailed	detailed	ADJ
ajmri-3088	9	10	findings	finding	NOUN
ajmri-3088	9	11	,	,	PUNCT
ajmri-3088	9	12	can	can	AUX
ajmri-3088	9	13	potentially	potentially	ADV
ajmri-3088	9	14	improve	improve	VERB
ajmri-3088	9	15	patient	patient	ADJ
ajmri-3088	9	16	outcomes	outcome	NOUN
ajmri-3088	9	17	despite	despite	SCONJ
ajmri-3088	9	18	this	this	DET
ajmri-3088	9	19	difficult	difficult	ADJ
ajmri-3088	9	20	coinfection	coinfection	NOUN
ajmri-3088	9	21	setting	setting	NOUN
ajmri-3088	9	22	.	.	PUNCT
ajmri-3088	10	1	to	to	PART
ajmri-3088	10	2	manage	manage	VERB
ajmri-3088	10	3	the	the	DET
ajmri-3088	10	4	difficulties	difficulty	NOUN
ajmri-3088	10	5	of	of	ADP
ajmri-3088	10	6	hiv	hiv	PROPN
ajmri-3088	10	7	/	/	SYM
ajmri-3088	10	8	hbv	hbv	NOUN
ajmri-3088	10	9	coinfection	coinfection	NOUN
ajmri-3088	10	10	,	,	PUNCT
ajmri-3088	10	11	the	the	DET
ajmri-3088	10	12	research	research	NOUN
ajmri-3088	10	13	emphasizes	emphasize	VERB
ajmri-3088	10	14	the	the	DET
ajmri-3088	10	15	importance	importance	NOUN
ajmri-3088	10	16	of	of	ADP
ajmri-3088	10	17	ongoing	ongoing	ADJ
ajmri-3088	10	18	attention	attention	NOUN
ajmri-3088	10	19	and	and	CCONJ
ajmri-3088	10	20	the	the	DET
ajmri-3088	10	21	incorporation	incorporation	NOUN
ajmri-3088	10	22	of	of	ADP
ajmri-3088	10	23	cutting	cut	VERB
ajmri-3088	10	24	-	-	PUNCT
ajmri-3088	10	25	edge	edge	NOUN
ajmri-3088	10	26	diagnostic	diagnostic	ADJ
ajmri-3088	10	27	techniques	technique	NOUN
ajmri-3088	10	28	,	,	PUNCT
ajmri-3088	10	29	eventually	eventually	ADV
ajmri-3088	10	30	advancing	advance	VERB
ajmri-3088	10	31	public	public	ADJ
ajmri-3088	10	32	health	health	NOUN
ajmri-3088	10	33	activities	activity	NOUN
ajmri-3088	10	34	.	.	PUNCT
ajmri-3088	11	1	keywords	keyword	VERB
ajmri-3088	11	2	cd+8	cd+8	NUM
ajmri-3088	11	3	tcells	tcell	NOUN
ajmri-3088	11	4	,	,	PUNCT
ajmri-3088	11	5	cd4	cd4	PROPN
ajmri-3088	11	6	+	+	PROPN
ajmri-3088	11	7	t	t	PROPN
ajmri-3088	11	8	-	-	PUNCT
ajmri-3088	11	9	cells	cell	NOUN
ajmri-3088	11	10	,	,	PUNCT
ajmri-3088	11	11	cd8	cd8	PROPN
ajmri-3088	11	12	+	+	SYM
ajmri-3088	11	13	cell	cell	NOUN
ajmri-3088	11	14	exhaustion	exhaustion	NOUN
ajmri-3088	11	15	,	,	PUNCT
ajmri-3088	11	16	hiv/	hiv/	NOUN
ajmri-3088	11	17	hbv	hbv	NOUN
ajmri-3088	11	18	infection	infection	NOUN
ajmri-3088	11	19	,	,	PUNCT
ajmri-3088	11	20	lymphocyte	lymphocyte	ADJ
ajmri-3088	11	21	subpopulations	subpopulation	NOUN
ajmri-3088	11	22	,	,	PUNCT
ajmri-3088	11	23	weak	weak	ADJ
ajmri-3088	11	24	immune	immune	ADJ
ajmri-3088	11	25	system	system	NOUN
ajmri-3088	11	26	introduction	introduction	NOUN
ajmri-3088	11	27	human	human	ADJ
ajmri-3088	11	28	immunodeficiency	immunodeficiency	NOUN
ajmri-3088	11	29	virus	virus	NOUN
ajmri-3088	11	30	hiv	hiv	PROPN
ajmri-3088	11	31	mainly	mainly	ADV
ajmri-3088	11	32	targets	target	VERB
ajmri-3088	11	33	the	the	DET
ajmri-3088	11	34	immune	immune	ADJ
ajmri-3088	11	35	systems	system	NOUN
ajmri-3088	11	36	and	and	CCONJ
ajmri-3088	11	37	triggers	trigger	VERB
ajmri-3088	11	38	the	the	DET
ajmri-3088	11	39	autoimmune	autoimmune	ADJ
ajmri-3088	11	40	response	response	NOUN
ajmri-3088	11	41	leading	lead	VERB
ajmri-3088	11	42	to	to	ADP
ajmri-3088	11	43	acquired	acquire	VERB
ajmri-3088	11	44	immunodeficiency	immunodeficiency	NOUN
ajmri-3088	11	45	syndrome	syndrome	NOUN
ajmri-3088	11	46	(	(	PUNCT
ajmri-3088	11	47	aids	aids	PROPN
ajmri-3088	11	48	)	)	PUNCT
ajmri-3088	11	49	.	.	PUNCT
ajmri-3088	12	1	aids	aids	PROPN
ajmri-3088	12	2	is	be	AUX
ajmri-3088	12	3	categorized	categorize	VERB
ajmri-3088	12	4	as	as	ADP
ajmri-3088	12	5	one	one	NUM
ajmri-3088	12	6	of	of	ADP
ajmri-3088	12	7	the	the	DET
ajmri-3088	12	8	most	most	ADV
ajmri-3088	12	9	destructive	destructive	ADJ
ajmri-3088	12	10	epidemics	epidemic	NOUN
ajmri-3088	12	11	that	that	PRON
ajmri-3088	12	12	derogate	derogate	VERB
ajmri-3088	12	13	the	the	DET
ajmri-3088	12	14	lymphocyte	lymphocyte	ADJ
ajmri-3088	12	15	subpopulations	subpopulation	NOUN
ajmri-3088	12	16	,	,	PUNCT
ajmri-3088	12	17	eventually	eventually	ADV
ajmri-3088	12	18	leading	lead	VERB
ajmri-3088	12	19	to	to	ADP
ajmri-3088	12	20	various	various	ADJ
ajmri-3088	12	21	infections	infection	NOUN
ajmri-3088	12	22	and	and	CCONJ
ajmri-3088	12	23	carcinomas	carcinoma	NOUN
ajmri-3088	12	24	.	.	PUNCT
ajmri-3088	13	1	previous	previous	ADJ
ajmri-3088	13	2	studies	study	NOUN
ajmri-3088	13	3	have	have	AUX
ajmri-3088	13	4	focused	focus	VERB
ajmri-3088	13	5	on	on	ADP
ajmri-3088	13	6	cd4	cd4	PROPN
ajmri-3088	13	7	+	+	PROPN
ajmri-3088	13	8	t	t	PROPN
ajmri-3088	13	9	-	-	PUNCT
ajmri-3088	13	10	cell	cell	NOUN
ajmri-3088	13	11	population	population	NOUN
ajmri-3088	13	12	variations	variation	NOUN
ajmri-3088	13	13	(	(	PUNCT
ajmri-3088	13	14	yuan	yuan	NOUN
ajmri-3088	13	15	et	et	PROPN
ajmri-3088	13	16	al	al	PROPN
ajmri-3088	13	17	.	.	PROPN
ajmri-3088	13	18	,	,	PUNCT
ajmri-3088	13	19	2023	2023	NUM
ajmri-3088	13	20	)	)	PUNCT
ajmri-3088	13	21	.	.	PUNCT
ajmri-3088	14	1	hiv	hiv	PROPN
ajmri-3088	14	2	binds	bind	VERB
ajmri-3088	14	3	to	to	ADP
ajmri-3088	14	4	the	the	DET
ajmri-3088	14	5	chemokine	chemokine	ADJ
ajmri-3088	14	6	receptors	receptor	NOUN
ajmri-3088	14	7	ccr5	ccr5	NOUN
ajmri-3088	14	8	or	or	CCONJ
ajmri-3088	14	9	cxcr4	cxcr4	NOUN
ajmri-3088	14	10	and	and	CCONJ
ajmri-3088	14	11	glycoprotein	glycoprotein	NOUN
ajmri-3088	14	12	such	such	ADJ
ajmri-3088	14	13	as	as	ADP
ajmri-3088	14	14	gp120	gp120	NOUN
ajmri-3088	14	15	on	on	ADP
ajmri-3088	14	16	cd4	cd4	PROPN
ajmri-3088	14	17	t	t	PROPN
ajmri-3088	14	18	cells	cell	NOUN
ajmri-3088	14	19	(	(	PUNCT
ajmri-3088	14	20	cd4tl	cd4tl	NOUN
ajmri-3088	14	21	)	)	PUNCT
ajmri-3088	14	22	,	,	PUNCT
ajmri-3088	14	23	which	which	PRON
ajmri-3088	14	24	allow	allow	VERB
ajmri-3088	14	25	hiv	hiv	PROPN
ajmri-3088	14	26	rna	rna	PROPN
ajmri-3088	14	27	to	to	PART
ajmri-3088	14	28	enter	enter	VERB
ajmri-3088	14	29	the	the	DET
ajmri-3088	14	30	lymphocyte	lymphocyte	ADJ
ajmri-3088	14	31	cells	cell	NOUN
ajmri-3088	14	32	,	,	PUNCT
ajmri-3088	14	33	hijack	hijack	VERB
ajmri-3088	14	34	the	the	DET
ajmri-3088	14	35	machinery	machinery	NOUN
ajmri-3088	14	36	and	and	CCONJ
ajmri-3088	14	37	cause	cause	VERB
ajmri-3088	14	38	apoptosis	apoptosis	NOUN
ajmri-3088	14	39	(	(	PUNCT
ajmri-3088	14	40	armani	armani	NOUN
ajmri-3088	14	41	-	-	PUNCT
ajmri-3088	14	42	tourret	tourret	NOUN
ajmri-3088	14	43	et	et	PROPN
ajmri-3088	14	44	al	al	PROPN
ajmri-3088	14	45	.	.	PROPN
ajmri-3088	14	46	,	,	PUNCT
ajmri-3088	14	47	2021	2021	NUM
ajmri-3088	14	48	)	)	PUNCT
ajmri-3088	14	49	.	.	PUNCT
ajmri-3088	15	1	hiv	hiv	PROPN
ajmri-3088	15	2	leads	lead	VERB
ajmri-3088	15	3	to	to	ADP
ajmri-3088	15	4	impairment	impairment	NOUN
ajmri-3088	15	5	of	of	ADP
ajmri-3088	15	6	t	t	NOUN
ajmri-3088	15	7	-	-	PUNCT
ajmri-3088	15	8	cell	cell	NOUN
ajmri-3088	15	9	subsets	subset	NOUN
ajmri-3088	15	10	by	by	ADP
ajmri-3088	15	11	systematically	systematically	ADV
ajmri-3088	15	12	blocking	block	VERB
ajmri-3088	15	13	the	the	DET
ajmri-3088	15	14	immune	immune	ADJ
ajmri-3088	15	15	activation	activation	NOUN
ajmri-3088	15	16	and	and	CCONJ
ajmri-3088	15	17	promoting	promote	VERB
ajmri-3088	15	18	t	t	NOUN
ajmri-3088	15	19	-	-	PUNCT
ajmri-3088	15	20	cell	cell	NOUN
ajmri-3088	15	21	dysregulation	dysregulation	NOUN
ajmri-3088	15	22	in	in	ADP
ajmri-3088	15	23	lymphoid	lymphoid	ADJ
ajmri-3088	15	24	tissues	tissue	NOUN
ajmri-3088	15	25	and	and	CCONJ
ajmri-3088	15	26	peripheral	peripheral	ADJ
ajmri-3088	15	27	blood	blood	NOUN
ajmri-3088	15	28	(	(	PUNCT
ajmri-3088	15	29	barber	barber	NOUN
ajmri-3088	15	30	-	-	PUNCT
ajmri-3088	15	31	axthelm	axthelm	NOUN
ajmri-3088	15	32	et	et	PROPN
ajmri-3088	15	33	al	al	PROPN
ajmri-3088	15	34	.	.	PROPN
ajmri-3088	15	35	,	,	PUNCT
ajmri-3088	15	36	2020	2020	NUM
ajmri-3088	15	37	)	)	PUNCT
ajmri-3088	15	38	.	.	PUNCT
ajmri-3088	16	1	hiv	hiv	PROPN
ajmri-3088	16	2	causes	cause	VERB
ajmri-3088	16	3	functional	functional	ADJ
ajmri-3088	16	4	impairment	impairment	NOUN
ajmri-3088	16	5	of	of	ADP
ajmri-3088	16	6	hiv	hiv	PROPN
ajmri-3088	16	7	-	-	PUNCT
ajmri-3088	16	8	associated	associate	VERB
ajmri-3088	16	9	cd8	cd8	PROPN
ajmri-3088	16	10	+	+	PROPN
ajmri-3088	16	11	t	t	PROPN
ajmri-3088	16	12	-	-	PUNCT
ajmri-3088	16	13	cells	cell	NOUN
ajmri-3088	16	14	,	,	PUNCT
ajmri-3088	16	15	resulting	result	VERB
ajmri-3088	16	16	in	in	ADP
ajmri-3088	16	17	t	t	NOUN
ajmri-3088	16	18	-	-	PUNCT
ajmri-3088	16	19	cell	cell	NOUN
ajmri-3088	16	20	exhaustion	exhaustion	NOUN
ajmri-3088	16	21	.	.	PUNCT
ajmri-3088	17	1	t	t	NOUN
ajmri-3088	17	2	-	-	PUNCT
ajmri-3088	17	3	cell	cell	NOUN
ajmri-3088	17	4	exhaustion	exhaustion	NOUN
ajmri-3088	17	5	is	be	AUX
ajmri-3088	17	6	characterized	characterize	VERB
ajmri-3088	17	7	by	by	ADP
ajmri-3088	17	8	reduced	reduce	VERB
ajmri-3088	17	9	glycolytic	glycolytic	ADJ
ajmri-3088	17	10	activity	activity	NOUN
ajmri-3088	17	11	,	,	PUNCT
ajmri-3088	17	12	enhanced	enhance	VERB
ajmri-3088	17	13	oxphos	oxphos	NOUN
ajmri-3088	17	14	demands	demand	NOUN
ajmri-3088	17	15	,	,	PUNCT
ajmri-3088	17	16	deregulated	deregulated	ADJ
ajmri-3088	17	17	mtor	mtor	NOUN
ajmri-3088	17	18	,	,	PUNCT
ajmri-3088	17	19	and	and	CCONJ
ajmri-3088	17	20	reduced	reduce	VERB
ajmri-3088	17	21	cytoplasmic	cytoplasmic	ADJ
ajmri-3088	17	22	gapdh	gapdh	NOUN
ajmri-3088	17	23	(	(	PUNCT
ajmri-3088	17	24	kirchmair	kirchmair	PROPN
ajmri-3088	17	25	et	et	PROPN
ajmri-3088	17	26	al	al	PROPN
ajmri-3088	17	27	.	.	PROPN
ajmri-3088	17	28	,	,	PUNCT
ajmri-3088	17	29	2023	2023	NUM
ajmri-3088	17	30	)	)	PUNCT
ajmri-3088	17	31	.	.	PUNCT
ajmri-3088	18	1	ultimately	ultimately	ADV
ajmri-3088	18	2	depleting	deplete	VERB
ajmri-3088	18	3	the	the	DET
ajmri-3088	18	4	cd8	cd8	PROPN
ajmri-3088	18	5	+	+	PROPN
ajmri-3088	18	6	population	population	NOUN
ajmri-3088	18	7	,	,	PUNCT
ajmri-3088	18	8	due	due	ADP
ajmri-3088	18	9	to	to	ADP
ajmri-3088	18	10	which	which	PRON
ajmri-3088	18	11	the	the	DET
ajmri-3088	18	12	majority	majority	NOUN
ajmri-3088	18	13	of	of	ADP
ajmri-3088	18	14	immunotherapies	immunotherapy	NOUN
ajmri-3088	18	15	failed	fail	VERB
ajmri-3088	18	16	to	to	PART
ajmri-3088	18	17	cure	cure	VERB
ajmri-3088	18	18	it	it	PRON
ajmri-3088	18	19	(	(	PUNCT
ajmri-3088	18	20	rahman	rahman	PROPN
ajmri-3088	18	21	et	et	PROPN
ajmri-3088	18	22	al	al	PROPN
ajmri-3088	18	23	.	.	PROPN
ajmri-3088	18	24	,	,	PUNCT
ajmri-3088	18	25	2021	2021	NUM
ajmri-3088	18	26	)	)	PUNCT
ajmri-3088	18	27	.	.	PUNCT
ajmri-3088	19	1	not	not	PART
ajmri-3088	19	2	only	only	ADV
ajmri-3088	19	3	cd4	cd4	PROPN
ajmri-3088	19	4	+	+	PROPN
ajmri-3088	19	5	and	and	CCONJ
ajmri-3088	19	6	cd8	cd8	PROPN
ajmri-3088	19	7	+	+	PROPN
ajmri-3088	19	8	t	t	NOUN
ajmri-3088	19	9	cells	cell	NOUN
ajmri-3088	19	10	but	but	CCONJ
ajmri-3088	19	11	natural	natural	ADJ
ajmri-3088	19	12	killing	killing	NOUN
ajmri-3088	19	13	cells	cell	NOUN
ajmri-3088	19	14	are	be	AUX
ajmri-3088	19	15	equally	equally	ADV
ajmri-3088	19	16	affected	affect	VERB
ajmri-3088	19	17	by	by	ADP
ajmri-3088	19	18	hiv	hiv	PROPN
ajmri-3088	19	19	infection	infection	NOUN
ajmri-3088	19	20	.	.	PUNCT
ajmri-3088	20	1	natural	natural	ADJ
ajmri-3088	20	2	killer	killer	NOUN
ajmri-3088	20	3	(	(	PUNCT
ajmri-3088	20	4	nk	nk	PROPN
ajmri-3088	20	5	)	)	PUNCT
ajmri-3088	20	6	cells	cell	NOUN
ajmri-3088	20	7	are	be	AUX
ajmri-3088	20	8	immune	immune	ADJ
ajmri-3088	20	9	effectors	effector	NOUN
ajmri-3088	20	10	whose	whose	DET
ajmri-3088	20	11	activities	activity	NOUN
ajmri-3088	20	12	are	be	AUX
ajmri-3088	20	13	intimately	intimately	ADV
ajmri-3088	20	14	associated	associate	VERB
ajmri-3088	20	15	with	with	ADP
ajmri-3088	20	16	the	the	DET
ajmri-3088	20	17	advancement	advancement	NOUN
ajmri-3088	20	18	of	of	ADP
ajmri-3088	20	19	hiv-1	hiv-1	PUNCT
ajmri-3088	20	20	infection	infection	NOUN
ajmri-3088	20	21	(	(	PUNCT
ajmri-3088	20	22	cao	cao	PROPN
ajmri-3088	20	23	et	et	PROPN
ajmri-3088	20	24	al	al	PROPN
ajmri-3088	20	25	.	.	PROPN
ajmri-3088	20	26	,	,	PUNCT
ajmri-3088	20	27	2022	2022	NUM
ajmri-3088	20	28	)	)	PUNCT
ajmri-3088	20	29	.	.	PUNCT
ajmri-3088	21	1	several	several	ADJ
ajmri-3088	21	2	studies	study	NOUN
ajmri-3088	21	3	have	have	AUX
ajmri-3088	21	4	shown	show	VERB
ajmri-3088	21	5	that	that	SCONJ
ajmri-3088	21	6	during	during	ADP
ajmri-3088	21	7	hiv-1	hiv-1	VERB
ajmri-3088	21	8	infection	infection	NOUN
ajmri-3088	21	9	,	,	PUNCT
ajmri-3088	21	10	there	there	PRON
ajmri-3088	21	11	is	be	VERB
ajmri-3088	21	12	an	an	DET
ajmri-3088	21	13	overexpression	overexpression	NOUN
ajmri-3088	21	14	of	of	ADP
ajmri-3088	21	15	inhibitory	inhibitory	ADJ
ajmri-3088	21	16	receptors	receptor	NOUN
ajmri-3088	21	17	and	and	CCONJ
ajmri-3088	21	18	a	a	DET
ajmri-3088	21	19	downregulation	downregulation	NOUN
ajmri-3088	21	20	of	of	ADP
ajmri-3088	21	21	activating	activate	VERB
ajmri-3088	21	22	receptors	receptor	NOUN
ajmri-3088	21	23	,	,	PUNCT
ajmri-3088	21	24	which	which	PRON
ajmri-3088	21	25	leads	lead	VERB
ajmri-3088	21	26	to	to	ADP
ajmri-3088	21	27	nk	nk	PROPN
ajmri-3088	21	28	cell	cell	NOUN
ajmri-3088	21	29	insensitivity	insensitivity	NOUN
ajmri-3088	21	30	and	and	CCONJ
ajmri-3088	21	31	decreased	decrease	VERB
ajmri-3088	21	32	killing	killing	NOUN
ajmri-3088	21	33	capacity	capacity	NOUN
ajmri-3088	21	34	(	(	PUNCT
ajmri-3088	21	35	cao	cao	PROPN
ajmri-3088	21	36	et	et	PROPN
ajmri-3088	21	37	al	al	PROPN
ajmri-3088	21	38	.	.	PROPN
ajmri-3088	21	39	,	,	PUNCT
ajmri-3088	21	40	2022	2022	NUM
ajmri-3088	21	41	)	)	PUNCT
ajmri-3088	21	42	.	.	PUNCT
ajmri-3088	22	1	it	it	PRON
ajmri-3088	22	2	has	have	AUX
ajmri-3088	22	3	also	also	ADV
ajmri-3088	22	4	been	be	AUX
ajmri-3088	22	5	reported	report	VERB
ajmri-3088	22	6	that	that	SCONJ
ajmri-3088	22	7	there	there	PRON
ajmri-3088	22	8	is	be	VERB
ajmri-3088	22	9	a	a	DET
ajmri-3088	22	10	preferential	preferential	ADJ
ajmri-3088	22	11	depletion	depletion	NOUN
ajmri-3088	22	12	of	of	ADP
ajmri-3088	22	13	cd45ra+cd4	cd45ra+cd4	PROPN
ajmri-3088	22	14	+	+	SYM
ajmri-3088	22	15	cells	cell	NOUN
ajmri-3088	22	16	in	in	ADP
ajmri-3088	22	17	hiv-1	hiv-1	X
ajmri-3088	22	18	-	-	PUNCT
ajmri-3088	22	19	infected	infected	ADJ
ajmri-3088	22	20	patients	patient	NOUN
ajmri-3088	22	21	,	,	PUNCT
ajmri-3088	22	22	with	with	ADP
ajmri-3088	22	23	symptoms	symptom	NOUN
ajmri-3088	22	24	being	be	AUX
ajmri-3088	22	25	more	more	ADV
ajmri-3088	22	26	prominent	prominent	ADJ
ajmri-3088	22	27	in	in	ADP
ajmri-3088	22	28	patients	patient	NOUN
ajmri-3088	22	29	.	.	PUNCT
ajmri-3088	23	1	in	in	ADP
ajmri-3088	23	2	hiv	hiv	PROPN
ajmri-3088	23	3	-	-	PUNCT
ajmri-3088	23	4	positive	positive	ADJ
ajmri-3088	23	5	cd45ra+	cd45ra+	NOUN
ajmri-3088	23	6	,	,	PUNCT
ajmri-3088	23	7	there	there	PRON
ajmri-3088	23	8	is	be	VERB
ajmri-3088	23	9	an	an	DET
ajmri-3088	23	10	increase	increase	NOUN
ajmri-3088	23	11	in	in	ADP
ajmri-3088	23	12	the	the	DET
ajmri-3088	23	13	level	level	NOUN
ajmri-3088	23	14	of	of	ADP
ajmri-3088	23	15	oxidized	oxidize	VERB
ajmri-3088	23	16	glutathione	glutathione	NOUN
ajmri-3088	23	17	and	and	CCONJ
ajmri-3088	23	18	a	a	DET
ajmri-3088	23	19	decreased	decrease	VERB
ajmri-3088	23	20	ratio	ratio	NOUN
ajmri-3088	23	21	of	of	ADP
ajmri-3088	23	22	reduced	reduce	VERB
ajmri-3088	23	23	to	to	ADP
ajmri-3088	23	24	total	total	ADJ
ajmri-3088	23	25	glutathione	glutathione	NOUN
ajmri-3088	23	26	as	as	ADP
ajmri-3088	23	27	the	the	DET
ajmri-3088	23	28	major	major	ADJ
ajmri-3088	23	29	characteristics	characteristic	NOUN
ajmri-3088	23	30	(	(	PUNCT
ajmri-3088	23	31	kirchmair	kirchmair	PROPN
ajmri-3088	23	32	et	et	PROPN
ajmri-3088	23	33	al	al	PROPN
ajmri-3088	23	34	.	.	PROPN
ajmri-3088	23	35	,	,	PUNCT
ajmri-3088	23	36	2023	2023	NUM
ajmri-3088	23	37	)	)	PUNCT
ajmri-3088	23	38	.	.	PUNCT
ajmri-3088	24	1	the	the	DET
ajmri-3088	24	2	glutathione	glutathione	NOUN
ajmri-3088	24	3	abnormalities	abnormality	NOUN
ajmri-3088	24	4	in	in	ADP
ajmri-3088	24	5	cd45ra+cd4	cd45ra+cd4	PROPN
ajmri-3088	24	6	+	+	NOUN
ajmri-3088	24	7	lymphocytes	lymphocyte	NOUN
ajmri-3088	24	8	showed	show	VERB
ajmri-3088	24	9	significantly	significantly	ADV
ajmri-3088	24	10	low	low	ADJ
ajmri-3088	24	11	numbers	number	NOUN
ajmri-3088	24	12	of	of	ADP
ajmri-3088	24	13	total	total	ADJ
ajmri-3088	24	14	cd4	cd4	PROPN
ajmri-3088	24	15	+	+	PROPN
ajmri-3088	24	16	lymphocytes	lymphocyte	NOUN
ajmri-3088	24	17	,	,	PUNCT
ajmri-3088	24	18	ultimately	ultimately	ADV
ajmri-3088	24	19	decreasing	decrease	VERB
ajmri-3088	24	20	the	the	DET
ajmri-3088	24	21	proportion	proportion	NOUN
ajmri-3088	24	22	of	of	ADP
ajmri-3088	24	23	cd45ra+cd4	cd45ra+cd4	PROPN
ajmri-3088	24	24	+	+	NOUN
ajmri-3088	24	25	lymphocytes	lymphocyte	NOUN
ajmri-3088	24	26	in	in	ADP
ajmri-3088	24	27	peripheral	peripheral	ADJ
ajmri-3088	24	28	blood	blood	NOUN
ajmri-3088	24	29	(	(	PUNCT
ajmri-3088	24	30	kirchmair	kirchmair	NOUN
ajmri-3088	24	31	et	et	PROPN
ajmri-3088	24	32	al	al	PROPN
ajmri-3088	24	33	.	.	PROPN
ajmri-3088	24	34	,	,	PUNCT
ajmri-3088	24	35	2023	2023	NUM
ajmri-3088	24	36	)	)	PUNCT
ajmri-3088	24	37	.	.	PUNCT
ajmri-3088	25	1	hiv	hiv	PROPN
ajmri-3088	25	2	infection	infection	NOUN
ajmri-3088	25	3	leads	lead	VERB
ajmri-3088	25	4	to	to	ADP
ajmri-3088	25	5	the	the	DET
ajmri-3088	25	6	weakening	weakening	NOUN
ajmri-3088	25	7	of	of	ADP
ajmri-3088	25	8	the	the	DET
ajmri-3088	25	9	immune	immune	ADJ
ajmri-3088	25	10	system	system	NOUN
ajmri-3088	25	11	,	,	PUNCT
ajmri-3088	25	12	providing	provide	VERB
ajmri-3088	25	13	opportunities	opportunity	NOUN
ajmri-3088	25	14	for	for	ADP
ajmri-3088	25	15	coinfection	coinfection	NOUN
ajmri-3088	25	16	.	.	PUNCT
ajmri-3088	26	1	hiv	hiv	PROPN
ajmri-3088	26	2	is	be	AUX
ajmri-3088	26	3	well	well	ADV
ajmri-3088	26	4	known	known	ADJ
ajmri-3088	26	5	for	for	ADP
ajmri-3088	26	6	its	its	PRON
ajmri-3088	26	7	coinfection	coinfection	NOUN
ajmri-3088	26	8	with	with	ADP
ajmri-3088	26	9	hbv	hbv	NOUN
ajmri-3088	26	10	.	.	PUNCT
ajmri-3088	27	1	hepatocellular	hepatocellular	ADJ
ajmri-3088	27	2	carcinoma	carcinoma	NOUN
ajmri-3088	27	3	,	,	PUNCT
ajmri-3088	27	4	liver	liver	NOUN
ajmri-3088	27	5	cirrhosis	cirrhosis	NOUN
ajmri-3088	27	6	,	,	PUNCT
ajmri-3088	27	7	and	and	CCONJ
ajmri-3088	27	8	chronic	chronic	ADJ
ajmri-3088	27	9	hepatitis	hepatitis	NOUN
ajmri-3088	27	10	are	be	AUX
ajmri-3088	27	11	frequently	frequently	ADV
ajmri-3088	27	12	caused	cause	VERB
ajmri-3088	27	13	by	by	ADP
ajmri-3088	27	14	hepatitis	hepatitis	PROPN
ajmri-3088	27	15	b	b	PROPN
ajmri-3088	27	16	virus	virus	NOUN
ajmri-3088	27	17	(	(	PUNCT
ajmri-3088	27	18	hbv	hbv	NOUN
ajmri-3088	27	19	)	)	PUNCT
ajmri-3088	27	20	infection	infection	NOUN
ajmri-3088	27	21	(	(	PUNCT
ajmri-3088	27	22	weldemhret	weldemhret	NOUN
ajmri-3088	27	23	,	,	PUNCT
ajmri-3088	27	24	2021	2021	NUM
ajmri-3088	27	25	)	)	PUNCT
ajmri-3088	27	26	.	.	PUNCT
ajmri-3088	28	1	both	both	DET
ajmri-3088	28	2	viral	viral	ADJ
ajmri-3088	28	3	infections	infection	NOUN
ajmri-3088	28	4	,	,	PUNCT
ajmri-3088	28	5	the	the	DET
ajmri-3088	28	6	human	human	ADJ
ajmri-3088	28	7	immunodeficiency	immunodeficiency	NOUN
ajmri-3088	28	8	virus	virus	NOUN
ajmri-3088	28	9	(	(	PUNCT
ajmri-3088	28	10	hiv	hiv	PROPN
ajmri-3088	28	11	)	)	PUNCT
ajmri-3088	28	12	and	and	CCONJ
ajmri-3088	28	13	hbv	hbv	NOUN
ajmri-3088	28	14	,	,	PUNCT
ajmri-3088	28	15	share	share	VERB
ajmri-3088	28	16	a	a	DET
ajmri-3088	28	17	mutual	mutual	ADJ
ajmri-3088	28	18	mode	mode	NOUN
ajmri-3088	28	19	of	of	ADP
ajmri-3088	28	20	transmission	transmission	NOUN
ajmri-3088	28	21	,	,	PUNCT
ajmri-3088	28	22	such	such	ADJ
ajmri-3088	28	23	as	as	ADP
ajmri-3088	28	24	unprotected	unprotected	ADJ
ajmri-3088	28	25	sexual	sexual	ADJ
ajmri-3088	28	26	1	1	NUM
ajmri-3088	28	27	ain	ain	NOUN
ajmri-3088	28	28	shams	sham	NOUN
ajmri-3088	28	29	university	university	NOUN
ajmri-3088	28	30	,	,	PUNCT
ajmri-3088	28	31	faculty	faculty	NOUN
ajmri-3088	28	32	of	of	ADP
ajmri-3088	28	33	medicine	medicine	NOUN
ajmri-3088	28	34	,	,	PUNCT
ajmri-3088	28	35	cairo	cairo	PROPN
ajmri-3088	28	36	,	,	PUNCT
ajmri-3088	28	37	egypt	egypt	PROPN
ajmri-3088	28	38	*	*	PUNCT
ajmri-3088	28	39	corresponding	correspond	VERB
ajmri-3088	28	40	author	author	NOUN
ajmri-3088	28	41	’s	’s	PART
ajmri-3088	28	42	e	e	NOUN
ajmri-3088	28	43	-	-	NOUN
ajmri-3088	28	44	mail	mail	NOUN
ajmri-3088	28	45	:	:	PUNCT
ajmri-3088	29	1	suzaneid@hotmail.com	suzaneid@hotmail.com	X
ajmri-3088	30	1	pa	pa	PROPN
ajmri-3088	30	2	ge	ge	PROPN
ajmri-3088	30	3	51	51	NUM
ajmri-3088	30	4	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	30	5	am	am	NOUN
ajmri-3088	30	6	.	.	PUNCT
ajmri-3088	31	1	j.	j.	PROPN
ajmri-3088	31	2	multidis	multidis	PROPN
ajmri-3088	31	3	.	.	PUNCT
ajmri-3088	32	1	res	re	NOUN
ajmri-3088	32	2	.	.	PUNCT
ajmri-3088	33	1	innov	innov	PROPN
ajmri-3088	33	2	.	.	PUNCT
ajmri-3088	34	1	3(5	3(5	NUM
ajmri-3088	34	2	)	)	PUNCT
ajmri-3088	34	3	50	50	NUM
ajmri-3088	34	4	-	-	SYM
ajmri-3088	34	5	60	60	NUM
ajmri-3088	34	6	,	,	PUNCT
ajmri-3088	34	7	2024	2024	NUM
ajmri-3088	34	8	activities	activity	NOUN
ajmri-3088	34	9	,	,	PUNCT
ajmri-3088	34	10	unhygienic	unhygienic	ADJ
ajmri-3088	34	11	surroundings	surrounding	NOUN
ajmri-3088	34	12	,	,	PUNCT
ajmri-3088	34	13	perinatal	perinatal	ADJ
ajmri-3088	34	14	transmission	transmission	NOUN
ajmri-3088	34	15	,	,	PUNCT
ajmri-3088	34	16	and	and	CCONJ
ajmri-3088	34	17	intravenous	intravenous	ADJ
ajmri-3088	34	18	drug	drug	NOUN
ajmri-3088	34	19	usage	usage	NOUN
ajmri-3088	34	20	(	(	PUNCT
ajmri-3088	34	21	corcorran	corcorran	PROPN
ajmri-3088	34	22	&	&	CCONJ
ajmri-3088	34	23	kim	kim	PROPN
ajmri-3088	34	24	,	,	PUNCT
ajmri-3088	34	25	2023	2023	NUM
ajmri-3088	34	26	)	)	PUNCT
ajmri-3088	34	27	.	.	PUNCT
ajmri-3088	35	1	in	in	ADP
ajmri-3088	35	2	the	the	DET
ajmri-3088	35	3	case	case	NOUN
ajmri-3088	35	4	of	of	ADP
ajmri-3088	35	5	hbv	hbv	NOUN
ajmri-3088	35	6	infection	infection	NOUN
ajmri-3088	35	7	,	,	PUNCT
ajmri-3088	35	8	the	the	DET
ajmri-3088	35	9	t	t	PROPN
ajmri-3088	35	10	-	-	PUNCT
ajmri-3088	35	11	lymphocyte	lymphocyte	NOUN
ajmri-3088	35	12	population	population	NOUN
ajmri-3088	35	13	decreases	decrease	VERB
ajmri-3088	35	14	due	due	ADJ
ajmri-3088	35	15	to	to	ADP
ajmri-3088	35	16	hbeag	hbeag	ADJ
ajmri-3088	35	17	positivity	positivity	NOUN
ajmri-3088	35	18	and	and	CCONJ
ajmri-3088	35	19	increased	increase	VERB
ajmri-3088	35	20	levels	level	NOUN
ajmri-3088	35	21	of	of	ADP
ajmri-3088	35	22	viremia	viremia	NOUN
ajmri-3088	35	23	(	(	PUNCT
ajmri-3088	35	24	kirkoyun	kirkoyun	PROPN
ajmri-3088	35	25	uysal	uysal	PROPN
ajmri-3088	35	26	et	et	PROPN
ajmri-3088	35	27	al	al	PROPN
ajmri-3088	35	28	.	.	PROPN
ajmri-3088	35	29	,	,	PUNCT
ajmri-3088	35	30	2023	2023	NUM
ajmri-3088	35	31	)	)	PUNCT
ajmri-3088	35	32	.	.	PUNCT
ajmri-3088	36	1	the	the	DET
ajmri-3088	36	2	immune	immune	ADJ
ajmri-3088	36	3	response	response	NOUN
ajmri-3088	36	4	to	to	ADP
ajmri-3088	36	5	chronic	chronic	ADJ
ajmri-3088	36	6	hbv	hbv	NOUN
ajmri-3088	36	7	infection	infection	NOUN
ajmri-3088	36	8	plays	play	VERB
ajmri-3088	36	9	a	a	DET
ajmri-3088	36	10	multiple	multiple	ADJ
ajmri-3088	36	11	complex	complex	ADJ
ajmri-3088	36	12	function	function	NOUN
ajmri-3088	36	13	;	;	PUNCT
ajmri-3088	36	14	the	the	DET
ajmri-3088	36	15	duration	duration	NOUN
ajmri-3088	36	16	and	and	CCONJ
ajmri-3088	36	17	point	point	NOUN
ajmri-3088	36	18	of	of	ADP
ajmri-3088	36	19	liver	liver	NOUN
ajmri-3088	36	20	damage	damage	NOUN
ajmri-3088	36	21	can	can	AUX
ajmri-3088	36	22	be	be	AUX
ajmri-3088	36	23	determined	determine	VERB
ajmri-3088	36	24	by	by	ADP
ajmri-3088	36	25	the	the	DET
ajmri-3088	36	26	type	type	NOUN
ajmri-3088	36	27	of	of	ADP
ajmri-3088	36	28	t	t	NOUN
ajmri-3088	36	29	-	-	PUNCT
ajmri-3088	36	30	cell	cell	NOUN
ajmri-3088	36	31	response	response	NOUN
ajmri-3088	36	32	to	to	ADP
ajmri-3088	36	33	this	this	DET
ajmri-3088	36	34	infection	infection	NOUN
ajmri-3088	36	35	(	(	PUNCT
ajmri-3088	36	36	yu	yu	PROPN
ajmri-3088	36	37	et	et	PROPN
ajmri-3088	36	38	al	al	PROPN
ajmri-3088	36	39	.	.	PROPN
ajmri-3088	36	40	,	,	PUNCT
ajmri-3088	36	41	2023	2023	NUM
ajmri-3088	36	42	)	)	PUNCT
ajmri-3088	36	43	.	.	PUNCT
ajmri-3088	37	1	one	one	NUM
ajmri-3088	37	2	crucial	crucial	ADJ
ajmri-3088	37	3	component	component	NOUN
ajmri-3088	37	4	in	in	ADP
ajmri-3088	37	5	developing	develop	VERB
ajmri-3088	37	6	hepatitis	hepatitis	PROPN
ajmri-3088	37	7	b	b	PROPN
ajmri-3088	37	8	is	be	AUX
ajmri-3088	37	9	the	the	DET
ajmri-3088	37	10	cellular	cellular	ADJ
ajmri-3088	37	11	immune	immune	ADJ
ajmri-3088	37	12	response	response	NOUN
ajmri-3088	37	13	dysfunction	dysfunction	NOUN
ajmri-3088	37	14	mediated	mediate	VERB
ajmri-3088	37	15	by	by	ADP
ajmri-3088	37	16	t	t	NOUN
ajmri-3088	37	17	cells	cell	NOUN
ajmri-3088	37	18	(	(	PUNCT
ajmri-3088	37	19	dumolard	dumolard	NOUN
ajmri-3088	37	20	et	et	PROPN
ajmri-3088	37	21	al	al	PROPN
ajmri-3088	37	22	.	.	PROPN
ajmri-3088	37	23	,	,	PUNCT
ajmri-3088	37	24	2023	2023	NUM
ajmri-3088	37	25	)	)	PUNCT
ajmri-3088	37	26	.	.	PUNCT
ajmri-3088	38	1	according	accord	VERB
ajmri-3088	38	2	to	to	ADP
ajmri-3088	38	3	reports	report	NOUN
ajmri-3088	38	4	,	,	PUNCT
ajmri-3088	38	5	abnormalities	abnormality	NOUN
ajmri-3088	38	6	of	of	ADP
ajmri-3088	38	7	t	t	NOUN
ajmri-3088	38	8	lymphocytes	lymphocyte	NOUN
ajmri-3088	38	9	and	and	CCONJ
ajmri-3088	38	10	their	their	PRON
ajmri-3088	38	11	subsets	subset	NOUN
ajmri-3088	38	12	frequently	frequently	ADV
ajmri-3088	38	13	arise	arise	VERB
ajmri-3088	38	14	following	follow	VERB
ajmri-3088	38	15	hepatitis	hepatitis	PROPN
ajmri-3088	38	16	b	b	NOUN
ajmri-3088	38	17	infection	infection	NOUN
ajmri-3088	38	18	,	,	PUNCT
ajmri-3088	38	19	which	which	PRON
ajmri-3088	38	20	is	be	AUX
ajmri-3088	38	21	typically	typically	ADV
ajmri-3088	38	22	characterized	characterize	VERB
ajmri-3088	38	23	by	by	ADP
ajmri-3088	38	24	an	an	DET
ajmri-3088	38	25	imbalance	imbalance	NOUN
ajmri-3088	38	26	in	in	ADP
ajmri-3088	38	27	th1	th1	PROPN
ajmri-3088	38	28	/	/	SYM
ajmri-3088	38	29	th2	th2	PROPN
ajmri-3088	38	30	lymphocytes	lymphocyte	VERB
ajmri-3088	38	31	,	,	PUNCT
ajmri-3088	38	32	an	an	DET
ajmri-3088	38	33	increase	increase	NOUN
ajmri-3088	38	34	in	in	ADP
ajmri-3088	38	35	cd8	cd8	PROPN
ajmri-3088	38	36	+	+	PROPN
ajmri-3088	38	37	t	t	PROPN
ajmri-3088	38	38	lymphocytes	lymphocyte	NOUN
ajmri-3088	38	39	,	,	PUNCT
ajmri-3088	38	40	and	and	CCONJ
ajmri-3088	38	41	a	a	DET
ajmri-3088	38	42	decrease	decrease	NOUN
ajmri-3088	38	43	in	in	ADP
ajmri-3088	38	44	cd4	cd4	PROPN
ajmri-3088	38	45	+	+	PROPN
ajmri-3088	38	46	t	t	PROPN
ajmri-3088	38	47	cells	cell	NOUN
ajmri-3088	38	48	(	(	PUNCT
ajmri-3088	38	49	zhang	zhang	PROPN
ajmri-3088	38	50	&	&	CCONJ
ajmri-3088	38	51	ruan	ruan	PROPN
ajmri-3088	38	52	,	,	PUNCT
ajmri-3088	38	53	2023	2023	NUM
ajmri-3088	38	54	)	)	PUNCT
ajmri-3088	38	55	.	.	PUNCT
ajmri-3088	39	1	this	this	DET
ajmri-3088	39	2	type	type	NOUN
ajmri-3088	39	3	of	of	ADP
ajmri-3088	39	4	shift	shift	NOUN
ajmri-3088	39	5	frequently	frequently	ADV
ajmri-3088	39	6	results	result	VERB
ajmri-3088	39	7	in	in	ADP
ajmri-3088	39	8	an	an	DET
ajmri-3088	39	9	impairment	impairment	NOUN
ajmri-3088	39	10	in	in	ADP
ajmri-3088	39	11	the	the	DET
ajmri-3088	39	12	organism	organism	NOUN
ajmri-3088	39	13	’s	’s	PART
ajmri-3088	39	14	immune	immune	ADJ
ajmri-3088	39	15	function	function	NOUN
ajmri-3088	39	16	,	,	PUNCT
ajmri-3088	39	17	a	a	DET
ajmri-3088	39	18	cell	cell	NOUN
ajmri-3088	39	19	immune	immune	ADJ
ajmri-3088	39	20	insufficiency	insufficiency	NOUN
ajmri-3088	39	21	,	,	PUNCT
ajmri-3088	39	22	difficulty	difficulty	NOUN
ajmri-3088	39	23	clearing	clear	VERB
ajmri-3088	39	24	the	the	DET
ajmri-3088	39	25	virus	virus	NOUN
ajmri-3088	39	26	,	,	PUNCT
ajmri-3088	39	27	a	a	DET
ajmri-3088	39	28	protracted	protract	VERB
ajmri-3088	39	29	illness	illness	NOUN
ajmri-3088	39	30	,	,	PUNCT
ajmri-3088	39	31	and	and	CCONJ
ajmri-3088	39	32	a	a	DET
ajmri-3088	39	33	failure	failure	NOUN
ajmri-3088	39	34	to	to	PART
ajmri-3088	39	35	heal	heal	VERB
ajmri-3088	39	36	.	.	PUNCT
ajmri-3088	40	1	hepatitis	hepatitis	PROPN
ajmri-3088	40	2	b	b	PROPN
ajmri-3088	40	3	surface	surface	NOUN
ajmri-3088	40	4	antigen	antigen	NOUN
ajmri-3088	40	5	(	(	PUNCT
ajmri-3088	40	6	hbsag	hbsag	NOUN
ajmri-3088	40	7	)	)	PUNCT
ajmri-3088	40	8	expression	expression	NOUN
ajmri-3088	40	9	during	during	ADP
ajmri-3088	40	10	chronic	chronic	ADJ
ajmri-3088	40	11	infection	infection	NOUN
ajmri-3088	40	12	is	be	AUX
ajmri-3088	40	13	frequently	frequently	ADV
ajmri-3088	40	14	attributed	attribute	VERB
ajmri-3088	40	15	to	to	ADP
ajmri-3088	40	16	hbv	hbv	NOUN
ajmri-3088	40	17	integration	integration	NOUN
ajmri-3088	40	18	into	into	ADP
ajmri-3088	40	19	the	the	DET
ajmri-3088	40	20	host	host	NOUN
ajmri-3088	40	21	genome	genome	NOUN
ajmri-3088	40	22	,	,	PUNCT
ajmri-3088	40	23	which	which	PRON
ajmri-3088	40	24	may	may	AUX
ajmri-3088	40	25	lead	lead	VERB
ajmri-3088	40	26	to	to	ADP
ajmri-3088	40	27	defective	defective	ADJ
ajmri-3088	40	28	t	t	NOUN
ajmri-3088	40	29	-	-	PUNCT
ajmri-3088	40	30	cell	cell	NOUN
ajmri-3088	40	31	responses	response	NOUN
ajmri-3088	40	32	and	and	CCONJ
ajmri-3088	40	33	promote	promote	VERB
ajmri-3088	40	34	autoimmune	autoimmune	ADJ
ajmri-3088	40	35	responses	response	NOUN
ajmri-3088	40	36	(	(	PUNCT
ajmri-3088	40	37	wu	wu	PROPN
ajmri-3088	40	38	et	et	PROPN
ajmri-3088	40	39	al	al	PROPN
ajmri-3088	40	40	.	.	PROPN
ajmri-3088	40	41	,	,	PUNCT
ajmri-3088	40	42	2020	2020	NUM
ajmri-3088	40	43	)	)	PUNCT
ajmri-3088	40	44	the	the	DET
ajmri-3088	40	45	rationale	rationale	NOUN
ajmri-3088	40	46	of	of	ADP
ajmri-3088	40	47	the	the	DET
ajmri-3088	40	48	study	study	NOUN
ajmri-3088	40	49	there	there	PRON
ajmri-3088	40	50	are	be	VERB
ajmri-3088	40	51	an	an	DET
ajmri-3088	40	52	estimated	estimate	VERB
ajmri-3088	40	53	two	two	NUM
ajmri-3088	40	54	to	to	PART
ajmri-3088	40	55	296	296	NUM
ajmri-3088	40	56	million	million	NUM
ajmri-3088	40	57	people	people	NOUN
ajmri-3088	40	58	with	with	ADP
ajmri-3088	40	59	chronic	chronic	ADJ
ajmri-3088	40	60	hepatitis	hepatitis	PROPN
ajmri-3088	40	61	b	b	PROPN
ajmri-3088	40	62	(	(	PUNCT
ajmri-3088	40	63	chb	chb	NOUN
ajmri-3088	40	64	)	)	PUNCT
ajmri-3088	40	65	in	in	ADP
ajmri-3088	40	66	egypt	egypt	PROPN
ajmri-3088	40	67	,	,	PUNCT
ajmri-3088	40	68	which	which	PRON
ajmri-3088	40	69	means	mean	VERB
ajmri-3088	40	70	nearly	nearly	ADV
ajmri-3088	40	71	29.6	29.6	NUM
ajmri-3088	40	72	million	million	NUM
ajmri-3088	40	73	people	people	NOUN
ajmri-3088	40	74	are	be	AUX
ajmri-3088	40	75	suspected	suspect	VERB
ajmri-3088	40	76	to	to	PART
ajmri-3088	40	77	be	be	AUX
ajmri-3088	40	78	hiv	hiv	ADV
ajmri-3088	40	79	positive	positive	ADJ
ajmri-3088	40	80	as	as	ADV
ajmri-3088	40	81	well	well	ADV
ajmri-3088	40	82	.	.	PUNCT
ajmri-3088	41	1	it	it	PRON
ajmri-3088	41	2	is	be	AUX
ajmri-3088	41	3	safe	safe	ADJ
ajmri-3088	41	4	to	to	PART
ajmri-3088	41	5	say	say	VERB
ajmri-3088	41	6	that	that	SCONJ
ajmri-3088	41	7	about	about	ADV
ajmri-3088	41	8	10	10	NUM
ajmri-3088	41	9	%	%	NOUN
ajmri-3088	41	10	of	of	ADP
ajmri-3088	41	11	hiv	hiv	PROPN
ajmri-3088	41	12	-	-	PUNCT
ajmri-3088	41	13	positive	positive	ADJ
ajmri-3088	41	14	individuals	individual	NOUN
ajmri-3088	41	15	also	also	ADV
ajmri-3088	41	16	have	have	VERB
ajmri-3088	41	17	hbv	hbv	NOUN
ajmri-3088	41	18	coinfection	coinfection	NOUN
ajmri-3088	41	19	(	(	PUNCT
ajmri-3088	41	20	youssif	youssif	NOUN
ajmri-3088	41	21	et	et	PROPN
ajmri-3088	41	22	al	al	PROPN
ajmri-3088	41	23	.	.	PROPN
ajmri-3088	41	24	,	,	PUNCT
ajmri-3088	41	25	2023	2023	NUM
ajmri-3088	41	26	)	)	PUNCT
ajmri-3088	41	27	.	.	PUNCT
ajmri-3088	42	1	according	accord	VERB
ajmri-3088	42	2	to	to	ADP
ajmri-3088	42	3	previous	previous	ADJ
ajmri-3088	42	4	studies	study	NOUN
ajmri-3088	42	5	,	,	PUNCT
ajmri-3088	42	6	in	in	ADP
ajmri-3088	42	7	comparison	comparison	NOUN
ajmri-3088	42	8	to	to	ADP
ajmri-3088	42	9	chronic	chronic	ADJ
ajmri-3088	42	10	hbv	hbv	NOUN
ajmri-3088	42	11	mono	mono	NOUN
ajmri-3088	42	12	-	-	PUNCT
ajmri-3088	42	13	infection	infection	NOUN
ajmri-3088	42	14	,	,	PUNCT
ajmri-3088	42	15	hiv	hiv	PROPN
ajmri-3088	42	16	/	/	SYM
ajmri-3088	42	17	hbv	hbv	NOUN
ajmri-3088	42	18	coinfection	coinfection	NOUN
ajmri-3088	42	19	accelerates	accelerate	VERB
ajmri-3088	42	20	the	the	DET
ajmri-3088	42	21	development	development	NOUN
ajmri-3088	42	22	of	of	ADP
ajmri-3088	42	23	chronic	chronic	ADJ
ajmri-3088	42	24	hbv	hbv	NOUN
ajmri-3088	42	25	into	into	ADP
ajmri-3088	42	26	cirrhosis	cirrhosis	NOUN
ajmri-3088	42	27	,	,	PUNCT
ajmri-3088	42	28	end	end	NOUN
ajmri-3088	42	29	-	-	PUNCT
ajmri-3088	42	30	stage	stage	NOUN
ajmri-3088	42	31	liver	liver	NOUN
ajmri-3088	42	32	disease	disease	NOUN
ajmri-3088	42	33	,	,	PUNCT
ajmri-3088	42	34	or	or	CCONJ
ajmri-3088	42	35	hepatocellular	hepatocellular	ADJ
ajmri-3088	42	36	carcinoma	carcinoma	NOUN
ajmri-3088	42	37	(	(	PUNCT
ajmri-3088	42	38	ruta	ruta	NOUN
ajmri-3088	42	39	et	et	PROPN
ajmri-3088	42	40	al	al	PROPN
ajmri-3088	42	41	.	.	PROPN
ajmri-3088	42	42	,	,	PUNCT
ajmri-3088	42	43	2023	2023	NUM
ajmri-3088	42	44	)	)	PUNCT
ajmri-3088	42	45	.	.	PUNCT
ajmri-3088	43	1	the	the	DET
ajmri-3088	43	2	hiv	hiv	PROPN
ajmri-3088	43	3	/	/	SYM
ajmri-3088	43	4	hbv	hbv	NOUN
ajmri-3088	43	5	coinfection	coinfection	NOUN
ajmri-3088	43	6	has	have	AUX
ajmri-3088	43	7	become	become	VERB
ajmri-3088	43	8	a	a	DET
ajmri-3088	43	9	serious	serious	ADJ
ajmri-3088	43	10	challenge	challenge	NOUN
ajmri-3088	43	11	for	for	ADP
ajmri-3088	43	12	antiviral	antiviral	ADJ
ajmri-3088	43	13	therapies	therapy	NOUN
ajmri-3088	43	14	.	.	PUNCT
ajmri-3088	44	1	the	the	DET
ajmri-3088	44	2	severity	severity	NOUN
ajmri-3088	44	3	of	of	ADP
ajmri-3088	44	4	viral	viral	ADJ
ajmri-3088	44	5	infection	infection	NOUN
ajmri-3088	44	6	in	in	ADP
ajmri-3088	44	7	patients	patient	NOUN
ajmri-3088	44	8	with	with	ADP
ajmri-3088	44	9	chronic	chronic	ADJ
ajmri-3088	44	10	hiv/	hiv/	NOUN
ajmri-3088	44	11	hbv	hbv	NOUN
ajmri-3088	44	12	coinfection	coinfection	NOUN
ajmri-3088	44	13	is	be	AUX
ajmri-3088	44	14	caused	cause	VERB
ajmri-3088	44	15	by	by	ADP
ajmri-3088	44	16	a	a	DET
ajmri-3088	44	17	decline	decline	NOUN
ajmri-3088	44	18	in	in	ADP
ajmri-3088	44	19	the	the	DET
ajmri-3088	44	20	number	number	NOUN
ajmri-3088	44	21	of	of	ADP
ajmri-3088	44	22	hbv	hbv	NOUN
ajmri-3088	44	23	-	-	PUNCT
ajmri-3088	44	24	specific	specific	NOUN
ajmri-3088	44	25	cd8	cd8	PROPN
ajmri-3088	44	26	+	+	PROPN
ajmri-3088	44	27	t	t	NOUN
ajmri-3088	44	28	cells	cell	NOUN
ajmri-3088	44	29	that	that	PRON
ajmri-3088	44	30	produce	produce	VERB
ajmri-3088	44	31	interferon	interferon	NOUN
ajmri-3088	44	32	(	(	PUNCT
ajmri-3088	44	33	ifn	ifn	PROPN
ajmri-3088	44	34	)	)	PUNCT
ajmri-3088	44	35	as	as	SCONJ
ajmri-3088	44	36	the	the	DET
ajmri-3088	44	37	disease	disease	NOUN
ajmri-3088	44	38	progresses	progress	VERB
ajmri-3088	44	39	(	(	PUNCT
ajmri-3088	44	40	lim	lim	PROPN
ajmri-3088	44	41	et	et	PROPN
ajmri-3088	44	42	al	al	PROPN
ajmri-3088	44	43	.	.	PROPN
ajmri-3088	44	44	,	,	PUNCT
ajmri-3088	44	45	2023	2023	NUM
ajmri-3088	44	46	)	)	PUNCT
ajmri-3088	44	47	.	.	PUNCT
ajmri-3088	45	1	this	this	DET
ajmri-3088	45	2	research	research	NOUN
ajmri-3088	45	3	aims	aim	VERB
ajmri-3088	45	4	to	to	PART
ajmri-3088	45	5	study	study	VERB
ajmri-3088	45	6	variations	variation	NOUN
ajmri-3088	45	7	in	in	ADP
ajmri-3088	45	8	lymphocyte	lymphocyte	ADJ
ajmri-3088	45	9	subsets	subset	NOUN
ajmri-3088	45	10	such	such	ADJ
ajmri-3088	45	11	as	as	ADP
ajmri-3088	45	12	cd4	cd4	PROPN
ajmri-3088	45	13	+	+	PROPN
ajmri-3088	45	14	,	,	PUNCT
ajmri-3088	45	15	cd8	cd8	PROPN
ajmri-3088	45	16	+	+	PROPN
ajmri-3088	45	17	,	,	PUNCT
ajmri-3088	45	18	cd45ro	cd45ro	NOUN
ajmri-3088	45	19	,	,	PUNCT
ajmri-3088	45	20	cd16	cd16	PROPN
ajmri-3088	45	21	+	+	PROPN
ajmri-3088	45	22	56	56	NUM
ajmri-3088	45	23	,	,	PUNCT
ajmri-3088	45	24	and	and	CCONJ
ajmri-3088	45	25	cd45ra	cd45ra	VERB
ajmri-3088	45	26	in	in	ADP
ajmri-3088	45	27	patients	patient	NOUN
ajmri-3088	45	28	co	co	VERB
ajmri-3088	45	29	-	-	VERB
ajmri-3088	45	30	infected	infected	ADJ
ajmri-3088	45	31	with	with	ADP
ajmri-3088	45	32	hiv	hiv	PROPN
ajmri-3088	45	33	/	/	SYM
ajmri-3088	45	34	hbv	hbv	NOUN
ajmri-3088	45	35	.	.	PUNCT
ajmri-3088	46	1	significance	significance	NOUN
ajmri-3088	46	2	of	of	ADP
ajmri-3088	46	3	monitoring	monitor	VERB
ajmri-3088	46	4	the	the	DET
ajmri-3088	46	5	t	t	PROPN
ajmri-3088	46	6	-	-	PUNCT
ajmri-3088	46	7	lymphocyte	lymphocyte	ADJ
ajmri-3088	46	8	population	population	NOUN
ajmri-3088	46	9	monitoring	monitor	VERB
ajmri-3088	46	10	lymphocyte	lymphocyte	ADJ
ajmri-3088	46	11	subpopulations	subpopulation	NOUN
ajmri-3088	46	12	in	in	ADP
ajmri-3088	46	13	the	the	DET
ajmri-3088	46	14	context	context	NOUN
ajmri-3088	46	15	of	of	ADP
ajmri-3088	46	16	coinfection	coinfection	NOUN
ajmri-3088	46	17	with	with	ADP
ajmri-3088	46	18	hiv	hiv	PROPN
ajmri-3088	46	19	/	/	SYM
ajmri-3088	46	20	hbv	hbv	NOUN
ajmri-3088	46	21	provides	provide	VERB
ajmri-3088	46	22	an	an	DET
ajmri-3088	46	23	in	in	ADP
ajmri-3088	46	24	-	-	PUNCT
ajmri-3088	46	25	depth	depth	NOUN
ajmri-3088	46	26	understanding	understanding	NOUN
ajmri-3088	46	27	of	of	ADP
ajmri-3088	46	28	the	the	DET
ajmri-3088	46	29	immune	immune	ADJ
ajmri-3088	46	30	system	system	NOUN
ajmri-3088	46	31	’s	’s	PART
ajmri-3088	46	32	dynamic	dynamic	ADJ
ajmri-3088	46	33	response	response	NOUN
ajmri-3088	46	34	and	and	CCONJ
ajmri-3088	46	35	the	the	DET
ajmri-3088	46	36	manner	manner	NOUN
ajmri-3088	46	37	in	in	ADP
ajmri-3088	46	38	which	which	PRON
ajmri-3088	46	39	it	it	PRON
ajmri-3088	46	40	affects	affect	VERB
ajmri-3088	46	41	the	the	DET
ajmri-3088	46	42	progression	progression	NOUN
ajmri-3088	46	43	of	of	ADP
ajmri-3088	46	44	the	the	DET
ajmri-3088	46	45	disease	disease	NOUN
ajmri-3088	46	46	(	(	PUNCT
ajmri-3088	46	47	zhang	zhang	PROPN
ajmri-3088	46	48	&	&	CCONJ
ajmri-3088	46	49	ruan	ruan	PROPN
ajmri-3088	46	50	,	,	PUNCT
ajmri-3088	46	51	2023	2023	NUM
ajmri-3088	46	52	)	)	PUNCT
ajmri-3088	46	53	.	.	PUNCT
ajmri-3088	47	1	four	four	NUM
ajmri-3088	47	2	prominent	prominent	ADJ
ajmri-3088	47	3	subpopulations	subpopulation	NOUN
ajmri-3088	47	4	—	—	PUNCT
ajmri-3088	47	5	cd4	cd4	PROPN
ajmri-3088	47	6	,	,	PUNCT
ajmri-3088	47	7	cd8	cd8	PROPN
ajmri-3088	47	8	,	,	PUNCT
ajmri-3088	47	9	cd45ro	cd45ro	NOUN
ajmri-3088	47	10	,	,	PUNCT
ajmri-3088	47	11	and	and	CCONJ
ajmri-3088	47	12	cd45ra	cd45ra	ADJ
ajmri-3088	47	13	—	—	PUNCT
ajmri-3088	47	14	offer	offer	VERB
ajmri-3088	47	15	significant	significant	ADJ
ajmri-3088	47	16	data	datum	NOUN
ajmri-3088	47	17	on	on	ADP
ajmri-3088	47	18	the	the	DET
ajmri-3088	47	19	immunological	immunological	ADJ
ajmri-3088	47	20	response	response	NOUN
ajmri-3088	47	21	’s	’s	PART
ajmri-3088	47	22	dynamics	dynamic	NOUN
ajmri-3088	47	23	.	.	PUNCT
ajmri-3088	48	1	however	however	ADV
ajmri-3088	48	2	,	,	PUNCT
ajmri-3088	48	3	prolonged	prolong	VERB
ajmri-3088	48	4	cd8	cd8	PROPN
ajmri-3088	48	5	t	t	PROPN
ajmri-3088	48	6	-	-	PUNCT
ajmri-3088	48	7	cell	cell	NOUN
ajmri-3088	48	8	activation	activation	NOUN
ajmri-3088	48	9	may	may	AUX
ajmri-3088	48	10	trigger	trigger	VERB
ajmri-3088	48	11	immunological	immunological	ADJ
ajmri-3088	48	12	exhaustion	exhaustion	NOUN
ajmri-3088	48	13	,	,	PUNCT
ajmri-3088	48	14	emphasizing	emphasize	VERB
ajmri-3088	48	15	the	the	DET
ajmri-3088	48	16	delicate	delicate	ADJ
ajmri-3088	48	17	balance	balance	NOUN
ajmri-3088	48	18	required	require	VERB
ajmri-3088	48	19	for	for	ADP
ajmri-3088	48	20	efficient	efficient	ADJ
ajmri-3088	48	21	immune	immune	ADJ
ajmri-3088	48	22	system	system	NOUN
ajmri-3088	48	23	regulation	regulation	NOUN
ajmri-3088	48	24	(	(	PUNCT
ajmri-3088	48	25	zhu	zhu	X
ajmri-3088	48	26	et	et	PROPN
ajmri-3088	48	27	al	al	PROPN
ajmri-3088	48	28	.	.	PROPN
ajmri-3088	48	29	,	,	PUNCT
ajmri-3088	48	30	2022	2022	NUM
ajmri-3088	48	31	)	)	PUNCT
ajmri-3088	48	32	.	.	PUNCT
ajmri-3088	49	1	t	t	NOUN
ajmri-3088	49	2	-	-	PUNCT
ajmri-3088	49	3	cell	cell	NOUN
ajmri-3088	49	4	populations	population	NOUN
ajmri-3088	49	5	are	be	AUX
ajmri-3088	49	6	represented	represent	VERB
ajmri-3088	49	7	by	by	ADP
ajmri-3088	49	8	cd45ra	cd45ra	NOUN
ajmri-3088	49	9	and	and	CCONJ
ajmri-3088	49	10	cd45ro	cd45ro	NOUN
ajmri-3088	49	11	,	,	PUNCT
ajmri-3088	49	12	which	which	PRON
ajmri-3088	49	13	stand	stand	VERB
ajmri-3088	49	14	for	for	ADP
ajmri-3088	49	15	naïve	naïve	ADJ
ajmri-3088	49	16	and	and	CCONJ
ajmri-3088	49	17	memory	memory	NOUN
ajmri-3088	49	18	,	,	PUNCT
ajmri-3088	49	19	respectively	respectively	ADV
ajmri-3088	49	20	.	.	PUNCT
ajmri-3088	50	1	the	the	DET
ajmri-3088	50	2	immunological	immunological	ADJ
ajmri-3088	50	3	response	response	NOUN
ajmri-3088	50	4	can	can	AUX
ajmri-3088	50	5	be	be	AUX
ajmri-3088	50	6	evaluated	evaluate	VERB
ajmri-3088	50	7	by	by	ADP
ajmri-3088	50	8	examining	examine	VERB
ajmri-3088	50	9	the	the	DET
ajmri-3088	50	10	ratio	ratio	NOUN
ajmri-3088	50	11	of	of	ADP
ajmri-3088	50	12	cd45ra	cd45ra	NOUN
ajmri-3088	50	13	to	to	ADP
ajmri-3088	50	14	cd45ro	cd45ro	NOUN
ajmri-3088	50	15	(	(	PUNCT
ajmri-3088	50	16	tang	tang	X
ajmri-3088	50	17	et	et	PROPN
ajmri-3088	50	18	al	al	PROPN
ajmri-3088	50	19	.	.	PROPN
ajmri-3088	50	20	,	,	PUNCT
ajmri-3088	50	21	2020	2020	NUM
ajmri-3088	50	22	)	)	PUNCT
ajmri-3088	50	23	.	.	PUNCT
ajmri-3088	51	1	while	while	SCONJ
ajmri-3088	51	2	an	an	DET
ajmri-3088	51	3	increase	increase	NOUN
ajmri-3088	51	4	in	in	ADP
ajmri-3088	51	5	cd45ro+	cd45ro+	PROPN
ajmri-3088	51	6	memory	memory	NOUN
ajmri-3088	51	7	t	t	PROPN
ajmri-3088	51	8	-	-	PUNCT
ajmri-3088	51	9	cells	cell	NOUN
ajmri-3088	51	10	indicates	indicate	VERB
ajmri-3088	51	11	heightened	heighten	VERB
ajmri-3088	51	12	immunological	immunological	ADJ
ajmri-3088	51	13	activation	activation	NOUN
ajmri-3088	51	14	,	,	PUNCT
ajmri-3088	51	15	the	the	DET
ajmri-3088	51	16	depletion	depletion	NOUN
ajmri-3088	51	17	of	of	ADP
ajmri-3088	51	18	cd45ra+	cd45ra+	PROPN
ajmri-3088	51	19	naïve	naïve	PROPN
ajmri-3088	51	20	t	t	PROPN
ajmri-3088	51	21	-	-	PUNCT
ajmri-3088	51	22	cells	cell	NOUN
ajmri-3088	51	23	impairs	impair	VERB
ajmri-3088	51	24	the	the	DET
ajmri-3088	51	25	development	development	NOUN
ajmri-3088	51	26	of	of	ADP
ajmri-3088	51	27	new	new	ADJ
ajmri-3088	51	28	immune	immune	ADJ
ajmri-3088	51	29	responses	response	NOUN
ajmri-3088	51	30	(	(	PUNCT
ajmri-3088	51	31	bono	bono	X
ajmri-3088	51	32	et	et	PROPN
ajmri-3088	51	33	al	al	PROPN
ajmri-3088	51	34	.	.	PROPN
ajmri-3088	51	35	,	,	PUNCT
ajmri-3088	51	36	2022	2022	NUM
ajmri-3088	51	37	)	)	PUNCT
ajmri-3088	51	38	.	.	PUNCT
ajmri-3088	52	1	it	it	PRON
ajmri-3088	52	2	is	be	AUX
ajmri-3088	52	3	necessary	necessary	ADJ
ajmri-3088	52	4	to	to	PART
ajmri-3088	52	5	keep	keep	VERB
ajmri-3088	52	6	these	these	DET
ajmri-3088	52	7	subgroups	subgroup	NOUN
ajmri-3088	52	8	under	under	ADP
ajmri-3088	52	9	continuous	continuous	ADJ
ajmri-3088	52	10	monitoring	monitoring	NOUN
ajmri-3088	52	11	,	,	PUNCT
ajmri-3088	52	12	determining	determine	VERB
ajmri-3088	52	13	the	the	DET
ajmri-3088	52	14	efficacy	efficacy	NOUN
ajmri-3088	52	15	of	of	ADP
ajmri-3088	52	16	treatment	treatment	NOUN
ajmri-3088	52	17	as	as	ADV
ajmri-3088	52	18	well	well	ADV
ajmri-3088	52	19	as	as	ADP
ajmri-3088	52	20	for	for	ADP
ajmri-3088	52	21	comprehending	comprehend	VERB
ajmri-3088	52	22	the	the	DET
ajmri-3088	52	23	direct	direct	ADJ
ajmri-3088	52	24	effects	effect	NOUN
ajmri-3088	52	25	of	of	ADP
ajmri-3088	52	26	hiv	hiv	PROPN
ajmri-3088	52	27	/	/	SYM
ajmri-3088	52	28	hbv	hbv	PROPN
ajmri-3088	52	29	coinfection	coinfection	NOUN
ajmri-3088	52	30	.	.	PUNCT
ajmri-3088	53	1	a	a	DET
ajmri-3088	53	2	balanced	balanced	ADJ
ajmri-3088	53	3	cd4	cd4	PROPN
ajmri-3088	53	4	/	/	SYM
ajmri-3088	53	5	cd8	cd8	PROPN
ajmri-3088	53	6	ratio	ratio	NOUN
ajmri-3088	53	7	and	and	CCONJ
ajmri-3088	53	8	the	the	DET
ajmri-3088	53	9	restoration	restoration	NOUN
ajmri-3088	53	10	of	of	ADP
ajmri-3088	53	11	cd4	cd4	PROPN
ajmri-3088	53	12	levels	level	NOUN
ajmri-3088	53	13	are	be	AUX
ajmri-3088	53	14	common	common	ADJ
ajmri-3088	53	15	indicators	indicator	NOUN
ajmri-3088	53	16	of	of	ADP
ajmri-3088	53	17	successful	successful	ADJ
ajmri-3088	53	18	art	art	NOUN
ajmri-3088	53	19	outcomes	outcome	NOUN
ajmri-3088	53	20	(	(	PUNCT
ajmri-3088	53	21	serrano	serrano	NOUN
ajmri-3088	53	22	-	-	PUNCT
ajmri-3088	53	23	villar	villar	PROPN
ajmri-3088	53	24	et	et	PROPN
ajmri-3088	53	25	al	al	PROPN
ajmri-3088	53	26	.	.	PROPN
ajmri-3088	53	27	,	,	PUNCT
ajmri-3088	53	28	2022	2022	NUM
ajmri-3088	53	29	)	)	PUNCT
ajmri-3088	53	30	.	.	PUNCT
ajmri-3088	54	1	hiv	hiv	PROPN
ajmri-3088	54	2	primarily	primarily	ADV
ajmri-3088	54	3	targets	target	VERB
ajmri-3088	54	4	cd4	cd4	PROPN
ajmri-3088	54	5	t	t	PROPN
ajmri-3088	54	6	-	-	PUNCT
ajmri-3088	54	7	cells	cell	NOUN
ajmri-3088	54	8	,	,	PUNCT
ajmri-3088	54	9	which	which	PRON
ajmri-3088	54	10	are	be	AUX
ajmri-3088	54	11	responsible	responsible	ADJ
ajmri-3088	54	12	for	for	ADP
ajmri-3088	54	13	managing	manage	VERB
ajmri-3088	54	14	the	the	DET
ajmri-3088	54	15	immunological	immunological	ADJ
ajmri-3088	54	16	response	response	NOUN
ajmri-3088	54	17	.	.	PUNCT
ajmri-3088	55	1	for	for	ADP
ajmri-3088	55	2	the	the	DET
ajmri-3088	55	3	purpose	purpose	NOUN
ajmri-3088	55	4	of	of	ADP
ajmri-3088	55	5	determining	determine	VERB
ajmri-3088	55	6	the	the	DET
ajmri-3088	55	7	severity	severity	NOUN
ajmri-3088	55	8	of	of	ADP
ajmri-3088	55	9	hiv	hiv	PROPN
ajmri-3088	55	10	infection	infection	NOUN
ajmri-3088	55	11	and	and	CCONJ
ajmri-3088	55	12	directing	direct	VERB
ajmri-3088	55	13	the	the	DET
ajmri-3088	55	14	start	start	NOUN
ajmri-3088	55	15	of	of	ADP
ajmri-3088	55	16	antiretroviral	antiretroviral	ADJ
ajmri-3088	55	17	therapy	therapy	NOUN
ajmri-3088	55	18	(	(	PUNCT
ajmri-3088	55	19	art	art	NOUN
ajmri-3088	55	20	)	)	PUNCT
ajmri-3088	55	21	,	,	PUNCT
ajmri-3088	55	22	it	it	PRON
ajmri-3088	55	23	is	be	AUX
ajmri-3088	55	24	imperative	imperative	ADJ
ajmri-3088	55	25	to	to	PART
ajmri-3088	55	26	monitor	monitor	VERB
ajmri-3088	55	27	their	their	PRON
ajmri-3088	55	28	levels	level	NOUN
ajmri-3088	55	29	.	.	PUNCT
ajmri-3088	56	1	a	a	DET
ajmri-3088	56	2	drop	drop	NOUN
ajmri-3088	56	3	in	in	ADP
ajmri-3088	56	4	cd4	cd4	PROPN
ajmri-3088	56	5	counts	count	NOUN
ajmri-3088	56	6	indicates	indicate	VERB
ajmri-3088	56	7	weakened	weaken	VERB
ajmri-3088	56	8	immunity	immunity	NOUN
ajmri-3088	56	9	,	,	PUNCT
ajmri-3088	56	10	which	which	PRON
ajmri-3088	56	11	makes	make	VERB
ajmri-3088	56	12	it	it	PRON
ajmri-3088	56	13	a	a	DET
ajmri-3088	56	14	crucial	crucial	ADJ
ajmri-3088	56	15	factor	factor	NOUN
ajmri-3088	56	16	in	in	ADP
ajmri-3088	56	17	hiv	hiv	PROPN
ajmri-3088	56	18	management	management	NOUN
ajmri-3088	56	19	(	(	PUNCT
ajmri-3088	56	20	perez	perez	PROPN
ajmri-3088	56	21	-	-	PUNCT
ajmri-3088	56	22	molina	molina	PROPN
ajmri-3088	56	23	et	et	PROPN
ajmri-3088	56	24	al	al	PROPN
ajmri-3088	56	25	.	.	PROPN
ajmri-3088	56	26	,	,	PUNCT
ajmri-3088	56	27	2023	2023	NUM
ajmri-3088	56	28	)	)	PUNCT
ajmri-3088	56	29	.	.	PUNCT
ajmri-3088	57	1	however	however	ADV
ajmri-3088	57	2	,	,	PUNCT
ajmri-3088	57	3	cd8	cd8	PROPN
ajmri-3088	57	4	t	t	PROPN
ajmri-3088	57	5	-	-	PUNCT
ajmri-3088	57	6	cells	cell	NOUN
ajmri-3088	57	7	are	be	AUX
ajmri-3088	57	8	essential	essential	ADJ
ajmri-3088	57	9	for	for	ADP
ajmri-3088	57	10	inhibiting	inhibit	VERB
ajmri-3088	57	11	the	the	DET
ajmri-3088	57	12	spread	spread	NOUN
ajmri-3088	57	13	of	of	ADP
ajmri-3088	57	14	viruses	virus	NOUN
ajmri-3088	57	15	.	.	PUNCT
ajmri-3088	58	1	during	during	ADP
ajmri-3088	58	2	the	the	DET
ajmri-3088	58	3	chronic	chronic	ADJ
ajmri-3088	58	4	phase	phase	NOUN
ajmri-3088	58	5	of	of	ADP
ajmri-3088	58	6	hiv	hiv	PROPN
ajmri-3088	58	7	infection	infection	NOUN
ajmri-3088	58	8	,	,	PUNCT
ajmri-3088	58	9	elevated	elevated	ADJ
ajmri-3088	58	10	cd8	cd8	PROPN
ajmri-3088	58	11	counts	count	NOUN
ajmri-3088	58	12	are	be	AUX
ajmri-3088	58	13	frequently	frequently	ADV
ajmri-3088	58	14	seen	see	VERB
ajmri-3088	58	15	,	,	PUNCT
ajmri-3088	58	16	suggesting	suggest	VERB
ajmri-3088	58	17	an	an	DET
ajmri-3088	58	18	augmented	augment	VERB
ajmri-3088	58	19	immunological	immunological	ADJ
ajmri-3088	58	20	response	response	NOUN
ajmri-3088	58	21	.	.	PUNCT
ajmri-3088	59	1	furthermore	furthermore	ADV
ajmri-3088	59	2	,	,	PUNCT
ajmri-3088	59	3	monitoring	monitor	VERB
ajmri-3088	59	4	cd45ro+	cd45ro+	VERB
ajmri-3088	59	5	memory	memory	NOUN
ajmri-3088	59	6	t	t	PROPN
ajmri-3088	59	7	-	-	PUNCT
ajmri-3088	59	8	cells	cell	NOUN
ajmri-3088	59	9	influences	influence	VERB
ajmri-3088	59	10	the	the	DET
ajmri-3088	59	11	long	long	ADJ
ajmri-3088	59	12	-	-	PUNCT
ajmri-3088	59	13	term	term	NOUN
ajmri-3088	59	14	health	health	NOUN
ajmri-3088	59	15	outcomes	outcome	NOUN
ajmri-3088	59	16	of	of	ADP
ajmri-3088	59	17	coinfected	coinfecte	VERB
ajmri-3088	59	18	patients	patient	NOUN
ajmri-3088	59	19	by	by	ADP
ajmri-3088	59	20	assessing	assess	VERB
ajmri-3088	59	21	the	the	DET
ajmri-3088	59	22	effectiveness	effectiveness	NOUN
ajmri-3088	59	23	of	of	ADP
ajmri-3088	59	24	immune	immune	ADJ
ajmri-3088	59	25	reconstitution	reconstitution	NOUN
ajmri-3088	59	26	.	.	PUNCT
ajmri-3088	60	1	thus	thus	ADV
ajmri-3088	60	2	,	,	PUNCT
ajmri-3088	60	3	an	an	DET
ajmri-3088	60	4	extensive	extensive	ADJ
ajmri-3088	60	5	comprehension	comprehension	NOUN
ajmri-3088	60	6	of	of	ADP
ajmri-3088	60	7	the	the	DET
ajmri-3088	60	8	host	host	NOUN
ajmri-3088	60	9	’s	’s	PART
ajmri-3088	60	10	immune	immune	ADJ
ajmri-3088	60	11	response	response	NOUN
ajmri-3088	60	12	in	in	ADP
ajmri-3088	60	13	the	the	DET
ajmri-3088	60	14	context	context	NOUN
ajmri-3088	60	15	of	of	ADP
ajmri-3088	60	16	coinfection	coinfection	NOUN
ajmri-3088	60	17	with	with	ADP
ajmri-3088	60	18	hiv	hiv	PROPN
ajmri-3088	60	19	and	and	CCONJ
ajmri-3088	60	20	hbv	hbv	NOUN
ajmri-3088	60	21	is	be	AUX
ajmri-3088	60	22	provided	provide	VERB
ajmri-3088	60	23	by	by	ADP
ajmri-3088	60	24	the	the	DET
ajmri-3088	60	25	thorough	thorough	ADJ
ajmri-3088	60	26	investigation	investigation	NOUN
ajmri-3088	60	27	of	of	ADP
ajmri-3088	60	28	lymphocyte	lymphocyte	ADJ
ajmri-3088	60	29	subpopulations	subpopulation	NOUN
ajmri-3088	60	30	.	.	PUNCT
ajmri-3088	61	1	in	in	ADP
ajmri-3088	61	2	this	this	DET
ajmri-3088	61	3	highly	highly	ADV
ajmri-3088	61	4	complicated	complicated	ADJ
ajmri-3088	61	5	situation	situation	NOUN
ajmri-3088	61	6	,	,	PUNCT
ajmri-3088	61	7	this	this	DET
ajmri-3088	61	8	knowledge	knowledge	NOUN
ajmri-3088	61	9	aids	aid	VERB
ajmri-3088	61	10	in	in	ADP
ajmri-3088	61	11	developing	develop	VERB
ajmri-3088	61	12	targeted	target	VERB
ajmri-3088	61	13	therapies	therapy	NOUN
ajmri-3088	61	14	and	and	CCONJ
ajmri-3088	61	15	targeted	target	VERB
ajmri-3088	61	16	therapeutic	therapeutic	ADJ
ajmri-3088	61	17	techniques	technique	NOUN
ajmri-3088	61	18	,	,	PUNCT
ajmri-3088	61	19	eventually	eventually	ADV
ajmri-3088	61	20	improving	improve	VERB
ajmri-3088	61	21	patient	patient	ADJ
ajmri-3088	61	22	outcomes	outcome	NOUN
ajmri-3088	61	23	.	.	PUNCT
ajmri-3088	62	1	materials	material	NOUN
ajmri-3088	62	2	and	and	CCONJ
ajmri-3088	62	3	methods	method	NOUN
ajmri-3088	62	4	sample	sample	NOUN
ajmri-3088	62	5	collection	collection	NOUN
ajmri-3088	62	6	the	the	DET
ajmri-3088	62	7	study	study	NOUN
ajmri-3088	62	8	comprises	comprise	VERB
ajmri-3088	62	9	35	35	NUM
ajmri-3088	62	10	peripheral	peripheral	ADJ
ajmri-3088	62	11	blood	blood	NOUN
ajmri-3088	62	12	samples	sample	NOUN
ajmri-3088	62	13	collected	collect	VERB
ajmri-3088	62	14	from	from	ADP
ajmri-3088	62	15	two	two	NUM
ajmri-3088	62	16	hospitals	hospital	NOUN
ajmri-3088	62	17	in	in	ADP
ajmri-3088	62	18	cairo	cairo	PROPN
ajmri-3088	62	19	,	,	PUNCT
ajmri-3088	62	20	egypt	egypt	PROPN
ajmri-3088	62	21	,	,	PUNCT
ajmri-3088	62	22	and	and	CCONJ
ajmri-3088	62	23	samples	sample	NOUN
ajmri-3088	62	24	of	of	ADP
ajmri-3088	62	25	infants	infant	NOUN
ajmri-3088	62	26	were	be	AUX
ajmri-3088	62	27	collected	collect	VERB
ajmri-3088	62	28	from	from	ADP
ajmri-3088	62	29	two	two	NUM
ajmri-3088	62	30	maternity	maternity	NOUN
ajmri-3088	62	31	centers	center	NOUN
ajmri-3088	62	32	.	.	PUNCT
ajmri-3088	63	1	all	all	DET
ajmri-3088	63	2	cryopreserved	cryopreserved	ADJ
ajmri-3088	63	3	and	and	CCONJ
ajmri-3088	63	4	fresh	fresh	ADJ
ajmri-3088	63	5	blood	blood	NOUN
ajmri-3088	63	6	samples	sample	NOUN
ajmri-3088	63	7	were	be	AUX
ajmri-3088	63	8	drawn	draw	VERB
ajmri-3088	63	9	from	from	ADP
ajmri-3088	63	10	patients	patient	NOUN
ajmri-3088	63	11	who	who	PRON
ajmri-3088	63	12	tested	test	VERB
ajmri-3088	63	13	positive	positive	ADJ
ajmri-3088	63	14	for	for	ADP
ajmri-3088	63	15	hiv	hiv	PROPN
ajmri-3088	63	16	and	and	CCONJ
ajmri-3088	63	17	hbv	hbv	NOUN
ajmri-3088	63	18	.	.	PUNCT
ajmri-3088	64	1	all	all	DET
ajmri-3088	64	2	concerned	concerned	ADJ
ajmri-3088	64	3	parties	party	NOUN
ajmri-3088	64	4	were	be	AUX
ajmri-3088	64	5	well	well	ADV
ajmri-3088	64	6	informed	inform	VERB
ajmri-3088	64	7	about	about	ADP
ajmri-3088	64	8	the	the	DET
ajmri-3088	64	9	study	study	NOUN
ajmri-3088	64	10	,	,	PUNCT
ajmri-3088	64	11	and	and	CCONJ
ajmri-3088	64	12	samples	sample	NOUN
ajmri-3088	64	13	were	be	AUX
ajmri-3088	64	14	only	only	ADV
ajmri-3088	64	15	included	include	VERB
ajmri-3088	64	16	in	in	ADP
ajmri-3088	64	17	the	the	DET
ajmri-3088	64	18	study	study	NOUN
ajmri-3088	64	19	after	after	ADP
ajmri-3088	64	20	receiving	receive	VERB
ajmri-3088	64	21	proper	proper	ADJ
ajmri-3088	64	22	consent	consent	NOUN
ajmri-3088	64	23	.	.	PUNCT
ajmri-3088	65	1	serological	serological	ADJ
ajmri-3088	65	2	assessment	assessment	NOUN
ajmri-3088	65	3	all	all	DET
ajmri-3088	65	4	hiv	hiv	PROPN
ajmri-3088	65	5	-	-	PUNCT
ajmri-3088	65	6	positive	positive	ADJ
ajmri-3088	65	7	peripheral	peripheral	ADJ
ajmri-3088	65	8	blood	blood	NOUN
ajmri-3088	65	9	samples	sample	NOUN
ajmri-3088	65	10	were	be	AUX
ajmri-3088	65	11	tested	test	VERB
ajmri-3088	65	12	for	for	ADP
ajmri-3088	65	13	the	the	DET
ajmri-3088	65	14	presence	presence	NOUN
ajmri-3088	65	15	of	of	ADP
ajmri-3088	65	16	hbv	hbv	NOUN
ajmri-3088	65	17	surface	surface	NOUN
ajmri-3088	65	18	antigen	antigen	NOUN
ajmri-3088	65	19	(	(	PUNCT
ajmri-3088	65	20	hbsag	hbsag	NOUN
ajmri-3088	65	21	)	)	PUNCT
ajmri-3088	65	22	to	to	PART
ajmri-3088	65	23	identify	identify	VERB
ajmri-3088	65	24	the	the	DET
ajmri-3088	65	25	presence	presence	NOUN
ajmri-3088	65	26	of	of	ADP
ajmri-3088	65	27	hiv	hiv	PROPN
ajmri-3088	65	28	/	/	SYM
ajmri-3088	65	29	hbv	hbv	NOUN
ajmri-3088	65	30	coinfection	coinfection	NOUN
ajmri-3088	65	31	with	with	ADP
ajmri-3088	65	32	the	the	DET
ajmri-3088	65	33	help	help	NOUN
ajmri-3088	65	34	of	of	ADP
ajmri-3088	65	35	commercial	commercial	ADJ
ajmri-3088	65	36	enzyme	enzyme	NOUN
ajmri-3088	65	37	-	-	PUNCT
ajmri-3088	65	38	linked	link	VERB
ajmri-3088	65	39	immunosorbent	immunosorbent	NOUN
ajmri-3088	65	40	assay	assay	PROPN
ajmri-3088	65	41	(	(	PUNCT
ajmri-3088	65	42	elisa	elisa	NOUN
ajmri-3088	65	43	)	)	PUNCT
ajmri-3088	65	44	kits	kit	NOUN
ajmri-3088	65	45	(	(	PUNCT
ajmri-3088	65	46	kehua	kehua	PROPN
ajmri-3088	65	47	biotech	biotech	NOUN
ajmri-3088	65	48	,	,	PUNCT
ajmri-3088	65	49	shanghai	shanghai	PROPN
ajmri-3088	65	50	,	,	PUNCT
ajmri-3088	65	51	china	china	PROPN
ajmri-3088	65	52	)	)	PUNCT
ajmri-3088	65	53	as	as	ADP
ajmri-3088	65	54	per	per	ADP
ajmri-3088	65	55	manufacturer	manufacturer	NOUN
ajmri-3088	65	56	instructions	instruction	NOUN
ajmri-3088	65	57	(	(	PUNCT
ajmri-3088	65	58	cai	cai	X
ajmri-3088	65	59	et	et	PROPN
ajmri-3088	65	60	al	al	PROPN
ajmri-3088	65	61	.	.	PROPN
ajmri-3088	65	62	,	,	PUNCT
ajmri-3088	65	63	2023	2023	NUM
ajmri-3088	65	64	)	)	PUNCT
ajmri-3088	65	65	.	.	PUNCT
ajmri-3088	66	1	the	the	DET
ajmri-3088	66	2	same	same	ADJ
ajmri-3088	66	3	protocol	protocol	NOUN
ajmri-3088	66	4	was	be	AUX
ajmri-3088	66	5	followed	follow	VERB
ajmri-3088	66	6	for	for	ADP
ajmri-3088	66	7	hbv	hbv	NOUN
ajmri-3088	66	8	-	-	PUNCT
ajmri-3088	66	9	positive	positive	ADJ
ajmri-3088	66	10	samples	sample	NOUN
ajmri-3088	66	11	;	;	PUNCT
ajmri-3088	66	12	they	they	PRON
ajmri-3088	66	13	were	be	AUX
ajmri-3088	66	14	tested	test	VERB
ajmri-3088	66	15	to	to	PART
ajmri-3088	66	16	identify	identify	VERB
ajmri-3088	66	17	the	the	DET
ajmri-3088	66	18	presence	presence	NOUN
ajmri-3088	66	19	of	of	ADP
ajmri-3088	66	20	gp120	gp120	PROPN
ajmri-3088	66	21	,	,	PUNCT
ajmri-3088	66	22	a	a	DET
ajmri-3088	66	23	glycoprotein	glycoprotein	NOUN
ajmri-3088	66	24	marker	marker	NOUN
ajmri-3088	66	25	for	for	ADP
ajmri-3088	66	26	the	the	DET
ajmri-3088	66	27	presence	presence	NOUN
ajmri-3088	66	28	of	of	ADP
ajmri-3088	66	29	hiv	hiv	PROPN
ajmri-3088	66	30	.	.	PUNCT
ajmri-3088	67	1	the	the	DET
ajmri-3088	67	2	samples	sample	NOUN
ajmri-3088	67	3	were	be	AUX
ajmri-3088	67	4	then	then	ADV
ajmri-3088	67	5	pa	pa	PROPN
ajmri-3088	67	6	ge	ge	PROPN
ajmri-3088	67	7	52	52	NUM
ajmri-3088	67	8	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	67	9	am	am	NOUN
ajmri-3088	67	10	.	.	PUNCT
ajmri-3088	68	1	j.	j.	PROPN
ajmri-3088	68	2	multidis	multidis	PROPN
ajmri-3088	68	3	.	.	PUNCT
ajmri-3088	69	1	res	re	NOUN
ajmri-3088	69	2	.	.	PUNCT
ajmri-3088	70	1	innov	innov	PROPN
ajmri-3088	70	2	.	.	PUNCT
ajmri-3088	71	1	3(5	3(5	NUM
ajmri-3088	71	2	)	)	PUNCT
ajmri-3088	71	3	50	50	NUM
ajmri-3088	71	4	-	-	SYM
ajmri-3088	71	5	60	60	NUM
ajmri-3088	71	6	,	,	PUNCT
ajmri-3088	71	7	2024	2024	NUM
ajmri-3088	71	8	purified	purify	VERB
ajmri-3088	71	9	to	to	PART
ajmri-3088	71	10	extract	extract	VERB
ajmri-3088	71	11	lymphocyte	lymphocyte	ADJ
ajmri-3088	71	12	subpopulations	subpopulation	NOUN
ajmri-3088	71	13	.	.	PUNCT
ajmri-3088	72	1	this	this	PRON
ajmri-3088	72	2	was	be	AUX
ajmri-3088	72	3	done	do	VERB
ajmri-3088	72	4	with	with	ADP
ajmri-3088	72	5	the	the	DET
ajmri-3088	72	6	help	help	NOUN
ajmri-3088	72	7	of	of	ADP
ajmri-3088	72	8	microfluidic	microfluidic	ADJ
ajmri-3088	72	9	inertial	inertial	ADJ
ajmri-3088	72	10	separation	separation	NOUN
ajmri-3088	72	11	.	.	PUNCT
ajmri-3088	73	1	anticoagulants	anticoagulant	NOUN
ajmri-3088	73	2	are	be	AUX
ajmri-3088	73	3	added	add	VERB
ajmri-3088	73	4	to	to	ADP
ajmri-3088	73	5	retrieved	retrieve	VERB
ajmri-3088	73	6	cryopreserved	cryopreserve	VERB
ajmri-3088	73	7	whole	whole	ADJ
ajmri-3088	73	8	blood	blood	NOUN
ajmri-3088	73	9	samples	sample	NOUN
ajmri-3088	73	10	to	to	PART
ajmri-3088	73	11	prevent	prevent	VERB
ajmri-3088	73	12	coagulation	coagulation	NOUN
ajmri-3088	73	13	.	.	PUNCT
ajmri-3088	74	1	the	the	DET
ajmri-3088	74	2	next	next	ADJ
ajmri-3088	74	3	step	step	NOUN
ajmri-3088	74	4	is	be	AUX
ajmri-3088	74	5	to	to	PART
ajmri-3088	74	6	set	set	VERB
ajmri-3088	74	7	up	up	ADP
ajmri-3088	74	8	the	the	DET
ajmri-3088	74	9	microfluidic	microfluidic	ADJ
ajmri-3088	74	10	device	device	NOUN
ajmri-3088	74	11	for	for	ADP
ajmri-3088	74	12	the	the	DET
ajmri-3088	74	13	separation	separation	NOUN
ajmri-3088	74	14	of	of	ADP
ajmri-3088	74	15	lymphocyte	lymphocyte	ADJ
ajmri-3088	74	16	subpopulation	subpopulation	NOUN
ajmri-3088	74	17	.	.	PUNCT
ajmri-3088	75	1	this	this	DET
ajmri-3088	75	2	device	device	NOUN
ajmri-3088	75	3	has	have	VERB
ajmri-3088	75	4	the	the	DET
ajmri-3088	75	5	properties	property	NOUN
ajmri-3088	75	6	of	of	ADP
ajmri-3088	75	7	an	an	DET
ajmri-3088	75	8	inertial	inertial	ADJ
ajmri-3088	75	9	spiral	spiral	ADJ
ajmri-3088	75	10	design	design	NOUN
ajmri-3088	75	11	,	,	PUNCT
ajmri-3088	75	12	which	which	PRON
ajmri-3088	75	13	can	can	AUX
ajmri-3088	75	14	efficiently	efficiently	ADV
ajmri-3088	75	15	extract	extract	VERB
ajmri-3088	75	16	lymphocyte	lymphocyte	ADJ
ajmri-3088	75	17	subpopulations	subpopulation	NOUN
ajmri-3088	75	18	.	.	PUNCT
ajmri-3088	76	1	the	the	DET
ajmri-3088	76	2	whole	whole	ADJ
ajmri-3088	76	3	blood	blood	NOUN
ajmri-3088	76	4	sample	sample	NOUN
ajmri-3088	76	5	containing	contain	VERB
ajmri-3088	76	6	erythrocytes	erythrocyte	NOUN
ajmri-3088	76	7	,	,	PUNCT
ajmri-3088	76	8	lymphocytes	lymphocyte	NOUN
ajmri-3088	76	9	,	,	PUNCT
ajmri-3088	76	10	and	and	CCONJ
ajmri-3088	76	11	other	other	ADJ
ajmri-3088	76	12	blood	blood	NOUN
ajmri-3088	76	13	components	component	NOUN
ajmri-3088	76	14	was	be	AUX
ajmri-3088	76	15	injected	inject	VERB
ajmri-3088	76	16	through	through	ADP
ajmri-3088	76	17	the	the	DET
ajmri-3088	76	18	inlet	inlet	NOUN
ajmri-3088	76	19	into	into	ADP
ajmri-3088	76	20	the	the	DET
ajmri-3088	76	21	microfluidic	microfluidic	ADJ
ajmri-3088	76	22	device	device	NOUN
ajmri-3088	76	23	.	.	PUNCT
ajmri-3088	77	1	different	different	ADJ
ajmri-3088	77	2	-	-	PUNCT
ajmri-3088	77	3	sized	sized	ADJ
ajmri-3088	77	4	cells	cell	NOUN
ajmri-3088	77	5	separate	separate	ADJ
ajmri-3088	77	6	in	in	ADP
ajmri-3088	77	7	microfluidic	microfluidic	ADJ
ajmri-3088	77	8	channels	channel	NOUN
ajmri-3088	77	9	due	due	ADP
ajmri-3088	77	10	to	to	ADP
ajmri-3088	77	11	inertial	inertial	ADJ
ajmri-3088	77	12	forces	force	NOUN
ajmri-3088	77	13	.	.	PUNCT
ajmri-3088	78	1	lymphocytes	lymphocyte	NOUN
ajmri-3088	78	2	fall	fall	VERB
ajmri-3088	78	3	into	into	ADP
ajmri-3088	78	4	a	a	DET
ajmri-3088	78	5	particular	particular	ADJ
ajmri-3088	78	6	size	size	NOUN
ajmri-3088	78	7	range	range	NOUN
ajmri-3088	78	8	and	and	CCONJ
ajmri-3088	78	9	travel	travel	VERB
ajmri-3088	78	10	to	to	ADP
ajmri-3088	78	11	a	a	DET
ajmri-3088	78	12	collection	collection	NOUN
ajmri-3088	78	13	chamber	chamber	NOUN
ajmri-3088	78	14	from	from	ADP
ajmri-3088	78	15	where	where	SCONJ
ajmri-3088	78	16	they	they	PRON
ajmri-3088	78	17	are	be	AUX
ajmri-3088	78	18	collected	collect	VERB
ajmri-3088	78	19	.	.	PUNCT
ajmri-3088	79	1	lymphocyte	lymphocyte	ADJ
ajmri-3088	79	2	subpopulation	subpopulation	NOUN
ajmri-3088	79	3	extraction	extraction	NOUN
ajmri-3088	79	4	peripheral	peripheral	ADJ
ajmri-3088	79	5	blood	blood	NOUN
ajmri-3088	79	6	mononuclear	mononuclear	ADJ
ajmri-3088	79	7	cells	cell	NOUN
ajmri-3088	79	8	were	be	AUX
ajmri-3088	79	9	separated	separate	VERB
ajmri-3088	79	10	,	,	PUNCT
ajmri-3088	79	11	and	and	CCONJ
ajmri-3088	79	12	preserved	preserve	VERB
ajmri-3088	79	13	blood	blood	NOUN
ajmri-3088	79	14	was	be	AUX
ajmri-3088	79	15	collected	collect	VERB
ajmri-3088	79	16	with	with	ADP
ajmri-3088	79	17	the	the	DET
ajmri-3088	79	18	help	help	NOUN
ajmri-3088	79	19	of	of	ADP
ajmri-3088	79	20	density	density	NOUN
ajmri-3088	79	21	gradient	gradient	NOUN
ajmri-3088	79	22	centrifugation	centrifugation	NOUN
ajmri-3088	79	23	using	use	VERB
ajmri-3088	79	24	ficoll	ficoll	NOUN
ajmri-3088	79	25	-	-	PUNCT
ajmri-3088	79	26	paque	paque	PROPN
ajmri-3088	79	27	plus	plus	CCONJ
ajmri-3088	79	28	density	density	NOUN
ajmri-3088	79	29	gradient	gradient	NOUN
ajmri-3088	79	30	media	medium	NOUN
ajmri-3088	79	31	.	.	PUNCT
ajmri-3088	80	1	once	once	ADV
ajmri-3088	80	2	pbmc	pbmc	NOUN
ajmri-3088	80	3	was	be	AUX
ajmri-3088	80	4	isolated	isolate	VERB
ajmri-3088	80	5	,	,	PUNCT
ajmri-3088	80	6	lymphocyte	lymphocyte	ADJ
ajmri-3088	80	7	subsets	subset	NOUN
ajmri-3088	80	8	were	be	AUX
ajmri-3088	80	9	isolated	isolate	VERB
ajmri-3088	80	10	.	.	PUNCT
ajmri-3088	81	1	cd4	cd4	PROPN
ajmri-3088	81	2	+	+	NOUN
ajmri-3088	81	3	cells	cell	NOUN
ajmri-3088	81	4	were	be	AUX
ajmri-3088	81	5	isolated	isolate	VERB
ajmri-3088	81	6	with	with	ADP
ajmri-3088	81	7	the	the	DET
ajmri-3088	81	8	help	help	NOUN
ajmri-3088	81	9	of	of	ADP
ajmri-3088	81	10	an	an	DET
ajmri-3088	81	11	isolation	isolation	NOUN
ajmri-3088	81	12	kit	kit	NOUN
ajmri-3088	81	13	for	for	ADP
ajmri-3088	81	14	cd4	cd4	PROPN
ajmri-3088	81	15	+	+	CCONJ
ajmri-3088	81	16	(	(	PUNCT
ajmri-3088	81	17	miltenyi	miltenyi	PROPN
ajmri-3088	81	18	,	,	PUNCT
ajmri-3088	81	19	bergisch	bergisch	PRON
ajmri-3088	81	20	gladbach	gladbach	PROPN
ajmri-3088	81	21	,	,	PUNCT
ajmri-3088	81	22	germany	germany	PROPN
ajmri-3088	81	23	)	)	PUNCT
ajmri-3088	81	24	.	.	PUNCT
ajmri-3088	82	1	cd8	cd8	PROPN
ajmri-3088	82	2	+	+	PROPN
ajmri-3088	82	3	subpopulation	subpopulation	NOUN
ajmri-3088	82	4	was	be	AUX
ajmri-3088	82	5	isolated	isolate	VERB
ajmri-3088	82	6	with	with	ADP
ajmri-3088	82	7	the	the	DET
ajmri-3088	82	8	help	help	NOUN
ajmri-3088	82	9	of	of	ADP
ajmri-3088	82	10	an	an	DET
ajmri-3088	82	11	immunomagnetic	immunomagnetic	ADJ
ajmri-3088	82	12	,	,	PUNCT
ajmri-3088	82	13	column	column	NOUN
ajmri-3088	82	14	-	-	PUNCT
ajmri-3088	82	15	free	free	ADJ
ajmri-3088	82	16	cell	cell	NOUN
ajmri-3088	82	17	separation	separation	NOUN
ajmri-3088	82	18	(	(	PUNCT
ajmri-3088	82	19	easysep	easysep	PROPN
ajmri-3088	82	20	™	™	NOUN
ajmri-3088	82	21	)	)	PUNCT
ajmri-3088	82	22	kit	kit	NOUN
ajmri-3088	82	23	.	.	PUNCT
ajmri-3088	83	1	the	the	DET
ajmri-3088	83	2	remaining	remain	VERB
ajmri-3088	83	3	subsets	subset	NOUN
ajmri-3088	83	4	,	,	PUNCT
ajmri-3088	83	5	including	include	VERB
ajmri-3088	83	6	cd45ro	cd45ro	NOUN
ajmri-3088	83	7	,	,	PUNCT
ajmri-3088	83	8	cd16	cd16	PROPN
ajmri-3088	83	9	+	+	PROPN
ajmri-3088	83	10	56	56	NUM
ajmri-3088	83	11	,	,	PUNCT
ajmri-3088	83	12	and	and	CCONJ
ajmri-3088	83	13	cd45ra	cd45ra	NOUN
ajmri-3088	83	14	,	,	PUNCT
ajmri-3088	83	15	were	be	AUX
ajmri-3088	83	16	extracted	extract	VERB
ajmri-3088	83	17	by	by	ADP
ajmri-3088	83	18	the	the	DET
ajmri-3088	83	19	lymphoprep	lymphoprep	ADJ
ajmri-3088	83	20	method	method	NOUN
ajmri-3088	83	21	.	.	PUNCT
ajmri-3088	84	1	immunophenotyping	immunophenotype	VERB
ajmri-3088	84	2	of	of	ADP
ajmri-3088	84	3	lymphocyte	lymphocyte	ADJ
ajmri-3088	84	4	subsets	subset	NOUN
ajmri-3088	84	5	the	the	DET
ajmri-3088	84	6	immunophenotyping	immunophenotyping	NOUN
ajmri-3088	84	7	of	of	ADP
ajmri-3088	84	8	isolated	isolated	ADJ
ajmri-3088	84	9	subsets	subset	NOUN
ajmri-3088	84	10	of	of	ADP
ajmri-3088	84	11	lymphocytes	lymphocyte	NOUN
ajmri-3088	84	12	was	be	AUX
ajmri-3088	84	13	done	do	VERB
ajmri-3088	84	14	using	use	VERB
ajmri-3088	84	15	the	the	DET
ajmri-3088	84	16	facs	fac	NOUN
ajmri-3088	84	17	canto	canto	PROPN
ajmri-3088	84	18	-	-	PUNCT
ajmri-3088	84	19	ii	ii	PROPN
ajmri-3088	84	20	flow	flow	NOUN
ajmri-3088	84	21	cytometer	cytometer	NOUN
ajmri-3088	84	22	.	.	PUNCT
ajmri-3088	85	1	the	the	DET
ajmri-3088	85	2	subsets	subset	NOUN
ajmri-3088	85	3	of	of	ADP
ajmri-3088	85	4	lymphocytes	lymphocyte	NOUN
ajmri-3088	85	5	,	,	PUNCT
ajmri-3088	85	6	including	include	VERB
ajmri-3088	85	7	cd4	cd4	PROPN
ajmri-3088	85	8	+	+	PROPN
ajmri-3088	85	9	,	,	PUNCT
ajmri-3088	85	10	cd8	cd8	PROPN
ajmri-3088	85	11	+	+	PROPN
ajmri-3088	85	12	,	,	PUNCT
ajmri-3088	85	13	cd45ro	cd45ro	NOUN
ajmri-3088	85	14	,	,	PUNCT
ajmri-3088	85	15	cd16	cd16	PROPN
ajmri-3088	85	16	+	+	PROPN
ajmri-3088	85	17	56	56	NUM
ajmri-3088	85	18	,	,	PUNCT
ajmri-3088	85	19	and	and	CCONJ
ajmri-3088	85	20	cd45ra	cd45ra	ADJ
ajmri-3088	85	21	,	,	PUNCT
ajmri-3088	85	22	were	be	AUX
ajmri-3088	85	23	immune	immune	NOUN
ajmri-3088	85	24	-	-	PUNCT
ajmri-3088	85	25	labeled	label	VERB
ajmri-3088	85	26	with	with	ADP
ajmri-3088	85	27	the	the	DET
ajmri-3088	85	28	help	help	NOUN
ajmri-3088	85	29	of	of	ADP
ajmri-3088	85	30	monoclonal	monoclonal	NOUN
ajmri-3088	85	31	antibodies	antibodie	VERB
ajmri-3088	85	32	.	.	PUNCT
ajmri-3088	86	1	the	the	DET
ajmri-3088	86	2	cells	cell	NOUN
ajmri-3088	86	3	were	be	AUX
ajmri-3088	86	4	first	first	ADV
ajmri-3088	86	5	washed	wash	VERB
ajmri-3088	86	6	with	with	ADP
ajmri-3088	86	7	a	a	DET
ajmri-3088	86	8	staining	stain	VERB
ajmri-3088	86	9	buffer	buffer	NOUN
ajmri-3088	86	10	and	and	CCONJ
ajmri-3088	86	11	were	be	AUX
ajmri-3088	86	12	then	then	ADV
ajmri-3088	86	13	incubated	incubate	VERB
ajmri-3088	86	14	with	with	ADP
ajmri-3088	86	15	fluorescent	fluorescent	NOUN
ajmri-3088	86	16	-	-	PUNCT
ajmri-3088	86	17	labeled	label	VERB
ajmri-3088	86	18	monoclonal	monoclonal	NOUN
ajmri-3088	86	19	antibodies	antibody	NOUN
ajmri-3088	86	20	for	for	ADP
ajmri-3088	86	21	15	15	NUM
ajmri-3088	86	22	minutes	minute	NOUN
ajmri-3088	86	23	.	.	PUNCT
ajmri-3088	87	1	each	each	DET
ajmri-3088	87	2	antibody	antibody	NOUN
ajmri-3088	87	3	was	be	AUX
ajmri-3088	87	4	labeled	label	VERB
ajmri-3088	87	5	with	with	ADP
ajmri-3088	87	6	a	a	DET
ajmri-3088	87	7	different	different	ADJ
ajmri-3088	87	8	fluorescence	fluorescence	NOUN
ajmri-3088	87	9	dye	dye	NOUN
ajmri-3088	87	10	,	,	PUNCT
ajmri-3088	87	11	mainly	mainly	ADV
ajmri-3088	87	12	with	with	ADP
ajmri-3088	87	13	fluorescein	fluorescein	ADJ
ajmri-3088	87	14	isothiocyanate	isothiocyanate	NOUN
ajmri-3088	87	15	(	(	PUNCT
ajmri-3088	87	16	fitc	fitc	PROPN
ajmri-3088	87	17	)	)	PUNCT
ajmri-3088	87	18	,	,	PUNCT
ajmri-3088	87	19	phycoerythrin	phycoerythrin	NOUN
ajmri-3088	87	20	(	(	PUNCT
ajmri-3088	87	21	pe	pe	NOUN
ajmri-3088	87	22	)	)	PUNCT
ajmri-3088	87	23	,	,	PUNCT
ajmri-3088	87	24	and	and	CCONJ
ajmri-3088	87	25	peridinin	peridinin	ADJ
ajmri-3088	87	26	chlorophyll	chlorophyll	NOUN
ajmri-3088	87	27	protein	protein	NOUN
ajmri-3088	87	28	(	(	PUNCT
ajmri-3088	87	29	percp	percp	PROPN
ajmri-3088	87	30	)	)	PUNCT
ajmri-3088	87	31	.	.	PUNCT
ajmri-3088	88	1	these	these	DET
ajmri-3088	88	2	antibodies	antibody	NOUN
ajmri-3088	88	3	were	be	AUX
ajmri-3088	88	4	directed	direct	VERB
ajmri-3088	88	5	against	against	ADP
ajmri-3088	88	6	particular	particular	ADJ
ajmri-3088	88	7	cell	cell	NOUN
ajmri-3088	88	8	surface	surface	NOUN
ajmri-3088	88	9	markers	marker	NOUN
ajmri-3088	88	10	.	.	PUNCT
ajmri-3088	89	1	sk1	sk1	PROPN
ajmri-3088	89	2	antibodies	antibody	NOUN
ajmri-3088	89	3	were	be	AUX
ajmri-3088	89	4	used	use	VERB
ajmri-3088	89	5	for	for	ADP
ajmri-3088	89	6	cd8	cd8	PROPN
ajmri-3088	89	7	+	+	PROPN
ajmri-3088	89	8	t	t	PROPN
ajmri-3088	89	9	-	-	PUNCT
ajmri-3088	89	10	cells	cell	NOUN
ajmri-3088	89	11	,	,	PUNCT
ajmri-3088	89	12	sk3	sk3	NOUN
ajmri-3088	89	13	for	for	ADP
ajmri-3088	89	14	cd4	cd4	PROPN
ajmri-3088	89	15	+	+	PROPN
ajmri-3088	89	16	cells	cell	NOUN
ajmri-3088	89	17	,	,	PUNCT
ajmri-3088	89	18	ncam16.2	ncam16.2	NOUN
ajmri-3088	89	19	for	for	ADP
ajmri-3088	89	20	cd16	cd16	PROPN
ajmri-3088	89	21	+	+	PROPN
ajmri-3088	89	22	56	56	NUM
ajmri-3088	89	23	,	,	PUNCT
ajmri-3088	89	24	l48	l48	NOUN
ajmri-3088	89	25	for	for	ADP
ajmri-3088	89	26	cd45ra	cd45ra	ADJ
ajmri-3088	89	27	,	,	PUNCT
ajmri-3088	89	28	and	and	CCONJ
ajmri-3088	89	29	uchl1	uchl1	NOUN
ajmri-3088	89	30	for	for	ADP
ajmri-3088	89	31	cd45ro.the	cd45ro.the	DET
ajmri-3088	89	32	cells	cell	NOUN
ajmri-3088	89	33	were	be	AUX
ajmri-3088	89	34	then	then	ADV
ajmri-3088	89	35	washed	wash	VERB
ajmri-3088	89	36	twice	twice	ADV
ajmri-3088	89	37	again	again	ADV
ajmri-3088	89	38	with	with	ADP
ajmri-3088	89	39	a	a	DET
ajmri-3088	89	40	staining	stain	VERB
ajmri-3088	89	41	buffer	buffer	NOUN
ajmri-3088	89	42	.	.	PUNCT
ajmri-3088	90	1	the	the	DET
ajmri-3088	90	2	excessive	excessive	ADJ
ajmri-3088	90	3	stain	stain	NOUN
ajmri-3088	90	4	was	be	AUX
ajmri-3088	90	5	washed	wash	VERB
ajmri-3088	90	6	off	off	ADP
ajmri-3088	90	7	.	.	PUNCT
ajmri-3088	91	1	the	the	DET
ajmri-3088	91	2	stain	stain	NOUN
ajmri-3088	91	3	that	that	PRON
ajmri-3088	91	4	remained	remain	VERB
ajmri-3088	91	5	bound	bind	VERB
ajmri-3088	91	6	to	to	ADP
ajmri-3088	91	7	cells	cell	NOUN
ajmri-3088	91	8	was	be	AUX
ajmri-3088	91	9	then	then	ADV
ajmri-3088	91	10	fixated	fixated	ADJ
ajmri-3088	91	11	with	with	ADP
ajmri-3088	91	12	a	a	DET
ajmri-3088	91	13	fixation	fixation	NOUN
ajmri-3088	91	14	buffer	buffer	NOUN
ajmri-3088	91	15	and	and	CCONJ
ajmri-3088	91	16	was	be	AUX
ajmri-3088	91	17	allowed	allow	VERB
ajmri-3088	91	18	to	to	PART
ajmri-3088	91	19	incubate	incubate	VERB
ajmri-3088	91	20	for	for	ADP
ajmri-3088	91	21	20	20	NUM
ajmri-3088	91	22	minutes	minute	NOUN
ajmri-3088	91	23	.	.	PUNCT
ajmri-3088	92	1	the	the	DET
ajmri-3088	92	2	cells	cell	NOUN
ajmri-3088	92	3	were	be	AUX
ajmri-3088	92	4	then	then	ADV
ajmri-3088	92	5	permeabilized	permeabilize	VERB
ajmri-3088	92	6	,	,	PUNCT
ajmri-3088	92	7	which	which	PRON
ajmri-3088	92	8	allowed	allow	VERB
ajmri-3088	92	9	intracellular	intracellular	ADJ
ajmri-3088	92	10	staining	staining	NOUN
ajmri-3088	92	11	of	of	ADP
ajmri-3088	92	12	cell	cell	NOUN
ajmri-3088	92	13	markers	marker	NOUN
ajmri-3088	92	14	and	and	CCONJ
ajmri-3088	92	15	glycoprotein	glycoprotein	NOUN
ajmri-3088	92	16	.	.	PUNCT
ajmri-3088	93	1	the	the	DET
ajmri-3088	93	2	cells	cell	NOUN
ajmri-3088	93	3	were	be	AUX
ajmri-3088	93	4	stained	stain	VERB
ajmri-3088	93	5	with	with	ADP
ajmri-3088	93	6	fluorescently	fluorescently	ADV
ajmri-3088	93	7	labeled	label	VERB
ajmri-3088	93	8	antibodies	antibody	NOUN
ajmri-3088	93	9	and	and	CCONJ
ajmri-3088	93	10	were	be	AUX
ajmri-3088	93	11	incubated	incubate	VERB
ajmri-3088	93	12	for	for	ADP
ajmri-3088	93	13	20	20	NUM
ajmri-3088	93	14	minutes	minute	NOUN
ajmri-3088	93	15	.	.	PUNCT
ajmri-3088	94	1	isotope	isotope	NOUN
ajmri-3088	94	2	controls	control	NOUN
ajmri-3088	94	3	were	be	AUX
ajmri-3088	94	4	also	also	ADV
ajmri-3088	94	5	included	include	VERB
ajmri-3088	94	6	in	in	ADP
ajmri-3088	94	7	the	the	DET
ajmri-3088	94	8	antibody	antibody	NOUN
ajmri-3088	94	9	panel	panel	NOUN
ajmri-3088	94	10	to	to	PART
ajmri-3088	94	11	differentiate	differentiate	VERB
ajmri-3088	94	12	antibody	antibody	NOUN
ajmri-3088	94	13	-	-	PUNCT
ajmri-3088	94	14	specific	specific	ADJ
ajmri-3088	94	15	signals	signal	NOUN
ajmri-3088	94	16	from	from	ADP
ajmri-3088	94	17	non	non	ADJ
ajmri-3088	94	18	-	-	ADJ
ajmri-3088	94	19	specific	specific	ADJ
ajmri-3088	94	20	signals	signal	NOUN
ajmri-3088	94	21	generated	generate	VERB
ajmri-3088	94	22	in	in	ADP
ajmri-3088	94	23	the	the	DET
ajmri-3088	94	24	background	background	NOUN
ajmri-3088	94	25	.	.	PUNCT
ajmri-3088	95	1	all	all	DET
ajmri-3088	95	2	these	these	DET
ajmri-3088	95	3	monoclonal	monoclonal	NOUN
ajmri-3088	95	4	antibodies	antibody	NOUN
ajmri-3088	95	5	and	and	CCONJ
ajmri-3088	95	6	isotope	isotope	NOUN
ajmri-3088	95	7	controls	control	NOUN
ajmri-3088	95	8	were	be	AUX
ajmri-3088	95	9	sourced	source	VERB
ajmri-3088	95	10	from	from	ADP
ajmri-3088	95	11	immunotech	immunotech	PROPN
ajmri-3088	95	12	,	,	PUNCT
ajmri-3088	95	13	france	france	PROPN
ajmri-3088	95	14	.	.	PUNCT
ajmri-3088	96	1	the	the	DET
ajmri-3088	96	2	lymphocyte	lymphocyte	ADJ
ajmri-3088	96	3	cell	cell	NOUN
ajmri-3088	96	4	counts	count	NOUN
ajmri-3088	96	5	were	be	AUX
ajmri-3088	96	6	analyzed	analyze	VERB
ajmri-3088	96	7	using	use	VERB
ajmri-3088	96	8	flow	flow	NOUN
ajmri-3088	96	9	jo	jo	PROPN
ajmri-3088	96	10	v	v	NUM
ajmri-3088	96	11	10	10	NUM
ajmri-3088	96	12	(	(	PUNCT
ajmri-3088	96	13	flowjotm	flowjotm	ADJ
ajmri-3088	96	14	software	software	NOUN
ajmri-3088	96	15	)	)	PUNCT
ajmri-3088	96	16	.	.	PUNCT
ajmri-3088	97	1	data	datum	NOUN
ajmri-3088	97	2	analysis	analysis	NOUN
ajmri-3088	97	3	all	all	DET
ajmri-3088	97	4	the	the	DET
ajmri-3088	97	5	statistical	statistical	ADJ
ajmri-3088	97	6	analyses	analysis	NOUN
ajmri-3088	97	7	were	be	AUX
ajmri-3088	97	8	done	do	VERB
ajmri-3088	97	9	using	use	VERB
ajmri-3088	97	10	spss	spss	PROPN
ajmri-3088	97	11	,	,	PUNCT
ajmri-3088	97	12	and	and	CCONJ
ajmri-3088	97	13	the	the	DET
ajmri-3088	97	14	standard	standard	ADJ
ajmri-3088	97	15	deviation	deviation	NOUN
ajmri-3088	97	16	was	be	AUX
ajmri-3088	97	17	calculated	calculate	VERB
ajmri-3088	97	18	for	for	ADP
ajmri-3088	97	19	the	the	DET
ajmri-3088	97	20	population	population	NOUN
ajmri-3088	97	21	’s	’s	PART
ajmri-3088	97	22	demographic	demographic	ADJ
ajmri-3088	97	23	characteristics	characteristic	NOUN
ajmri-3088	97	24	.	.	PUNCT
ajmri-3088	98	1	the	the	DET
ajmri-3088	98	2	two	two	NUM
ajmri-3088	98	3	-	-	PUNCT
ajmri-3088	98	4	tailed	tail	VERB
ajmri-3088	98	5	unpaired	unpaired	ADJ
ajmri-3088	98	6	or	or	CCONJ
ajmri-3088	98	7	paired	pair	VERB
ajmri-3088	98	8	student	student	NOUN
ajmri-3088	98	9	’s	’s	PART
ajmri-3088	98	10	t	t	PROPN
ajmri-3088	98	11	-	-	PUNCT
ajmri-3088	98	12	test	test	NOUN
ajmri-3088	98	13	was	be	AUX
ajmri-3088	98	14	used	use	VERB
ajmri-3088	98	15	to	to	PART
ajmri-3088	98	16	figure	figure	VERB
ajmri-3088	98	17	out	out	ADP
ajmri-3088	98	18	the	the	DET
ajmri-3088	98	19	statistical	statistical	ADJ
ajmri-3088	98	20	differences	difference	NOUN
ajmri-3088	98	21	between	between	ADP
ajmri-3088	98	22	the	the	DET
ajmri-3088	98	23	two	two	NUM
ajmri-3088	98	24	groups	group	NOUN
ajmri-3088	98	25	.	.	PUNCT
ajmri-3088	99	1	multiple	multiple	ADJ
ajmri-3088	99	2	regression	regression	NOUN
ajmri-3088	99	3	was	be	AUX
ajmri-3088	99	4	calculated	calculate	VERB
ajmri-3088	99	5	to	to	PART
ajmri-3088	99	6	identify	identify	VERB
ajmri-3088	99	7	a	a	DET
ajmri-3088	99	8	correlation	correlation	NOUN
ajmri-3088	99	9	between	between	ADP
ajmri-3088	99	10	variables	variable	NOUN
ajmri-3088	99	11	.	.	PUNCT
ajmri-3088	100	1	odds	odd	NOUN
ajmri-3088	100	2	ratios	ratio	NOUN
ajmri-3088	100	3	were	be	AUX
ajmri-3088	100	4	also	also	ADV
ajmri-3088	100	5	calculated	calculate	VERB
ajmri-3088	100	6	.	.	PUNCT
ajmri-3088	101	1	hypothesis	hypothesis	NOUN
ajmri-3088	101	2	testing	testing	NOUN
ajmri-3088	101	3	for	for	ADP
ajmri-3088	101	4	all	all	DET
ajmri-3088	101	5	statistical	statistical	ADJ
ajmri-3088	101	6	analyses	analysis	NOUN
ajmri-3088	101	7	was	be	AUX
ajmri-3088	101	8	conducted	conduct	VERB
ajmri-3088	101	9	at	at	ADP
ajmri-3088	101	10	a	a	DET
ajmri-3088	101	11	significance	significance	NOUN
ajmri-3088	101	12	level	level	NOUN
ajmri-3088	101	13	of	of	ADP
ajmri-3088	101	14	p<0.01	p<0.01	PROPN
ajmri-3088	101	15	.	.	PUNCT
ajmri-3088	101	16	results	result	NOUN
ajmri-3088	101	17	and	and	CCONJ
ajmri-3088	101	18	discussion	discussion	NOUN
ajmri-3088	101	19	results	result	NOUN
ajmri-3088	101	20	studied	study	VERB
ajmri-3088	101	21	parameters	parameter	NOUN
ajmri-3088	101	22	initially	initially	ADV
ajmri-3088	101	23	,	,	PUNCT
ajmri-3088	101	24	50	50	NUM
ajmri-3088	101	25	peripheral	peripheral	ADJ
ajmri-3088	101	26	samples	sample	NOUN
ajmri-3088	101	27	were	be	AUX
ajmri-3088	101	28	collected	collect	VERB
ajmri-3088	101	29	from	from	ADP
ajmri-3088	101	30	hospitals	hospital	NOUN
ajmri-3088	101	31	and	and	CCONJ
ajmri-3088	101	32	maternity	maternity	NOUN
ajmri-3088	101	33	centers	center	NOUN
ajmri-3088	101	34	.	.	PUNCT
ajmri-3088	102	1	eight	eight	NUM
ajmri-3088	102	2	of	of	ADP
ajmri-3088	102	3	them	they	PRON
ajmri-3088	102	4	were	be	AUX
ajmri-3088	102	5	given	give	VERB
ajmri-3088	102	6	antiviral	antiviral	ADJ
ajmri-3088	102	7	vaccination	vaccination	NOUN
ajmri-3088	102	8	and	and	CCONJ
ajmri-3088	102	9	so	so	ADV
ajmri-3088	102	10	were	be	AUX
ajmri-3088	102	11	excluded	exclude	VERB
ajmri-3088	102	12	from	from	ADP
ajmri-3088	102	13	the	the	DET
ajmri-3088	102	14	study	study	NOUN
ajmri-3088	102	15	as	as	ADP
ajmri-3088	102	16	intake	intake	NOUN
ajmri-3088	102	17	of	of	ADP
ajmri-3088	102	18	antiviral	antiviral	NOUN
ajmri-3088	102	19	can	can	AUX
ajmri-3088	102	20	influence	influence	VERB
ajmri-3088	102	21	the	the	DET
ajmri-3088	102	22	overall	overall	ADJ
ajmri-3088	102	23	impact	impact	NOUN
ajmri-3088	102	24	of	of	ADP
ajmri-3088	102	25	hiv	hiv	PROPN
ajmri-3088	102	26	,	,	PUNCT
ajmri-3088	102	27	hbv	hbv	PROPN
ajmri-3088	102	28	mono	mono	NOUN
ajmri-3088	102	29	-	-	PUNCT
ajmri-3088	102	30	infection	infection	NOUN
ajmri-3088	102	31	,	,	PUNCT
ajmri-3088	102	32	and	and	CCONJ
ajmri-3088	102	33	coinfection	coinfection	NOUN
ajmri-3088	102	34	of	of	ADP
ajmri-3088	102	35	hiv	hiv	PROPN
ajmri-3088	102	36	/	/	SYM
ajmri-3088	102	37	hbv	hbv	NOUN
ajmri-3088	102	38	on	on	ADP
ajmri-3088	102	39	lymphocyte	lymphocyte	ADJ
ajmri-3088	102	40	subpopulations	subpopulation	NOUN
ajmri-3088	102	41	.	.	PUNCT
ajmri-3088	103	1	out	out	ADP
ajmri-3088	103	2	of	of	ADP
ajmri-3088	103	3	the	the	DET
ajmri-3088	103	4	remaining	remain	VERB
ajmri-3088	103	5	42	42	NUM
ajmri-3088	103	6	samples	sample	NOUN
ajmri-3088	103	7	,	,	PUNCT
ajmri-3088	103	8	4	4	NUM
ajmri-3088	103	9	samples	sample	NOUN
ajmri-3088	103	10	were	be	AUX
ajmri-3088	103	11	excluded	exclude	VERB
ajmri-3088	103	12	as	as	SCONJ
ajmri-3088	103	13	they	they	PRON
ajmri-3088	103	14	gave	give	VERB
ajmri-3088	103	15	a	a	DET
ajmri-3088	103	16	cell	cell	NOUN
ajmri-3088	103	17	count	count	NOUN
ajmri-3088	103	18	of	of	ADP
ajmri-3088	103	19	around	around	ADP
ajmri-3088	103	20	800	800	NUM
ajmri-3088	103	21	cells	cell	NOUN
ajmri-3088	103	22	/	/	SYM
ajmri-3088	103	23	mm3	mm3	NOUN
ajmri-3088	103	24	and	and	CCONJ
ajmri-3088	103	25	did	do	AUX
ajmri-3088	103	26	not	not	PART
ajmri-3088	103	27	align	align	VERB
ajmri-3088	103	28	with	with	ADP
ajmri-3088	103	29	the	the	DET
ajmri-3088	103	30	chosen	choose	VERB
ajmri-3088	103	31	criteria	criterion	NOUN
ajmri-3088	103	32	for	for	ADP
ajmri-3088	103	33	the	the	DET
ajmri-3088	103	34	study	study	NOUN
ajmri-3088	103	35	.	.	PUNCT
ajmri-3088	104	1	3	3	NUM
ajmri-3088	104	2	more	more	ADJ
ajmri-3088	104	3	samples	sample	NOUN
ajmri-3088	104	4	were	be	AUX
ajmri-3088	104	5	excluded	exclude	VERB
ajmri-3088	104	6	as	as	ADP
ajmri-3088	104	7	the	the	DET
ajmri-3088	104	8	concerned	concerned	ADJ
ajmri-3088	104	9	parties	party	NOUN
ajmri-3088	104	10	did	do	AUX
ajmri-3088	104	11	not	not	PART
ajmri-3088	104	12	give	give	VERB
ajmri-3088	104	13	their	their	PRON
ajmri-3088	104	14	consent	consent	NOUN
ajmri-3088	104	15	to	to	PART
ajmri-3088	104	16	proceed	proceed	VERB
ajmri-3088	104	17	with	with	ADP
ajmri-3088	104	18	the	the	DET
ajmri-3088	104	19	study	study	NOUN
ajmri-3088	104	20	.	.	PUNCT
ajmri-3088	105	1	after	after	ADP
ajmri-3088	105	2	applying	apply	VERB
ajmri-3088	105	3	inclusion	inclusion	NOUN
ajmri-3088	105	4	and	and	CCONJ
ajmri-3088	105	5	exclusion	exclusion	NOUN
ajmri-3088	105	6	criteria	criterion	NOUN
ajmri-3088	105	7	,	,	PUNCT
ajmri-3088	105	8	the	the	DET
ajmri-3088	105	9	study	study	NOUN
ajmri-3088	105	10	proceeded	proceed	VERB
ajmri-3088	105	11	with	with	ADP
ajmri-3088	105	12	35	35	NUM
ajmri-3088	105	13	participants	participant	NOUN
ajmri-3088	105	14	.	.	PUNCT
ajmri-3088	106	1	immunophenotyping	immunophenotype	VERB
ajmri-3088	106	2	of	of	ADP
ajmri-3088	106	3	lymphocyte	lymphocyte	ADJ
ajmri-3088	106	4	subsets	subset	NOUN
ajmri-3088	106	5	cd8	cd8	PROPN
ajmri-3088	106	6	+	+	PROPN
ajmri-3088	106	7	cell	cell	NOUN
ajmri-3088	106	8	subsets	subset	VERB
ajmri-3088	106	9	three	three	NUM
ajmri-3088	106	10	sets	set	NOUN
ajmri-3088	106	11	of	of	ADP
ajmri-3088	106	12	cells	cell	NOUN
ajmri-3088	106	13	were	be	AUX
ajmri-3088	106	14	subjected	subject	VERB
ajmri-3088	106	15	to	to	ADP
ajmri-3088	106	16	immunophenotyping	immunophenotype	VERB
ajmri-3088	106	17	table	table	NOUN
ajmri-3088	106	18	1	1	NUM
ajmri-3088	106	19	:	:	PUNCT
ajmri-3088	106	20	demographic	demographic	ADJ
ajmri-3088	106	21	and	and	CCONJ
ajmri-3088	106	22	clinical	clinical	ADJ
ajmri-3088	106	23	parameters	parameter	NOUN
ajmri-3088	106	24	of	of	ADP
ajmri-3088	106	25	patients	patient	NOUN
ajmri-3088	106	26	infected	infect	VERB
ajmri-3088	106	27	with	with	ADP
ajmri-3088	106	28	hiv	hiv	PROPN
ajmri-3088	106	29	,	,	PUNCT
ajmri-3088	106	30	hbv	hbv	NOUN
ajmri-3088	106	31	,	,	PUNCT
ajmri-3088	106	32	and	and	CCONJ
ajmri-3088	106	33	coinfected	coinfecte	VERB
ajmri-3088	106	34	with	with	ADP
ajmri-3088	106	35	hiv/	hiv/	NOUN
ajmri-3088	106	36	hbv	hbv	NOUN
ajmri-3088	106	37	and	and	CCONJ
ajmri-3088	106	38	their	their	PRON
ajmri-3088	106	39	cell	cell	NOUN
ajmri-3088	106	40	count	count	NOUN
ajmri-3088	106	41	studied	study	VERB
ajmri-3088	106	42	parameters	parameter	NOUN
ajmri-3088	106	43	hiv	hiv	PROPN
ajmri-3088	106	44	-	-	PUNCT
ajmri-3088	106	45	infected	infect	VERB
ajmri-3088	106	46	patients	patient	NOUN
ajmri-3088	106	47	(	(	PUNCT
ajmri-3088	106	48	n%	n%	NOUN
ajmri-3088	106	49	)	)	PUNCT
ajmri-3088	106	50	hbv	hbv	NOUN
ajmri-3088	106	51	-	-	PUNCT
ajmri-3088	106	52	infected	infect	VERB
ajmri-3088	106	53	patients	patient	NOUN
ajmri-3088	106	54	(	(	PUNCT
ajmri-3088	106	55	n%	n%	X
ajmri-3088	106	56	)	)	PUNCT
ajmri-3088	106	57	hiv	hiv	PROPN
ajmri-3088	106	58	patients	patient	NOUN
ajmri-3088	106	59	co	co	VERB
ajmri-3088	106	60	-	-	VERB
ajmri-3088	106	61	infected	infect	VERB
ajmri-3088	106	62	with	with	ADP
ajmri-3088	106	63	hbv	hbv	NOUN
ajmri-3088	106	64	(	(	PUNCT
ajmri-3088	106	65	n%	n%	NOUN
ajmri-3088	106	66	)	)	PUNCT
ajmri-3088	106	67	no	no	NOUN
ajmri-3088	106	68	of	of	ADP
ajmri-3088	106	69	participants	participant	NOUN
ajmri-3088	106	70	(	(	PUNCT
ajmri-3088	106	71	35	35	NUM
ajmri-3088	106	72	)	)	PUNCT
ajmri-3088	106	73	12	12	NUM
ajmri-3088	106	74	(	(	PUNCT
ajmri-3088	106	75	100.00	100.00	NUM
ajmri-3088	106	76	)	)	PUNCT
ajmri-3088	106	77	9	9	NUM
ajmri-3088	106	78	(	(	PUNCT
ajmri-3088	106	79	100.00	100.00	NUM
ajmri-3088	106	80	)	)	PUNCT
ajmri-3088	106	81	14(100.00	14(100.00	NUM
ajmri-3088	106	82	)	)	PUNCT
ajmri-3088	106	83	age	age	NOUN
ajmri-3088	106	84	factor	factor	NOUN
ajmri-3088	106	85	(	(	PUNCT
ajmri-3088	106	86	years	year	NOUN
ajmri-3088	106	87	)	)	PUNCT
ajmri-3088	106	88	mean	mean	VERB
ajmri-3088	106	89	±sd	±sd	PRON
ajmri-3088	106	90	21.43±4.08	21.43±4.08	NUM
ajmri-3088	106	91	24.01±3.01	24.01±3.01	NUM
ajmri-3088	106	92	26.07±3.11	26.07±3.11	NUM
ajmri-3088	106	93	0	0	NUM
ajmri-3088	106	94	-	-	SYM
ajmri-3088	106	95	15	15	NUM
ajmri-3088	106	96	years	year	NOUN
ajmri-3088	106	97	1	1	NUM
ajmri-3088	106	98	(	(	PUNCT
ajmri-3088	106	99	8.3	8.3	NUM
ajmri-3088	106	100	)	)	PUNCT
ajmri-3088	106	101	3	3	NUM
ajmri-3088	106	102	(	(	PUNCT
ajmri-3088	106	103	33.33	33.33	NUM
ajmri-3088	106	104	)	)	PUNCT
ajmri-3088	106	105	2	2	NUM
ajmri-3088	106	106	(	(	PUNCT
ajmri-3088	106	107	14.28	14.28	NUM
ajmri-3088	106	108	)	)	PUNCT
ajmri-3088	106	109	16	16	NUM
ajmri-3088	106	110	-	-	SYM
ajmri-3088	106	111	21	21	NUM
ajmri-3088	106	112	years	year	NOUN
ajmri-3088	106	113	4	4	NUM
ajmri-3088	106	114	(	(	PUNCT
ajmri-3088	106	115	33.3	33.3	NUM
ajmri-3088	106	116	)	)	SYM
ajmri-3088	106	117	2	2	NUM
ajmri-3088	106	118	(	(	PUNCT
ajmri-3088	106	119	22.22	22.22	NUM
ajmri-3088	106	120	)	)	PUNCT
ajmri-3088	106	121	3	3	NUM
ajmri-3088	106	122	(	(	PUNCT
ajmri-3088	106	123	21.42	21.42	NUM
ajmri-3088	106	124	)	)	PUNCT
ajmri-3088	106	125	22	22	NUM
ajmri-3088	106	126	-	-	SYM
ajmri-3088	106	127	37	37	NUM
ajmri-3088	106	128	years	year	NOUN
ajmri-3088	106	129	5	5	NUM
ajmri-3088	106	130	(	(	PUNCT
ajmri-3088	106	131	41.66	41.66	NUM
ajmri-3088	106	132	)	)	PUNCT
ajmri-3088	106	133	3	3	NUM
ajmri-3088	106	134	(	(	PUNCT
ajmri-3088	106	135	33.33	33.33	NUM
ajmri-3088	106	136	)	)	PUNCT
ajmri-3088	106	137	8	8	NUM
ajmri-3088	106	138	(	(	PUNCT
ajmri-3088	106	139	57.14	57.14	NUM
ajmri-3088	106	140	)	)	PUNCT
ajmri-3088	106	141	38	38	NUM
ajmri-3088	106	142	-	-	SYM
ajmri-3088	106	143	53	53	NUM
ajmri-3088	106	144	years	year	NOUN
ajmri-3088	106	145	1	1	NUM
ajmri-3088	106	146	(	(	PUNCT
ajmri-3088	106	147	8.3	8.3	NUM
ajmri-3088	106	148	)	)	SYM
ajmri-3088	106	149	1	1	NUM
ajmri-3088	106	150	(	(	PUNCT
ajmri-3088	106	151	11.11	11.11	NUM
ajmri-3088	106	152	)	)	PUNCT
ajmri-3088	106	153	1	1	NUM
ajmri-3088	106	154	(	(	PUNCT
ajmri-3088	106	155	7.14	7.14	NUM
ajmri-3088	106	156	)	)	PUNCT
ajmri-3088	106	157	pa	pa	PROPN
ajmri-3088	106	158	ge	ge	PROPN
ajmri-3088	107	1	53	53	NUM
ajmri-3088	108	1	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	108	2	am	am	NOUN
ajmri-3088	108	3	.	.	PUNCT
ajmri-3088	109	1	j.	j.	PROPN
ajmri-3088	109	2	multidis	multidis	PROPN
ajmri-3088	109	3	.	.	PUNCT
ajmri-3088	110	1	res	re	NOUN
ajmri-3088	110	2	.	.	PUNCT
ajmri-3088	111	1	innov	innov	PROPN
ajmri-3088	111	2	.	.	PUNCT
ajmri-3088	112	1	3(5	3(5	NUM
ajmri-3088	112	2	)	)	PUNCT
ajmri-3088	112	3	50	50	NUM
ajmri-3088	112	4	-	-	SYM
ajmri-3088	112	5	60	60	NUM
ajmri-3088	112	6	,	,	PUNCT
ajmri-3088	112	7	2024	2024	NUM
ajmri-3088	112	8	>	>	SYM
ajmri-3088	112	9	53	53	NUM
ajmri-3088	112	10	years	year	NOUN
ajmri-3088	112	11	1	1	NUM
ajmri-3088	112	12	(	(	PUNCT
ajmri-3088	112	13	8.3	8.3	NUM
ajmri-3088	112	14	)	)	PUNCT
ajmri-3088	112	15	0(0.00	0(0.00	NUM
ajmri-3088	112	16	)	)	PUNCT
ajmri-3088	112	17	0	0	NUM
ajmri-3088	113	1	(	(	PUNCT
ajmri-3088	113	2	0.00	0.00	NUM
ajmri-3088	113	3	)	)	PUNCT
ajmri-3088	113	4	gender	gender	NOUN
ajmri-3088	113	5	male	male	NOUN
ajmri-3088	113	6	3	3	NUM
ajmri-3088	113	7	(	(	PUNCT
ajmri-3088	113	8	25	25	NUM
ajmri-3088	113	9	)	)	PUNCT
ajmri-3088	113	10	4	4	NUM
ajmri-3088	113	11	(	(	PUNCT
ajmri-3088	113	12	44.44	44.44	NUM
ajmri-3088	113	13	)	)	PUNCT
ajmri-3088	113	14	5	5	NUM
ajmri-3088	113	15	(	(	PUNCT
ajmri-3088	113	16	35.7	35.7	NUM
ajmri-3088	113	17	)	)	PUNCT
ajmri-3088	113	18	female	female	ADJ
ajmri-3088	113	19	9	9	NUM
ajmri-3088	113	20	(	(	PUNCT
ajmri-3088	113	21	75	75	NUM
ajmri-3088	113	22	)	)	PUNCT
ajmri-3088	113	23	5	5	NUM
ajmri-3088	113	24	(	(	PUNCT
ajmri-3088	113	25	55.55	55.55	NUM
ajmri-3088	113	26	)	)	PUNCT
ajmri-3088	113	27	9	9	NUM
ajmri-3088	113	28	(	(	PUNCT
ajmri-3088	113	29	64.28	64.28	NUM
ajmri-3088	113	30	)	)	PUNCT
ajmri-3088	113	31	mode	mode	NOUN
ajmri-3088	113	32	of	of	ADP
ajmri-3088	113	33	acquired	acquire	VERB
ajmri-3088	113	34	infection	infection	NOUN
ajmri-3088	113	35	intravenous	intravenous	ADJ
ajmri-3088	113	36	drug	drug	NOUN
ajmri-3088	113	37	usage	usage	NOUN
ajmri-3088	113	38	3	3	NUM
ajmri-3088	113	39	(	(	PUNCT
ajmri-3088	113	40	25	25	NUM
ajmri-3088	113	41	)	)	PUNCT
ajmri-3088	113	42	1	1	NUM
ajmri-3088	113	43	(	(	PUNCT
ajmri-3088	113	44	11.11	11.11	NUM
ajmri-3088	113	45	)	)	PUNCT
ajmri-3088	113	46	3	3	NUM
ajmri-3088	113	47	(	(	PUNCT
ajmri-3088	113	48	21.42	21.42	NUM
ajmri-3088	113	49	)	)	PUNCT
ajmri-3088	113	50	sexual	sexual	ADJ
ajmri-3088	113	51	practices	practice	NOUN
ajmri-3088	113	52	3	3	NUM
ajmri-3088	113	53	(	(	PUNCT
ajmri-3088	113	54	25	25	NUM
ajmri-3088	113	55	)	)	PUNCT
ajmri-3088	113	56	3	3	NUM
ajmri-3088	113	57	(	(	PUNCT
ajmri-3088	113	58	33.33	33.33	NUM
ajmri-3088	113	59	)	)	PUNCT
ajmri-3088	113	60	4	4	NUM
ajmri-3088	113	61	(	(	PUNCT
ajmri-3088	113	62	28.57	28.57	NUM
ajmri-3088	113	63	)	)	PUNCT
ajmri-3088	113	64	vertical	vertical	ADJ
ajmri-3088	113	65	transmissions	transmission	NOUN
ajmri-3088	113	66	4	4	NUM
ajmri-3088	113	67	(	(	PUNCT
ajmri-3088	113	68	30.7	30.7	NUM
ajmri-3088	113	69	)	)	SYM
ajmri-3088	113	70	2	2	NUM
ajmri-3088	113	71	(	(	PUNCT
ajmri-3088	113	72	22.22	22.22	NUM
ajmri-3088	113	73	)	)	PUNCT
ajmri-3088	113	74	5	5	NUM
ajmri-3088	113	75	(	(	PUNCT
ajmri-3088	113	76	35.71	35.71	NUM
ajmri-3088	113	77	)	)	PUNCT
ajmri-3088	113	78	unhygenic	unhygenic	ADJ
ajmri-3088	113	79	surroundings	surrounding	NOUN
ajmri-3088	113	80	2	2	NUM
ajmri-3088	113	81	(	(	PUNCT
ajmri-3088	113	82	16.66	16.66	NUM
ajmri-3088	113	83	)	)	PUNCT
ajmri-3088	113	84	3	3	NUM
ajmri-3088	113	85	(	(	PUNCT
ajmri-3088	113	86	33.33	33.33	NUM
ajmri-3088	113	87	)	)	PUNCT
ajmri-3088	113	88	2	2	NUM
ajmri-3088	113	89	(	(	PUNCT
ajmri-3088	113	90	14.28	14.28	NUM
ajmri-3088	113	91	)	)	PUNCT
ajmri-3088	113	92	duration	duration	NOUN
ajmri-3088	113	93	of	of	ADP
ajmri-3088	113	94	diagnosis	diagnosis	NOUN
ajmri-3088	113	95	0	0	NUM
ajmri-3088	113	96	-	-	SYM
ajmri-3088	113	97	6	6	NUM
ajmri-3088	113	98	months	month	NOUN
ajmri-3088	113	99	3	3	NUM
ajmri-3088	113	100	(	(	PUNCT
ajmri-3088	113	101	25	25	NUM
ajmri-3088	113	102	)	)	SYM
ajmri-3088	113	103	2	2	NUM
ajmri-3088	113	104	(	(	PUNCT
ajmri-3088	113	105	22.22	22.22	NUM
ajmri-3088	113	106	)	)	PUNCT
ajmri-3088	113	107	6	6	NUM
ajmri-3088	113	108	(	(	PUNCT
ajmri-3088	113	109	35.29	35.29	NUM
ajmri-3088	113	110	)	)	PUNCT
ajmri-3088	113	111	7	7	NUM
ajmri-3088	113	112	-	-	SYM
ajmri-3088	113	113	12	12	NUM
ajmri-3088	113	114	months	month	NOUN
ajmri-3088	113	115	6	6	NUM
ajmri-3088	113	116	(	(	PUNCT
ajmri-3088	113	117	50	50	NUM
ajmri-3088	113	118	)	)	PUNCT
ajmri-3088	113	119	3	3	NUM
ajmri-3088	113	120	(	(	PUNCT
ajmri-3088	113	121	33.33	33.33	NUM
ajmri-3088	113	122	)	)	PUNCT
ajmri-3088	113	123	4	4	NUM
ajmri-3088	113	124	(	(	PUNCT
ajmri-3088	113	125	28.57	28.57	NUM
ajmri-3088	113	126	)	)	PUNCT
ajmri-3088	113	127	13	13	NUM
ajmri-3088	113	128	-	-	SYM
ajmri-3088	113	129	19	19	NUM
ajmri-3088	113	130	months	month	NOUN
ajmri-3088	113	131	3	3	NUM
ajmri-3088	113	132	(	(	PUNCT
ajmri-3088	113	133	25	25	NUM
ajmri-3088	113	134	)	)	PUNCT
ajmri-3088	113	135	3	3	NUM
ajmri-3088	113	136	(	(	PUNCT
ajmri-3088	113	137	33.33	33.33	NUM
ajmri-3088	113	138	)	)	PUNCT
ajmri-3088	113	139	2	2	NUM
ajmri-3088	113	140	(	(	PUNCT
ajmri-3088	113	141	14.28	14.28	NUM
ajmri-3088	113	142	)	)	PUNCT
ajmri-3088	113	143	20	20	NUM
ajmri-3088	113	144	-	-	SYM
ajmri-3088	113	145	26	26	NUM
ajmri-3088	113	146	months	month	NOUN
ajmri-3088	113	147	0	0	PUNCT
ajmri-3088	113	148	(	(	PUNCT
ajmri-3088	113	149	0.00	0.00	NUM
ajmri-3088	113	150	)	)	PUNCT
ajmri-3088	113	151	1(1.11	1(1.11	NUM
ajmri-3088	113	152	)	)	PUNCT
ajmri-3088	113	153	2	2	NUM
ajmri-3088	113	154	(	(	PUNCT
ajmri-3088	113	155	14.28	14.28	NUM
ajmri-3088	113	156	)	)	PUNCT
ajmri-3088	113	157	cd8	cd8	PROPN
ajmri-3088	113	158	cell	cell	NOUN
ajmri-3088	113	159	count	count	NOUN
ajmri-3088	113	160	:	:	PUNCT
ajmri-3088	113	161	>	>	PUNCT
ajmri-3088	113	162	500	500	NUM
ajmri-3088	113	163	2	2	NUM
ajmri-3088	113	164	(	(	PUNCT
ajmri-3088	113	165	16.66	16.66	NUM
ajmri-3088	113	166	)	)	PUNCT
ajmri-3088	113	167	1	1	NUM
ajmri-3088	113	168	(	(	PUNCT
ajmri-3088	113	169	11.11	11.11	NUM
ajmri-3088	113	170	)	)	PUNCT
ajmri-3088	113	171	1	1	NUM
ajmri-3088	113	172	(	(	PUNCT
ajmri-3088	113	173	7	7	NUM
ajmri-3088	113	174	)	)	PUNCT
ajmri-3088	113	175	350	350	NUM
ajmri-3088	113	176	-	-	SYM
ajmri-3088	113	177	500	500	NUM
ajmri-3088	113	178	2	2	NUM
ajmri-3088	113	179	(	(	PUNCT
ajmri-3088	113	180	16.66	16.66	NUM
ajmri-3088	113	181	)	)	PUNCT
ajmri-3088	113	182	3	3	NUM
ajmri-3088	113	183	(	(	PUNCT
ajmri-3088	113	184	33.33	33.33	NUM
ajmri-3088	113	185	)	)	PUNCT
ajmri-3088	113	186	2	2	NUM
ajmri-3088	113	187	(	(	PUNCT
ajmri-3088	113	188	14.28	14.28	NUM
ajmri-3088	113	189	)	)	PUNCT
ajmri-3088	113	190	200	200	NUM
ajmri-3088	113	191	-	-	SYM
ajmri-3088	113	192	350	350	NUM
ajmri-3088	113	193	6	6	NUM
ajmri-3088	113	194	(	(	PUNCT
ajmri-3088	113	195	50	50	NUM
ajmri-3088	113	196	)	)	PUNCT
ajmri-3088	113	197	3	3	NUM
ajmri-3088	113	198	(	(	PUNCT
ajmri-3088	113	199	33.33	33.33	NUM
ajmri-3088	113	200	)	)	PUNCT
ajmri-3088	113	201	8	8	NUM
ajmri-3088	113	202	(	(	PUNCT
ajmri-3088	113	203	57.1	57.1	NUM
ajmri-3088	113	204	)	)	PUNCT
ajmri-3088	113	205	<	<	X
ajmri-3088	113	206	200	200	NUM
ajmri-3088	113	207	3	3	NUM
ajmri-3088	113	208	(	(	PUNCT
ajmri-3088	113	209	25	25	NUM
ajmri-3088	113	210	)	)	SYM
ajmri-3088	113	211	2	2	NUM
ajmri-3088	113	212	(	(	PUNCT
ajmri-3088	113	213	22.22	22.22	NUM
ajmri-3088	113	214	)	)	PUNCT
ajmri-3088	113	215	2	2	NUM
ajmri-3088	113	216	(	(	PUNCT
ajmri-3088	113	217	14.28	14.28	NUM
ajmri-3088	113	218	)	)	PUNCT
ajmri-3088	113	219	to	to	PART
ajmri-3088	113	220	determine	determine	VERB
ajmri-3088	113	221	the	the	DET
ajmri-3088	113	222	variations	variation	NOUN
ajmri-3088	113	223	in	in	ADP
ajmri-3088	113	224	cd8	cd8	PROPN
ajmri-3088	113	225	cells	cell	NOUN
ajmri-3088	113	226	.	.	PUNCT
ajmri-3088	114	1	nearly	nearly	ADV
ajmri-3088	114	2	50	50	NUM
ajmri-3088	114	3	%	%	NOUN
ajmri-3088	114	4	of	of	ADP
ajmri-3088	114	5	mono	mono	NOUN
ajmri-3088	114	6	-	-	PUNCT
ajmri-3088	114	7	infected	infect	VERB
ajmri-3088	114	8	hiv	hiv	PROPN
ajmri-3088	114	9	patients	patient	NOUN
ajmri-3088	114	10	had	have	VERB
ajmri-3088	114	11	cd8	cd8	PROPN
ajmri-3088	114	12	cell	cell	NOUN
ajmri-3088	114	13	count	count	NOUN
ajmri-3088	114	14	in	in	ADP
ajmri-3088	114	15	ranges	range	NOUN
ajmri-3088	114	16	of	of	ADP
ajmri-3088	114	17	250	250	NUM
ajmri-3088	114	18	-	-	SYM
ajmri-3088	114	19	300	300	NUM
ajmri-3088	114	20	cells	cell	NOUN
ajmri-3088	114	21	/	/	SYM
ajmri-3088	114	22	mm3	mm3	NOUN
ajmri-3088	114	23	.	.	PUNCT
ajmri-3088	115	1	in	in	ADP
ajmri-3088	115	2	the	the	DET
ajmri-3088	115	3	case	case	NOUN
ajmri-3088	115	4	of	of	ADP
ajmri-3088	115	5	acute	acute	ADJ
ajmri-3088	115	6	hepatitis	hepatitis	PROPN
ajmri-3088	115	7	b	b	PROPN
ajmri-3088	115	8	,	,	PUNCT
ajmri-3088	115	9	nearly	nearly	ADV
ajmri-3088	115	10	33.33	33.33	NUM
ajmri-3088	115	11	%	%	NOUN
ajmri-3088	115	12	of	of	ADP
ajmri-3088	115	13	patients	patient	NOUN
ajmri-3088	115	14	showed	show	VERB
ajmri-3088	115	15	cd8	cd8	PROPN
ajmri-3088	115	16	cell	cell	NOUN
ajmri-3088	115	17	count	count	NOUN
ajmri-3088	115	18	lesser	less	ADJ
ajmri-3088	115	19	than	than	ADP
ajmri-3088	115	20	300	300	NUM
ajmri-3088	115	21	cells	cell	NOUN
ajmri-3088	115	22	/	/	SYM
ajmri-3088	115	23	mm3	mm3	NOUN
ajmri-3088	115	24	.	.	PUNCT
ajmri-3088	116	1	the	the	DET
ajmri-3088	116	2	same	same	ADJ
ajmri-3088	116	3	pattern	pattern	NOUN
ajmri-3088	116	4	was	be	AUX
ajmri-3088	116	5	followed	follow	VERB
ajmri-3088	116	6	by	by	ADP
ajmri-3088	116	7	patients	patient	NOUN
ajmri-3088	116	8	co	co	VERB
ajmri-3088	116	9	-	-	VERB
ajmri-3088	116	10	infected	infected	ADJ
ajmri-3088	116	11	with	with	ADP
ajmri-3088	116	12	hiv	hiv	PROPN
ajmri-3088	116	13	/	/	SYM
ajmri-3088	116	14	hbv	hbv	NOUN
ajmri-3088	116	15	,	,	PUNCT
ajmri-3088	116	16	as	as	SCONJ
ajmri-3088	116	17	nearly	nearly	ADV
ajmri-3088	116	18	57	57	NUM
ajmri-3088	116	19	%	%	NOUN
ajmri-3088	116	20	of	of	ADP
ajmri-3088	116	21	them	they	PRON
ajmri-3088	116	22	showed	show	VERB
ajmri-3088	116	23	cell	cell	NOUN
ajmri-3088	116	24	count	count	NOUN
ajmri-3088	116	25	below	below	ADP
ajmri-3088	116	26	the	the	DET
ajmri-3088	116	27	range	range	NOUN
ajmri-3088	116	28	of	of	ADP
ajmri-3088	116	29	350	350	NUM
ajmri-3088	116	30	.	.	PUNCT
ajmri-3088	117	1	these	these	DET
ajmri-3088	117	2	results	result	NOUN
ajmri-3088	117	3	portrayed	portray	VERB
ajmri-3088	117	4	the	the	DET
ajmri-3088	117	5	inverse	inverse	NOUN
ajmri-3088	117	6	relation	relation	NOUN
ajmri-3088	117	7	between	between	ADP
ajmri-3088	117	8	cell	cell	NOUN
ajmri-3088	117	9	count	count	NOUN
ajmri-3088	117	10	and	and	CCONJ
ajmri-3088	117	11	infection	infection	NOUN
ajmri-3088	117	12	progression	progression	NOUN
ajmri-3088	117	13	.	.	PUNCT
ajmri-3088	118	1	mentioned	mention	VERB
ajmri-3088	118	2	below	below	ADV
ajmri-3088	118	3	is	be	AUX
ajmri-3088	118	4	the	the	DET
ajmri-3088	118	5	tabular	tabular	ADJ
ajmri-3088	118	6	visualization	visualization	NOUN
ajmri-3088	118	7	of	of	ADP
ajmri-3088	118	8	data	data	PROPN
ajmri-3088	118	9	.	.	PUNCT
ajmri-3088	119	1	table	table	NOUN
ajmri-3088	119	2	1	1	NUM
ajmri-3088	119	3	shows	show	VERB
ajmri-3088	119	4	the	the	DET
ajmri-3088	119	5	demographic	demographic	ADJ
ajmri-3088	119	6	and	and	CCONJ
ajmri-3088	119	7	clinical	clinical	ADJ
ajmri-3088	119	8	parameters	parameter	NOUN
ajmri-3088	119	9	undertaken	undertake	VERB
ajmri-3088	119	10	to	to	PART
ajmri-3088	119	11	conduct	conduct	VERB
ajmri-3088	119	12	the	the	DET
ajmri-3088	119	13	study	study	NOUN
ajmri-3088	119	14	.	.	PUNCT
ajmri-3088	120	1	the	the	DET
ajmri-3088	120	2	median	median	ADJ
ajmri-3088	120	3	age	age	NOUN
ajmri-3088	120	4	for	for	ADP
ajmri-3088	120	5	hiv	hiv	PROPN
ajmri-3088	120	6	-	-	PUNCT
ajmri-3088	120	7	positive	positive	ADJ
ajmri-3088	120	8	patients	patient	NOUN
ajmri-3088	120	9	is	be	AUX
ajmri-3088	120	10	21.43±4.08	21.43±4.08	NUM
ajmri-3088	120	11	;	;	PUNCT
ajmri-3088	120	12	for	for	ADP
ajmri-3088	120	13	hbv	hbv	NOUN
ajmri-3088	120	14	-	-	PUNCT
ajmri-3088	120	15	positive	positive	ADJ
ajmri-3088	120	16	patients	patient	NOUN
ajmri-3088	120	17	,	,	PUNCT
ajmri-3088	120	18	24.01±3.01	24.01±3.01	NUM
ajmri-3088	120	19	,	,	PUNCT
ajmri-3088	120	20	and	and	CCONJ
ajmri-3088	120	21	for	for	ADP
ajmri-3088	120	22	hiv	hiv	PROPN
ajmri-3088	120	23	/	/	SYM
ajmri-3088	120	24	hbv	hbv	NOUN
ajmri-3088	120	25	patients	patient	NOUN
ajmri-3088	120	26	is	be	AUX
ajmri-3088	120	27	26.07±3.11	26.07±3.11	NUM
ajmri-3088	120	28	.	.	PUNCT
ajmri-3088	121	1	the	the	DET
ajmri-3088	121	2	significance	significance	NOUN
ajmri-3088	121	3	value	value	NOUN
ajmri-3088	121	4	for	for	ADP
ajmri-3088	121	5	cd8	cd8	PROPN
ajmri-3088	121	6	cell	cell	NOUN
ajmri-3088	121	7	count	count	NOUN
ajmri-3088	121	8	is	be	AUX
ajmri-3088	121	9	<	<	X
ajmri-3088	121	10	0.01	0.01	NUM
ajmri-3088	121	11	.	.	PUNCT
ajmri-3088	122	1	approximately	approximately	ADV
ajmri-3088	122	2	57.1	57.1	NUM
ajmri-3088	122	3	%	%	NOUN
ajmri-3088	122	4	of	of	ADP
ajmri-3088	122	5	hiv	hiv	PROPN
ajmri-3088	122	6	/	/	SYM
ajmri-3088	122	7	hbv	hbv	PROPN
ajmri-3088	122	8	coinfected	coinfecte	VERB
ajmri-3088	122	9	patients	patient	NOUN
ajmri-3088	122	10	had	have	VERB
ajmri-3088	122	11	a	a	DET
ajmri-3088	122	12	low	low	ADJ
ajmri-3088	122	13	300	300	NUM
ajmri-3088	122	14	cells	cell	NOUN
ajmri-3088	122	15	/	/	SYM
ajmri-3088	122	16	mm3	mm3	NOUN
ajmri-3088	122	17	population	population	NOUN
ajmri-3088	122	18	.	.	PUNCT
ajmri-3088	123	1	out	out	ADP
ajmri-3088	123	2	of	of	ADP
ajmri-3088	123	3	14	14	NUM
ajmri-3088	123	4	patients	patient	NOUN
ajmri-3088	123	5	,	,	PUNCT
ajmri-3088	123	6	nearly	nearly	ADV
ajmri-3088	123	7	2	2	NUM
ajmri-3088	123	8	patients	patient	NOUN
ajmri-3088	123	9	showed	show	VERB
ajmri-3088	123	10	more	more	ADJ
ajmri-3088	123	11	than	than	ADP
ajmri-3088	123	12	350	350	NUM
ajmri-3088	123	13	cells	cell	NOUN
ajmri-3088	123	14	/	/	SYM
ajmri-3088	123	15	mm3	mm3	NOUN
ajmri-3088	123	16	populations	population	NOUN
ajmri-3088	123	17	.	.	PUNCT
ajmri-3088	124	1	this	this	DET
ajmri-3088	124	2	variation	variation	NOUN
ajmri-3088	124	3	may	may	AUX
ajmri-3088	124	4	be	be	AUX
ajmri-3088	124	5	due	due	ADJ
ajmri-3088	124	6	to	to	ADP
ajmri-3088	124	7	the	the	DET
ajmri-3088	124	8	fact	fact	NOUN
ajmri-3088	124	9	that	that	SCONJ
ajmri-3088	124	10	either	either	CCONJ
ajmri-3088	124	11	the	the	DET
ajmri-3088	124	12	person	person	NOUN
ajmri-3088	124	13	’s	’s	PART
ajmri-3088	124	14	immune	immune	ADJ
ajmri-3088	124	15	system	system	NOUN
ajmri-3088	124	16	is	be	AUX
ajmri-3088	124	17	comparatively	comparatively	ADV
ajmri-3088	124	18	strong	strong	ADJ
ajmri-3088	124	19	or	or	CCONJ
ajmri-3088	124	20	the	the	DET
ajmri-3088	124	21	viral	viral	ADJ
ajmri-3088	124	22	exposure	exposure	NOUN
ajmri-3088	124	23	time	time	NOUN
ajmri-3088	124	24	is	be	AUX
ajmri-3088	124	25	comparatively	comparatively	ADV
ajmri-3088	124	26	short	short	ADJ
ajmri-3088	124	27	.	.	PUNCT
ajmri-3088	125	1	in	in	ADP
ajmri-3088	125	2	the	the	DET
ajmri-3088	125	3	case	case	NOUN
ajmri-3088	125	4	of	of	ADP
ajmri-3088	125	5	hiv	hiv	PROPN
ajmri-3088	125	6	mono	mono	NOUN
ajmri-3088	125	7	-	-	PUNCT
ajmri-3088	125	8	infection	infection	NOUN
ajmri-3088	125	9	,	,	PUNCT
ajmri-3088	125	10	nearly	nearly	ADV
ajmri-3088	125	11	25	25	NUM
ajmri-3088	125	12	patients	patient	NOUN
ajmri-3088	125	13	showed	show	VERB
ajmri-3088	125	14	less	less	ADJ
ajmri-3088	125	15	than	than	ADP
ajmri-3088	125	16	300	300	NUM
ajmri-3088	125	17	cells	cell	NOUN
ajmri-3088	125	18	/	/	SYM
ajmri-3088	125	19	mm3	mm3	PROPN
ajmri-3088	126	1	cd8	cd8	PROPN
ajmri-3088	126	2	+	+	X
ajmri-3088	126	3	count	count	NOUN
ajmri-3088	126	4	,	,	PUNCT
ajmri-3088	126	5	and	and	CCONJ
ajmri-3088	126	6	22.22	22.22	NUM
ajmri-3088	126	7	%	%	NOUN
ajmri-3088	126	8	of	of	ADP
ajmri-3088	126	9	hvb	hvb	NOUN
ajmri-3088	126	10	monoinfected	monoinfecte	VERB
ajmri-3088	126	11	patients	patient	NOUN
ajmri-3088	126	12	showed	show	VERB
ajmri-3088	126	13	depleted	depleted	ADJ
ajmri-3088	126	14	cd8	cd8	PROPN
ajmri-3088	126	15	+	+	PROPN
ajmri-3088	126	16	population	population	NOUN
ajmri-3088	126	17	.	.	PUNCT
ajmri-3088	127	1	it	it	PRON
ajmri-3088	127	2	is	be	AUX
ajmri-3088	127	3	notable	notable	ADJ
ajmri-3088	127	4	that	that	SCONJ
ajmri-3088	127	5	hiv	hiv	PROPN
ajmri-3088	127	6	/	/	SYM
ajmri-3088	127	7	hbv	hbv	NOUN
ajmri-3088	127	8	coinfection	coinfection	NOUN
ajmri-3088	127	9	decreases	decrease	VERB
ajmri-3088	127	10	the	the	DET
ajmri-3088	127	11	cd8	cd8	PROPN
ajmri-3088	127	12	+	+	PROPN
ajmri-3088	127	13	population	population	NOUN
ajmri-3088	127	14	in	in	ADP
ajmri-3088	127	15	an	an	DET
ajmri-3088	127	16	exponential	exponential	ADJ
ajmri-3088	127	17	pattern	pattern	NOUN
ajmri-3088	127	18	.	.	PUNCT
ajmri-3088	128	1	natural	natural	ADJ
ajmri-3088	128	2	killing	killing	NOUN
ajmri-3088	128	3	cells	cell	NOUN
ajmri-3088	128	4	(	(	PUNCT
ajmri-3088	128	5	cd16	cd16	PROPN
ajmri-3088	128	6	+	+	NOUN
ajmri-3088	128	7	56	56	NUM
ajmri-3088	128	8	)	)	PUNCT
ajmri-3088	128	9	subsets	subset	NOUN
ajmri-3088	128	10	cd16	cd16	PROPN
ajmri-3088	128	11	+	+	NOUN
ajmri-3088	128	12	56	56	NUM
ajmri-3088	128	13	cells	cell	NOUN
ajmri-3088	128	14	exhibit	exhibit	VERB
ajmri-3088	128	15	natural	natural	ADJ
ajmri-3088	128	16	antiviral	antiviral	ADJ
ajmri-3088	128	17	properties	property	NOUN
ajmri-3088	128	18	;	;	PUNCT
ajmri-3088	128	19	however	however	ADV
ajmri-3088	128	20	,	,	PUNCT
ajmri-3088	128	21	in	in	ADP
ajmri-3088	128	22	case	case	NOUN
ajmri-3088	128	23	of	of	ADP
ajmri-3088	128	24	hiv	hiv	PROPN
ajmri-3088	128	25	invasion	invasion	NOUN
ajmri-3088	128	26	,	,	PUNCT
ajmri-3088	128	27	the	the	DET
ajmri-3088	128	28	functioning	functioning	NOUN
ajmri-3088	128	29	and	and	CCONJ
ajmri-3088	128	30	population	population	NOUN
ajmri-3088	128	31	of	of	ADP
ajmri-3088	128	32	cd16	cd16	PROPN
ajmri-3088	128	33	+	+	PROPN
ajmri-3088	128	34	56	56	NUM
ajmri-3088	128	35	get	get	VERB
ajmri-3088	128	36	highly	highly	ADV
ajmri-3088	128	37	disturbed	disturbed	ADJ
ajmri-3088	128	38	.	.	PUNCT
ajmri-3088	129	1	this	this	PRON
ajmri-3088	129	2	usually	usually	ADV
ajmri-3088	129	3	results	result	VERB
ajmri-3088	129	4	in	in	ADP
ajmri-3088	129	5	a	a	DET
ajmri-3088	129	6	low	low	ADJ
ajmri-3088	129	7	cd16	cd16	PROPN
ajmri-3088	129	8	+	+	NOUN
ajmri-3088	129	9	56	56	NUM
ajmri-3088	129	10	population	population	NOUN
ajmri-3088	129	11	in	in	ADP
ajmri-3088	129	12	peripheral	peripheral	ADJ
ajmri-3088	129	13	blood	blood	NOUN
ajmri-3088	129	14	.	.	PUNCT
ajmri-3088	130	1	in	in	ADP
ajmri-3088	130	2	our	our	PRON
ajmri-3088	130	3	study	study	NOUN
ajmri-3088	130	4	,	,	PUNCT
ajmri-3088	130	5	nearly	nearly	ADV
ajmri-3088	130	6	50	50	NUM
ajmri-3088	130	7	%	%	NOUN
ajmri-3088	130	8	of	of	ADP
ajmri-3088	130	9	hiv	hiv	PROPN
ajmri-3088	130	10	patients	patient	NOUN
ajmri-3088	130	11	showed	show	VERB
ajmri-3088	130	12	(	(	PUNCT
ajmri-3088	130	13	cd16	cd16	PROPN
ajmri-3088	130	14	+	+	NOUN
ajmri-3088	130	15	56	56	NUM
ajmri-3088	130	16	)	)	PUNCT
ajmri-3088	130	17	cell	cell	NOUN
ajmri-3088	130	18	count	count	NOUN
ajmri-3088	130	19	lower	low	ADJ
ajmri-3088	130	20	than	than	ADP
ajmri-3088	130	21	300	300	NUM
ajmri-3088	130	22	cells	cell	NOUN
ajmri-3088	130	23	/	/	SYM
ajmri-3088	130	24	mm3	mm3	PROPN
ajmri-3088	130	25	.	.	PUNCT
ajmri-3088	131	1	a	a	DET
ajmri-3088	131	2	similar	similar	ADJ
ajmri-3088	131	3	trend	trend	NOUN
ajmri-3088	131	4	was	be	AUX
ajmri-3088	131	5	followed	follow	VERB
ajmri-3088	131	6	by	by	ADP
ajmri-3088	131	7	hbv	hbv	NOUN
ajmri-3088	131	8	patients	patient	NOUN
ajmri-3088	131	9	and	and	CCONJ
ajmri-3088	131	10	coinfected	coinfecte	VERB
ajmri-3088	131	11	hiv	hiv	PROPN
ajmri-3088	131	12	/	/	SYM
ajmri-3088	131	13	hbv	hbv	NOUN
ajmri-3088	131	14	patients	patient	NOUN
ajmri-3088	131	15	as	as	SCONJ
ajmri-3088	131	16	nearly	nearly	ADV
ajmri-3088	131	17	44	44	NUM
ajmri-3088	131	18	%	%	NOUN
ajmri-3088	131	19	and	and	CCONJ
ajmri-3088	131	20	64	64	NUM
ajmri-3088	131	21	%	%	NOUN
ajmri-3088	131	22	of	of	ADP
ajmri-3088	131	23	patients	patient	NOUN
ajmri-3088	131	24	showed	show	VERB
ajmri-3088	131	25	cell	cell	NOUN
ajmri-3088	131	26	count	count	NOUN
ajmri-3088	131	27	below	below	ADP
ajmri-3088	131	28	300	300	NUM
ajmri-3088	131	29	cell	cell	NOUN
ajmri-3088	131	30	/	/	SYM
ajmri-3088	131	31	mm3	mm3	NOUN
ajmri-3088	131	32	,	,	PUNCT
ajmri-3088	131	33	as	as	SCONJ
ajmri-3088	131	34	shown	show	VERB
ajmri-3088	131	35	in	in	ADP
ajmri-3088	131	36	table	table	NOUN
ajmri-3088	131	37	2	2	NUM
ajmri-3088	131	38	:	:	PUNCT
ajmri-3088	131	39	table	table	NOUN
ajmri-3088	131	40	2	2	NUM
ajmri-3088	131	41	shows	show	VERB
ajmri-3088	131	42	the	the	DET
ajmri-3088	131	43	demographic	demographic	ADJ
ajmri-3088	131	44	and	and	CCONJ
ajmri-3088	131	45	clinical	clinical	ADJ
ajmri-3088	131	46	parameters	parameter	NOUN
ajmri-3088	131	47	table	table	VERB
ajmri-3088	131	48	2	2	NUM
ajmri-3088	131	49	:	:	PUNCT
ajmri-3088	131	50	demographic	demographic	ADJ
ajmri-3088	131	51	and	and	CCONJ
ajmri-3088	131	52	clinical	clinical	ADJ
ajmri-3088	131	53	parameters	parameter	NOUN
ajmri-3088	131	54	of	of	ADP
ajmri-3088	131	55	patients	patient	NOUN
ajmri-3088	131	56	infected	infect	VERB
ajmri-3088	131	57	with	with	ADP
ajmri-3088	131	58	hiv	hiv	PROPN
ajmri-3088	131	59	,	,	PUNCT
ajmri-3088	131	60	hbv	hbv	NOUN
ajmri-3088	131	61	,	,	PUNCT
ajmri-3088	131	62	and	and	CCONJ
ajmri-3088	131	63	coinfected	coinfecte	VERB
ajmri-3088	131	64	with	with	ADP
ajmri-3088	131	65	hiv/	hiv/	NOUN
ajmri-3088	131	66	hbv	hbv	NOUN
ajmri-3088	131	67	and	and	CCONJ
ajmri-3088	131	68	cd16	cd16	PROPN
ajmri-3088	131	69	+	+	PROPN
ajmri-3088	131	70	56	56	NUM
ajmri-3088	131	71	count	count	NOUN
ajmri-3088	131	72	studied	study	VERB
ajmri-3088	131	73	parameters	parameter	NOUN
ajmri-3088	131	74	hiv	hiv	PROPN
ajmri-3088	131	75	-	-	PUNCT
ajmri-3088	131	76	infected	infect	VERB
ajmri-3088	131	77	patients	patient	NOUN
ajmri-3088	131	78	(	(	PUNCT
ajmri-3088	131	79	n%	n%	NOUN
ajmri-3088	131	80	)	)	PUNCT
ajmri-3088	131	81	hbv	hbv	NOUN
ajmri-3088	131	82	-	-	PUNCT
ajmri-3088	131	83	infected	infect	VERB
ajmri-3088	131	84	patients	patient	NOUN
ajmri-3088	131	85	(	(	PUNCT
ajmri-3088	131	86	n%	n%	X
ajmri-3088	131	87	)	)	PUNCT
ajmri-3088	131	88	hiv	hiv	PROPN
ajmri-3088	131	89	patients	patient	NOUN
ajmri-3088	131	90	co	co	VERB
ajmri-3088	131	91	-	-	VERB
ajmri-3088	131	92	infected	infect	VERB
ajmri-3088	131	93	with	with	ADP
ajmri-3088	131	94	hbv	hbv	NOUN
ajmri-3088	131	95	(	(	PUNCT
ajmri-3088	131	96	n%	n%	NOUN
ajmri-3088	131	97	)	)	PUNCT
ajmri-3088	131	98	no	no	NOUN
ajmri-3088	131	99	of	of	ADP
ajmri-3088	131	100	participants	participant	NOUN
ajmri-3088	131	101	(	(	PUNCT
ajmri-3088	131	102	35	35	NUM
ajmri-3088	131	103	)	)	PUNCT
ajmri-3088	131	104	12	12	NUM
ajmri-3088	131	105	(	(	PUNCT
ajmri-3088	131	106	100.00	100.00	NUM
ajmri-3088	131	107	)	)	PUNCT
ajmri-3088	131	108	9	9	NUM
ajmri-3088	131	109	(	(	PUNCT
ajmri-3088	131	110	100.00	100.00	NUM
ajmri-3088	131	111	)	)	PUNCT
ajmri-3088	131	112	14(100.00	14(100.00	NUM
ajmri-3088	131	113	)	)	PUNCT
ajmri-3088	131	114	age	age	NOUN
ajmri-3088	131	115	factor	factor	NOUN
ajmri-3088	131	116	(	(	PUNCT
ajmri-3088	131	117	years	year	NOUN
ajmri-3088	131	118	)	)	PUNCT
ajmri-3088	131	119	mean	mean	VERB
ajmri-3088	131	120	±sd	±sd	PRON
ajmri-3088	131	121	21.43±4.08	21.43±4.08	NUM
ajmri-3088	131	122	17.01±3.01	17.01±3.01	NUM
ajmri-3088	131	123	16.07±3.11	16.07±3.11	NUM
ajmri-3088	131	124	0	0	NUM
ajmri-3088	131	125	-	-	SYM
ajmri-3088	131	126	15	15	NUM
ajmri-3088	131	127	years	year	NOUN
ajmri-3088	131	128	1	1	NUM
ajmri-3088	131	129	(	(	PUNCT
ajmri-3088	131	130	8.3	8.3	NUM
ajmri-3088	131	131	)	)	PUNCT
ajmri-3088	131	132	3	3	NUM
ajmri-3088	131	133	(	(	PUNCT
ajmri-3088	131	134	33.33	33.33	NUM
ajmri-3088	131	135	)	)	PUNCT
ajmri-3088	131	136	2	2	NUM
ajmri-3088	131	137	(	(	PUNCT
ajmri-3088	131	138	14.28	14.28	NUM
ajmri-3088	131	139	)	)	PUNCT
ajmri-3088	131	140	16	16	NUM
ajmri-3088	131	141	-	-	SYM
ajmri-3088	131	142	21	21	NUM
ajmri-3088	131	143	years	year	NOUN
ajmri-3088	131	144	4	4	NUM
ajmri-3088	131	145	(	(	PUNCT
ajmri-3088	131	146	33.3	33.3	NUM
ajmri-3088	131	147	)	)	SYM
ajmri-3088	131	148	2	2	NUM
ajmri-3088	131	149	(	(	PUNCT
ajmri-3088	131	150	22.22	22.22	NUM
ajmri-3088	131	151	)	)	PUNCT
ajmri-3088	131	152	3	3	NUM
ajmri-3088	131	153	(	(	PUNCT
ajmri-3088	131	154	21.42	21.42	NUM
ajmri-3088	131	155	)	)	PUNCT
ajmri-3088	131	156	22	22	NUM
ajmri-3088	131	157	-	-	SYM
ajmri-3088	131	158	37	37	NUM
ajmri-3088	131	159	years	year	NOUN
ajmri-3088	131	160	5	5	NUM
ajmri-3088	131	161	(	(	PUNCT
ajmri-3088	131	162	41.66	41.66	NUM
ajmri-3088	131	163	)	)	PUNCT
ajmri-3088	131	164	3	3	NUM
ajmri-3088	131	165	(	(	PUNCT
ajmri-3088	131	166	33.33	33.33	NUM
ajmri-3088	131	167	)	)	PUNCT
ajmri-3088	131	168	8	8	NUM
ajmri-3088	131	169	(	(	PUNCT
ajmri-3088	131	170	57.14	57.14	NUM
ajmri-3088	131	171	)	)	PUNCT
ajmri-3088	131	172	38	38	NUM
ajmri-3088	131	173	-	-	SYM
ajmri-3088	131	174	53	53	NUM
ajmri-3088	131	175	years	year	NOUN
ajmri-3088	131	176	1	1	NUM
ajmri-3088	131	177	(	(	PUNCT
ajmri-3088	131	178	8.3	8.3	NUM
ajmri-3088	131	179	)	)	SYM
ajmri-3088	131	180	1	1	NUM
ajmri-3088	131	181	(	(	PUNCT
ajmri-3088	131	182	11.11	11.11	NUM
ajmri-3088	131	183	)	)	PUNCT
ajmri-3088	131	184	1	1	NUM
ajmri-3088	131	185	(	(	PUNCT
ajmri-3088	131	186	7.14	7.14	NUM
ajmri-3088	131	187	)	)	PUNCT
ajmri-3088	131	188	pa	pa	PROPN
ajmri-3088	131	189	ge	ge	PROPN
ajmri-3088	131	190	54	54	NUM
ajmri-3088	131	191	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	131	192	am	am	NOUN
ajmri-3088	131	193	.	.	PUNCT
ajmri-3088	132	1	j.	j.	PROPN
ajmri-3088	132	2	multidis	multidis	PROPN
ajmri-3088	132	3	.	.	PUNCT
ajmri-3088	133	1	res	re	NOUN
ajmri-3088	133	2	.	.	PUNCT
ajmri-3088	134	1	innov	innov	PROPN
ajmri-3088	134	2	.	.	PUNCT
ajmri-3088	135	1	3(5	3(5	NUM
ajmri-3088	135	2	)	)	PUNCT
ajmri-3088	135	3	50	50	NUM
ajmri-3088	135	4	-	-	SYM
ajmri-3088	135	5	60	60	NUM
ajmri-3088	135	6	,	,	PUNCT
ajmri-3088	135	7	2024	2024	NUM
ajmri-3088	135	8	>	>	SYM
ajmri-3088	135	9	53	53	NUM
ajmri-3088	135	10	years	year	NOUN
ajmri-3088	135	11	1	1	NUM
ajmri-3088	135	12	(	(	PUNCT
ajmri-3088	135	13	8.3	8.3	NUM
ajmri-3088	135	14	)	)	PUNCT
ajmri-3088	135	15	0(0.00	0(0.00	NUM
ajmri-3088	135	16	)	)	PUNCT
ajmri-3088	135	17	0	0	NUM
ajmri-3088	136	1	(	(	PUNCT
ajmri-3088	136	2	0.00	0.00	NUM
ajmri-3088	136	3	)	)	PUNCT
ajmri-3088	136	4	gender	gender	NOUN
ajmri-3088	136	5	male	male	NOUN
ajmri-3088	136	6	3	3	NUM
ajmri-3088	136	7	(	(	PUNCT
ajmri-3088	136	8	25	25	NUM
ajmri-3088	136	9	)	)	PUNCT
ajmri-3088	136	10	4	4	NUM
ajmri-3088	136	11	(	(	PUNCT
ajmri-3088	136	12	44.44	44.44	NUM
ajmri-3088	136	13	)	)	PUNCT
ajmri-3088	136	14	5	5	NUM
ajmri-3088	136	15	(	(	PUNCT
ajmri-3088	136	16	35.7	35.7	NUM
ajmri-3088	136	17	)	)	PUNCT
ajmri-3088	136	18	female	female	ADJ
ajmri-3088	136	19	9	9	NUM
ajmri-3088	136	20	(	(	PUNCT
ajmri-3088	136	21	75	75	NUM
ajmri-3088	136	22	)	)	PUNCT
ajmri-3088	136	23	5	5	NUM
ajmri-3088	136	24	(	(	PUNCT
ajmri-3088	136	25	55.55	55.55	NUM
ajmri-3088	136	26	)	)	PUNCT
ajmri-3088	136	27	9	9	NUM
ajmri-3088	136	28	(	(	PUNCT
ajmri-3088	136	29	64.28	64.28	NUM
ajmri-3088	136	30	)	)	PUNCT
ajmri-3088	136	31	mode	mode	NOUN
ajmri-3088	136	32	of	of	ADP
ajmri-3088	136	33	acquired	acquire	VERB
ajmri-3088	136	34	infection	infection	NOUN
ajmri-3088	136	35	intravenous	intravenous	ADJ
ajmri-3088	136	36	drug	drug	NOUN
ajmri-3088	136	37	usage	usage	NOUN
ajmri-3088	136	38	3	3	NUM
ajmri-3088	136	39	(	(	PUNCT
ajmri-3088	136	40	25	25	NUM
ajmri-3088	136	41	)	)	PUNCT
ajmri-3088	136	42	1	1	NUM
ajmri-3088	136	43	(	(	PUNCT
ajmri-3088	136	44	11.11	11.11	NUM
ajmri-3088	136	45	)	)	PUNCT
ajmri-3088	136	46	3	3	NUM
ajmri-3088	136	47	(	(	PUNCT
ajmri-3088	136	48	21.42	21.42	NUM
ajmri-3088	136	49	)	)	PUNCT
ajmri-3088	136	50	sexual	sexual	ADJ
ajmri-3088	136	51	practices	practice	NOUN
ajmri-3088	136	52	3	3	NUM
ajmri-3088	136	53	(	(	PUNCT
ajmri-3088	136	54	25	25	NUM
ajmri-3088	136	55	)	)	PUNCT
ajmri-3088	136	56	3	3	NUM
ajmri-3088	136	57	(	(	PUNCT
ajmri-3088	136	58	33.33	33.33	NUM
ajmri-3088	136	59	)	)	PUNCT
ajmri-3088	136	60	4	4	NUM
ajmri-3088	136	61	(	(	PUNCT
ajmri-3088	136	62	28.57	28.57	NUM
ajmri-3088	136	63	)	)	PUNCT
ajmri-3088	136	64	vertical	vertical	ADJ
ajmri-3088	136	65	transmissions	transmission	NOUN
ajmri-3088	136	66	4	4	NUM
ajmri-3088	136	67	(	(	PUNCT
ajmri-3088	136	68	30.7	30.7	NUM
ajmri-3088	136	69	)	)	SYM
ajmri-3088	136	70	2	2	NUM
ajmri-3088	136	71	(	(	PUNCT
ajmri-3088	136	72	22.22	22.22	NUM
ajmri-3088	136	73	)	)	PUNCT
ajmri-3088	136	74	5	5	NUM
ajmri-3088	136	75	(	(	PUNCT
ajmri-3088	136	76	35.71	35.71	NUM
ajmri-3088	136	77	)	)	PUNCT
ajmri-3088	136	78	unhygienic	unhygienic	ADJ
ajmri-3088	136	79	surroundings	surrounding	NOUN
ajmri-3088	136	80	2	2	NUM
ajmri-3088	136	81	(	(	PUNCT
ajmri-3088	136	82	16.66	16.66	NUM
ajmri-3088	136	83	)	)	PUNCT
ajmri-3088	136	84	3	3	NUM
ajmri-3088	136	85	(	(	PUNCT
ajmri-3088	136	86	33.33	33.33	NUM
ajmri-3088	136	87	)	)	PUNCT
ajmri-3088	136	88	2	2	NUM
ajmri-3088	136	89	(	(	PUNCT
ajmri-3088	136	90	14.28	14.28	NUM
ajmri-3088	136	91	)	)	PUNCT
ajmri-3088	136	92	duration	duration	NOUN
ajmri-3088	136	93	of	of	ADP
ajmri-3088	136	94	diagnosis	diagnosis	NOUN
ajmri-3088	136	95	0	0	NUM
ajmri-3088	136	96	-	-	SYM
ajmri-3088	136	97	6	6	NUM
ajmri-3088	136	98	months	month	NOUN
ajmri-3088	136	99	3	3	NUM
ajmri-3088	136	100	(	(	PUNCT
ajmri-3088	136	101	25	25	NUM
ajmri-3088	136	102	)	)	SYM
ajmri-3088	136	103	2	2	NUM
ajmri-3088	136	104	(	(	PUNCT
ajmri-3088	136	105	22.22	22.22	NUM
ajmri-3088	136	106	)	)	PUNCT
ajmri-3088	136	107	6	6	NUM
ajmri-3088	136	108	(	(	PUNCT
ajmri-3088	136	109	35.29	35.29	NUM
ajmri-3088	136	110	)	)	PUNCT
ajmri-3088	136	111	7	7	NUM
ajmri-3088	136	112	-	-	SYM
ajmri-3088	136	113	12	12	NUM
ajmri-3088	136	114	months	month	NOUN
ajmri-3088	136	115	6	6	NUM
ajmri-3088	136	116	(	(	PUNCT
ajmri-3088	136	117	50	50	NUM
ajmri-3088	136	118	)	)	PUNCT
ajmri-3088	136	119	3	3	NUM
ajmri-3088	136	120	(	(	PUNCT
ajmri-3088	136	121	33.33	33.33	NUM
ajmri-3088	136	122	)	)	PUNCT
ajmri-3088	136	123	4	4	NUM
ajmri-3088	136	124	(	(	PUNCT
ajmri-3088	136	125	28.57	28.57	NUM
ajmri-3088	136	126	)	)	PUNCT
ajmri-3088	136	127	13	13	NUM
ajmri-3088	136	128	-	-	SYM
ajmri-3088	136	129	19	19	NUM
ajmri-3088	136	130	months	month	NOUN
ajmri-3088	136	131	3	3	NUM
ajmri-3088	136	132	(	(	PUNCT
ajmri-3088	136	133	25	25	NUM
ajmri-3088	136	134	)	)	PUNCT
ajmri-3088	136	135	3	3	NUM
ajmri-3088	136	136	(	(	PUNCT
ajmri-3088	136	137	33.33	33.33	NUM
ajmri-3088	136	138	)	)	PUNCT
ajmri-3088	136	139	2	2	NUM
ajmri-3088	136	140	(	(	PUNCT
ajmri-3088	136	141	14.28	14.28	NUM
ajmri-3088	136	142	)	)	PUNCT
ajmri-3088	136	143	20	20	NUM
ajmri-3088	136	144	-	-	SYM
ajmri-3088	136	145	26	26	NUM
ajmri-3088	136	146	months	month	NOUN
ajmri-3088	136	147	0	0	PUNCT
ajmri-3088	136	148	(	(	PUNCT
ajmri-3088	136	149	0.00	0.00	NUM
ajmri-3088	136	150	)	)	PUNCT
ajmri-3088	136	151	1(1.11	1(1.11	NUM
ajmri-3088	136	152	)	)	PUNCT
ajmri-3088	136	153	2	2	NUM
ajmri-3088	136	154	(	(	PUNCT
ajmri-3088	136	155	14.28	14.28	NUM
ajmri-3088	136	156	)	)	PUNCT
ajmri-3088	136	157	cd16	cd16	PROPN
ajmri-3088	136	158	+	+	PROPN
ajmri-3088	136	159	56	56	NUM
ajmri-3088	136	160	>	>	SYM
ajmri-3088	136	161	500	500	NUM
ajmri-3088	136	162	1	1	NUM
ajmri-3088	136	163	(	(	PUNCT
ajmri-3088	136	164	8.33	8.33	NUM
ajmri-3088	136	165	)	)	PUNCT
ajmri-3088	136	166	2	2	NUM
ajmri-3088	136	167	(	(	PUNCT
ajmri-3088	136	168	11.11	11.11	NUM
ajmri-3088	136	169	)	)	PUNCT
ajmri-3088	136	170	2	2	NUM
ajmri-3088	136	171	(	(	PUNCT
ajmri-3088	136	172	14.28	14.28	NUM
ajmri-3088	136	173	)	)	PUNCT
ajmri-3088	136	174	350	350	NUM
ajmri-3088	136	175	-	-	SYM
ajmri-3088	136	176	500	500	NUM
ajmri-3088	136	177	2	2	NUM
ajmri-3088	136	178	(	(	PUNCT
ajmri-3088	136	179	16.66	16.66	NUM
ajmri-3088	136	180	)	)	SYM
ajmri-3088	136	181	2	2	NUM
ajmri-3088	136	182	(	(	PUNCT
ajmri-3088	136	183	22.22	22.22	NUM
ajmri-3088	136	184	)	)	PUNCT
ajmri-3088	136	185	1	1	NUM
ajmri-3088	136	186	(	(	PUNCT
ajmri-3088	136	187	7	7	NUM
ajmri-3088	136	188	)	)	PUNCT
ajmri-3088	136	189	200	200	NUM
ajmri-3088	136	190	-	-	SYM
ajmri-3088	136	191	350	350	NUM
ajmri-3088	136	192	6	6	NUM
ajmri-3088	136	193	(	(	PUNCT
ajmri-3088	136	194	50	50	NUM
ajmri-3088	136	195	)	)	PUNCT
ajmri-3088	136	196	4	4	NUM
ajmri-3088	136	197	(	(	PUNCT
ajmri-3088	136	198	44.44	44.44	NUM
ajmri-3088	136	199	)	)	PUNCT
ajmri-3088	136	200	9	9	NUM
ajmri-3088	136	201	(	(	PUNCT
ajmri-3088	136	202	64	64	NUM
ajmri-3088	136	203	)	)	PUNCT
ajmri-3088	137	1	<	<	X
ajmri-3088	137	2	200	200	NUM
ajmri-3088	137	3	4	4	NUM
ajmri-3088	137	4	(	(	PUNCT
ajmri-3088	137	5	25	25	NUM
ajmri-3088	137	6	)	)	PUNCT
ajmri-3088	137	7	1	1	NUM
ajmri-3088	137	8	(	(	PUNCT
ajmri-3088	137	9	11.11	11.11	NUM
ajmri-3088	137	10	)	)	PUNCT
ajmri-3088	137	11	2	2	NUM
ajmri-3088	137	12	(	(	PUNCT
ajmri-3088	137	13	14.28	14.28	NUM
ajmri-3088	137	14	)	)	PUNCT
ajmri-3088	137	15	undertaken	undertake	VERB
ajmri-3088	137	16	to	to	PART
ajmri-3088	137	17	conduct	conduct	VERB
ajmri-3088	137	18	the	the	DET
ajmri-3088	137	19	study	study	NOUN
ajmri-3088	137	20	.	.	PUNCT
ajmri-3088	138	1	the	the	DET
ajmri-3088	138	2	median	median	ADJ
ajmri-3088	138	3	age	age	NOUN
ajmri-3088	138	4	for	for	ADP
ajmri-3088	138	5	hiv	hiv	PROPN
ajmri-3088	138	6	-	-	PUNCT
ajmri-3088	138	7	positive	positive	ADJ
ajmri-3088	138	8	patients	patient	NOUN
ajmri-3088	138	9	is	be	AUX
ajmri-3088	138	10	21.43±4.08	21.43±4.08	NUM
ajmri-3088	138	11	.	.	PUNCT
ajmri-3088	139	1	for	for	ADP
ajmri-3088	139	2	hbv	hbv	NOUN
ajmri-3088	139	3	-	-	PUNCT
ajmri-3088	139	4	positive	positive	ADJ
ajmri-3088	139	5	patients	patient	NOUN
ajmri-3088	139	6	,	,	PUNCT
ajmri-3088	139	7	it	it	PRON
ajmri-3088	139	8	is	be	AUX
ajmri-3088	139	9	24.01±3.01	24.01±3.01	NUM
ajmri-3088	139	10	,	,	PUNCT
ajmri-3088	139	11	and	and	CCONJ
ajmri-3088	139	12	for	for	ADP
ajmri-3088	139	13	hiv	hiv	PROPN
ajmri-3088	139	14	/	/	SYM
ajmri-3088	139	15	hbv	hbv	NOUN
ajmri-3088	139	16	patients	patient	NOUN
ajmri-3088	139	17	is	be	AUX
ajmri-3088	139	18	26.07±3.11	26.07±3.11	NUM
ajmri-3088	139	19	.	.	PUNCT
ajmri-3088	140	1	the	the	DET
ajmri-3088	140	2	significance	significance	NOUN
ajmri-3088	140	3	value	value	NOUN
ajmri-3088	140	4	for	for	ADP
ajmri-3088	140	5	cd16	cd16	PROPN
ajmri-3088	140	6	+	+	NOUN
ajmri-3088	140	7	56	56	NUM
ajmri-3088	140	8	cell	cell	NOUN
ajmri-3088	140	9	count	count	NOUN
ajmri-3088	140	10	is	be	AUX
ajmri-3088	140	11	<	<	X
ajmri-3088	140	12	0.01	0.01	NUM
ajmri-3088	140	13	cdcd16	cdcd16	NOUN
ajmri-3088	140	14	+	+	SYM
ajmri-3088	140	15	56	56	NUM
ajmri-3088	140	16	population	population	NOUN
ajmri-3088	140	17	has	have	AUX
ajmri-3088	140	18	also	also	ADV
ajmri-3088	140	19	shown	show	VERB
ajmri-3088	140	20	prominent	prominent	ADJ
ajmri-3088	140	21	variation	variation	NOUN
ajmri-3088	140	22	in	in	ADP
ajmri-3088	140	23	all	all	DET
ajmri-3088	140	24	three	three	NUM
ajmri-3088	140	25	sets	set	NOUN
ajmri-3088	140	26	of	of	ADP
ajmri-3088	140	27	samples	sample	NOUN
ajmri-3088	140	28	,	,	PUNCT
ajmri-3088	140	29	i.e.	i.e.	X
ajmri-3088	140	30	,	,	PUNCT
ajmri-3088	140	31	hiv	hiv	PROPN
ajmri-3088	140	32	monoinfected	monoinfecte	VERB
ajmri-3088	140	33	patients	patient	NOUN
ajmri-3088	140	34	,	,	PUNCT
ajmri-3088	140	35	hib	hib	PROPN
ajmri-3088	140	36	mono	mono	NOUN
ajmri-3088	140	37	-	-	PUNCT
ajmri-3088	140	38	infected	infect	VERB
ajmri-3088	140	39	patients	patient	NOUN
ajmri-3088	140	40	,	,	PUNCT
ajmri-3088	140	41	and	and	CCONJ
ajmri-3088	140	42	hiv/	hiv/	PROPN
ajmri-3088	140	43	hbv	hbv	NOUN
ajmri-3088	140	44	coinfected	coinfecte	VERB
ajmri-3088	140	45	patients	patient	NOUN
ajmri-3088	140	46	.	.	PUNCT
ajmri-3088	141	1	64	64	NUM
ajmri-3088	141	2	%	%	NOUN
ajmri-3088	141	3	of	of	ADP
ajmri-3088	141	4	hiv	hiv	PROPN
ajmri-3088	141	5	/	/	SYM
ajmri-3088	141	6	hbv	hbv	PROPN
ajmri-3088	141	7	coinfected	coinfecte	VERB
ajmri-3088	141	8	patients	patient	NOUN
ajmri-3088	141	9	had	have	AUX
ajmri-3088	141	10	cdcd16	cdcd16	ADJ
ajmri-3088	141	11	+	+	ADP
ajmri-3088	141	12	56	56	NUM
ajmri-3088	141	13	depleted	deplete	VERB
ajmri-3088	141	14	to	to	ADP
ajmri-3088	141	15	dangerous	dangerous	ADJ
ajmri-3088	141	16	levels	level	NOUN
ajmri-3088	141	17	.	.	PUNCT
ajmri-3088	142	1	the	the	DET
ajmri-3088	142	2	cell	cell	NOUN
ajmri-3088	142	3	count	count	NOUN
ajmri-3088	142	4	depletion	depletion	NOUN
ajmri-3088	142	5	in	in	ADP
ajmri-3088	142	6	hiv	hiv	PROPN
ajmri-3088	142	7	/	/	SYM
ajmri-3088	142	8	hbv	hbv	PROPN
ajmri-3088	142	9	was	be	AUX
ajmri-3088	142	10	14	14	NUM
ajmri-3088	142	11	%	%	NOUN
ajmri-3088	142	12	more	more	ADJ
ajmri-3088	142	13	in	in	ADP
ajmri-3088	142	14	mono	mono	NOUN
ajmri-3088	142	15	-	-	PUNCT
ajmri-3088	142	16	infected	infect	VERB
ajmri-3088	142	17	hiv	hiv	PROPN
ajmri-3088	142	18	patients	patient	NOUN
ajmri-3088	142	19	and	and	CCONJ
ajmri-3088	142	20	nearly	nearly	ADV
ajmri-3088	142	21	20	20	NUM
ajmri-3088	142	22	%	%	NOUN
ajmri-3088	142	23	more	more	ADJ
ajmri-3088	142	24	in	in	ADP
ajmri-3088	142	25	hbv	hbv	NOUN
ajmri-3088	142	26	mono	mono	NOUN
ajmri-3088	142	27	-	-	PUNCT
ajmri-3088	142	28	infected	infect	VERB
ajmri-3088	142	29	patients	patient	NOUN
ajmri-3088	142	30	.	.	PUNCT
ajmri-3088	143	1	implicating	implicate	VERB
ajmri-3088	143	2	the	the	DET
ajmri-3088	143	3	results	result	NOUN
ajmri-3088	143	4	attained	attain	VERB
ajmri-3088	143	5	through	through	ADP
ajmri-3088	143	6	this	this	DET
ajmri-3088	143	7	research	research	NOUN
ajmri-3088	143	8	,	,	PUNCT
ajmri-3088	143	9	the	the	DET
ajmri-3088	143	10	complex	complex	ADJ
ajmri-3088	143	11	interactions	interaction	NOUN
ajmri-3088	143	12	between	between	ADP
ajmri-3088	143	13	coinfections	coinfection	NOUN
ajmri-3088	143	14	with	with	ADP
ajmri-3088	143	15	hiv	hiv	PROPN
ajmri-3088	143	16	and	and	CCONJ
ajmri-3088	143	17	hbv	hbv	NOUN
ajmri-3088	143	18	can	can	AUX
ajmri-3088	143	19	be	be	AUX
ajmri-3088	143	20	better	well	ADV
ajmri-3088	143	21	understood	understand	VERB
ajmri-3088	143	22	,	,	PUNCT
ajmri-3088	143	23	and	and	CCONJ
ajmri-3088	143	24	potential	potential	ADJ
ajmri-3088	143	25	synergistic	synergistic	ADJ
ajmri-3088	143	26	effects	effect	NOUN
ajmri-3088	143	27	that	that	PRON
ajmri-3088	143	28	could	could	AUX
ajmri-3088	143	29	worsen	worsen	VERB
ajmri-3088	143	30	cellular	cellular	ADJ
ajmri-3088	143	31	depletion	depletion	NOUN
ajmri-3088	143	32	are	be	AUX
ajmri-3088	143	33	shown	show	VERB
ajmri-3088	143	34	.	.	PUNCT
ajmri-3088	144	1	understanding	understand	VERB
ajmri-3088	144	2	these	these	DET
ajmri-3088	144	3	disparities	disparity	NOUN
ajmri-3088	144	4	is	be	AUX
ajmri-3088	144	5	crucial	crucial	ADJ
ajmri-3088	144	6	for	for	ADP
ajmri-3088	144	7	customized	customize	VERB
ajmri-3088	144	8	treatment	treatment	NOUN
ajmri-3088	144	9	approaches	approach	NOUN
ajmri-3088	144	10	and	and	CCONJ
ajmri-3088	144	11	emphasizes	emphasize	VERB
ajmri-3088	144	12	the	the	DET
ajmri-3088	144	13	necessity	necessity	NOUN
ajmri-3088	144	14	of	of	ADP
ajmri-3088	144	15	attentive	attentive	ADJ
ajmri-3088	144	16	observation	observation	NOUN
ajmri-3088	144	17	in	in	ADP
ajmri-3088	144	18	coinfected	coinfecte	VERB
ajmri-3088	144	19	groups	group	NOUN
ajmri-3088	144	20	to	to	PART
ajmri-3088	144	21	alleviate	alleviate	VERB
ajmri-3088	144	22	unfavorable	unfavorable	ADJ
ajmri-3088	144	23	consequences	consequence	NOUN
ajmri-3088	144	24	linked	link	VERB
ajmri-3088	144	25	to	to	AUX
ajmri-3088	144	26	cdcd16	cdcd16	VERB
ajmri-3088	144	27	+	+	PROPN
ajmri-3088	144	28	56	56	NUM
ajmri-3088	144	29	depletion	depletion	NOUN
ajmri-3088	144	30	.	.	PUNCT
ajmri-3088	145	1	naive	naive	ADJ
ajmri-3088	145	2	t	t	PROPN
ajmri-3088	145	3	-	-	PUNCT
ajmri-3088	145	4	cells	cell	NOUN
ajmri-3088	145	5	(	(	PUNCT
ajmri-3088	145	6	cd45ra	cd45ra	ADJ
ajmri-3088	145	7	subsets	subset	NOUN
ajmri-3088	145	8	)	)	PUNCT
ajmri-3088	145	9	correlational	correlational	ADJ
ajmri-3088	145	10	analysis	analysis	NOUN
ajmri-3088	145	11	of	of	ADP
ajmri-3088	145	12	(	(	PUNCT
ajmri-3088	145	13	cd16	cd16	PROPN
ajmri-3088	145	14	+	+	NOUN
ajmri-3088	145	15	56	56	NUM
ajmri-3088	145	16	)	)	PUNCT
ajmri-3088	145	17	cell	cell	NOUN
ajmri-3088	145	18	count	count	NOUN
ajmri-3088	145	19	and	and	CCONJ
ajmri-3088	145	20	coinfection	coinfection	NOUN
ajmri-3088	145	21	of	of	ADP
ajmri-3088	145	22	hiv	hiv	PROPN
ajmri-3088	145	23	/	/	SYM
ajmri-3088	145	24	hbv	hbv	PROPN
ajmri-3088	145	25	showed	show	VERB
ajmri-3088	145	26	a	a	DET
ajmri-3088	145	27	negative	negative	ADJ
ajmri-3088	145	28	association	association	NOUN
ajmri-3088	145	29	between	between	ADP
ajmri-3088	145	30	them	they	PRON
ajmri-3088	145	31	.	.	PUNCT
ajmri-3088	146	1	the	the	DET
ajmri-3088	146	2	same	same	ADJ
ajmri-3088	146	3	results	result	NOUN
ajmri-3088	146	4	were	be	AUX
ajmri-3088	146	5	obtained	obtain	VERB
ajmri-3088	146	6	for	for	ADP
ajmri-3088	146	7	monoinfection	monoinfection	NOUN
ajmri-3088	146	8	of	of	ADP
ajmri-3088	146	9	hiv	hiv	PROPN
ajmri-3088	146	10	and	and	CCONJ
ajmri-3088	146	11	hbv	hbv	NOUN
ajmri-3088	146	12	.	.	PUNCT
ajmri-3088	147	1	this	this	DET
ajmri-3088	147	2	negative	negative	ADJ
ajmri-3088	147	3	association	association	NOUN
ajmri-3088	147	4	proved	prove	VERB
ajmri-3088	147	5	to	to	PART
ajmri-3088	147	6	be	be	AUX
ajmri-3088	147	7	significant	significant	ADJ
ajmri-3088	147	8	statistically	statistically	ADV
ajmri-3088	147	9	,	,	PUNCT
ajmri-3088	147	10	giving	give	VERB
ajmri-3088	147	11	a	a	DET
ajmri-3088	147	12	p	p	NOUN
ajmri-3088	147	13	-	-	PUNCT
ajmri-3088	147	14	value	value	NOUN
ajmri-3088	147	15	of	of	ADP
ajmri-3088	147	16	<	<	X
ajmri-3088	147	17	0.01	0.01	NUM
ajmri-3088	147	18	.	.	PUNCT
ajmri-3088	147	19	table	table	NOUN
ajmri-3088	147	20	3	3	NUM
ajmri-3088	147	21	below	below	ADV
ajmri-3088	147	22	indicates	indicate	VERB
ajmri-3088	147	23	58.33	58.33	NUM
ajmri-3088	147	24	%	%	NOUN
ajmri-3088	147	25	hiv	hiv	PROPN
ajmri-3088	147	26	,	,	PUNCT
ajmri-3088	147	27	55.55	55.55	NUM
ajmri-3088	147	28	%	%	NOUN
ajmri-3088	147	29	hbv	hbv	NOUN
ajmri-3088	147	30	,	,	PUNCT
ajmri-3088	147	31	and	and	CCONJ
ajmri-3088	147	32	64.28	64.28	NUM
ajmri-3088	147	33	%	%	NOUN
ajmri-3088	147	34	hiv	hiv	PROPN
ajmri-3088	147	35	/	/	SYM
ajmri-3088	147	36	hbv	hbv	NOUN
ajmri-3088	147	37	patients	patient	NOUN
ajmri-3088	147	38	showed	show	VERB
ajmri-3088	147	39	cell	cell	NOUN
ajmri-3088	147	40	count	count	NOUN
ajmri-3088	147	41	below	below	ADP
ajmri-3088	147	42	normal	normal	ADJ
ajmri-3088	147	43	ranges	range	NOUN
ajmri-3088	147	44	,	,	PUNCT
ajmri-3088	147	45	i.e.	i.e.	X
ajmri-3088	147	46	,	,	PUNCT
ajmri-3088	147	47	300	300	NUM
ajmri-3088	147	48	-	-	SYM
ajmri-3088	147	49	350	350	NUM
ajmri-3088	147	50	cells	cell	NOUN
ajmri-3088	147	51	/	/	SYM
ajmri-3088	147	52	mm3	mm3	NOUN
ajmri-3088	147	53	.	.	PUNCT
ajmri-3088	147	54	table	table	NOUN
ajmri-3088	147	55	3	3	NUM
ajmri-3088	147	56	shows	show	VERB
ajmri-3088	147	57	the	the	DET
ajmri-3088	147	58	demographic	demographic	ADJ
ajmri-3088	147	59	and	and	CCONJ
ajmri-3088	147	60	clinical	clinical	ADJ
ajmri-3088	147	61	parameters	parameter	NOUN
ajmri-3088	147	62	table	table	VERB
ajmri-3088	147	63	3	3	NUM
ajmri-3088	147	64	:	:	PUNCT
ajmri-3088	147	65	demographic	demographic	ADJ
ajmri-3088	147	66	and	and	CCONJ
ajmri-3088	147	67	clinical	clinical	ADJ
ajmri-3088	147	68	parameters	parameter	NOUN
ajmri-3088	147	69	of	of	ADP
ajmri-3088	147	70	patients	patient	NOUN
ajmri-3088	147	71	infected	infect	VERB
ajmri-3088	147	72	with	with	ADP
ajmri-3088	147	73	hiv	hiv	PROPN
ajmri-3088	147	74	,	,	PUNCT
ajmri-3088	147	75	hbv	hbv	NOUN
ajmri-3088	147	76	,	,	PUNCT
ajmri-3088	147	77	and	and	CCONJ
ajmri-3088	147	78	coinfected	coinfecte	VERB
ajmri-3088	147	79	with	with	ADP
ajmri-3088	147	80	hiv/	hiv/	NOUN
ajmri-3088	147	81	hbv	hbv	NOUN
ajmri-3088	147	82	and	and	CCONJ
ajmri-3088	147	83	cd45ra	cd45ra	ADJ
ajmri-3088	147	84	cell	cell	NOUN
ajmri-3088	147	85	count	count	NOUN
ajmri-3088	147	86	studied	study	VERB
ajmri-3088	147	87	parameters	parameter	NOUN
ajmri-3088	147	88	hiv	hiv	PROPN
ajmri-3088	147	89	-	-	PUNCT
ajmri-3088	147	90	infected	infect	VERB
ajmri-3088	147	91	patients	patient	NOUN
ajmri-3088	147	92	(	(	PUNCT
ajmri-3088	147	93	n%	n%	NOUN
ajmri-3088	147	94	)	)	PUNCT
ajmri-3088	147	95	hbv	hbv	NOUN
ajmri-3088	147	96	-	-	PUNCT
ajmri-3088	147	97	infected	infect	VERB
ajmri-3088	147	98	patients	patient	NOUN
ajmri-3088	147	99	(	(	PUNCT
ajmri-3088	147	100	n%	n%	X
ajmri-3088	147	101	)	)	PUNCT
ajmri-3088	147	102	hiv	hiv	PROPN
ajmri-3088	147	103	co	co	VERB
ajmri-3088	147	104	-	-	VERB
ajmri-3088	147	105	infected	infect	VERB
ajmri-3088	147	106	with	with	ADP
ajmri-3088	147	107	hbv%	hbv%	NOUN
ajmri-3088	147	108	)	)	PUNCT
ajmri-3088	147	109	no	no	NOUN
ajmri-3088	147	110	of	of	ADP
ajmri-3088	147	111	participants	participant	NOUN
ajmri-3088	147	112	(	(	PUNCT
ajmri-3088	147	113	35	35	NUM
ajmri-3088	147	114	)	)	PUNCT
ajmri-3088	147	115	12	12	NUM
ajmri-3088	147	116	(	(	PUNCT
ajmri-3088	147	117	100.00	100.00	NUM
ajmri-3088	147	118	)	)	PUNCT
ajmri-3088	147	119	9	9	NUM
ajmri-3088	147	120	(	(	PUNCT
ajmri-3088	147	121	100.00	100.00	NUM
ajmri-3088	147	122	)	)	PUNCT
ajmri-3088	147	123	14(100.00	14(100.00	NUM
ajmri-3088	147	124	)	)	PUNCT
ajmri-3088	147	125	age	age	NOUN
ajmri-3088	147	126	factor	factor	NOUN
ajmri-3088	147	127	(	(	PUNCT
ajmri-3088	147	128	years	year	NOUN
ajmri-3088	147	129	)	)	PUNCT
ajmri-3088	147	130	mean	mean	VERB
ajmri-3088	147	131	±sd	±sd	PRON
ajmri-3088	147	132	21.43±4.08	21.43±4.08	NUM
ajmri-3088	147	133	17.01±3.01	17.01±3.01	NUM
ajmri-3088	147	134	16.07±3.11	16.07±3.11	NUM
ajmri-3088	147	135	0	0	NUM
ajmri-3088	147	136	-	-	SYM
ajmri-3088	147	137	15	15	NUM
ajmri-3088	147	138	years	year	NOUN
ajmri-3088	147	139	1	1	NUM
ajmri-3088	147	140	(	(	PUNCT
ajmri-3088	147	141	8.3	8.3	NUM
ajmri-3088	147	142	)	)	PUNCT
ajmri-3088	147	143	3	3	NUM
ajmri-3088	147	144	(	(	PUNCT
ajmri-3088	147	145	33.33	33.33	NUM
ajmri-3088	147	146	)	)	PUNCT
ajmri-3088	147	147	2	2	NUM
ajmri-3088	147	148	(	(	PUNCT
ajmri-3088	147	149	14.28	14.28	NUM
ajmri-3088	147	150	)	)	PUNCT
ajmri-3088	147	151	16	16	NUM
ajmri-3088	147	152	-	-	SYM
ajmri-3088	147	153	21	21	NUM
ajmri-3088	147	154	years	year	NOUN
ajmri-3088	147	155	4	4	NUM
ajmri-3088	147	156	(	(	PUNCT
ajmri-3088	147	157	33.3	33.3	NUM
ajmri-3088	147	158	)	)	SYM
ajmri-3088	147	159	2	2	NUM
ajmri-3088	147	160	(	(	PUNCT
ajmri-3088	147	161	22.22	22.22	NUM
ajmri-3088	147	162	)	)	PUNCT
ajmri-3088	147	163	3	3	NUM
ajmri-3088	147	164	(	(	PUNCT
ajmri-3088	147	165	21.42	21.42	NUM
ajmri-3088	147	166	)	)	PUNCT
ajmri-3088	147	167	22	22	NUM
ajmri-3088	147	168	-	-	SYM
ajmri-3088	147	169	37	37	NUM
ajmri-3088	147	170	years	year	NOUN
ajmri-3088	147	171	5	5	NUM
ajmri-3088	147	172	(	(	PUNCT
ajmri-3088	147	173	41.66	41.66	NUM
ajmri-3088	147	174	)	)	PUNCT
ajmri-3088	147	175	3	3	NUM
ajmri-3088	147	176	(	(	PUNCT
ajmri-3088	147	177	33.33	33.33	NUM
ajmri-3088	147	178	)	)	PUNCT
ajmri-3088	147	179	8	8	NUM
ajmri-3088	147	180	(	(	PUNCT
ajmri-3088	147	181	57.14	57.14	NUM
ajmri-3088	147	182	)	)	PUNCT
ajmri-3088	147	183	38	38	NUM
ajmri-3088	147	184	-	-	SYM
ajmri-3088	147	185	53	53	NUM
ajmri-3088	147	186	years	year	NOUN
ajmri-3088	147	187	1	1	NUM
ajmri-3088	147	188	(	(	PUNCT
ajmri-3088	147	189	8.3	8.3	NUM
ajmri-3088	147	190	)	)	SYM
ajmri-3088	147	191	1	1	NUM
ajmri-3088	147	192	(	(	PUNCT
ajmri-3088	147	193	11.11	11.11	NUM
ajmri-3088	147	194	)	)	PUNCT
ajmri-3088	147	195	1	1	NUM
ajmri-3088	147	196	(	(	PUNCT
ajmri-3088	147	197	7.14	7.14	NUM
ajmri-3088	147	198	)	)	PUNCT
ajmri-3088	147	199	>	>	PUNCT
ajmri-3088	147	200	53	53	NUM
ajmri-3088	147	201	years	year	NOUN
ajmri-3088	147	202	1	1	NUM
ajmri-3088	147	203	(	(	PUNCT
ajmri-3088	147	204	8.3	8.3	NUM
ajmri-3088	147	205	)	)	PUNCT
ajmri-3088	147	206	0(0.00	0(0.00	NUM
ajmri-3088	147	207	)	)	PUNCT
ajmri-3088	147	208	0	0	NUM
ajmri-3088	148	1	(	(	PUNCT
ajmri-3088	148	2	0.00	0.00	NUM
ajmri-3088	148	3	)	)	PUNCT
ajmri-3088	148	4	gender	gender	NOUN
ajmri-3088	148	5	male	male	NOUN
ajmri-3088	148	6	3	3	NUM
ajmri-3088	148	7	(	(	PUNCT
ajmri-3088	148	8	25	25	NUM
ajmri-3088	148	9	)	)	PUNCT
ajmri-3088	148	10	4	4	NUM
ajmri-3088	148	11	(	(	PUNCT
ajmri-3088	148	12	44.44	44.44	NUM
ajmri-3088	148	13	)	)	PUNCT
ajmri-3088	148	14	5	5	NUM
ajmri-3088	148	15	(	(	PUNCT
ajmri-3088	148	16	35.7	35.7	NUM
ajmri-3088	148	17	)	)	PUNCT
ajmri-3088	148	18	pa	pa	PROPN
ajmri-3088	148	19	ge	ge	PROPN
ajmri-3088	148	20	55	55	NUM
ajmri-3088	148	21	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	148	22	am	am	NOUN
ajmri-3088	148	23	.	.	PUNCT
ajmri-3088	149	1	j.	j.	PROPN
ajmri-3088	149	2	multidis	multidis	PROPN
ajmri-3088	149	3	.	.	PUNCT
ajmri-3088	150	1	res	re	NOUN
ajmri-3088	150	2	.	.	PUNCT
ajmri-3088	151	1	innov	innov	PROPN
ajmri-3088	151	2	.	.	PUNCT
ajmri-3088	152	1	3(5	3(5	NUM
ajmri-3088	152	2	)	)	PUNCT
ajmri-3088	152	3	50	50	NUM
ajmri-3088	152	4	-	-	SYM
ajmri-3088	152	5	60	60	NUM
ajmri-3088	152	6	,	,	PUNCT
ajmri-3088	152	7	2024	2024	NUM
ajmri-3088	152	8	female	female	ADJ
ajmri-3088	152	9	9	9	NUM
ajmri-3088	152	10	(	(	PUNCT
ajmri-3088	152	11	75	75	NUM
ajmri-3088	152	12	)	)	PUNCT
ajmri-3088	152	13	5	5	NUM
ajmri-3088	152	14	(	(	PUNCT
ajmri-3088	152	15	55.55	55.55	NUM
ajmri-3088	152	16	)	)	PUNCT
ajmri-3088	152	17	9	9	NUM
ajmri-3088	152	18	(	(	PUNCT
ajmri-3088	152	19	64.28	64.28	NUM
ajmri-3088	152	20	)	)	PUNCT
ajmri-3088	152	21	mode	mode	NOUN
ajmri-3088	152	22	of	of	ADP
ajmri-3088	152	23	acquired	acquire	VERB
ajmri-3088	152	24	infection	infection	NOUN
ajmri-3088	152	25	intravenous	intravenous	ADJ
ajmri-3088	152	26	drug	drug	NOUN
ajmri-3088	152	27	usage	usage	NOUN
ajmri-3088	152	28	3	3	NUM
ajmri-3088	152	29	(	(	PUNCT
ajmri-3088	152	30	25	25	NUM
ajmri-3088	152	31	)	)	PUNCT
ajmri-3088	152	32	1	1	NUM
ajmri-3088	152	33	(	(	PUNCT
ajmri-3088	152	34	11.11	11.11	NUM
ajmri-3088	152	35	)	)	PUNCT
ajmri-3088	152	36	3	3	NUM
ajmri-3088	152	37	(	(	PUNCT
ajmri-3088	152	38	21.42	21.42	NUM
ajmri-3088	152	39	)	)	PUNCT
ajmri-3088	152	40	sexual	sexual	ADJ
ajmri-3088	152	41	practices	practice	NOUN
ajmri-3088	152	42	3	3	NUM
ajmri-3088	152	43	(	(	PUNCT
ajmri-3088	152	44	25	25	NUM
ajmri-3088	152	45	)	)	PUNCT
ajmri-3088	152	46	3	3	NUM
ajmri-3088	152	47	(	(	PUNCT
ajmri-3088	152	48	33.33	33.33	NUM
ajmri-3088	152	49	)	)	PUNCT
ajmri-3088	152	50	4	4	NUM
ajmri-3088	152	51	(	(	PUNCT
ajmri-3088	152	52	28.57	28.57	NUM
ajmri-3088	152	53	)	)	PUNCT
ajmri-3088	152	54	vertical	vertical	ADJ
ajmri-3088	152	55	transmissions	transmission	NOUN
ajmri-3088	152	56	4	4	NUM
ajmri-3088	152	57	(	(	PUNCT
ajmri-3088	152	58	30.7	30.7	NUM
ajmri-3088	152	59	)	)	SYM
ajmri-3088	152	60	2	2	NUM
ajmri-3088	152	61	(	(	PUNCT
ajmri-3088	152	62	22.22	22.22	NUM
ajmri-3088	152	63	)	)	PUNCT
ajmri-3088	152	64	5	5	NUM
ajmri-3088	152	65	(	(	PUNCT
ajmri-3088	152	66	35.71	35.71	NUM
ajmri-3088	152	67	)	)	PUNCT
ajmri-3088	152	68	unhygienic	unhygienic	ADJ
ajmri-3088	152	69	surroundings	surrounding	NOUN
ajmri-3088	152	70	2	2	NUM
ajmri-3088	152	71	(	(	PUNCT
ajmri-3088	152	72	16.66	16.66	NUM
ajmri-3088	152	73	)	)	PUNCT
ajmri-3088	152	74	3	3	NUM
ajmri-3088	152	75	(	(	PUNCT
ajmri-3088	152	76	33.33	33.33	NUM
ajmri-3088	152	77	)	)	PUNCT
ajmri-3088	152	78	2	2	NUM
ajmri-3088	152	79	(	(	PUNCT
ajmri-3088	152	80	14.28	14.28	NUM
ajmri-3088	152	81	)	)	PUNCT
ajmri-3088	152	82	duration	duration	NOUN
ajmri-3088	152	83	of	of	ADP
ajmri-3088	152	84	diagnosis	diagnosis	NOUN
ajmri-3088	152	85	(	(	PUNCT
ajmri-3088	152	86	months	month	NOUN
ajmri-3088	152	87	)	)	PUNCT
ajmri-3088	152	88	0	0	NUM
ajmri-3088	152	89	-	-	SYM
ajmri-3088	152	90	6	6	NUM
ajmri-3088	152	91	months	month	NOUN
ajmri-3088	152	92	3	3	NUM
ajmri-3088	152	93	(	(	PUNCT
ajmri-3088	152	94	25	25	NUM
ajmri-3088	152	95	)	)	SYM
ajmri-3088	152	96	2	2	NUM
ajmri-3088	152	97	(	(	PUNCT
ajmri-3088	152	98	22.22	22.22	NUM
ajmri-3088	152	99	)	)	PUNCT
ajmri-3088	152	100	6	6	NUM
ajmri-3088	152	101	(	(	PUNCT
ajmri-3088	152	102	35.29	35.29	NUM
ajmri-3088	152	103	)	)	PUNCT
ajmri-3088	152	104	7	7	NUM
ajmri-3088	152	105	-	-	SYM
ajmri-3088	152	106	12	12	NUM
ajmri-3088	152	107	months	month	NOUN
ajmri-3088	152	108	6	6	NUM
ajmri-3088	152	109	(	(	PUNCT
ajmri-3088	152	110	50	50	NUM
ajmri-3088	152	111	)	)	PUNCT
ajmri-3088	152	112	3	3	NUM
ajmri-3088	152	113	(	(	PUNCT
ajmri-3088	152	114	33.33	33.33	NUM
ajmri-3088	152	115	)	)	PUNCT
ajmri-3088	152	116	4	4	NUM
ajmri-3088	152	117	(	(	PUNCT
ajmri-3088	152	118	28.57	28.57	NUM
ajmri-3088	152	119	)	)	PUNCT
ajmri-3088	152	120	13	13	NUM
ajmri-3088	152	121	-	-	SYM
ajmri-3088	152	122	19	19	NUM
ajmri-3088	152	123	months	month	NOUN
ajmri-3088	152	124	3	3	NUM
ajmri-3088	152	125	(	(	PUNCT
ajmri-3088	152	126	25	25	NUM
ajmri-3088	152	127	)	)	PUNCT
ajmri-3088	152	128	3	3	NUM
ajmri-3088	152	129	(	(	PUNCT
ajmri-3088	152	130	33.33	33.33	NUM
ajmri-3088	152	131	)	)	PUNCT
ajmri-3088	152	132	2	2	NUM
ajmri-3088	152	133	(	(	PUNCT
ajmri-3088	152	134	14.28	14.28	NUM
ajmri-3088	152	135	)	)	PUNCT
ajmri-3088	152	136	20	20	NUM
ajmri-3088	152	137	-	-	SYM
ajmri-3088	152	138	26	26	NUM
ajmri-3088	152	139	months	month	NOUN
ajmri-3088	152	140	0	0	PUNCT
ajmri-3088	152	141	(	(	PUNCT
ajmri-3088	152	142	0.00	0.00	NUM
ajmri-3088	152	143	)	)	PUNCT
ajmri-3088	152	144	1(1.11	1(1.11	NUM
ajmri-3088	152	145	)	)	PUNCT
ajmri-3088	152	146	2	2	NUM
ajmri-3088	152	147	(	(	PUNCT
ajmri-3088	152	148	14.28	14.28	NUM
ajmri-3088	152	149	)	)	PUNCT
ajmri-3088	152	150	cd45ra	cd45ra	VERB
ajmri-3088	152	151	>	>	SYM
ajmri-3088	152	152	500	500	NUM
ajmri-3088	152	153	1	1	NUM
ajmri-3088	152	154	(	(	PUNCT
ajmri-3088	152	155	8.33	8.33	NUM
ajmri-3088	152	156	)	)	PUNCT
ajmri-3088	152	157	1	1	NUM
ajmri-3088	152	158	(	(	PUNCT
ajmri-3088	152	159	11.11	11.11	NUM
ajmri-3088	152	160	)	)	PUNCT
ajmri-3088	152	161	2	2	NUM
ajmri-3088	152	162	(	(	PUNCT
ajmri-3088	152	163	14.28	14.28	NUM
ajmri-3088	152	164	)	)	PUNCT
ajmri-3088	152	165	350	350	NUM
ajmri-3088	152	166	-	-	SYM
ajmri-3088	152	167	500	500	NUM
ajmri-3088	152	168	2	2	NUM
ajmri-3088	152	169	(	(	PUNCT
ajmri-3088	152	170	16.66	16.66	NUM
ajmri-3088	152	171	)	)	SYM
ajmri-3088	152	172	2	2	NUM
ajmri-3088	152	173	(	(	PUNCT
ajmri-3088	152	174	22.22	22.22	NUM
ajmri-3088	152	175	)	)	PUNCT
ajmri-3088	152	176	1	1	NUM
ajmri-3088	152	177	(	(	PUNCT
ajmri-3088	152	178	7	7	NUM
ajmri-3088	152	179	)	)	PUNCT
ajmri-3088	152	180	200	200	NUM
ajmri-3088	152	181	-	-	SYM
ajmri-3088	152	182	350	350	NUM
ajmri-3088	152	183	7	7	NUM
ajmri-3088	152	184	(	(	PUNCT
ajmri-3088	152	185	58.33	58.33	NUM
ajmri-3088	152	186	)	)	PUNCT
ajmri-3088	152	187	5	5	NUM
ajmri-3088	152	188	(	(	PUNCT
ajmri-3088	152	189	55.55	55.55	NUM
ajmri-3088	152	190	)	)	PUNCT
ajmri-3088	152	191	9	9	NUM
ajmri-3088	152	192	(	(	PUNCT
ajmri-3088	152	193	64.28	64.28	NUM
ajmri-3088	152	194	)	)	PUNCT
ajmri-3088	152	195	<	<	X
ajmri-3088	152	196	200	200	NUM
ajmri-3088	152	197	3	3	NUM
ajmri-3088	152	198	(	(	PUNCT
ajmri-3088	152	199	21.4	21.4	NUM
ajmri-3088	152	200	)	)	SYM
ajmri-3088	152	201	1	1	NUM
ajmri-3088	152	202	(	(	PUNCT
ajmri-3088	152	203	11.11	11.11	NUM
ajmri-3088	152	204	)	)	PUNCT
ajmri-3088	152	205	2	2	NUM
ajmri-3088	152	206	(	(	PUNCT
ajmri-3088	152	207	14.28	14.28	NUM
ajmri-3088	152	208	)	)	PUNCT
ajmri-3088	152	209	undertaken	undertake	VERB
ajmri-3088	152	210	to	to	PART
ajmri-3088	152	211	conduct	conduct	VERB
ajmri-3088	152	212	the	the	DET
ajmri-3088	152	213	study	study	NOUN
ajmri-3088	152	214	.	.	PUNCT
ajmri-3088	153	1	the	the	DET
ajmri-3088	153	2	median	median	ADJ
ajmri-3088	153	3	age	age	NOUN
ajmri-3088	153	4	for	for	ADP
ajmri-3088	153	5	hiv	hiv	PROPN
ajmri-3088	153	6	-	-	PUNCT
ajmri-3088	153	7	positive	positive	ADJ
ajmri-3088	153	8	patients	patient	NOUN
ajmri-3088	153	9	is	be	AUX
ajmri-3088	153	10	21.43±4.08	21.43±4.08	NUM
ajmri-3088	153	11	,	,	PUNCT
ajmri-3088	153	12	and	and	CCONJ
ajmri-3088	153	13	for	for	ADP
ajmri-3088	153	14	hbv	hbv	NOUN
ajmri-3088	153	15	-	-	PUNCT
ajmri-3088	153	16	positive	positive	ADJ
ajmri-3088	153	17	patients	patient	NOUN
ajmri-3088	153	18	,	,	PUNCT
ajmri-3088	153	19	24.01±3.01	24.01±3.01	NUM
ajmri-3088	153	20	.	.	PUNCT
ajmri-3088	154	1	and	and	CCONJ
ajmri-3088	154	2	for	for	ADP
ajmri-3088	154	3	hiv	hiv	PROPN
ajmri-3088	154	4	/	/	SYM
ajmri-3088	154	5	hbv	hbv	NOUN
ajmri-3088	154	6	patients	patient	NOUN
ajmri-3088	154	7	,	,	PUNCT
ajmri-3088	154	8	it	it	PRON
ajmri-3088	154	9	is	be	AUX
ajmri-3088	154	10	26.07±3.11	26.07±3.11	NUM
ajmri-3088	154	11	.	.	PUNCT
ajmri-3088	155	1	the	the	DET
ajmri-3088	155	2	significance	significance	NOUN
ajmri-3088	155	3	value	value	NOUN
ajmri-3088	155	4	for	for	ADP
ajmri-3088	155	5	cd45ra	cd45ra	ADJ
ajmri-3088	155	6	cell	cell	NOUN
ajmri-3088	155	7	count	count	NOUN
ajmri-3088	155	8	is	be	AUX
ajmri-3088	155	9	<	<	X
ajmri-3088	155	10	0.01	0.01	NUM
ajmri-3088	155	11	memory	memory	NOUN
ajmri-3088	155	12	t	t	PROPN
ajmri-3088	155	13	-	-	PUNCT
ajmri-3088	155	14	cells	cell	NOUN
ajmri-3088	155	15	(	(	PUNCT
ajmri-3088	155	16	cd45ro	cd45ro	NOUN
ajmri-3088	155	17	)	)	PUNCT
ajmri-3088	155	18	in	in	ADP
ajmri-3088	155	19	the	the	DET
ajmri-3088	155	20	case	case	NOUN
ajmri-3088	155	21	of	of	ADP
ajmri-3088	155	22	hiv	hiv	PROPN
ajmri-3088	155	23	infection	infection	NOUN
ajmri-3088	155	24	,	,	PUNCT
ajmri-3088	155	25	cd45ro	cd45ro	NOUN
ajmri-3088	155	26	shows	show	VERB
ajmri-3088	155	27	an	an	DET
ajmri-3088	155	28	interesting	interesting	ADJ
ajmri-3088	155	29	trend	trend	NOUN
ajmri-3088	155	30	as	as	SCONJ
ajmri-3088	155	31	it	it	PRON
ajmri-3088	155	32	reduces	reduce	VERB
ajmri-3088	155	33	with	with	ADP
ajmri-3088	155	34	increased	increase	VERB
ajmri-3088	155	35	viral	viral	ADJ
ajmri-3088	155	36	titer	titer	NOUN
ajmri-3088	155	37	.	.	PUNCT
ajmri-3088	156	1	the	the	DET
ajmri-3088	156	2	hbv	hbv	NOUN
ajmri-3088	156	3	infection	infection	NOUN
ajmri-3088	156	4	and	and	CCONJ
ajmri-3088	156	5	coinfection	coinfection	NOUN
ajmri-3088	156	6	of	of	ADP
ajmri-3088	156	7	hiv	hiv	PROPN
ajmri-3088	156	8	/	/	SYM
ajmri-3088	156	9	hbv	hbv	PROPN
ajmri-3088	156	10	also	also	ADV
ajmri-3088	156	11	showed	show	VERB
ajmri-3088	156	12	reduced	reduced	ADJ
ajmri-3088	156	13	cd45ro	cd45ro	NOUN
ajmri-3088	156	14	population	population	NOUN
ajmri-3088	156	15	as	as	ADP
ajmri-3088	156	16	the	the	DET
ajmri-3088	156	17	infection	infection	NOUN
ajmri-3088	156	18	severs	sever	NOUN
ajmri-3088	156	19	.	.	PUNCT
ajmri-3088	157	1	table	table	NOUN
ajmri-3088	157	2	4	4	NUM
ajmri-3088	157	3	shows	show	VERB
ajmri-3088	157	4	that	that	SCONJ
ajmri-3088	157	5	57.1	57.1	NUM
ajmri-3088	157	6	%	%	NOUN
ajmri-3088	157	7	of	of	ADP
ajmri-3088	157	8	patients	patient	NOUN
ajmri-3088	157	9	with	with	ADP
ajmri-3088	157	10	hiv	hiv	PROPN
ajmri-3088	157	11	/	/	SYM
ajmri-3088	157	12	hbv	hbv	NOUN
ajmri-3088	157	13	table	table	NOUN
ajmri-3088	157	14	4	4	NUM
ajmri-3088	157	15	:	:	PUNCT
ajmri-3088	157	16	demographic	demographic	ADJ
ajmri-3088	157	17	and	and	CCONJ
ajmri-3088	157	18	clinical	clinical	ADJ
ajmri-3088	157	19	parameters	parameter	NOUN
ajmri-3088	157	20	of	of	ADP
ajmri-3088	157	21	patients	patient	NOUN
ajmri-3088	157	22	infected	infect	VERB
ajmri-3088	157	23	with	with	ADP
ajmri-3088	157	24	hiv	hiv	PROPN
ajmri-3088	157	25	,	,	PUNCT
ajmri-3088	157	26	hbv	hbv	NOUN
ajmri-3088	157	27	,	,	PUNCT
ajmri-3088	157	28	and	and	CCONJ
ajmri-3088	157	29	coinfected	coinfecte	VERB
ajmri-3088	157	30	with	with	ADP
ajmri-3088	157	31	hiv/	hiv/	NOUN
ajmri-3088	157	32	hbv	hbv	NOUN
ajmri-3088	157	33	and	and	CCONJ
ajmri-3088	157	34	cd45ra	cd45ra	ADJ
ajmri-3088	157	35	cell	cell	NOUN
ajmri-3088	157	36	count	count	NOUN
ajmri-3088	157	37	studied	study	VERB
ajmri-3088	157	38	parameters	parameter	NOUN
ajmri-3088	157	39	hiv	hiv	PROPN
ajmri-3088	157	40	-	-	PUNCT
ajmri-3088	157	41	infected	infect	VERB
ajmri-3088	157	42	patients	patient	NOUN
ajmri-3088	157	43	(	(	PUNCT
ajmri-3088	157	44	n%	n%	NOUN
ajmri-3088	157	45	)	)	PUNCT
ajmri-3088	157	46	hbv	hbv	NOUN
ajmri-3088	157	47	-	-	PUNCT
ajmri-3088	157	48	infected	infect	VERB
ajmri-3088	157	49	patients	patient	NOUN
ajmri-3088	157	50	(	(	PUNCT
ajmri-3088	157	51	n%	n%	X
ajmri-3088	157	52	)	)	PUNCT
ajmri-3088	157	53	hiv	hiv	PROPN
ajmri-3088	157	54	co	co	VERB
ajmri-3088	157	55	-	-	VERB
ajmri-3088	157	56	infected	infect	VERB
ajmri-3088	157	57	with	with	ADP
ajmri-3088	157	58	hbv	hbv	NOUN
ajmri-3088	157	59	patients	patient	NOUN
ajmri-3088	157	60	(	(	PUNCT
ajmri-3088	157	61	%	%	INTJ
ajmri-3088	157	62	)	)	PUNCT
ajmri-3088	157	63	no	no	PRON
ajmri-3088	157	64	of	of	ADP
ajmri-3088	157	65	participants	participant	NOUN
ajmri-3088	157	66	(	(	PUNCT
ajmri-3088	157	67	35	35	NUM
ajmri-3088	157	68	)	)	PUNCT
ajmri-3088	157	69	12	12	NUM
ajmri-3088	157	70	(	(	PUNCT
ajmri-3088	157	71	100.00	100.00	NUM
ajmri-3088	157	72	)	)	PUNCT
ajmri-3088	157	73	9	9	NUM
ajmri-3088	157	74	(	(	PUNCT
ajmri-3088	157	75	100.00	100.00	NUM
ajmri-3088	157	76	)	)	PUNCT
ajmri-3088	157	77	14(100.00	14(100.00	NUM
ajmri-3088	157	78	)	)	PUNCT
ajmri-3088	157	79	age	age	NOUN
ajmri-3088	157	80	factor	factor	NOUN
ajmri-3088	157	81	(	(	PUNCT
ajmri-3088	157	82	years	year	NOUN
ajmri-3088	157	83	)	)	PUNCT
ajmri-3088	157	84	mean	mean	VERB
ajmri-3088	157	85	±sd	±sd	PRON
ajmri-3088	157	86	21.43±4.08	21.43±4.08	NUM
ajmri-3088	157	87	17.01±3.01	17.01±3.01	NUM
ajmri-3088	157	88	16.07±3.11	16.07±3.11	NUM
ajmri-3088	157	89	0	0	NUM
ajmri-3088	157	90	-	-	SYM
ajmri-3088	157	91	15	15	NUM
ajmri-3088	157	92	years	year	NOUN
ajmri-3088	157	93	1	1	NUM
ajmri-3088	157	94	(	(	PUNCT
ajmri-3088	157	95	8.3	8.3	NUM
ajmri-3088	157	96	)	)	PUNCT
ajmri-3088	157	97	3	3	NUM
ajmri-3088	157	98	(	(	PUNCT
ajmri-3088	157	99	33.33	33.33	NUM
ajmri-3088	157	100	)	)	PUNCT
ajmri-3088	157	101	2	2	NUM
ajmri-3088	157	102	(	(	PUNCT
ajmri-3088	157	103	14.28	14.28	NUM
ajmri-3088	157	104	)	)	PUNCT
ajmri-3088	157	105	16	16	NUM
ajmri-3088	157	106	-	-	SYM
ajmri-3088	157	107	21	21	NUM
ajmri-3088	157	108	years	year	NOUN
ajmri-3088	157	109	4	4	NUM
ajmri-3088	157	110	(	(	PUNCT
ajmri-3088	157	111	33.3	33.3	NUM
ajmri-3088	157	112	)	)	SYM
ajmri-3088	157	113	2	2	NUM
ajmri-3088	157	114	(	(	PUNCT
ajmri-3088	157	115	22.22	22.22	NUM
ajmri-3088	157	116	)	)	PUNCT
ajmri-3088	157	117	3	3	NUM
ajmri-3088	157	118	(	(	PUNCT
ajmri-3088	157	119	21.42	21.42	NUM
ajmri-3088	157	120	)	)	PUNCT
ajmri-3088	157	121	22	22	NUM
ajmri-3088	157	122	-	-	SYM
ajmri-3088	157	123	37	37	NUM
ajmri-3088	157	124	years	year	NOUN
ajmri-3088	157	125	5	5	NUM
ajmri-3088	157	126	(	(	PUNCT
ajmri-3088	157	127	41.66	41.66	NUM
ajmri-3088	157	128	)	)	PUNCT
ajmri-3088	157	129	3	3	NUM
ajmri-3088	157	130	(	(	PUNCT
ajmri-3088	157	131	33.33	33.33	NUM
ajmri-3088	157	132	)	)	PUNCT
ajmri-3088	157	133	8	8	NUM
ajmri-3088	157	134	(	(	PUNCT
ajmri-3088	157	135	57.14	57.14	NUM
ajmri-3088	157	136	)	)	PUNCT
ajmri-3088	157	137	38	38	NUM
ajmri-3088	157	138	-	-	SYM
ajmri-3088	157	139	53	53	NUM
ajmri-3088	157	140	years	year	NOUN
ajmri-3088	157	141	1	1	NUM
ajmri-3088	157	142	(	(	PUNCT
ajmri-3088	157	143	8.3	8.3	NUM
ajmri-3088	157	144	)	)	SYM
ajmri-3088	157	145	1	1	NUM
ajmri-3088	157	146	(	(	PUNCT
ajmri-3088	157	147	11.11	11.11	NUM
ajmri-3088	157	148	)	)	PUNCT
ajmri-3088	157	149	1	1	NUM
ajmri-3088	157	150	(	(	PUNCT
ajmri-3088	157	151	7.14	7.14	NUM
ajmri-3088	157	152	)	)	PUNCT
ajmri-3088	157	153	>	>	PUNCT
ajmri-3088	157	154	53	53	NUM
ajmri-3088	157	155	years	year	NOUN
ajmri-3088	157	156	1	1	NUM
ajmri-3088	157	157	(	(	PUNCT
ajmri-3088	157	158	8.3	8.3	NUM
ajmri-3088	157	159	)	)	PUNCT
ajmri-3088	157	160	0(0.00	0(0.00	NUM
ajmri-3088	157	161	)	)	PUNCT
ajmri-3088	157	162	0	0	NUM
ajmri-3088	158	1	(	(	PUNCT
ajmri-3088	158	2	0.00	0.00	NUM
ajmri-3088	158	3	)	)	PUNCT
ajmri-3088	158	4	gender	gender	NOUN
ajmri-3088	158	5	male	male	NOUN
ajmri-3088	158	6	3	3	NUM
ajmri-3088	158	7	(	(	PUNCT
ajmri-3088	158	8	25	25	NUM
ajmri-3088	158	9	)	)	PUNCT
ajmri-3088	158	10	4	4	NUM
ajmri-3088	158	11	(	(	PUNCT
ajmri-3088	158	12	44.44	44.44	NUM
ajmri-3088	158	13	)	)	PUNCT
ajmri-3088	158	14	5	5	NUM
ajmri-3088	158	15	(	(	PUNCT
ajmri-3088	158	16	35.7	35.7	NUM
ajmri-3088	158	17	)	)	PUNCT
ajmri-3088	158	18	female	female	ADJ
ajmri-3088	158	19	9	9	NUM
ajmri-3088	158	20	(	(	PUNCT
ajmri-3088	158	21	75	75	NUM
ajmri-3088	158	22	)	)	PUNCT
ajmri-3088	158	23	5	5	NUM
ajmri-3088	158	24	(	(	PUNCT
ajmri-3088	158	25	55.55	55.55	NUM
ajmri-3088	158	26	)	)	PUNCT
ajmri-3088	158	27	9	9	NUM
ajmri-3088	158	28	(	(	PUNCT
ajmri-3088	158	29	64.28	64.28	NUM
ajmri-3088	158	30	)	)	PUNCT
ajmri-3088	158	31	mode	mode	NOUN
ajmri-3088	158	32	of	of	ADP
ajmri-3088	158	33	acquired	acquire	VERB
ajmri-3088	158	34	infection	infection	NOUN
ajmri-3088	158	35	intravenous	intravenous	ADJ
ajmri-3088	158	36	drug	drug	NOUN
ajmri-3088	158	37	usage	usage	NOUN
ajmri-3088	158	38	3	3	NUM
ajmri-3088	158	39	(	(	PUNCT
ajmri-3088	158	40	25	25	NUM
ajmri-3088	158	41	)	)	PUNCT
ajmri-3088	158	42	1	1	NUM
ajmri-3088	158	43	(	(	PUNCT
ajmri-3088	158	44	11.11	11.11	NUM
ajmri-3088	158	45	)	)	PUNCT
ajmri-3088	158	46	3	3	NUM
ajmri-3088	158	47	(	(	PUNCT
ajmri-3088	158	48	21.42	21.42	NUM
ajmri-3088	158	49	)	)	PUNCT
ajmri-3088	158	50	sexual	sexual	ADJ
ajmri-3088	158	51	practices	practice	NOUN
ajmri-3088	158	52	3	3	NUM
ajmri-3088	158	53	(	(	PUNCT
ajmri-3088	158	54	25	25	NUM
ajmri-3088	158	55	)	)	PUNCT
ajmri-3088	158	56	3	3	NUM
ajmri-3088	158	57	(	(	PUNCT
ajmri-3088	158	58	33.33	33.33	NUM
ajmri-3088	158	59	)	)	PUNCT
ajmri-3088	158	60	4	4	NUM
ajmri-3088	158	61	(	(	PUNCT
ajmri-3088	158	62	28.57	28.57	NUM
ajmri-3088	158	63	)	)	PUNCT
ajmri-3088	158	64	vertical	vertical	ADJ
ajmri-3088	158	65	transmissions	transmission	NOUN
ajmri-3088	158	66	4	4	NUM
ajmri-3088	158	67	(	(	PUNCT
ajmri-3088	158	68	30.7	30.7	NUM
ajmri-3088	158	69	)	)	SYM
ajmri-3088	158	70	2	2	NUM
ajmri-3088	158	71	(	(	PUNCT
ajmri-3088	158	72	22.22	22.22	NUM
ajmri-3088	158	73	)	)	PUNCT
ajmri-3088	158	74	5	5	NUM
ajmri-3088	158	75	(	(	PUNCT
ajmri-3088	158	76	35.71	35.71	NUM
ajmri-3088	158	77	)	)	PUNCT
ajmri-3088	158	78	unhygienic	unhygienic	ADJ
ajmri-3088	158	79	surroundings	surrounding	NOUN
ajmri-3088	158	80	2	2	NUM
ajmri-3088	158	81	(	(	PUNCT
ajmri-3088	158	82	16.66	16.66	NUM
ajmri-3088	158	83	)	)	PUNCT
ajmri-3088	158	84	3	3	NUM
ajmri-3088	158	85	(	(	PUNCT
ajmri-3088	158	86	33.33	33.33	NUM
ajmri-3088	158	87	)	)	PUNCT
ajmri-3088	158	88	2	2	NUM
ajmri-3088	158	89	(	(	PUNCT
ajmri-3088	158	90	14.28	14.28	NUM
ajmri-3088	158	91	)	)	PUNCT
ajmri-3088	158	92	duration	duration	NOUN
ajmri-3088	158	93	of	of	ADP
ajmri-3088	158	94	diagnosis	diagnosis	NOUN
ajmri-3088	158	95	(	(	PUNCT
ajmri-3088	158	96	months	month	NOUN
ajmri-3088	158	97	)	)	PUNCT
ajmri-3088	158	98	0	0	NUM
ajmri-3088	158	99	-	-	SYM
ajmri-3088	158	100	6	6	NUM
ajmri-3088	158	101	months	month	NOUN
ajmri-3088	158	102	3	3	NUM
ajmri-3088	158	103	(	(	PUNCT
ajmri-3088	158	104	25	25	NUM
ajmri-3088	158	105	)	)	SYM
ajmri-3088	158	106	2	2	NUM
ajmri-3088	158	107	(	(	PUNCT
ajmri-3088	158	108	22.22	22.22	NUM
ajmri-3088	158	109	)	)	PUNCT
ajmri-3088	158	110	6	6	NUM
ajmri-3088	158	111	(	(	PUNCT
ajmri-3088	158	112	35.29	35.29	NUM
ajmri-3088	158	113	)	)	PUNCT
ajmri-3088	158	114	7	7	NUM
ajmri-3088	158	115	-	-	SYM
ajmri-3088	158	116	12	12	NUM
ajmri-3088	158	117	months	month	NOUN
ajmri-3088	158	118	6	6	NUM
ajmri-3088	158	119	(	(	PUNCT
ajmri-3088	158	120	50	50	NUM
ajmri-3088	158	121	)	)	PUNCT
ajmri-3088	158	122	3	3	NUM
ajmri-3088	158	123	(	(	PUNCT
ajmri-3088	158	124	33.33	33.33	NUM
ajmri-3088	158	125	)	)	PUNCT
ajmri-3088	158	126	4	4	NUM
ajmri-3088	158	127	(	(	PUNCT
ajmri-3088	158	128	28.57	28.57	NUM
ajmri-3088	158	129	)	)	PUNCT
ajmri-3088	158	130	13	13	NUM
ajmri-3088	158	131	-	-	SYM
ajmri-3088	158	132	19	19	NUM
ajmri-3088	158	133	months	month	NOUN
ajmri-3088	158	134	3	3	NUM
ajmri-3088	158	135	(	(	PUNCT
ajmri-3088	158	136	25	25	NUM
ajmri-3088	158	137	)	)	PUNCT
ajmri-3088	158	138	3	3	NUM
ajmri-3088	158	139	(	(	PUNCT
ajmri-3088	158	140	33.33	33.33	NUM
ajmri-3088	158	141	)	)	PUNCT
ajmri-3088	158	142	2	2	NUM
ajmri-3088	158	143	(	(	PUNCT
ajmri-3088	158	144	14.28	14.28	NUM
ajmri-3088	158	145	)	)	PUNCT
ajmri-3088	158	146	20	20	NUM
ajmri-3088	158	147	-	-	SYM
ajmri-3088	158	148	26	26	NUM
ajmri-3088	158	149	months	month	NOUN
ajmri-3088	158	150	0	0	PUNCT
ajmri-3088	158	151	(	(	PUNCT
ajmri-3088	158	152	0.00	0.00	NUM
ajmri-3088	158	153	)	)	PUNCT
ajmri-3088	158	154	1(1.11	1(1.11	NUM
ajmri-3088	158	155	)	)	PUNCT
ajmri-3088	158	156	2	2	NUM
ajmri-3088	158	157	(	(	PUNCT
ajmri-3088	158	158	14.28	14.28	NUM
ajmri-3088	158	159	)	)	PUNCT
ajmri-3088	158	160	pa	pa	PROPN
ajmri-3088	158	161	ge	ge	PROPN
ajmri-3088	158	162	56	56	NUM
ajmri-3088	158	163	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	158	164	am	am	NOUN
ajmri-3088	158	165	.	.	PUNCT
ajmri-3088	159	1	j.	j.	PROPN
ajmri-3088	159	2	multidis	multidis	PROPN
ajmri-3088	159	3	.	.	PUNCT
ajmri-3088	160	1	res	re	NOUN
ajmri-3088	160	2	.	.	PUNCT
ajmri-3088	161	1	innov	innov	PROPN
ajmri-3088	161	2	.	.	PUNCT
ajmri-3088	162	1	3(5	3(5	NUM
ajmri-3088	162	2	)	)	PUNCT
ajmri-3088	162	3	50	50	NUM
ajmri-3088	162	4	-	-	SYM
ajmri-3088	162	5	60	60	NUM
ajmri-3088	162	6	,	,	PUNCT
ajmri-3088	162	7	2024	2024	NUM
ajmri-3088	162	8	cd45ro	cd45ro	NOUN
ajmri-3088	162	9	>	>	PUNCT
ajmri-3088	162	10	500	500	NUM
ajmri-3088	162	11	3	3	NUM
ajmri-3088	162	12	(	(	PUNCT
ajmri-3088	162	13	25	25	NUM
ajmri-3088	162	14	)	)	PUNCT
ajmri-3088	162	15	1	1	NUM
ajmri-3088	162	16	(	(	PUNCT
ajmri-3088	162	17	11.11	11.11	NUM
ajmri-3088	162	18	)	)	PUNCT
ajmri-3088	162	19	2	2	NUM
ajmri-3088	162	20	(	(	PUNCT
ajmri-3088	162	21	14.28	14.28	NUM
ajmri-3088	162	22	)	)	PUNCT
ajmri-3088	162	23	350	350	NUM
ajmri-3088	162	24	-	-	SYM
ajmri-3088	162	25	500	500	NUM
ajmri-3088	162	26	2	2	NUM
ajmri-3088	162	27	(	(	PUNCT
ajmri-3088	162	28	16.66	16.66	NUM
ajmri-3088	162	29	)	)	SYM
ajmri-3088	162	30	2	2	NUM
ajmri-3088	162	31	(	(	PUNCT
ajmri-3088	162	32	22.22	22.22	NUM
ajmri-3088	162	33	)	)	PUNCT
ajmri-3088	162	34	1	1	NUM
ajmri-3088	162	35	(	(	PUNCT
ajmri-3088	162	36	7	7	NUM
ajmri-3088	162	37	)	)	PUNCT
ajmri-3088	162	38	200	200	NUM
ajmri-3088	162	39	-	-	SYM
ajmri-3088	162	40	350	350	NUM
ajmri-3088	162	41	7	7	NUM
ajmri-3088	162	42	(	(	PUNCT
ajmri-3088	162	43	58.33	58.33	NUM
ajmri-3088	162	44	)	)	PUNCT
ajmri-3088	162	45	5	5	NUM
ajmri-3088	162	46	(	(	PUNCT
ajmri-3088	162	47	55.55	55.55	NUM
ajmri-3088	162	48	)	)	PUNCT
ajmri-3088	162	49	9	9	NUM
ajmri-3088	162	50	(	(	PUNCT
ajmri-3088	162	51	64.28	64.28	NUM
ajmri-3088	162	52	)	)	PUNCT
ajmri-3088	162	53	<	<	X
ajmri-3088	162	54	200	200	NUM
ajmri-3088	162	55	1	1	NUM
ajmri-3088	162	56	(	(	PUNCT
ajmri-3088	162	57	8.33	8.33	NUM
ajmri-3088	162	58	)	)	PUNCT
ajmri-3088	162	59	1	1	NUM
ajmri-3088	162	60	(	(	PUNCT
ajmri-3088	162	61	11.11	11.11	NUM
ajmri-3088	162	62	)	)	PUNCT
ajmri-3088	162	63	2	2	NUM
ajmri-3088	162	64	(	(	PUNCT
ajmri-3088	162	65	14.28	14.28	NUM
ajmri-3088	162	66	)	)	PUNCT
ajmri-3088	162	67	coinfection	coinfection	NOUN
ajmri-3088	162	68	have	have	VERB
ajmri-3088	162	69	cell	cell	NOUN
ajmri-3088	162	70	count	count	NOUN
ajmri-3088	162	71	reduced	reduce	VERB
ajmri-3088	162	72	to	to	ADP
ajmri-3088	162	73	<	<	X
ajmri-3088	162	74	300	300	NUM
ajmri-3088	162	75	cells	cell	NOUN
ajmri-3088	162	76	/	/	SYM
ajmri-3088	162	77	mm3	mm3	NOUN
ajmri-3088	162	78	.	.	PUNCT
ajmri-3088	162	79	table	table	NOUN
ajmri-3088	162	80	4	4	NUM
ajmri-3088	162	81	shows	show	VERB
ajmri-3088	162	82	the	the	DET
ajmri-3088	162	83	demographic	demographic	ADJ
ajmri-3088	162	84	and	and	CCONJ
ajmri-3088	162	85	clinical	clinical	ADJ
ajmri-3088	162	86	parameters	parameter	NOUN
ajmri-3088	162	87	undertaken	undertake	VERB
ajmri-3088	162	88	to	to	PART
ajmri-3088	162	89	conduct	conduct	VERB
ajmri-3088	162	90	the	the	DET
ajmri-3088	162	91	study	study	NOUN
ajmri-3088	162	92	.	.	PUNCT
ajmri-3088	163	1	the	the	DET
ajmri-3088	163	2	median	median	ADJ
ajmri-3088	163	3	age	age	NOUN
ajmri-3088	163	4	for	for	ADP
ajmri-3088	163	5	hivpositive	hivpositive	ADJ
ajmri-3088	163	6	patients	patient	NOUN
ajmri-3088	163	7	is	be	AUX
ajmri-3088	163	8	21.43±4.08	21.43±4.08	NUM
ajmri-3088	163	9	;	;	PUNCT
ajmri-3088	163	10	for	for	ADP
ajmri-3088	163	11	hbv	hbv	NOUN
ajmri-3088	163	12	-	-	PUNCT
ajmri-3088	163	13	positive	positive	ADJ
ajmri-3088	163	14	patients	patient	NOUN
ajmri-3088	163	15	,	,	PUNCT
ajmri-3088	163	16	24.01±3.01	24.01±3.01	NUM
ajmri-3088	163	17	,	,	PUNCT
ajmri-3088	163	18	and	and	CCONJ
ajmri-3088	163	19	for	for	ADP
ajmri-3088	163	20	hiv	hiv	PROPN
ajmri-3088	163	21	/	/	SYM
ajmri-3088	163	22	hbv	hbv	NOUN
ajmri-3088	163	23	patients	patient	NOUN
ajmri-3088	163	24	is	be	AUX
ajmri-3088	163	25	26.07±3.11	26.07±3.11	NUM
ajmri-3088	163	26	.	.	PUNCT
ajmri-3088	164	1	the	the	DET
ajmri-3088	164	2	significance	significance	NOUN
ajmri-3088	164	3	value	value	NOUN
ajmri-3088	164	4	for	for	ADP
ajmri-3088	164	5	cd45ra	cd45ra	ADJ
ajmri-3088	164	6	cell	cell	NOUN
ajmri-3088	164	7	count	count	NOUN
ajmri-3088	164	8	is	be	AUX
ajmri-3088	164	9	<	<	X
ajmri-3088	164	10	0.01	0.01	NUM
ajmri-3088	164	11	.	.	PUNCT
ajmri-3088	165	1	the	the	DET
ajmri-3088	165	2	study	study	NOUN
ajmri-3088	165	3	further	far	ADV
ajmri-3088	165	4	explored	explore	VERB
ajmri-3088	165	5	that	that	SCONJ
ajmri-3088	165	6	the	the	DET
ajmri-3088	165	7	naive	naive	ADJ
ajmri-3088	165	8	t	t	PROPN
ajmri-3088	165	9	-	-	PUNCT
ajmri-3088	165	10	cells	cell	NOUN
ajmri-3088	165	11	also	also	ADV
ajmri-3088	165	12	showed	show	VERB
ajmri-3088	165	13	significant	significant	ADJ
ajmri-3088	165	14	variation	variation	NOUN
ajmri-3088	165	15	in	in	ADP
ajmri-3088	165	16	mono	mono	NOUN
ajmri-3088	165	17	-	-	PUNCT
ajmri-3088	165	18	infections	infection	NOUN
ajmri-3088	165	19	of	of	ADP
ajmri-3088	165	20	hiv	hiv	PROPN
ajmri-3088	165	21	and	and	CCONJ
ajmri-3088	165	22	hbv	hbv	NOUN
ajmri-3088	165	23	in	in	ADP
ajmri-3088	165	24	comparison	comparison	NOUN
ajmri-3088	165	25	to	to	ADP
ajmri-3088	165	26	coinfection	coinfection	NOUN
ajmri-3088	165	27	of	of	ADP
ajmri-3088	165	28	hiv	hiv	PROPN
ajmri-3088	165	29	/	/	SYM
ajmri-3088	165	30	hbv	hbv	NOUN
ajmri-3088	165	31	infection	infection	NOUN
ajmri-3088	165	32	.	.	PUNCT
ajmri-3088	166	1	cd45ro	cd45ro	NOUN
ajmri-3088	166	2	depleted	deplete	VERB
ajmri-3088	166	3	in	in	ADP
ajmri-3088	166	4	57.1	57.1	NUM
ajmri-3088	166	5	%	%	NOUN
ajmri-3088	166	6	of	of	ADP
ajmri-3088	166	7	patients	patient	NOUN
ajmri-3088	166	8	.	.	PUNCT
ajmri-3088	167	1	the	the	DET
ajmri-3088	167	2	decrease	decrease	NOUN
ajmri-3088	167	3	in	in	ADP
ajmri-3088	167	4	cd45ra	cd45ra	ADJ
ajmri-3088	167	5	and	and	CCONJ
ajmri-3088	167	6	cd45ro	cd45ro	NOUN
ajmri-3088	167	7	t	t	PROPN
ajmri-3088	167	8	-	-	PUNCT
ajmri-3088	167	9	cell	cell	NOUN
ajmri-3088	167	10	subsets	subset	NOUN
ajmri-3088	167	11	in	in	ADP
ajmri-3088	167	12	individuals	individual	NOUN
ajmri-3088	167	13	with	with	ADP
ajmri-3088	167	14	coinfection	coinfection	NOUN
ajmri-3088	167	15	can	can	AUX
ajmri-3088	167	16	possibly	possibly	ADV
ajmri-3088	167	17	be	be	AUX
ajmri-3088	167	18	caused	cause	VERB
ajmri-3088	167	19	by	by	ADP
ajmri-3088	167	20	the	the	DET
ajmri-3088	167	21	cumulative	cumulative	ADJ
ajmri-3088	167	22	impact	impact	NOUN
ajmri-3088	167	23	of	of	ADP
ajmri-3088	167	24	both	both	DET
ajmri-3088	167	25	infections	infection	NOUN
ajmri-3088	167	26	,	,	PUNCT
ajmri-3088	167	27	triggering	trigger	VERB
ajmri-3088	167	28	immunological	immunological	ADJ
ajmri-3088	167	29	dysregulation	dysregulation	NOUN
ajmri-3088	167	30	.	.	PUNCT
ajmri-3088	168	1	the	the	DET
ajmri-3088	168	2	fact	fact	NOUN
ajmri-3088	168	3	that	that	SCONJ
ajmri-3088	168	4	both	both	PRON
ajmri-3088	168	5	hiv	hiv	PROPN
ajmri-3088	168	6	and	and	CCONJ
ajmri-3088	168	7	hbv	hbv	NOUN
ajmri-3088	168	8	infections	infection	NOUN
ajmri-3088	168	9	are	be	AUX
ajmri-3088	168	10	chronic	chronic	ADJ
ajmri-3088	168	11	may	may	AUX
ajmri-3088	168	12	have	have	VERB
ajmri-3088	168	13	an	an	DET
ajmri-3088	168	14	impact	impact	NOUN
ajmri-3088	168	15	on	on	ADP
ajmri-3088	168	16	memory	memory	NOUN
ajmri-3088	168	17	t	t	PROPN
ajmri-3088	168	18	-	-	PUNCT
ajmri-3088	168	19	cell	cell	NOUN
ajmri-3088	168	20	exhaustion	exhaustion	NOUN
ajmri-3088	168	21	and	and	CCONJ
ajmri-3088	168	22	the	the	DET
ajmri-3088	168	23	transition	transition	NOUN
ajmri-3088	168	24	of	of	ADP
ajmri-3088	168	25	memory	memory	NOUN
ajmri-3088	168	26	t	t	PROPN
ajmri-3088	168	27	-	-	PUNCT
ajmri-3088	168	28	cells	cell	NOUN
ajmri-3088	168	29	to	to	ADP
ajmri-3088	168	30	a	a	DET
ajmri-3088	168	31	naive	naive	ADJ
ajmri-3088	168	32	t	t	NOUN
ajmri-3088	168	33	-	-	PUNCT
ajmri-3088	168	34	cell	cell	NOUN
ajmri-3088	168	35	phenotype	phenotype	NOUN
ajmri-3088	168	36	.	.	PUNCT
ajmri-3088	169	1	in	in	ADP
ajmri-3088	169	2	addition	addition	NOUN
ajmri-3088	169	3	,	,	PUNCT
ajmri-3088	169	4	these	these	DET
ajmri-3088	169	5	viruses	virus	NOUN
ajmri-3088	169	6	’	'	PUNCT
ajmri-3088	169	7	combined	combine	VERB
ajmri-3088	169	8	impacts	impact	NOUN
ajmri-3088	169	9	on	on	ADP
ajmri-3088	169	10	immune	immune	ADJ
ajmri-3088	169	11	response	response	NOUN
ajmri-3088	169	12	pathways	pathway	NOUN
ajmri-3088	169	13	may	may	AUX
ajmri-3088	169	14	have	have	VERB
ajmri-3088	169	15	a	a	DET
ajmri-3088	169	16	cascading	cascade	VERB
ajmri-3088	169	17	impact	impact	NOUN
ajmri-3088	169	18	,	,	PUNCT
ajmri-3088	169	19	accelerating	accelerate	VERB
ajmri-3088	169	20	the	the	DET
ajmri-3088	169	21	depletion	depletion	NOUN
ajmri-3088	169	22	of	of	ADP
ajmri-3088	169	23	t	t	NOUN
ajmri-3088	169	24	cells	cell	NOUN
ajmri-3088	169	25	and	and	CCONJ
ajmri-3088	169	26	changing	change	VERB
ajmri-3088	169	27	the	the	DET
ajmri-3088	169	28	delicate	delicate	ADJ
ajmri-3088	169	29	equilibrium	equilibrium	NOUN
ajmri-3088	169	30	between	between	ADP
ajmri-3088	169	31	memory	memory	NOUN
ajmri-3088	169	32	and	and	CCONJ
ajmri-3088	169	33	naive	naive	ADJ
ajmri-3088	169	34	t	t	NOUN
ajmri-3088	169	35	-	-	PUNCT
ajmri-3088	169	36	cell	cell	NOUN
ajmri-3088	169	37	populations	population	NOUN
ajmri-3088	169	38	.	.	PUNCT
ajmri-3088	170	1	cd4	cd4	PROPN
ajmri-3088	170	2	+	+	SYM
ajmri-3088	170	3	cells	cell	NOUN
ajmri-3088	170	4	as	as	ADP
ajmri-3088	170	5	table	table	NOUN
ajmri-3088	170	6	5	5	NUM
ajmri-3088	170	7	shows	show	NOUN
ajmri-3088	170	8	,	,	PUNCT
ajmri-3088	170	9	out	out	ADP
ajmri-3088	170	10	of	of	ADP
ajmri-3088	170	11	12	12	NUM
ajmri-3088	170	12	hiv	hiv	PROPN
ajmri-3088	170	13	patients	patient	NOUN
ajmri-3088	170	14	,	,	PUNCT
ajmri-3088	170	15	5	5	NUM
ajmri-3088	170	16	patients	patient	NOUN
ajmri-3088	170	17	had	have	VERB
ajmri-3088	170	18	a	a	DET
ajmri-3088	170	19	cell	cell	NOUN
ajmri-3088	170	20	count	count	NOUN
ajmri-3088	170	21	nearly	nearly	ADV
ajmri-3088	170	22	lower	low	ADJ
ajmri-3088	170	23	than	than	ADP
ajmri-3088	170	24	350	350	NUM
ajmri-3088	170	25	cells	cell	NOUN
ajmri-3088	170	26	/	/	SYM
ajmri-3088	170	27	mm3	mm3	NOUN
ajmri-3088	170	28	and	and	CCONJ
ajmri-3088	170	29	showed	show	VERB
ajmri-3088	170	30	severe	severe	ADJ
ajmri-3088	170	31	hiv	hiv	PROPN
ajmri-3088	170	32	/	/	SYM
ajmri-3088	170	33	hbv	hbv	NOUN
ajmri-3088	170	34	infection	infection	NOUN
ajmri-3088	170	35	.	.	PUNCT
ajmri-3088	171	1	out	out	ADP
ajmri-3088	171	2	of	of	ADP
ajmri-3088	171	3	9	9	NUM
ajmri-3088	171	4	hbv	hbv	NOUN
ajmri-3088	171	5	patients	patient	NOUN
ajmri-3088	171	6	,	,	PUNCT
ajmri-3088	171	7	5	5	NUM
ajmri-3088	171	8	patients	patient	NOUN
ajmri-3088	171	9	had	have	VERB
ajmri-3088	171	10	a	a	DET
ajmri-3088	171	11	cell	cell	NOUN
ajmri-3088	171	12	count	count	NOUN
ajmri-3088	171	13	below	below	ADP
ajmri-3088	171	14	350	350	NUM
ajmri-3088	171	15	cells	cell	NOUN
ajmri-3088	171	16	/	/	SYM
ajmri-3088	171	17	mm3	mm3	NOUN
ajmri-3088	171	18	,	,	PUNCT
ajmri-3088	171	19	and	and	CCONJ
ajmri-3088	171	20	in	in	ADP
ajmri-3088	171	21	14	14	NUM
ajmri-3088	171	22	positive	positive	ADJ
ajmri-3088	171	23	hiv	hiv	PROPN
ajmri-3088	171	24	/	/	SYM
ajmri-3088	171	25	hbv	hbv	NOUN
ajmri-3088	171	26	cases	case	NOUN
ajmri-3088	171	27	,	,	PUNCT
ajmri-3088	171	28	7	7	NUM
ajmri-3088	171	29	patients	patient	NOUN
ajmri-3088	171	30	showed	show	VERB
ajmri-3088	171	31	a	a	DET
ajmri-3088	171	32	cell	cell	NOUN
ajmri-3088	171	33	count	count	NOUN
ajmri-3088	171	34	below	below	ADP
ajmri-3088	171	35	350	350	NUM
ajmri-3088	171	36	cells	cell	NOUN
ajmri-3088	171	37	/	/	SYM
ajmri-3088	171	38	mm3	mm3	NOUN
ajmri-3088	171	39	.	.	PUNCT
ajmri-3088	172	1	the	the	DET
ajmri-3088	172	2	statistical	statistical	ADJ
ajmri-3088	172	3	analysis	analysis	NOUN
ajmri-3088	172	4	has	have	AUX
ajmri-3088	172	5	shown	show	VERB
ajmri-3088	172	6	a	a	DET
ajmri-3088	172	7	significant	significant	ADJ
ajmri-3088	172	8	negative	negative	ADJ
ajmri-3088	172	9	correlation	correlation	NOUN
ajmri-3088	172	10	between	between	ADP
ajmri-3088	172	11	the	the	DET
ajmri-3088	172	12	cell	cell	NOUN
ajmri-3088	172	13	count	count	NOUN
ajmri-3088	172	14	and	and	CCONJ
ajmri-3088	172	15	the	the	DET
ajmri-3088	172	16	severity	severity	NOUN
ajmri-3088	172	17	of	of	ADP
ajmri-3088	172	18	infection	infection	NOUN
ajmri-3088	172	19	,	,	PUNCT
ajmri-3088	172	20	giving	give	VERB
ajmri-3088	172	21	the	the	DET
ajmri-3088	172	22	p	p	NOUN
ajmri-3088	172	23	-	-	PUNCT
ajmri-3088	172	24	value	value	NOUN
ajmri-3088	172	25	of	of	ADP
ajmri-3088	172	26	<	<	NOUN
ajmri-3088	172	27	0.001	0.001	NUM
ajmri-3088	172	28	.	.	PUNCT
ajmri-3088	173	1	as	as	SCONJ
ajmri-3088	173	2	the	the	DET
ajmri-3088	173	3	hiv	hiv	PROPN
ajmri-3088	173	4	stage	stage	NOUN
ajmri-3088	173	5	advances	advance	VERB
ajmri-3088	173	6	from	from	ADP
ajmri-3088	173	7	stage	stage	NOUN
ajmri-3088	173	8	b	b	PROPN
ajmri-3088	173	9	to	to	PART
ajmri-3088	173	10	stage	stage	VERB
ajmri-3088	173	11	e	e	NOUN
ajmri-3088	173	12	,	,	PUNCT
ajmri-3088	173	13	the	the	DET
ajmri-3088	173	14	cell	cell	NOUN
ajmri-3088	173	15	count	count	NOUN
ajmri-3088	173	16	significantly	significantly	ADV
ajmri-3088	173	17	depletes	deplete	VERB
ajmri-3088	173	18	from	from	ADP
ajmri-3088	173	19	>	>	SYM
ajmri-3088	173	20	500	500	NUM
ajmri-3088	173	21	cells	cell	NOUN
ajmri-3088	173	22	to	to	ADP
ajmri-3088	173	23	200	200	NUM
ajmri-3088	173	24	,	,	PUNCT
ajmri-3088	173	25	which	which	PRON
ajmri-3088	173	26	table	table	VERB
ajmri-3088	173	27	5	5	NUM
ajmri-3088	173	28	:	:	PUNCT
ajmri-3088	173	29	demographic	demographic	ADJ
ajmri-3088	173	30	and	and	CCONJ
ajmri-3088	173	31	clinical	clinical	ADJ
ajmri-3088	173	32	parameters	parameter	NOUN
ajmri-3088	173	33	of	of	ADP
ajmri-3088	173	34	patients	patient	NOUN
ajmri-3088	173	35	infected	infect	VERB
ajmri-3088	173	36	with	with	ADP
ajmri-3088	173	37	hiv	hiv	PROPN
ajmri-3088	173	38	,	,	PUNCT
ajmri-3088	173	39	hbv	hbv	NOUN
ajmri-3088	173	40	,	,	PUNCT
ajmri-3088	173	41	and	and	CCONJ
ajmri-3088	173	42	coinfected	coinfecte	VERB
ajmri-3088	173	43	with	with	ADP
ajmri-3088	173	44	hiv/	hiv/	NOUN
ajmri-3088	173	45	hbv	hbv	NOUN
ajmri-3088	173	46	and	and	CCONJ
ajmri-3088	173	47	cd45ra	cd45ra	ADJ
ajmri-3088	173	48	cell	cell	NOUN
ajmri-3088	173	49	count	count	NOUN
ajmri-3088	173	50	studied	study	VERB
ajmri-3088	173	51	parameters	parameter	NOUN
ajmri-3088	173	52	hiv	hiv	PROPN
ajmri-3088	173	53	-	-	PUNCT
ajmri-3088	173	54	infected	infect	VERB
ajmri-3088	173	55	patients	patient	NOUN
ajmri-3088	173	56	(	(	PUNCT
ajmri-3088	173	57	n%	n%	NOUN
ajmri-3088	173	58	)	)	PUNCT
ajmri-3088	173	59	hbv	hbv	NOUN
ajmri-3088	173	60	-	-	PUNCT
ajmri-3088	173	61	infected	infect	VERB
ajmri-3088	173	62	patients	patient	NOUN
ajmri-3088	173	63	(	(	PUNCT
ajmri-3088	173	64	n%	n%	NOUN
ajmri-3088	173	65	)	)	PUNCT
ajmri-3088	173	66	hivco	hivco	NOUN
ajmri-3088	173	67	-	-	PUNCT
ajmri-3088	173	68	infected	infect	VERB
ajmri-3088	173	69	with	with	ADP
ajmri-3088	173	70	hbv%	hbv%	NOUN
ajmri-3088	173	71	)	)	PUNCT
ajmri-3088	173	72	no	no	NOUN
ajmri-3088	173	73	of	of	ADP
ajmri-3088	173	74	participants	participant	NOUN
ajmri-3088	173	75	(	(	PUNCT
ajmri-3088	173	76	35	35	NUM
ajmri-3088	173	77	)	)	PUNCT
ajmri-3088	173	78	12	12	NUM
ajmri-3088	173	79	(	(	PUNCT
ajmri-3088	173	80	100.00	100.00	NUM
ajmri-3088	173	81	)	)	PUNCT
ajmri-3088	173	82	9	9	NUM
ajmri-3088	173	83	(	(	PUNCT
ajmri-3088	173	84	100.00	100.00	NUM
ajmri-3088	173	85	)	)	PUNCT
ajmri-3088	173	86	14(100.00	14(100.00	NUM
ajmri-3088	173	87	)	)	PUNCT
ajmri-3088	173	88	age	age	NOUN
ajmri-3088	173	89	factor	factor	NOUN
ajmri-3088	173	90	(	(	PUNCT
ajmri-3088	173	91	years	year	NOUN
ajmri-3088	173	92	)	)	PUNCT
ajmri-3088	173	93	mean	mean	VERB
ajmri-3088	173	94	±sd	±sd	PRON
ajmri-3088	173	95	21.43±4.08	21.43±4.08	NUM
ajmri-3088	173	96	17.01±3.01	17.01±3.01	NUM
ajmri-3088	173	97	16.07±3.11	16.07±3.11	NUM
ajmri-3088	173	98	0	0	NUM
ajmri-3088	173	99	-	-	SYM
ajmri-3088	173	100	15	15	NUM
ajmri-3088	173	101	years	year	NOUN
ajmri-3088	173	102	1	1	NUM
ajmri-3088	173	103	(	(	PUNCT
ajmri-3088	173	104	8.3	8.3	NUM
ajmri-3088	173	105	)	)	PUNCT
ajmri-3088	173	106	3	3	NUM
ajmri-3088	173	107	(	(	PUNCT
ajmri-3088	173	108	33.33	33.33	NUM
ajmri-3088	173	109	)	)	PUNCT
ajmri-3088	173	110	2	2	NUM
ajmri-3088	173	111	(	(	PUNCT
ajmri-3088	173	112	14.28	14.28	NUM
ajmri-3088	173	113	)	)	PUNCT
ajmri-3088	173	114	16	16	NUM
ajmri-3088	173	115	-	-	SYM
ajmri-3088	173	116	21	21	NUM
ajmri-3088	173	117	years	year	NOUN
ajmri-3088	173	118	4	4	NUM
ajmri-3088	173	119	(	(	PUNCT
ajmri-3088	173	120	33.3	33.3	NUM
ajmri-3088	173	121	)	)	SYM
ajmri-3088	173	122	2	2	NUM
ajmri-3088	173	123	(	(	PUNCT
ajmri-3088	173	124	22.22	22.22	NUM
ajmri-3088	173	125	)	)	PUNCT
ajmri-3088	173	126	3	3	NUM
ajmri-3088	173	127	(	(	PUNCT
ajmri-3088	173	128	21.42	21.42	NUM
ajmri-3088	173	129	)	)	PUNCT
ajmri-3088	173	130	22	22	NUM
ajmri-3088	173	131	-	-	SYM
ajmri-3088	173	132	37	37	NUM
ajmri-3088	173	133	years	year	NOUN
ajmri-3088	173	134	5	5	NUM
ajmri-3088	173	135	(	(	PUNCT
ajmri-3088	173	136	41.66	41.66	NUM
ajmri-3088	173	137	)	)	PUNCT
ajmri-3088	173	138	3	3	NUM
ajmri-3088	173	139	(	(	PUNCT
ajmri-3088	173	140	33.33	33.33	NUM
ajmri-3088	173	141	)	)	PUNCT
ajmri-3088	173	142	8	8	NUM
ajmri-3088	173	143	(	(	PUNCT
ajmri-3088	173	144	57.14	57.14	NUM
ajmri-3088	173	145	)	)	PUNCT
ajmri-3088	173	146	38	38	NUM
ajmri-3088	173	147	-	-	SYM
ajmri-3088	173	148	53	53	NUM
ajmri-3088	173	149	years	year	NOUN
ajmri-3088	173	150	1	1	NUM
ajmri-3088	173	151	(	(	PUNCT
ajmri-3088	173	152	8.3	8.3	NUM
ajmri-3088	173	153	)	)	SYM
ajmri-3088	173	154	1	1	NUM
ajmri-3088	173	155	(	(	PUNCT
ajmri-3088	173	156	11.11	11.11	NUM
ajmri-3088	173	157	)	)	PUNCT
ajmri-3088	173	158	1	1	NUM
ajmri-3088	173	159	(	(	PUNCT
ajmri-3088	173	160	7.14	7.14	NUM
ajmri-3088	173	161	)	)	PUNCT
ajmri-3088	173	162	>	>	PUNCT
ajmri-3088	173	163	53	53	NUM
ajmri-3088	173	164	years	year	NOUN
ajmri-3088	173	165	1	1	NUM
ajmri-3088	173	166	(	(	PUNCT
ajmri-3088	173	167	8.3	8.3	NUM
ajmri-3088	173	168	)	)	PUNCT
ajmri-3088	173	169	0(0.00	0(0.00	NUM
ajmri-3088	173	170	)	)	PUNCT
ajmri-3088	173	171	0	0	NUM
ajmri-3088	174	1	(	(	PUNCT
ajmri-3088	174	2	0.00	0.00	NUM
ajmri-3088	174	3	)	)	PUNCT
ajmri-3088	174	4	gender	gender	NOUN
ajmri-3088	174	5	male	male	NOUN
ajmri-3088	174	6	3	3	NUM
ajmri-3088	174	7	(	(	PUNCT
ajmri-3088	174	8	25	25	NUM
ajmri-3088	174	9	)	)	PUNCT
ajmri-3088	174	10	4	4	NUM
ajmri-3088	174	11	(	(	PUNCT
ajmri-3088	174	12	44.44	44.44	NUM
ajmri-3088	174	13	)	)	PUNCT
ajmri-3088	174	14	5	5	NUM
ajmri-3088	174	15	(	(	PUNCT
ajmri-3088	174	16	35.7	35.7	NUM
ajmri-3088	174	17	)	)	PUNCT
ajmri-3088	174	18	female	female	ADJ
ajmri-3088	174	19	9	9	NUM
ajmri-3088	174	20	(	(	PUNCT
ajmri-3088	174	21	75	75	NUM
ajmri-3088	174	22	)	)	PUNCT
ajmri-3088	174	23	5	5	NUM
ajmri-3088	174	24	(	(	PUNCT
ajmri-3088	174	25	55.55	55.55	NUM
ajmri-3088	174	26	)	)	PUNCT
ajmri-3088	174	27	9	9	NUM
ajmri-3088	174	28	(	(	PUNCT
ajmri-3088	174	29	64.28	64.28	NUM
ajmri-3088	174	30	)	)	PUNCT
ajmri-3088	174	31	mode	mode	NOUN
ajmri-3088	174	32	of	of	ADP
ajmri-3088	174	33	acquired	acquire	VERB
ajmri-3088	174	34	infection	infection	NOUN
ajmri-3088	174	35	intravenous	intravenous	ADJ
ajmri-3088	174	36	drug	drug	NOUN
ajmri-3088	174	37	usage	usage	NOUN
ajmri-3088	174	38	3	3	NUM
ajmri-3088	174	39	(	(	PUNCT
ajmri-3088	174	40	25	25	NUM
ajmri-3088	174	41	)	)	PUNCT
ajmri-3088	174	42	1	1	NUM
ajmri-3088	174	43	(	(	PUNCT
ajmri-3088	174	44	11.11	11.11	NUM
ajmri-3088	174	45	)	)	PUNCT
ajmri-3088	174	46	3	3	NUM
ajmri-3088	174	47	(	(	PUNCT
ajmri-3088	174	48	21.42	21.42	NUM
ajmri-3088	174	49	)	)	PUNCT
ajmri-3088	174	50	sexual	sexual	ADJ
ajmri-3088	174	51	practices	practice	NOUN
ajmri-3088	174	52	3	3	NUM
ajmri-3088	174	53	(	(	PUNCT
ajmri-3088	174	54	25	25	NUM
ajmri-3088	174	55	)	)	PUNCT
ajmri-3088	174	56	3	3	NUM
ajmri-3088	174	57	(	(	PUNCT
ajmri-3088	174	58	33.33	33.33	NUM
ajmri-3088	174	59	)	)	PUNCT
ajmri-3088	174	60	4	4	NUM
ajmri-3088	174	61	(	(	PUNCT
ajmri-3088	174	62	28.57	28.57	NUM
ajmri-3088	174	63	)	)	PUNCT
ajmri-3088	174	64	vertical	vertical	ADJ
ajmri-3088	174	65	transmissions	transmission	NOUN
ajmri-3088	174	66	4	4	NUM
ajmri-3088	174	67	(	(	PUNCT
ajmri-3088	174	68	30.7	30.7	NUM
ajmri-3088	174	69	)	)	SYM
ajmri-3088	174	70	2	2	NUM
ajmri-3088	174	71	(	(	PUNCT
ajmri-3088	174	72	22.22	22.22	NUM
ajmri-3088	174	73	)	)	PUNCT
ajmri-3088	174	74	5	5	NUM
ajmri-3088	174	75	(	(	PUNCT
ajmri-3088	174	76	35.71	35.71	NUM
ajmri-3088	174	77	)	)	PUNCT
ajmri-3088	174	78	unhygienic	unhygienic	ADJ
ajmri-3088	174	79	surroundings	surrounding	NOUN
ajmri-3088	174	80	2	2	NUM
ajmri-3088	174	81	(	(	PUNCT
ajmri-3088	174	82	16.66	16.66	NUM
ajmri-3088	174	83	)	)	PUNCT
ajmri-3088	174	84	3	3	NUM
ajmri-3088	174	85	(	(	PUNCT
ajmri-3088	174	86	33.33	33.33	NUM
ajmri-3088	174	87	)	)	PUNCT
ajmri-3088	174	88	2	2	NUM
ajmri-3088	174	89	(	(	PUNCT
ajmri-3088	174	90	14.28	14.28	NUM
ajmri-3088	174	91	)	)	PUNCT
ajmri-3088	174	92	duration	duration	NOUN
ajmri-3088	174	93	of	of	ADP
ajmri-3088	174	94	diagnosis	diagnosis	NOUN
ajmri-3088	174	95	(	(	PUNCT
ajmri-3088	174	96	months	month	NOUN
ajmri-3088	174	97	)	)	PUNCT
ajmri-3088	174	98	0	0	NUM
ajmri-3088	174	99	-	-	SYM
ajmri-3088	174	100	6	6	NUM
ajmri-3088	174	101	months	month	NOUN
ajmri-3088	174	102	3	3	NUM
ajmri-3088	174	103	(	(	PUNCT
ajmri-3088	174	104	25	25	NUM
ajmri-3088	174	105	)	)	SYM
ajmri-3088	174	106	2	2	NUM
ajmri-3088	174	107	(	(	PUNCT
ajmri-3088	174	108	22.22	22.22	NUM
ajmri-3088	174	109	)	)	PUNCT
ajmri-3088	174	110	6	6	NUM
ajmri-3088	174	111	(	(	PUNCT
ajmri-3088	174	112	35.29	35.29	NUM
ajmri-3088	174	113	)	)	PUNCT
ajmri-3088	174	114	7	7	NUM
ajmri-3088	174	115	-	-	SYM
ajmri-3088	174	116	12	12	NUM
ajmri-3088	174	117	months	month	NOUN
ajmri-3088	174	118	6	6	NUM
ajmri-3088	174	119	(	(	PUNCT
ajmri-3088	174	120	50	50	NUM
ajmri-3088	174	121	)	)	PUNCT
ajmri-3088	174	122	3	3	NUM
ajmri-3088	174	123	(	(	PUNCT
ajmri-3088	174	124	33.33	33.33	NUM
ajmri-3088	174	125	)	)	PUNCT
ajmri-3088	174	126	4	4	NUM
ajmri-3088	174	127	(	(	PUNCT
ajmri-3088	174	128	28.57	28.57	NUM
ajmri-3088	174	129	)	)	PUNCT
ajmri-3088	174	130	13	13	NUM
ajmri-3088	174	131	-	-	SYM
ajmri-3088	174	132	19	19	NUM
ajmri-3088	174	133	months	month	NOUN
ajmri-3088	174	134	3	3	NUM
ajmri-3088	174	135	(	(	PUNCT
ajmri-3088	174	136	25	25	NUM
ajmri-3088	174	137	)	)	PUNCT
ajmri-3088	174	138	3	3	NUM
ajmri-3088	174	139	(	(	PUNCT
ajmri-3088	174	140	33.33	33.33	NUM
ajmri-3088	174	141	)	)	PUNCT
ajmri-3088	174	142	2	2	NUM
ajmri-3088	174	143	(	(	PUNCT
ajmri-3088	174	144	14.28	14.28	NUM
ajmri-3088	174	145	)	)	PUNCT
ajmri-3088	174	146	20	20	NUM
ajmri-3088	174	147	-	-	SYM
ajmri-3088	174	148	26	26	NUM
ajmri-3088	174	149	months	month	NOUN
ajmri-3088	174	150	0	0	PUNCT
ajmri-3088	174	151	(	(	PUNCT
ajmri-3088	174	152	0.00	0.00	NUM
ajmri-3088	174	153	)	)	PUNCT
ajmri-3088	174	154	1(1.11	1(1.11	NUM
ajmri-3088	174	155	)	)	PUNCT
ajmri-3088	174	156	2	2	NUM
ajmri-3088	174	157	(	(	PUNCT
ajmri-3088	174	158	14.28	14.28	NUM
ajmri-3088	174	159	)	)	PUNCT
ajmri-3088	174	160	cd4	cd4	PROPN
ajmri-3088	174	161	+	+	PROPN
ajmri-3088	174	162	>	>	X
ajmri-3088	174	163	500	500	NUM
ajmri-3088	174	164	1	1	NUM
ajmri-3088	174	165	(	(	PUNCT
ajmri-3088	174	166	8.3	8.3	NUM
ajmri-3088	174	167	)	)	PUNCT
ajmri-3088	174	168	0	0	NUM
ajmri-3088	174	169	(	(	PUNCT
ajmri-3088	174	170	00.00	00.00	NUM
ajmri-3088	174	171	)	)	PUNCT
ajmri-3088	174	172	1	1	NUM
ajmri-3088	174	173	(	(	PUNCT
ajmri-3088	174	174	7.14	7.14	NUM
ajmri-3088	174	175	)	)	PUNCT
ajmri-3088	174	176	pa	pa	PROPN
ajmri-3088	174	177	ge	ge	PROPN
ajmri-3088	174	178	57	57	NUM
ajmri-3088	174	179	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	174	180	am	am	NOUN
ajmri-3088	174	181	.	.	PUNCT
ajmri-3088	175	1	j.	j.	PROPN
ajmri-3088	175	2	multidis	multidis	PROPN
ajmri-3088	175	3	.	.	PUNCT
ajmri-3088	176	1	res	re	NOUN
ajmri-3088	176	2	.	.	PUNCT
ajmri-3088	177	1	innov	innov	PROPN
ajmri-3088	177	2	.	.	PUNCT
ajmri-3088	178	1	3(5	3(5	NUM
ajmri-3088	178	2	)	)	PUNCT
ajmri-3088	178	3	50	50	NUM
ajmri-3088	178	4	-	-	SYM
ajmri-3088	178	5	60	60	NUM
ajmri-3088	178	6	,	,	PUNCT
ajmri-3088	178	7	2024	2024	NUM
ajmri-3088	178	8	350	350	NUM
ajmri-3088	178	9	-	-	SYM
ajmri-3088	178	10	500	500	NUM
ajmri-3088	178	11	3	3	NUM
ajmri-3088	178	12	(	(	PUNCT
ajmri-3088	178	13	25	25	NUM
ajmri-3088	178	14	)	)	SYM
ajmri-3088	178	15	2	2	NUM
ajmri-3088	178	16	(	(	PUNCT
ajmri-3088	178	17	22.22	22.22	NUM
ajmri-3088	178	18	)	)	PUNCT
ajmri-3088	178	19	2	2	NUM
ajmri-3088	178	20	(	(	PUNCT
ajmri-3088	178	21	14.28	14.28	NUM
ajmri-3088	178	22	)	)	PUNCT
ajmri-3088	178	23	200	200	NUM
ajmri-3088	178	24	-	-	SYM
ajmri-3088	178	25	350	350	NUM
ajmri-3088	178	26	5	5	NUM
ajmri-3088	178	27	(	(	PUNCT
ajmri-3088	178	28	41.66	41.66	NUM
ajmri-3088	178	29	)	)	PUNCT
ajmri-3088	178	30	5	5	NUM
ajmri-3088	178	31	(	(	PUNCT
ajmri-3088	178	32	55.55	55.55	NUM
ajmri-3088	178	33	)	)	PUNCT
ajmri-3088	178	34	7	7	NUM
ajmri-3088	178	35	(	(	PUNCT
ajmri-3088	178	36	50	50	NUM
ajmri-3088	178	37	)	)	PUNCT
ajmri-3088	178	38	<	<	X
ajmri-3088	178	39	200	200	NUM
ajmri-3088	178	40	4	4	NUM
ajmri-3088	178	41	(	(	PUNCT
ajmri-3088	178	42	30.7	30.7	NUM
ajmri-3088	178	43	)	)	SYM
ajmri-3088	178	44	2	2	NUM
ajmri-3088	178	45	(	(	PUNCT
ajmri-3088	178	46	22.22	22.22	NUM
ajmri-3088	178	47	)	)	PUNCT
ajmri-3088	178	48	4	4	NUM
ajmri-3088	178	49	(	(	PUNCT
ajmri-3088	178	50	28.57	28.57	NUM
ajmri-3088	178	51	)	)	PUNCT
ajmri-3088	178	52	shows	show	VERB
ajmri-3088	178	53	a	a	DET
ajmri-3088	178	54	strong	strong	ADJ
ajmri-3088	178	55	decline	decline	NOUN
ajmri-3088	178	56	in	in	ADP
ajmri-3088	178	57	the	the	DET
ajmri-3088	178	58	cd4	cd4	PROPN
ajmri-3088	178	59	+	+	PROPN
ajmri-3088	178	60	population	population	NOUN
ajmri-3088	178	61	.	.	PUNCT
ajmri-3088	179	1	the	the	DET
ajmri-3088	179	2	study	study	NOUN
ajmri-3088	179	3	also	also	ADV
ajmri-3088	179	4	showed	show	VERB
ajmri-3088	179	5	that	that	SCONJ
ajmri-3088	179	6	nearly	nearly	ADV
ajmri-3088	179	7	50	50	NUM
ajmri-3088	179	8	%	%	NOUN
ajmri-3088	179	9	of	of	ADP
ajmri-3088	179	10	hiv	hiv	PROPN
ajmri-3088	179	11	/	/	SYM
ajmri-3088	179	12	hbv	hbv	PROPN
ajmri-3088	179	13	coinfected	coinfecte	VERB
ajmri-3088	179	14	patients	patient	NOUN
ajmri-3088	179	15	showed	show	VERB
ajmri-3088	179	16	cd4	cd4	PROPN
ajmri-3088	179	17	+	+	NOUN
ajmri-3088	179	18	cell	cell	NOUN
ajmri-3088	179	19	counts	count	NOUN
ajmri-3088	179	20	in	in	ADP
ajmri-3088	179	21	the	the	DET
ajmri-3088	179	22	range	range	NOUN
ajmri-3088	179	23	of	of	ADP
ajmri-3088	179	24	200	200	NUM
ajmri-3088	179	25	-	-	SYM
ajmri-3088	179	26	350	350	NUM
ajmri-3088	179	27	cells	cell	NOUN
ajmri-3088	179	28	/	/	SYM
ajmri-3088	179	29	mm3	mm3	PROPN
ajmri-3088	179	30	,	,	PUNCT
ajmri-3088	179	31	as	as	SCONJ
ajmri-3088	179	32	mentioned	mention	VERB
ajmri-3088	179	33	in	in	ADP
ajmri-3088	179	34	table	table	NOUN
ajmri-3088	179	35	5	5	NUM
ajmri-3088	179	36	.	.	PUNCT
ajmri-3088	179	37	previous	previous	ADJ
ajmri-3088	179	38	studies	study	NOUN
ajmri-3088	179	39	have	have	AUX
ajmri-3088	179	40	shown	show	VERB
ajmri-3088	179	41	that	that	SCONJ
ajmri-3088	179	42	hiv	hiv	PROPN
ajmri-3088	179	43	/	/	SYM
ajmri-3088	179	44	hbv	hbv	NOUN
ajmri-3088	179	45	coinfection	coinfection	NOUN
ajmri-3088	179	46	progression	progression	NOUN
ajmri-3088	179	47	is	be	AUX
ajmri-3088	179	48	usually	usually	ADV
ajmri-3088	179	49	evident	evident	ADJ
ajmri-3088	179	50	from	from	ADP
ajmri-3088	179	51	the	the	DET
ajmri-3088	179	52	cd4	cd4	PROPN
ajmri-3088	179	53	cell	cell	NOUN
ajmri-3088	179	54	count	count	NOUN
ajmri-3088	179	55	table	table	NOUN
ajmri-3088	179	56	5	5	NUM
ajmri-3088	179	57	:	:	PUNCT
ajmri-3088	179	58	ratios	ratio	NOUN
ajmri-3088	179	59	of	of	ADP
ajmri-3088	179	60	coinfected	coinfecte	VERB
ajmri-3088	179	61	patients	patient	NOUN
ajmri-3088	179	62	of	of	ADP
ajmri-3088	179	63	hiv	hiv	PROPN
ajmri-3088	179	64	/	/	SYM
ajmri-3088	179	65	hbv	hbv	NOUN
ajmri-3088	179	66	in	in	ADP
ajmri-3088	179	67	hiv	hiv	PROPN
ajmri-3088	179	68	patients	patient	NOUN
ajmri-3088	179	69	characteristics	characteristic	NOUN
ajmri-3088	179	70	coinfection	coinfection	NOUN
ajmri-3088	179	71	(	(	PUNCT
ajmri-3088	179	72	hiv	hiv	NOUN
ajmri-3088	179	73	/	/	SYM
ajmri-3088	179	74	hbv	hbv	NOUN
ajmri-3088	179	75	)	)	PUNCT
ajmri-3088	179	76	univariable	univariable	ADJ
ajmri-3088	179	77	model	model	NOUN
ajmri-3088	179	78	multiple	multiple	ADJ
ajmri-3088	179	79	variable	variable	ADJ
ajmri-3088	179	80	mode	mode	NOUN
ajmri-3088	179	81	studied	study	VERB
ajmri-3088	179	82	parameters	parameter	NOUN
ajmri-3088	179	83	or	or	CCONJ
ajmri-3088	179	84	95%cl	95%cl	ADJ
ajmri-3088	179	85	p	p	ADJ
ajmri-3088	179	86	-	-	PUNCT
ajmri-3088	179	87	value	value	NOUN
ajmri-3088	179	88	aor	aor	NOUN
ajmri-3088	179	89	95	95	NUM
ajmri-3088	179	90	%	%	NOUN
ajmri-3088	179	91	ci	ci	NOUN
ajmri-3088	179	92	p	p	NOUN
ajmri-3088	179	93	-	-	PUNCT
ajmri-3088	179	94	value	value	NOUN
ajmri-3088	180	1	yes	yes	INTJ
ajmri-3088	180	2	no	no	INTJ
ajmri-3088	180	3	<	<	NOUN
ajmri-3088	180	4	0.01	0.01	NUM
ajmri-3088	180	5	age	age	NOUN
ajmri-3088	180	6	factor	factor	NOUN
ajmri-3088	180	7	(	(	PUNCT
ajmri-3088	180	8	years	year	NOUN
ajmri-3088	180	9	)	)	PUNCT
ajmri-3088	180	10	<	<	X
ajmri-3088	180	11	37	37	NUM
ajmri-3088	180	12	9	9	NUM
ajmri-3088	180	13	10	10	NUM
ajmri-3088	180	14	1	1	NUM
ajmri-3088	180	15	(	(	PUNCT
ajmri-3088	180	16	referent	referent	NOUN
ajmri-3088	180	17	)	)	PUNCT
ajmri-3088	180	18	<	<	X
ajmri-3088	180	19	0.01	0.01	NUM
ajmri-3088	180	20	1	1	NUM
ajmri-3088	180	21	(	(	PUNCT
ajmri-3088	180	22	referent	referent	NOUN
ajmri-3088	180	23	)	)	PUNCT
ajmri-3088	180	24	>	>	X
ajmri-3088	180	25	37	37	NUM
ajmri-3088	180	26	12	12	NUM
ajmri-3088	180	27	4	4	NUM
ajmri-3088	180	28	3	3	NUM
ajmri-3088	180	29	0.180	0.180	NUM
ajmri-3088	180	30	,	,	PUNCT
ajmri-3088	180	31	1.95	1.95	NUM
ajmri-3088	180	32	0.42	0.42	NUM
ajmri-3088	180	33	0.180	0.180	NUM
ajmri-3088	180	34	,	,	PUNCT
ajmri-3088	180	35	1.90	1.90	NUM
ajmri-3088	180	36	<	<	NOUN
ajmri-3088	180	37	0.01	0.01	NUM
ajmri-3088	180	38	gender	gender	NOUN
ajmri-3088	180	39	male	male	NOUN
ajmri-3088	180	40	7	7	NUM
ajmri-3088	180	41	8	8	NUM
ajmri-3088	180	42	1	1	NUM
ajmri-3088	180	43	(	(	PUNCT
ajmri-3088	180	44	referent	referent	NOUN
ajmri-3088	180	45	)	)	PUNCT
ajmri-3088	180	46	0.36	0.36	NUM
ajmri-3088	180	47	1	1	NUM
ajmri-3088	180	48	(	(	PUNCT
ajmri-3088	180	49	referent	referent	NOUN
ajmri-3088	180	50	)	)	PUNCT
ajmri-3088	180	51	female	female	NOUN
ajmri-3088	180	52	14	14	NUM
ajmri-3088	180	53	6	6	NUM
ajmri-3088	180	54	2.333333333	2.333333333	NUM
ajmri-3088	180	55	8.75,1.030	8.75,1.030	NUM
ajmri-3088	180	56	0.1	0.1	NUM
ajmri-3088	180	57	8.65,1.025	8.65,1.025	NUM
ajmri-3088	180	58	0.2	0.2	NUM
ajmri-3088	180	59	mode	mode	NOUN
ajmri-3088	180	60	of	of	ADP
ajmri-3088	180	61	acquired	acquire	VERB
ajmri-3088	180	62	infection	infection	NOUN
ajmri-3088	180	63	vertical	vertical	ADJ
ajmri-3088	180	64	transmissions	transmission	NOUN
ajmri-3088	180	65	6	6	NUM
ajmri-3088	180	66	9	9	NUM
ajmri-3088	180	67	1	1	NUM
ajmri-3088	180	68	(	(	PUNCT
ajmri-3088	180	69	referent	referent	NOUN
ajmri-3088	180	70	)	)	PUNCT
ajmri-3088	180	71	0.11	0.11	NUM
ajmri-3088	180	72	1	1	NUM
ajmri-3088	180	73	(	(	PUNCT
ajmri-3088	180	74	referent	referent	NOUN
ajmri-3088	180	75	)	)	PUNCT
ajmri-3088	180	76	intravenous	intravenous	ADJ
ajmri-3088	180	77	drug	drug	NOUN
ajmri-3088	180	78	usage	usage	NOUN
ajmri-3088	180	79	and	and	CCONJ
ajmri-3088	180	80	other	other	ADJ
ajmri-3088	180	81	modes	mode	NOUN
ajmri-3088	180	82	15	15	NUM
ajmri-3088	180	83	5	5	NUM
ajmri-3088	180	84	3	3	NUM
ajmri-3088	180	85	8.75,1.29	8.75,1.29	NUM
ajmri-3088	180	86	0.31	0.31	NUM
ajmri-3088	180	87	2.13	2.13	NUM
ajmri-3088	180	88	duration	duration	NOUN
ajmri-3088	180	89	of	of	ADP
ajmri-3088	180	90	diagnosis	diagnosis	NOUN
ajmri-3088	180	91	(	(	PUNCT
ajmri-3088	180	92	months	month	NOUN
ajmri-3088	180	93	)	)	PUNCT
ajmri-3088	180	94	0	0	NUM
ajmri-3088	180	95	-	-	SYM
ajmri-3088	180	96	6	6	NUM
ajmri-3088	180	97	months	month	NOUN
ajmri-3088	180	98	18	18	NUM
ajmri-3088	180	99	2	2	NUM
ajmri-3088	180	100	1	1	NUM
ajmri-3088	180	101	(	(	PUNCT
ajmri-3088	180	102	referent	referent	NOUN
ajmri-3088	180	103	)	)	PUNCT
ajmri-3088	180	104	0.39	0.39	NUM
ajmri-3088	180	105	1	1	NUM
ajmri-3088	180	106	(	(	PUNCT
ajmri-3088	180	107	referent	referent	NOUN
ajmri-3088	180	108	)	)	PUNCT
ajmri-3088	180	109	>	>	SYM
ajmri-3088	180	110	6	6	NUM
ajmri-3088	180	111	months	month	NOUN
ajmri-3088	180	112	4	4	NUM
ajmri-3088	180	113	12	12	NUM
ajmri-3088	180	114	3	3	NUM
ajmri-3088	180	115	8.75,2.12	8.75,2.12	NUM
ajmri-3088	180	116	0.76	0.76	NUM
ajmri-3088	180	117	cd4	cd4	PROPN
ajmri-3088	180	118	cell	cell	NOUN
ajmri-3088	180	119	count	count	NOUN
ajmri-3088	180	120	(	(	PUNCT
ajmri-3088	180	121	cell	cell	NOUN
ajmri-3088	180	122	/	/	SYM
ajmri-3088	180	123	mm3	mm3	NOUN
ajmri-3088	180	124	)	)	PUNCT
ajmri-3088	180	125	>	>	X
ajmri-3088	180	126	350	350	NUM
ajmri-3088	180	127	5	5	NUM
ajmri-3088	180	128	10	10	NUM
ajmri-3088	180	129	1	1	NUM
ajmri-3088	180	130	(	(	PUNCT
ajmri-3088	180	131	referent	referent	NOUN
ajmri-3088	180	132	)	)	PUNCT
ajmri-3088	180	133	0.0008	0.0008	NUM
ajmri-3088	180	134	<	<	X
ajmri-3088	180	135	350	350	NUM
ajmri-3088	180	136	16	16	NUM
ajmri-3088	180	137	4	4	NUM
ajmri-3088	180	138	4	4	NUM
ajmri-3088	180	139	ranging	range	VERB
ajmri-3088	180	140	below	below	ADP
ajmri-3088	180	141	300	300	NUM
ajmri-3088	180	142	cell	cell	NOUN
ajmri-3088	180	143	count	count	NOUN
ajmri-3088	180	144	(	(	PUNCT
ajmri-3088	180	145	tortellini	tortellini	NOUN
ajmri-3088	180	146	et	et	PROPN
ajmri-3088	180	147	al	al	PROPN
ajmri-3088	180	148	.	.	PROPN
ajmri-3088	180	149	,	,	PUNCT
ajmri-3088	180	150	2023	2023	NUM
ajmri-3088	180	151	)	)	PUNCT
ajmri-3088	180	152	.	.	PUNCT
ajmri-3088	181	1	the	the	DET
ajmri-3088	181	2	results	result	NOUN
ajmri-3088	181	3	of	of	ADP
ajmri-3088	181	4	the	the	DET
ajmri-3088	181	5	study	study	NOUN
ajmri-3088	181	6	,	,	PUNCT
ajmri-3088	181	7	as	as	SCONJ
ajmri-3088	181	8	mentioned	mention	VERB
ajmri-3088	181	9	in	in	ADP
ajmri-3088	181	10	table	table	NOUN
ajmri-3088	181	11	6	6	NUM
ajmri-3088	181	12	,	,	PUNCT
ajmri-3088	181	13	revealed	reveal	VERB
ajmri-3088	181	14	a	a	DET
ajmri-3088	181	15	striking	strike	VERB
ajmri-3088	181	16	pattern	pattern	NOUN
ajmri-3088	181	17	:	:	PUNCT
ajmri-3088	181	18	nearly	nearly	ADV
ajmri-3088	181	19	half	half	NOUN
ajmri-3088	181	20	of	of	ADP
ajmri-3088	181	21	people	people	NOUN
ajmri-3088	181	22	with	with	ADP
ajmri-3088	181	23	coinfected	coinfecte	VERB
ajmri-3088	181	24	hiv	hiv	PROPN
ajmri-3088	181	25	and	and	CCONJ
ajmri-3088	181	26	hbv	hbv	PROPN
ajmri-3088	181	27	had	have	VERB
ajmri-3088	181	28	cd4	cd4	PROPN
ajmri-3088	181	29	+	+	NOUN
ajmri-3088	181	30	cell	cell	NOUN
ajmri-3088	181	31	counts	count	NOUN
ajmri-3088	181	32	between	between	ADP
ajmri-3088	181	33	200	200	NUM
ajmri-3088	181	34	and	and	CCONJ
ajmri-3088	181	35	350	350	NUM
ajmri-3088	181	36	cells	cell	NOUN
ajmri-3088	181	37	/	/	SYM
ajmri-3088	181	38	mm3	mm3	NOUN
ajmri-3088	181	39	.	.	PUNCT
ajmri-3088	182	1	this	this	DET
ajmri-3088	182	2	range	range	NOUN
ajmri-3088	182	3	is	be	AUX
ajmri-3088	182	4	important	important	ADJ
ajmri-3088	182	5	since	since	SCONJ
ajmri-3088	182	6	previous	previous	ADJ
ajmri-3088	182	7	research	research	NOUN
ajmri-3088	182	8	has	have	AUX
ajmri-3088	182	9	repeatedly	repeatedly	ADV
ajmri-3088	182	10	shown	show	VERB
ajmri-3088	182	11	that	that	SCONJ
ajmri-3088	182	12	the	the	DET
ajmri-3088	182	13	development	development	NOUN
ajmri-3088	182	14	of	of	ADP
ajmri-3088	182	15	hiv	hiv	PROPN
ajmri-3088	182	16	/	/	SYM
ajmri-3088	182	17	hbv	hbv	NOUN
ajmri-3088	182	18	coinfection	coinfection	NOUN
ajmri-3088	182	19	is	be	AUX
ajmri-3088	182	20	shown	show	VERB
ajmri-3088	182	21	when	when	SCONJ
ajmri-3088	182	22	cd4	cd4	PROPN
ajmri-3088	182	23	cell	cell	NOUN
ajmri-3088	182	24	counts	count	VERB
ajmri-3088	182	25	drop	drop	VERB
ajmri-3088	182	26	below	below	ADP
ajmri-3088	182	27	300	300	NUM
ajmri-3088	182	28	cells	cell	NOUN
ajmri-3088	182	29	/	/	SYM
ajmri-3088	182	30	mm3	mm3	PROPN
ajmri-3088	182	31	.	.	PUNCT
ajmri-3088	183	1	the	the	DET
ajmri-3088	183	2	results	result	NOUN
ajmri-3088	183	3	highlight	highlight	VERB
ajmri-3088	183	4	the	the	DET
ajmri-3088	183	5	likelihood	likelihood	NOUN
ajmri-3088	183	6	of	of	ADP
ajmri-3088	183	7	coinfected	coinfecte	VERB
ajmri-3088	183	8	individuals	individual	NOUN
ajmri-3088	183	9	and	and	CCONJ
ajmri-3088	183	10	emphasize	emphasize	VERB
ajmri-3088	183	11	the	the	DET
ajmri-3088	183	12	importance	importance	NOUN
ajmri-3088	183	13	of	of	ADP
ajmri-3088	183	14	tracking	track	VERB
ajmri-3088	183	15	cd4	cd4	PROPN
ajmri-3088	183	16	counts	count	NOUN
ajmri-3088	183	17	to	to	PART
ajmri-3088	183	18	determine	determine	VERB
ajmri-3088	183	19	the	the	DET
ajmri-3088	183	20	course	course	NOUN
ajmri-3088	183	21	of	of	ADP
ajmri-3088	183	22	the	the	DET
ajmri-3088	183	23	illness	illness	NOUN
ajmri-3088	183	24	.	.	PUNCT
ajmri-3088	184	1	these	these	DET
ajmri-3088	184	2	findings	finding	NOUN
ajmri-3088	184	3	provide	provide	VERB
ajmri-3088	184	4	important	important	ADJ
ajmri-3088	184	5	information	information	NOUN
ajmri-3088	184	6	about	about	ADP
ajmri-3088	184	7	the	the	DET
ajmri-3088	184	8	dynamics	dynamic	NOUN
ajmri-3088	184	9	of	of	ADP
ajmri-3088	184	10	coinfection	coinfection	NOUN
ajmri-3088	184	11	with	with	ADP
ajmri-3088	184	12	hiv/	hiv/	NOUN
ajmri-3088	184	13	hbv	hbv	NOUN
ajmri-3088	184	14	,	,	PUNCT
ajmri-3088	184	15	assisting	assist	VERB
ajmri-3088	184	16	physicians	physician	NOUN
ajmri-3088	184	17	in	in	ADP
ajmri-3088	184	18	putting	put	VERB
ajmri-3088	184	19	focused	focused	ADJ
ajmri-3088	184	20	therapies	therapy	NOUN
ajmri-3088	184	21	into	into	ADP
ajmri-3088	184	22	practice	practice	NOUN
ajmri-3088	184	23	and	and	CCONJ
ajmri-3088	184	24	improving	improve	VERB
ajmri-3088	184	25	patient	patient	ADJ
ajmri-3088	184	26	care	care	NOUN
ajmri-3088	184	27	approaches	approach	NOUN
ajmri-3088	184	28	for	for	ADP
ajmri-3088	184	29	this	this	DET
ajmri-3088	184	30	specific	specific	ADJ
ajmri-3088	184	31	population	population	NOUN
ajmri-3088	184	32	(	(	PUNCT
ajmri-3088	184	33	de	de	X
ajmri-3088	184	34	gea	gea	PROPN
ajmri-3088	184	35	-	-	PUNCT
ajmri-3088	184	36	grela	grela	PROPN
ajmri-3088	184	37	&	&	CCONJ
ajmri-3088	184	38	moreno	moreno	PROPN
ajmri-3088	184	39	,	,	PUNCT
ajmri-3088	184	40	2023	2023	NUM
ajmri-3088	184	41	)	)	PUNCT
ajmri-3088	184	42	.	.	PUNCT
ajmri-3088	185	1	in	in	ADP
ajmri-3088	185	2	the	the	DET
ajmri-3088	185	3	case	case	NOUN
ajmri-3088	185	4	of	of	ADP
ajmri-3088	185	5	hiv	hiv	PROPN
ajmri-3088	185	6	-	-	PUNCT
ajmri-3088	185	7	infected	infect	VERB
ajmri-3088	185	8	patients	patient	NOUN
ajmri-3088	185	9	,	,	PUNCT
ajmri-3088	185	10	41.66	41.66	NUM
ajmri-3088	185	11	%	%	NOUN
ajmri-3088	185	12	of	of	ADP
ajmri-3088	185	13	the	the	DET
ajmri-3088	185	14	cd4	cd4	PROPN
ajmri-3088	185	15	+	+	PROPN
ajmri-3088	185	16	cell	cell	NOUN
ajmri-3088	185	17	count	count	NOUN
ajmri-3088	185	18	was	be	AUX
ajmri-3088	185	19	noted	note	VERB
ajmri-3088	185	20	in	in	ADP
ajmri-3088	185	21	the	the	DET
ajmri-3088	185	22	range	range	NOUN
ajmri-3088	185	23	of	of	ADP
ajmri-3088	185	24	200	200	NUM
ajmri-3088	185	25	-	-	SYM
ajmri-3088	185	26	350	350	NUM
ajmri-3088	185	27	cells	cell	NOUN
ajmri-3088	185	28	/	/	SYM
ajmri-3088	185	29	mm3	mm3	NOUN
ajmri-3088	185	30	.	.	PUNCT
ajmri-3088	186	1	nearly	nearly	ADV
ajmri-3088	186	2	55.55	55.55	NUM
ajmri-3088	186	3	%	%	NOUN
ajmri-3088	186	4	of	of	ADP
ajmri-3088	186	5	positive	positive	ADJ
ajmri-3088	186	6	patients	patient	NOUN
ajmri-3088	186	7	showed	show	VERB
ajmri-3088	186	8	cd4	cd4	PROPN
ajmri-3088	186	9	+	+	NOUN
ajmri-3088	186	10	less	less	ADJ
ajmri-3088	186	11	than	than	ADP
ajmri-3088	186	12	350	350	NUM
ajmri-3088	186	13	cells	cell	NOUN
ajmri-3088	186	14	/	/	SYM
ajmri-3088	186	15	mm3	mm3	NOUN
ajmri-3088	186	16	.	.	PUNCT
ajmri-3088	187	1	ethical	ethical	ADJ
ajmri-3088	187	2	approval	approval	NOUN
ajmri-3088	187	3	ethical	ethical	ADJ
ajmri-3088	187	4	approval	approval	NOUN
ajmri-3088	187	5	was	be	AUX
ajmri-3088	187	6	obtained	obtain	VERB
ajmri-3088	187	7	from	from	ADP
ajmri-3088	187	8	the	the	DET
ajmri-3088	187	9	institutional	institutional	ADJ
ajmri-3088	187	10	review	review	PROPN
ajmri-3088	187	11	board	board	NOUN
ajmri-3088	187	12	(	(	PUNCT
ajmri-3088	187	13	irb	irb	PROPN
ajmri-3088	187	14	)	)	PUNCT
ajmri-3088	187	15	of	of	ADP
ajmri-3088	187	16	the	the	DET
ajmri-3088	187	17	health	health	PROPN
ajmri-3088	187	18	ministry	ministry	PROPN
ajmri-3088	187	19	.	.	PUNCT
ajmri-3088	188	1	written	write	VERB
ajmri-3088	188	2	informed	informed	ADJ
ajmri-3088	188	3	consent	consent	NOUN
ajmri-3088	188	4	was	be	AUX
ajmri-3088	188	5	obtained	obtain	VERB
ajmri-3088	188	6	from	from	ADP
ajmri-3088	188	7	participants	participant	NOUN
ajmri-3088	188	8	before	before	SCONJ
ajmri-3088	188	9	they	they	PRON
ajmri-3088	188	10	were	be	AUX
ajmri-3088	188	11	directly	directly	ADV
ajmri-3088	188	12	involved	involve	VERB
ajmri-3088	188	13	in	in	ADP
ajmri-3088	188	14	the	the	DET
ajmri-3088	188	15	study	study	NOUN
ajmri-3088	188	16	.	.	PUNCT
ajmri-3088	189	1	all	all	DET
ajmri-3088	189	2	the	the	DET
ajmri-3088	189	3	participants	participant	NOUN
ajmri-3088	189	4	were	be	AUX
ajmri-3088	189	5	briefed	brief	VERB
ajmri-3088	189	6	on	on	ADP
ajmri-3088	189	7	the	the	DET
ajmri-3088	189	8	objectives	objective	NOUN
ajmri-3088	189	9	of	of	ADP
ajmri-3088	189	10	this	this	DET
ajmri-3088	189	11	study	study	NOUN
ajmri-3088	189	12	and	and	CCONJ
ajmri-3088	189	13	the	the	DET
ajmri-3088	189	14	possible	possible	ADJ
ajmri-3088	189	15	expected	expect	VERB
ajmri-3088	189	16	outcomes	outcome	NOUN
ajmri-3088	189	17	of	of	ADP
ajmri-3088	189	18	participating	participate	VERB
ajmri-3088	189	19	in	in	ADP
ajmri-3088	189	20	the	the	DET
ajmri-3088	189	21	study	study	NOUN
ajmri-3088	189	22	.	.	PUNCT
ajmri-3088	190	1	they	they	PRON
ajmri-3088	190	2	were	be	AUX
ajmri-3088	190	3	also	also	ADV
ajmri-3088	190	4	assured	assure	VERB
ajmri-3088	190	5	that	that	SCONJ
ajmri-3088	190	6	there	there	PRON
ajmri-3088	190	7	was	be	VERB
ajmri-3088	190	8	no	no	DET
ajmri-3088	190	9	pressure	pressure	NOUN
ajmri-3088	190	10	,	,	PUNCT
ajmri-3088	190	11	that	that	SCONJ
ajmri-3088	190	12	their	their	PRON
ajmri-3088	190	13	participation	participation	NOUN
ajmri-3088	190	14	was	be	AUX
ajmri-3088	190	15	entirely	entirely	ADV
ajmri-3088	190	16	voluntary	voluntary	ADJ
ajmri-3088	190	17	,	,	PUNCT
ajmri-3088	190	18	and	and	CCONJ
ajmri-3088	190	19	that	that	SCONJ
ajmri-3088	190	20	they	they	PRON
ajmri-3088	190	21	could	could	AUX
ajmri-3088	190	22	quit	quit	VERB
ajmri-3088	190	23	the	the	DET
ajmri-3088	190	24	interview	interview	NOUN
ajmri-3088	190	25	at	at	ADP
ajmri-3088	190	26	any	any	DET
ajmri-3088	190	27	stage	stage	NOUN
ajmri-3088	190	28	.	.	PUNCT
ajmri-3088	191	1	discussion	discussion	NOUN
ajmri-3088	191	2	hiv	hiv	PROPN
ajmri-3088	191	3	,	,	PUNCT
ajmri-3088	191	4	known	know	VERB
ajmri-3088	191	5	to	to	PART
ajmri-3088	191	6	target	target	VERB
ajmri-3088	191	7	cd4	cd4	PROPN
ajmri-3088	191	8	t	t	PROPN
ajmri-3088	191	9	cells	cell	NOUN
ajmri-3088	191	10	,	,	PUNCT
ajmri-3088	191	11	causes	cause	VERB
ajmri-3088	191	12	a	a	DET
ajmri-3088	191	13	significant	significant	ADJ
ajmri-3088	191	14	decrease	decrease	NOUN
ajmri-3088	191	15	in	in	ADP
ajmri-3088	191	16	these	these	DET
ajmri-3088	191	17	cells	cell	NOUN
ajmri-3088	191	18	,	,	PUNCT
ajmri-3088	191	19	which	which	PRON
ajmri-3088	191	20	makes	make	VERB
ajmri-3088	191	21	it	it	PRON
ajmri-3088	191	22	more	more	ADV
ajmri-3088	191	23	difficult	difficult	ADJ
ajmri-3088	191	24	for	for	SCONJ
ajmri-3088	191	25	the	the	DET
ajmri-3088	191	26	immune	immune	ADJ
ajmri-3088	191	27	system	system	NOUN
ajmri-3088	191	28	to	to	PART
ajmri-3088	191	29	coordinate	coordinate	VERB
ajmri-3088	191	30	defenses	defense	NOUN
ajmri-3088	191	31	against	against	ADP
ajmri-3088	191	32	infections	infection	NOUN
ajmri-3088	191	33	.	.	PUNCT
ajmri-3088	192	1	the	the	DET
ajmri-3088	192	2	decreased	decrease	VERB
ajmri-3088	192	3	number	number	NOUN
ajmri-3088	192	4	of	of	ADP
ajmri-3088	192	5	t	t	PROPN
ajmri-3088	192	6	lymphocytes	lymphocyte	NOUN
ajmri-3088	192	7	is	be	AUX
ajmri-3088	192	8	made	make	VERB
ajmri-3088	192	9	worse	bad	ADJ
ajmri-3088	192	10	by	by	ADP
ajmri-3088	192	11	the	the	DET
ajmri-3088	192	12	extra	extra	ADJ
ajmri-3088	192	13	burden	burden	NOUN
ajmri-3088	192	14	of	of	ADP
ajmri-3088	192	15	hbv	hbv	NOUN
ajmri-3088	192	16	.	.	PUNCT
ajmri-3088	193	1	important	important	ADJ
ajmri-3088	193	2	for	for	ADP
ajmri-3088	193	3	eliminating	eliminate	VERB
ajmri-3088	193	4	viruses	virus	NOUN
ajmri-3088	193	5	,	,	PUNCT
ajmri-3088	193	6	cd8	cd8	PROPN
ajmri-3088	193	7	t	t	PROPN
ajmri-3088	193	8	cells	cell	NOUN
ajmri-3088	193	9	are	be	AUX
ajmri-3088	193	10	also	also	ADV
ajmri-3088	193	11	impacted	impact	VERB
ajmri-3088	193	12	,	,	PUNCT
ajmri-3088	193	13	most	most	ADV
ajmri-3088	193	14	likely	likely	ADJ
ajmri-3088	193	15	as	as	ADP
ajmri-3088	193	16	a	a	DET
ajmri-3088	193	17	result	result	NOUN
ajmri-3088	193	18	of	of	ADP
ajmri-3088	193	19	chronic	chronic	ADJ
ajmri-3088	193	20	stimulation	stimulation	NOUN
ajmri-3088	193	21	and	and	CCONJ
ajmri-3088	193	22	weariness	weariness	NOUN
ajmri-3088	193	23	from	from	ADP
ajmri-3088	193	24	ongoing	ongoing	ADJ
ajmri-3088	193	25	infections	infection	NOUN
ajmri-3088	193	26	.	.	PUNCT
ajmri-3088	194	1	immune	immune	ADJ
ajmri-3088	194	2	deficiency	deficiency	NOUN
ajmri-3088	194	3	is	be	AUX
ajmri-3088	194	4	worsened	worsen	VERB
ajmri-3088	194	5	by	by	ADP
ajmri-3088	194	6	t	t	PROPN
ajmri-3088	194	7	-	-	PUNCT
ajmri-3088	194	8	cell	cell	NOUN
ajmri-3088	194	9	depletion	depletion	NOUN
ajmri-3088	194	10	,	,	PUNCT
ajmri-3088	194	11	which	which	PRON
ajmri-3088	194	12	leaves	leave	VERB
ajmri-3088	194	13	the	the	DET
ajmri-3088	194	14	host	host	NOUN
ajmri-3088	194	15	vulnerable	vulnerable	ADJ
ajmri-3088	194	16	to	to	ADP
ajmri-3088	194	17	opportunistic	opportunistic	ADJ
ajmri-3088	194	18	infections	infection	NOUN
ajmri-3088	194	19	and	and	CCONJ
ajmri-3088	194	20	impairs	impair	VERB
ajmri-3088	194	21	the	the	DET
ajmri-3088	194	22	body	body	NOUN
ajmri-3088	194	23	’s	’s	PART
ajmri-3088	194	24	ability	ability	NOUN
ajmri-3088	194	25	to	to	PART
ajmri-3088	194	26	develop	develop	VERB
ajmri-3088	194	27	potent	potent	ADJ
ajmri-3088	194	28	antiviral	antiviral	ADJ
ajmri-3088	194	29	defenses	defense	NOUN
ajmri-3088	194	30	.	.	PUNCT
ajmri-3088	195	1	apoptosis	apoptosis	NOUN
ajmri-3088	195	2	,	,	PUNCT
ajmri-3088	195	3	immunological	immunological	ADJ
ajmri-3088	195	4	response	response	NOUN
ajmri-3088	195	5	dysregulation	dysregulation	NOUN
ajmri-3088	195	6	,	,	PUNCT
ajmri-3088	195	7	or	or	CCONJ
ajmri-3088	195	8	direct	direct	ADJ
ajmri-3088	195	9	viral	viral	ADJ
ajmri-3088	195	10	pa	pa	PROPN
ajmri-3088	195	11	ge	ge	PROPN
ajmri-3088	195	12	58	58	NUM
ajmri-3088	196	1	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	196	2	am	am	NOUN
ajmri-3088	196	3	.	.	PUNCT
ajmri-3088	197	1	j.	j.	PROPN
ajmri-3088	197	2	multidis	multidis	PROPN
ajmri-3088	197	3	.	.	PUNCT
ajmri-3088	198	1	res	re	NOUN
ajmri-3088	198	2	.	.	PUNCT
ajmri-3088	199	1	innov	innov	PROPN
ajmri-3088	199	2	.	.	PUNCT
ajmri-3088	200	1	3(5	3(5	NUM
ajmri-3088	200	2	)	)	PUNCT
ajmri-3088	200	3	50	50	NUM
ajmri-3088	200	4	-	-	SYM
ajmri-3088	200	5	60	60	NUM
ajmri-3088	200	6	,	,	PUNCT
ajmri-3088	200	7	2024	2024	NUM
ajmri-3088	200	8	impacts	impact	NOUN
ajmri-3088	200	9	could	could	AUX
ajmri-3088	200	10	be	be	AUX
ajmri-3088	200	11	the	the	DET
ajmri-3088	200	12	cause	cause	NOUN
ajmri-3088	200	13	of	of	ADP
ajmri-3088	200	14	the	the	DET
ajmri-3088	200	15	observed	observed	ADJ
ajmri-3088	200	16	reduction	reduction	NOUN
ajmri-3088	200	17	.	.	PUNCT
ajmri-3088	201	1	a	a	DET
ajmri-3088	201	2	total	total	NOUN
ajmri-3088	201	3	of	of	ADP
ajmri-3088	201	4	35	35	NUM
ajmri-3088	201	5	patients	patient	NOUN
ajmri-3088	201	6	between	between	ADP
ajmri-3088	201	7	the	the	DET
ajmri-3088	201	8	ages	age	NOUN
ajmri-3088	201	9	of	of	ADP
ajmri-3088	201	10	0	0	NUM
ajmri-3088	201	11	and	and	CCONJ
ajmri-3088	201	12	53	53	NUM
ajmri-3088	201	13	years	year	NOUN
ajmri-3088	201	14	were	be	AUX
ajmri-3088	201	15	involved	involve	VERB
ajmri-3088	201	16	in	in	ADP
ajmri-3088	201	17	the	the	DET
ajmri-3088	201	18	study	study	NOUN
ajmri-3088	201	19	.	.	PUNCT
ajmri-3088	202	1	the	the	DET
ajmri-3088	202	2	average	average	ADJ
ajmri-3088	202	3	age	age	NOUN
ajmri-3088	202	4	of	of	ADP
ajmri-3088	202	5	the	the	DET
ajmri-3088	202	6	hiv	hiv	PROPN
ajmri-3088	202	7	/	/	SYM
ajmri-3088	202	8	hbv	hbv	PROPN
ajmri-3088	202	9	coinfected	coinfecte	VERB
ajmri-3088	202	10	patients	patient	NOUN
ajmri-3088	202	11	was	be	AUX
ajmri-3088	202	12	26.07±3.11	26.07±3.11	NUM
ajmri-3088	202	13	.	.	PUNCT
ajmri-3088	203	1	there	there	PRON
ajmri-3088	203	2	were	be	VERB
ajmri-3088	203	3	higher	high	ADJ
ajmri-3088	203	4	proportions	proportion	NOUN
ajmri-3088	203	5	of	of	ADP
ajmri-3088	203	6	females	female	NOUN
ajmri-3088	203	7	(	(	PUNCT
ajmri-3088	203	8	64.28	64.28	NUM
ajmri-3088	203	9	%	%	NOUN
ajmri-3088	203	10	)	)	PUNCT
ajmri-3088	203	11	than	than	ADP
ajmri-3088	203	12	males	male	NOUN
ajmri-3088	203	13	(	(	PUNCT
ajmri-3088	203	14	35.72	35.72	NUM
ajmri-3088	203	15	%	%	NOUN
ajmri-3088	203	16	)	)	PUNCT
ajmri-3088	203	17	generally	generally	ADV
ajmri-3088	203	18	because	because	SCONJ
ajmri-3088	203	19	of	of	ADP
ajmri-3088	203	20	the	the	DET
ajmri-3088	203	21	higher	high	ADJ
ajmri-3088	203	22	proportion	proportion	NOUN
ajmri-3088	203	23	of	of	ADP
ajmri-3088	203	24	female	female	ADJ
ajmri-3088	203	25	participants	participant	NOUN
ajmri-3088	203	26	than	than	ADP
ajmri-3088	203	27	males	male	NOUN
ajmri-3088	203	28	and	and	CCONJ
ajmri-3088	203	29	also	also	ADV
ajmri-3088	203	30	due	due	ADP
ajmri-3088	203	31	to	to	ADP
ajmri-3088	203	32	the	the	DET
ajmri-3088	203	33	fact	fact	NOUN
ajmri-3088	203	34	that	that	SCONJ
ajmri-3088	203	35	women	woman	NOUN
ajmri-3088	203	36	are	be	AUX
ajmri-3088	203	37	more	more	ADV
ajmri-3088	203	38	prone	prone	ADJ
ajmri-3088	203	39	to	to	ADP
ajmri-3088	203	40	stds	stds	NOUN
ajmri-3088	203	41	(	(	PUNCT
ajmri-3088	203	42	gruszczyńska	gruszczyńska	PROPN
ajmri-3088	203	43	&	&	CCONJ
ajmri-3088	203	44	rzeszutek	rzeszutek	PROPN
ajmri-3088	203	45	,	,	PUNCT
ajmri-3088	203	46	2023	2023	NUM
ajmri-3088	203	47	)	)	PUNCT
ajmri-3088	203	48	.	.	PUNCT
ajmri-3088	204	1	stds	stds	PROPN
ajmri-3088	204	2	are	be	AUX
ajmri-3088	204	3	more	more	ADV
ajmri-3088	204	4	likely	likely	ADJ
ajmri-3088	204	5	to	to	PART
ajmri-3088	204	6	be	be	AUX
ajmri-3088	204	7	transferred	transfer	VERB
ajmri-3088	204	8	from	from	ADP
ajmri-3088	204	9	men	man	NOUN
ajmri-3088	204	10	to	to	ADP
ajmri-3088	204	11	women	woman	NOUN
ajmri-3088	204	12	than	than	ADP
ajmri-3088	204	13	women	woman	NOUN
ajmri-3088	204	14	to	to	ADP
ajmri-3088	204	15	men	man	NOUN
ajmri-3088	204	16	.	.	PUNCT
ajmri-3088	205	1	it	it	PRON
ajmri-3088	205	2	is	be	AUX
ajmri-3088	205	3	estimated	estimate	VERB
ajmri-3088	205	4	that	that	SCONJ
ajmri-3088	205	5	aids	aids	PROPN
ajmri-3088	205	6	is	be	AUX
ajmri-3088	205	7	2	2	NUM
ajmri-3088	205	8	times	time	NOUN
ajmri-3088	205	9	more	more	ADJ
ajmri-3088	205	10	prevalent	prevalent	ADJ
ajmri-3088	205	11	in	in	ADP
ajmri-3088	205	12	women	woman	NOUN
ajmri-3088	205	13	than	than	ADP
ajmri-3088	205	14	men	man	NOUN
ajmri-3088	205	15	(	(	PUNCT
ajmri-3088	205	16	nguyen	nguyen	NOUN
ajmri-3088	205	17	et	et	PROPN
ajmri-3088	205	18	al	al	PROPN
ajmri-3088	205	19	.	.	PROPN
ajmri-3088	205	20	,	,	PUNCT
ajmri-3088	205	21	2020	2020	NUM
ajmri-3088	205	22	)	)	PUNCT
ajmri-3088	205	23	.	.	PUNCT
ajmri-3088	206	1	aids	aids	PROPN
ajmri-3088	206	2	transmits	transmit	VERB
ajmri-3088	206	3	more	more	ADV
ajmri-3088	206	4	opportunistically	opportunistically	ADV
ajmri-3088	206	5	in	in	ADP
ajmri-3088	206	6	vaginal	vaginal	ADJ
ajmri-3088	206	7	sex	sex	NOUN
ajmri-3088	206	8	as	as	SCONJ
ajmri-3088	206	9	the	the	DET
ajmri-3088	206	10	vagina	vagina	NOUN
ajmri-3088	206	11	allows	allow	VERB
ajmri-3088	206	12	easy	easy	ADJ
ajmri-3088	206	13	passage	passage	NOUN
ajmri-3088	206	14	of	of	ADP
ajmri-3088	206	15	hiv	hiv	PROPN
ajmri-3088	206	16	infection	infection	NOUN
ajmri-3088	206	17	within	within	ADP
ajmri-3088	206	18	the	the	DET
ajmri-3088	206	19	body	body	NOUN
ajmri-3088	206	20	.	.	PUNCT
ajmri-3088	207	1	a	a	DET
ajmri-3088	207	2	higher	high	ADJ
ajmri-3088	207	3	proportion	proportion	NOUN
ajmri-3088	207	4	of	of	ADP
ajmri-3088	207	5	participants	participant	NOUN
ajmri-3088	207	6	(	(	PUNCT
ajmri-3088	207	7	57.41	57.41	NUM
ajmri-3088	207	8	%	%	NOUN
ajmri-3088	207	9	)	)	PUNCT
ajmri-3088	207	10	between	between	ADP
ajmri-3088	207	11	the	the	DET
ajmri-3088	207	12	ages	age	NOUN
ajmri-3088	207	13	of	of	ADP
ajmri-3088	207	14	22	22	NUM
ajmri-3088	207	15	and	and	CCONJ
ajmri-3088	207	16	37	37	NUM
ajmri-3088	207	17	years	year	NOUN
ajmri-3088	207	18	than	than	ADP
ajmri-3088	207	19	any	any	DET
ajmri-3088	207	20	other	other	ADJ
ajmri-3088	207	21	age	age	NOUN
ajmri-3088	207	22	group	group	NOUN
ajmri-3088	207	23	.	.	PUNCT
ajmri-3088	208	1	this	this	DET
ajmri-3088	208	2	study	study	NOUN
ajmri-3088	208	3	states	state	VERB
ajmri-3088	208	4	that	that	SCONJ
ajmri-3088	208	5	the	the	DET
ajmri-3088	208	6	prevalence	prevalence	NOUN
ajmri-3088	208	7	of	of	ADP
ajmri-3088	208	8	hiv	hiv	PROPN
ajmri-3088	208	9	/	/	SYM
ajmri-3088	208	10	hbv	hbv	NOUN
ajmri-3088	208	11	coinfection	coinfection	NOUN
ajmri-3088	208	12	among	among	ADP
ajmri-3088	208	13	patients	patient	NOUN
ajmri-3088	208	14	who	who	PRON
ajmri-3088	208	15	have	have	AUX
ajmri-3088	208	16	been	be	AUX
ajmri-3088	208	17	diagnosed	diagnose	VERB
ajmri-3088	208	18	for	for	ADP
ajmri-3088	208	19	more	more	ADJ
ajmri-3088	208	20	than	than	ADP
ajmri-3088	208	21	6	6	NUM
ajmri-3088	208	22	months	month	NOUN
ajmri-3088	208	23	has	have	AUX
ajmri-3088	208	24	been	be	AUX
ajmri-3088	208	25	34.2	34.2	NUM
ajmri-3088	208	26	%	%	NOUN
ajmri-3088	208	27	with	with	ADP
ajmri-3088	208	28	8.75,2.12	8.75,2.12	NUM
ajmri-3088	208	29	%	%	NOUN
ajmri-3088	208	30	value	value	NOUN
ajmri-3088	208	31	for	for	ADP
ajmri-3088	208	32	95	95	NUM
ajmri-3088	208	33	%	%	NOUN
ajmri-3088	208	34	confidence	confidence	NOUN
ajmri-3088	208	35	interval	interval	NOUN
ajmri-3088	208	36	.	.	PUNCT
ajmri-3088	209	1	a	a	DET
ajmri-3088	209	2	systematic	systematic	ADJ
ajmri-3088	209	3	study	study	NOUN
ajmri-3088	209	4	done	do	VERB
ajmri-3088	209	5	in	in	ADP
ajmri-3088	209	6	some	some	DET
ajmri-3088	209	7	regions	region	NOUN
ajmri-3088	209	8	of	of	ADP
ajmri-3088	209	9	cairo	cairo	PROPN
ajmri-3088	209	10	has	have	AUX
ajmri-3088	209	11	shown	show	VERB
ajmri-3088	209	12	the	the	DET
ajmri-3088	209	13	prevalence	prevalence	NOUN
ajmri-3088	209	14	rate	rate	NOUN
ajmri-3088	209	15	of	of	ADP
ajmri-3088	209	16	hbv	hbv	NOUN
ajmri-3088	209	17	at	at	ADP
ajmri-3088	209	18	2	2	NUM
ajmri-3088	209	19	%	%	NOUN
ajmri-3088	209	20	,	,	PUNCT
ajmri-3088	209	21	while	while	SCONJ
ajmri-3088	209	22	the	the	DET
ajmri-3088	209	23	hiv	hiv	PROPN
ajmri-3088	209	24	prevalence	prevalence	NOUN
ajmri-3088	209	25	rate	rate	NOUN
ajmri-3088	209	26	is	be	AUX
ajmri-3088	209	27	reported	report	VERB
ajmri-3088	209	28	to	to	PART
ajmri-3088	209	29	be	be	AUX
ajmri-3088	209	30	0.1	0.1	NUM
ajmri-3088	209	31	%	%	NOUN
ajmri-3088	209	32	(	(	PUNCT
ajmri-3088	209	33	azzam	azzam	PROPN
ajmri-3088	209	34	et	et	PROPN
ajmri-3088	209	35	al	al	PROPN
ajmri-3088	209	36	.	.	PROPN
ajmri-3088	209	37	,	,	PUNCT
ajmri-3088	209	38	2023	2023	NUM
ajmri-3088	209	39	)	)	PUNCT
ajmri-3088	209	40	.	.	PUNCT
ajmri-3088	210	1	the	the	DET
ajmri-3088	210	2	prevalence	prevalence	NOUN
ajmri-3088	210	3	rate	rate	NOUN
ajmri-3088	210	4	of	of	ADP
ajmri-3088	210	5	hiv/	hiv/	NOUN
ajmri-3088	210	6	hbv	hbv	NOUN
ajmri-3088	210	7	is	be	AUX
ajmri-3088	210	8	poorly	poorly	ADV
ajmri-3088	210	9	calculated	calculate	VERB
ajmri-3088	210	10	and	and	CCONJ
ajmri-3088	210	11	is	be	AUX
ajmri-3088	210	12	not	not	PART
ajmri-3088	210	13	reported	report	VERB
ajmri-3088	210	14	in	in	ADP
ajmri-3088	210	15	authentic	authentic	ADJ
ajmri-3088	210	16	repositories	repository	NOUN
ajmri-3088	210	17	.	.	PUNCT
ajmri-3088	211	1	hiv	hiv	PROPN
ajmri-3088	211	2	and	and	CCONJ
ajmri-3088	211	3	hbv	hbv	PROPN
ajmri-3088	211	4	are	be	AUX
ajmri-3088	211	5	most	most	ADV
ajmri-3088	211	6	likely	likely	ADJ
ajmri-3088	211	7	to	to	PART
ajmri-3088	211	8	co	co	VERB
ajmri-3088	211	9	-	-	VERB
ajmri-3088	211	10	infect	infect	ADJ
ajmri-3088	211	11	due	due	ADP
ajmri-3088	211	12	to	to	ADP
ajmri-3088	211	13	their	their	PRON
ajmri-3088	211	14	shared	share	VERB
ajmri-3088	211	15	routes	route	NOUN
ajmri-3088	211	16	of	of	ADP
ajmri-3088	211	17	transmission	transmission	NOUN
ajmri-3088	211	18	that	that	PRON
ajmri-3088	211	19	include	include	VERB
ajmri-3088	211	20	intravenous	intravenous	ADJ
ajmri-3088	211	21	drug	drug	NOUN
ajmri-3088	211	22	usage	usage	NOUN
ajmri-3088	211	23	,	,	PUNCT
ajmri-3088	211	24	sexual	sexual	ADJ
ajmri-3088	211	25	practices	practice	NOUN
ajmri-3088	211	26	,	,	PUNCT
ajmri-3088	211	27	including	include	VERB
ajmri-3088	211	28	hetero	hetero	NOUN
ajmri-3088	211	29	and	and	CCONJ
ajmri-3088	211	30	homosexual	homosexual	ADJ
ajmri-3088	211	31	practices	practice	NOUN
ajmri-3088	211	32	,	,	PUNCT
ajmri-3088	211	33	vertical	vertical	ADJ
ajmri-3088	211	34	transmission	transmission	NOUN
ajmri-3088	211	35	during	during	ADP
ajmri-3088	211	36	childbirth	childbirth	NOUN
ajmri-3088	211	37	,	,	PUNCT
ajmri-3088	211	38	and	and	CCONJ
ajmri-3088	211	39	unhygienic	unhygienic	ADJ
ajmri-3088	211	40	surroundings	surrounding	NOUN
ajmri-3088	211	41	(	(	PUNCT
ajmri-3088	211	42	mukasa	mukasa	PROPN
ajmri-3088	211	43	kafeero	kafeero	PROPN
ajmri-3088	211	44	et	et	PROPN
ajmri-3088	211	45	al	al	PROPN
ajmri-3088	211	46	.	.	PROPN
ajmri-3088	211	47	,	,	PUNCT
ajmri-3088	211	48	2006	2006	NUM
ajmri-3088	211	49	)	)	PUNCT
ajmri-3088	211	50	.	.	PUNCT
ajmri-3088	212	1	as	as	ADP
ajmri-3088	212	2	per	per	ADP
ajmri-3088	212	3	the	the	DET
ajmri-3088	212	4	demographic	demographic	ADJ
ajmri-3088	212	5	analysis	analysis	NOUN
ajmri-3088	212	6	of	of	ADP
ajmri-3088	212	7	this	this	DET
ajmri-3088	212	8	study	study	NOUN
ajmri-3088	212	9	,	,	PUNCT
ajmri-3088	212	10	most	most	ADJ
ajmri-3088	212	11	of	of	ADP
ajmri-3088	212	12	the	the	DET
ajmri-3088	212	13	patients	patient	NOUN
ajmri-3088	212	14	,	,	PUNCT
ajmri-3088	212	15	nearly	nearly	ADV
ajmri-3088	212	16	accounting	account	VERB
ajmri-3088	212	17	for	for	ADP
ajmri-3088	212	18	35.71	35.71	NUM
ajmri-3088	212	19	%	%	NOUN
ajmri-3088	212	20	,	,	PUNCT
ajmri-3088	212	21	acquired	acquire	VERB
ajmri-3088	212	22	hiv	hiv	PROPN
ajmri-3088	212	23	/	/	SYM
ajmri-3088	212	24	hbv	hbv	NOUN
ajmri-3088	212	25	through	through	ADP
ajmri-3088	212	26	vertical	vertical	ADJ
ajmri-3088	212	27	transmission	transmission	NOUN
ajmri-3088	212	28	,	,	PUNCT
ajmri-3088	212	29	i.e.	i.e.	X
ajmri-3088	212	30	,	,	PUNCT
ajmri-3088	212	31	from	from	ADP
ajmri-3088	212	32	mother	mother	NOUN
ajmri-3088	212	33	to	to	ADP
ajmri-3088	212	34	child	child	NOUN
ajmri-3088	212	35	.	.	PUNCT
ajmri-3088	213	1	however	however	ADV
ajmri-3088	213	2	,	,	PUNCT
ajmri-3088	213	3	the	the	DET
ajmri-3088	213	4	majority	majority	NOUN
ajmri-3088	213	5	of	of	ADP
ajmri-3088	213	6	infected	infected	ADJ
ajmri-3088	213	7	patients	patient	NOUN
ajmri-3088	213	8	lie	lie	VERB
ajmri-3088	213	9	in	in	ADP
ajmri-3088	213	10	the	the	DET
ajmri-3088	213	11	age	age	NOUN
ajmri-3088	213	12	group	group	NOUN
ajmri-3088	213	13	of	of	ADP
ajmri-3088	213	14	22	22	NUM
ajmri-3088	213	15	-	-	SYM
ajmri-3088	213	16	37	37	NUM
ajmri-3088	213	17	years	year	NOUN
ajmri-3088	213	18	,	,	PUNCT
ajmri-3088	213	19	which	which	PRON
ajmri-3088	213	20	may	may	AUX
ajmri-3088	213	21	be	be	AUX
ajmri-3088	213	22	due	due	ADJ
ajmri-3088	213	23	to	to	ADP
ajmri-3088	213	24	asymptomatic	asymptomatic	ADJ
ajmri-3088	213	25	infections	infection	NOUN
ajmri-3088	213	26	.	.	PUNCT
ajmri-3088	214	1	in	in	ADP
ajmri-3088	214	2	many	many	ADJ
ajmri-3088	214	3	cases	case	NOUN
ajmri-3088	214	4	of	of	ADP
ajmri-3088	214	5	hbv	hbv	NOUN
ajmri-3088	214	6	and	and	CCONJ
ajmri-3088	214	7	hiv	hiv	PROPN
ajmri-3088	214	8	,	,	PUNCT
ajmri-3088	214	9	the	the	DET
ajmri-3088	214	10	patients	patient	NOUN
ajmri-3088	214	11	carry	carry	VERB
ajmri-3088	214	12	the	the	DET
ajmri-3088	214	13	virus	virus	NOUN
ajmri-3088	214	14	without	without	ADP
ajmri-3088	214	15	showing	show	VERB
ajmri-3088	214	16	any	any	DET
ajmri-3088	214	17	prominent	prominent	ADJ
ajmri-3088	214	18	symptoms	symptom	NOUN
ajmri-3088	214	19	.	.	PUNCT
ajmri-3088	215	1	the	the	DET
ajmri-3088	215	2	contribution	contribution	NOUN
ajmri-3088	215	3	of	of	ADP
ajmri-3088	215	4	unprotected	unprotected	ADJ
ajmri-3088	215	5	sexual	sexual	ADJ
ajmri-3088	215	6	practices	practice	NOUN
ajmri-3088	215	7	and	and	CCONJ
ajmri-3088	215	8	intravenous	intravenous	ADJ
ajmri-3088	215	9	drug	drug	NOUN
ajmri-3088	215	10	usage	usage	NOUN
ajmri-3088	215	11	rises	rise	VERB
ajmri-3088	215	12	up	up	ADV
ajmri-3088	215	13	to	to	PART
ajmri-3088	215	14	50	50	NUM
ajmri-3088	215	15	%	%	NOUN
ajmri-3088	215	16	of	of	ADP
ajmri-3088	215	17	hiv	hiv	PROPN
ajmri-3088	215	18	/	/	SYM
ajmri-3088	215	19	hbv	hbv	NOUN
ajmri-3088	215	20	coinfected	coinfecte	VERB
ajmri-3088	215	21	cases	case	NOUN
ajmri-3088	215	22	(	(	PUNCT
ajmri-3088	215	23	breen	breen	PROPN
ajmri-3088	215	24	et	et	PROPN
ajmri-3088	215	25	al	al	PROPN
ajmri-3088	215	26	.	.	PROPN
ajmri-3088	215	27	,	,	PUNCT
ajmri-3088	215	28	2024	2024	NUM
ajmri-3088	215	29	)	)	PUNCT
ajmri-3088	215	30	.	.	PUNCT
ajmri-3088	216	1	non	non	ADJ
ajmri-3088	216	2	-	-	ADJ
ajmri-3088	216	3	usage	usage	NOUN
ajmri-3088	216	4	of	of	ADP
ajmri-3088	216	5	contraceptives	contraceptive	NOUN
ajmri-3088	216	6	,	,	PUNCT
ajmri-3088	216	7	men	man	NOUN
ajmri-3088	216	8	-	-	PUNCT
ajmri-3088	216	9	men	man	NOUN
ajmri-3088	216	10	sex	sex	NOUN
ajmri-3088	216	11	,	,	PUNCT
ajmri-3088	216	12	using	use	VERB
ajmri-3088	216	13	syringes	syrinx	NOUN
ajmri-3088	216	14	multiple	multiple	ADJ
ajmri-3088	216	15	times	time	NOUN
ajmri-3088	216	16	for	for	ADP
ajmri-3088	216	17	injecting	inject	VERB
ajmri-3088	216	18	intravenous	intravenous	ADJ
ajmri-3088	216	19	fluids	fluid	NOUN
ajmri-3088	216	20	or	or	CCONJ
ajmri-3088	216	21	drugs	drug	NOUN
ajmri-3088	216	22	,	,	PUNCT
ajmri-3088	216	23	and	and	CCONJ
ajmri-3088	216	24	improper	improper	ADJ
ajmri-3088	216	25	disposal	disposal	NOUN
ajmri-3088	216	26	of	of	ADP
ajmri-3088	216	27	body	body	NOUN
ajmri-3088	216	28	fluids	fluid	NOUN
ajmri-3088	216	29	,	,	PUNCT
ajmri-3088	216	30	medical	medical	ADJ
ajmri-3088	216	31	waves	wave	NOUN
ajmri-3088	216	32	pave	pave	VERB
ajmri-3088	216	33	the	the	DET
ajmri-3088	216	34	way	way	NOUN
ajmri-3088	216	35	to	to	PART
ajmri-3088	216	36	smooth	smooth	VERB
ajmri-3088	216	37	the	the	DET
ajmri-3088	216	38	prevalence	prevalence	NOUN
ajmri-3088	216	39	of	of	ADP
ajmri-3088	216	40	hiv/	hiv/	PROPN
ajmri-3088	216	41	hbv	hbv	NOUN
ajmri-3088	216	42	coinfection	coinfection	NOUN
ajmri-3088	216	43	(	(	PUNCT
ajmri-3088	216	44	breen	breen	PROPN
ajmri-3088	216	45	et	et	PROPN
ajmri-3088	216	46	al	al	PROPN
ajmri-3088	216	47	.	.	PROPN
ajmri-3088	216	48	,	,	PUNCT
ajmri-3088	216	49	2024	2024	NUM
ajmri-3088	216	50	)	)	PUNCT
ajmri-3088	216	51	.	.	PUNCT
ajmri-3088	217	1	the	the	DET
ajmri-3088	217	2	study	study	NOUN
ajmri-3088	217	3	also	also	ADV
ajmri-3088	217	4	showed	show	VERB
ajmri-3088	217	5	that	that	SCONJ
ajmri-3088	217	6	nearly	nearly	ADV
ajmri-3088	217	7	50	50	NUM
ajmri-3088	217	8	%	%	NOUN
ajmri-3088	217	9	of	of	ADP
ajmri-3088	217	10	hiv	hiv	PROPN
ajmri-3088	217	11	/	/	SYM
ajmri-3088	217	12	hbv	hbv	PROPN
ajmri-3088	217	13	coinfected	coinfecte	VERB
ajmri-3088	217	14	patients	patient	NOUN
ajmri-3088	217	15	showed	show	VERB
ajmri-3088	217	16	cd4	cd4	PROPN
ajmri-3088	217	17	+	+	NOUN
ajmri-3088	217	18	cell	cell	NOUN
ajmri-3088	217	19	counts	count	NOUN
ajmri-3088	217	20	in	in	ADP
ajmri-3088	217	21	the	the	DET
ajmri-3088	217	22	range	range	NOUN
ajmri-3088	217	23	of	of	ADP
ajmri-3088	217	24	200	200	NUM
ajmri-3088	217	25	-	-	SYM
ajmri-3088	217	26	350	350	NUM
ajmri-3088	217	27	cells	cell	NOUN
ajmri-3088	217	28	/	/	SYM
ajmri-3088	217	29	mm3	mm3	NOUN
ajmri-3088	217	30	.	.	PUNCT
ajmri-3088	218	1	previous	previous	ADJ
ajmri-3088	218	2	studies	study	NOUN
ajmri-3088	218	3	have	have	AUX
ajmri-3088	218	4	shown	show	VERB
ajmri-3088	218	5	that	that	SCONJ
ajmri-3088	218	6	hiv	hiv	PROPN
ajmri-3088	218	7	/	/	SYM
ajmri-3088	218	8	hbv	hbv	NOUN
ajmri-3088	218	9	coinfection	coinfection	NOUN
ajmri-3088	218	10	progression	progression	NOUN
ajmri-3088	218	11	is	be	AUX
ajmri-3088	218	12	usually	usually	ADV
ajmri-3088	218	13	evident	evident	ADJ
ajmri-3088	218	14	from	from	ADP
ajmri-3088	218	15	the	the	DET
ajmri-3088	218	16	cd4	cd4	PROPN
ajmri-3088	218	17	cell	cell	NOUN
ajmri-3088	218	18	count	count	NOUN
ajmri-3088	218	19	ranging	range	VERB
ajmri-3088	218	20	below	below	ADP
ajmri-3088	218	21	300	300	NUM
ajmri-3088	218	22	cell	cell	NOUN
ajmri-3088	218	23	count	count	NOUN
ajmri-3088	218	24	(	(	PUNCT
ajmri-3088	218	25	tortellini	tortellini	NOUN
ajmri-3088	218	26	et	et	PROPN
ajmri-3088	218	27	al	al	PROPN
ajmri-3088	218	28	.	.	PROPN
ajmri-3088	218	29	,	,	PUNCT
ajmri-3088	218	30	2023	2023	NUM
ajmri-3088	218	31	)	)	PUNCT
ajmri-3088	218	32	.	.	PUNCT
ajmri-3088	219	1	one	one	NUM
ajmri-3088	219	2	of	of	ADP
ajmri-3088	219	3	the	the	DET
ajmri-3088	219	4	main	main	ADJ
ajmri-3088	219	5	reasons	reason	NOUN
ajmri-3088	219	6	behind	behind	ADP
ajmri-3088	219	7	depleted	depleted	ADJ
ajmri-3088	219	8	t	t	PROPN
ajmri-3088	219	9	-	-	PUNCT
ajmri-3088	219	10	lymphocytes	lymphocyte	NOUN
ajmri-3088	219	11	in	in	ADP
ajmri-3088	219	12	patients	patient	NOUN
ajmri-3088	219	13	who	who	PRON
ajmri-3088	219	14	have	have	AUX
ajmri-3088	219	15	been	be	AUX
ajmri-3088	219	16	diagnosed	diagnose	VERB
ajmri-3088	219	17	for	for	ADP
ajmri-3088	219	18	more	more	ADJ
ajmri-3088	219	19	than	than	ADP
ajmri-3088	219	20	12	12	NUM
ajmri-3088	219	21	months	month	NOUN
ajmri-3088	219	22	must	must	AUX
ajmri-3088	219	23	be	be	AUX
ajmri-3088	219	24	the	the	DET
ajmri-3088	219	25	phenomenon	phenomenon	NOUN
ajmri-3088	219	26	of	of	ADP
ajmri-3088	219	27	cd8	cd8	PROPN
ajmri-3088	219	28	+	+	PROPN
ajmri-3088	219	29	t	t	PROPN
ajmri-3088	219	30	-	-	PUNCT
ajmri-3088	219	31	cells	cell	NOUN
ajmri-3088	219	32	immune	immune	ADJ
ajmri-3088	219	33	exhaustion	exhaustion	NOUN
ajmri-3088	219	34	.	.	PUNCT
ajmri-3088	220	1	exhaustion	exhaustion	NOUN
ajmri-3088	220	2	of	of	ADP
ajmri-3088	220	3	cd8	cd8	PROPN
ajmri-3088	220	4	t	t	PROPN
ajmri-3088	220	5	-	-	PUNCT
ajmri-3088	220	6	cells	cell	NOUN
ajmri-3088	220	7	can	can	AUX
ajmri-3088	220	8	have	have	VERB
ajmri-3088	220	9	a	a	DET
ajmri-3088	220	10	major	major	ADJ
ajmri-3088	220	11	impact	impact	NOUN
ajmri-3088	220	12	on	on	ADP
ajmri-3088	220	13	other	other	ADJ
ajmri-3088	220	14	immune	immune	ADJ
ajmri-3088	220	15	system	system	NOUN
ajmri-3088	220	16	lymphocytes	lymphocyte	VERB
ajmri-3088	220	17	.	.	PUNCT
ajmri-3088	221	1	prolonged	prolonged	ADJ
ajmri-3088	221	2	exposure	exposure	NOUN
ajmri-3088	221	3	to	to	ADP
ajmri-3088	221	4	antigens	antigen	NOUN
ajmri-3088	221	5	and	and	CCONJ
ajmri-3088	221	6	reduced	reduce	VERB
ajmri-3088	221	7	regulatory	regulatory	ADJ
ajmri-3088	221	8	capabilities	capability	NOUN
ajmri-3088	221	9	are	be	AUX
ajmri-3088	221	10	common	common	ADJ
ajmri-3088	221	11	characteristics	characteristic	NOUN
ajmri-3088	221	12	of	of	ADP
ajmri-3088	221	13	exhausted	exhausted	ADJ
ajmri-3088	221	14	cd8	cd8	PROPN
ajmri-3088	221	15	t	t	PROPN
ajmri-3088	221	16	cells	cell	NOUN
ajmri-3088	221	17	,	,	PUNCT
ajmri-3088	221	18	which	which	PRON
ajmri-3088	221	19	might	might	AUX
ajmri-3088	221	20	contribute	contribute	VERB
ajmri-3088	221	21	to	to	ADP
ajmri-3088	221	22	an	an	DET
ajmri-3088	221	23	immunosuppressive	immunosuppressive	ADJ
ajmri-3088	221	24	microenvironment	microenvironment	NOUN
ajmri-3088	221	25	for	for	ADP
ajmri-3088	221	26	t	t	NOUN
ajmri-3088	221	27	-	-	PUNCT
ajmri-3088	221	28	lymphocytes	lymphocyte	NOUN
ajmri-3088	221	29	(	(	PUNCT
ajmri-3088	221	30	zhu	zhu	X
ajmri-3088	221	31	et	et	PROPN
ajmri-3088	221	32	al	al	PROPN
ajmri-3088	221	33	.	.	PROPN
ajmri-3088	221	34	,	,	PUNCT
ajmri-3088	221	35	2022	2022	NUM
ajmri-3088	221	36	)	)	PUNCT
ajmri-3088	221	37	.	.	PUNCT
ajmri-3088	222	1	the	the	DET
ajmri-3088	222	2	immune	immune	ADJ
ajmri-3088	222	3	exhaustion	exhaustion	NOUN
ajmri-3088	222	4	caused	cause	VERB
ajmri-3088	222	5	by	by	ADP
ajmri-3088	222	6	delayed	delay	VERB
ajmri-3088	222	7	cd8	cd8	PROPN
ajmri-3088	222	8	+	+	PROPN
ajmri-3088	222	9	cells	cell	NOUN
ajmri-3088	222	10	may	may	AUX
ajmri-3088	222	11	affect	affect	VERB
ajmri-3088	222	12	how	how	SCONJ
ajmri-3088	222	13	other	other	ADJ
ajmri-3088	222	14	lymphocytes	lymphocyte	NOUN
ajmri-3088	222	15	behave	behave	VERB
ajmri-3088	222	16	and	and	CCONJ
ajmri-3088	222	17	perform	perform	VERB
ajmri-3088	222	18	.	.	PUNCT
ajmri-3088	223	1	exhausted	exhaust	VERB
ajmri-3088	223	2	cd8	cd8	PROPN
ajmri-3088	223	3	t	t	PROPN
ajmri-3088	223	4	cells	cell	NOUN
ajmri-3088	223	5	have	have	VERB
ajmri-3088	223	6	the	the	DET
ajmri-3088	223	7	potential	potential	NOUN
ajmri-3088	223	8	to	to	PART
ajmri-3088	223	9	generate	generate	VERB
ajmri-3088	223	10	cytokines	cytokine	NOUN
ajmri-3088	223	11	that	that	PRON
ajmri-3088	223	12	depress	depress	VERB
ajmri-3088	223	13	the	the	DET
ajmri-3088	223	14	immune	immune	ADJ
ajmri-3088	223	15	system	system	NOUN
ajmri-3088	223	16	,	,	PUNCT
ajmri-3088	223	17	like	like	ADP
ajmri-3088	223	18	interleukin-10	interleukin-10	PROPN
ajmri-3088	223	19	,	,	PUNCT
ajmri-3088	223	20	which	which	PRON
ajmri-3088	223	21	can	can	AUX
ajmri-3088	223	22	limit	limit	VERB
ajmri-3088	223	23	the	the	DET
ajmri-3088	223	24	function	function	NOUN
ajmri-3088	223	25	of	of	ADP
ajmri-3088	223	26	other	other	ADJ
ajmri-3088	223	27	immune	immune	ADJ
ajmri-3088	223	28	cells	cell	NOUN
ajmri-3088	223	29	.	.	PUNCT
ajmri-3088	224	1	furthermore	furthermore	ADV
ajmri-3088	224	2	,	,	PUNCT
ajmri-3088	224	3	worn	wear	VERB
ajmri-3088	224	4	-	-	PUNCT
ajmri-3088	224	5	out	out	ADP
ajmri-3088	224	6	cd8	cd8	PROPN
ajmri-3088	224	7	t	t	PROPN
ajmri-3088	224	8	cells	cell	NOUN
ajmri-3088	224	9	are	be	AUX
ajmri-3088	224	10	less	less	ADV
ajmri-3088	224	11	efficient	efficient	ADJ
ajmri-3088	224	12	at	at	ADP
ajmri-3088	224	13	eradicating	eradicate	VERB
ajmri-3088	224	14	aberrant	aberrant	ADJ
ajmri-3088	224	15	or	or	CCONJ
ajmri-3088	224	16	infected	infected	ADJ
ajmri-3088	224	17	cells	cell	NOUN
ajmri-3088	224	18	due	due	ADP
ajmri-3088	224	19	to	to	ADP
ajmri-3088	224	20	their	their	PRON
ajmri-3088	224	21	decreased	decrease	VERB
ajmri-3088	224	22	cytotoxicity	cytotoxicity	NOUN
ajmri-3088	224	23	,	,	PUNCT
ajmri-3088	224	24	which	which	PRON
ajmri-3088	224	25	permits	permit	VERB
ajmri-3088	224	26	these	these	DET
ajmri-3088	224	27	cells	cell	NOUN
ajmri-3088	224	28	to	to	PART
ajmri-3088	224	29	endure	endure	VERB
ajmri-3088	224	30	and	and	CCONJ
ajmri-3088	224	31	possibly	possibly	ADV
ajmri-3088	224	32	influence	influence	VERB
ajmri-3088	224	33	other	other	ADJ
ajmri-3088	224	34	lymphocytes	lymphocyte	NOUN
ajmri-3088	224	35	(	(	PUNCT
ajmri-3088	224	36	chaudhary	chaudhary	PROPN
ajmri-3088	224	37	et	et	PROPN
ajmri-3088	224	38	al	al	PROPN
ajmri-3088	224	39	.	.	PROPN
ajmri-3088	224	40	,	,	PUNCT
ajmri-3088	224	41	2022	2022	NUM
ajmri-3088	224	42	)	)	PUNCT
ajmri-3088	224	43	.	.	PUNCT
ajmri-3088	225	1	the	the	DET
ajmri-3088	225	2	depleting	deplete	VERB
ajmri-3088	225	3	trend	trend	NOUN
ajmri-3088	225	4	for	for	ADP
ajmri-3088	225	5	cd45ra	cd45ra	ADJ
ajmri-3088	225	6	and	and	CCONJ
ajmri-3088	225	7	cd45ro	cd45ro	NOUN
ajmri-3088	225	8	also	also	ADV
ajmri-3088	225	9	proves	prove	VERB
ajmri-3088	225	10	the	the	DET
ajmri-3088	225	11	fact	fact	NOUN
ajmri-3088	225	12	that	that	SCONJ
ajmri-3088	225	13	both	both	PRON
ajmri-3088	225	14	hiv	hiv	PROPN
ajmri-3088	225	15	and	and	CCONJ
ajmri-3088	225	16	hbv	hbv	NOUN
ajmri-3088	225	17	infections	infection	NOUN
ajmri-3088	225	18	are	be	AUX
ajmri-3088	225	19	chronic	chronic	ADJ
ajmri-3088	225	20	and	and	CCONJ
ajmri-3088	225	21	may	may	AUX
ajmri-3088	225	22	have	have	VERB
ajmri-3088	225	23	an	an	DET
ajmri-3088	225	24	impact	impact	NOUN
ajmri-3088	225	25	on	on	ADP
ajmri-3088	225	26	memory	memory	NOUN
ajmri-3088	225	27	t	t	PROPN
ajmri-3088	225	28	-	-	PUNCT
ajmri-3088	225	29	cell	cell	NOUN
ajmri-3088	225	30	exhaustion	exhaustion	NOUN
ajmri-3088	225	31	and	and	CCONJ
ajmri-3088	225	32	the	the	DET
ajmri-3088	225	33	transition	transition	NOUN
ajmri-3088	225	34	of	of	ADP
ajmri-3088	225	35	memory	memory	NOUN
ajmri-3088	225	36	t	t	PROPN
ajmri-3088	225	37	-	-	PUNCT
ajmri-3088	225	38	cells	cell	NOUN
ajmri-3088	225	39	to	to	ADP
ajmri-3088	225	40	a	a	DET
ajmri-3088	225	41	naive	naive	ADJ
ajmri-3088	225	42	t	t	NOUN
ajmri-3088	225	43	-	-	PUNCT
ajmri-3088	225	44	cell	cell	NOUN
ajmri-3088	225	45	phenotype	phenotype	NOUN
ajmri-3088	225	46	.	.	PUNCT
ajmri-3088	226	1	in	in	ADP
ajmri-3088	226	2	addition	addition	NOUN
ajmri-3088	226	3	,	,	PUNCT
ajmri-3088	226	4	these	these	DET
ajmri-3088	226	5	viruses	virus	NOUN
ajmri-3088	226	6	’	'	PUNCT
ajmri-3088	226	7	combined	combine	VERB
ajmri-3088	226	8	impacts	impact	NOUN
ajmri-3088	226	9	on	on	ADP
ajmri-3088	226	10	immune	immune	ADJ
ajmri-3088	226	11	response	response	NOUN
ajmri-3088	226	12	pathways	pathway	NOUN
ajmri-3088	226	13	may	may	AUX
ajmri-3088	226	14	have	have	VERB
ajmri-3088	226	15	a	a	DET
ajmri-3088	226	16	cascading	cascade	VERB
ajmri-3088	226	17	impact	impact	NOUN
ajmri-3088	226	18	,	,	PUNCT
ajmri-3088	226	19	accelerating	accelerate	VERB
ajmri-3088	226	20	the	the	DET
ajmri-3088	226	21	depletion	depletion	NOUN
ajmri-3088	226	22	of	of	ADP
ajmri-3088	226	23	t	t	NOUN
ajmri-3088	226	24	cells	cell	NOUN
ajmri-3088	226	25	and	and	CCONJ
ajmri-3088	226	26	changing	change	VERB
ajmri-3088	226	27	the	the	DET
ajmri-3088	226	28	delicate	delicate	ADJ
ajmri-3088	226	29	equilibrium	equilibrium	NOUN
ajmri-3088	226	30	between	between	ADP
ajmri-3088	226	31	memory	memory	NOUN
ajmri-3088	226	32	and	and	CCONJ
ajmri-3088	226	33	naive	naive	ADJ
ajmri-3088	226	34	t	t	NOUN
ajmri-3088	226	35	-	-	PUNCT
ajmri-3088	226	36	cell	cell	NOUN
ajmri-3088	226	37	populations	population	NOUN
ajmri-3088	226	38	(	(	PUNCT
ajmri-3088	226	39	fromentin	fromentin	PROPN
ajmri-3088	226	40	&	&	CCONJ
ajmri-3088	226	41	chomont	chomont	NOUN
ajmri-3088	226	42	,	,	PUNCT
ajmri-3088	226	43	2021	2021	NUM
ajmri-3088	226	44	)	)	PUNCT
ajmri-3088	226	45	.	.	PUNCT
ajmri-3088	227	1	these	these	DET
ajmri-3088	227	2	results	result	NOUN
ajmri-3088	227	3	enable	enable	VERB
ajmri-3088	227	4	us	we	PRON
ajmri-3088	227	5	to	to	PART
ajmri-3088	227	6	calculate	calculate	VERB
ajmri-3088	227	7	the	the	DET
ajmri-3088	227	8	variations	variation	NOUN
ajmri-3088	227	9	exhibited	exhibit	VERB
ajmri-3088	227	10	by	by	ADP
ajmri-3088	227	11	multiple	multiple	ADJ
ajmri-3088	227	12	sub	sub	NOUN
ajmri-3088	227	13	-	-	NOUN
ajmri-3088	227	14	populations	population	NOUN
ajmri-3088	227	15	of	of	ADP
ajmri-3088	227	16	t	t	NOUN
ajmri-3088	227	17	-	-	PUNCT
ajmri-3088	227	18	cell	cell	NOUN
ajmri-3088	227	19	lymphocytes	lymphocyte	NOUN
ajmri-3088	227	20	,	,	PUNCT
ajmri-3088	227	21	allowing	allow	VERB
ajmri-3088	227	22	us	we	PRON
ajmri-3088	227	23	to	to	PART
ajmri-3088	227	24	understand	understand	VERB
ajmri-3088	227	25	the	the	DET
ajmri-3088	227	26	underlying	underlying	ADJ
ajmri-3088	227	27	mechanism	mechanism	NOUN
ajmri-3088	227	28	that	that	PRON
ajmri-3088	227	29	suppresses	suppress	VERB
ajmri-3088	227	30	the	the	DET
ajmri-3088	227	31	immune	immune	ADJ
ajmri-3088	227	32	response	response	NOUN
ajmri-3088	227	33	in	in	ADP
ajmri-3088	227	34	patients	patient	NOUN
ajmri-3088	227	35	,	,	PUNCT
ajmri-3088	227	36	increasing	increase	VERB
ajmri-3088	227	37	severe	severe	ADJ
ajmri-3088	227	38	symptoms	symptom	NOUN
ajmri-3088	227	39	and	and	CCONJ
ajmri-3088	227	40	,	,	PUNCT
ajmri-3088	227	41	in	in	ADP
ajmri-3088	227	42	some	some	DET
ajmri-3088	227	43	cases	case	NOUN
ajmri-3088	227	44	,	,	PUNCT
ajmri-3088	227	45	leading	lead	VERB
ajmri-3088	227	46	to	to	ADP
ajmri-3088	227	47	mortality	mortality	NOUN
ajmri-3088	227	48	.	.	PUNCT
ajmri-3088	228	1	it	it	PRON
ajmri-3088	228	2	also	also	ADV
ajmri-3088	228	3	helps	help	VERB
ajmri-3088	228	4	us	we	PRON
ajmri-3088	228	5	to	to	PART
ajmri-3088	228	6	design	design	VERB
ajmri-3088	228	7	therapies	therapy	NOUN
ajmri-3088	228	8	to	to	PART
ajmri-3088	228	9	maintain	maintain	VERB
ajmri-3088	228	10	the	the	DET
ajmri-3088	228	11	t	t	PROPN
ajmri-3088	228	12	-	-	PUNCT
ajmri-3088	228	13	lymphocyte	lymphocyte	ADJ
ajmri-3088	228	14	population	population	NOUN
ajmri-3088	228	15	to	to	PART
ajmri-3088	228	16	strengthen	strengthen	VERB
ajmri-3088	228	17	the	the	DET
ajmri-3088	228	18	immune	immune	ADJ
ajmri-3088	228	19	system	system	NOUN
ajmri-3088	228	20	(	(	PUNCT
ajmri-3088	228	21	de	de	X
ajmri-3088	228	22	gea	gea	PROPN
ajmri-3088	228	23	-	-	PUNCT
ajmri-3088	228	24	grela	grela	PROPN
ajmri-3088	228	25	&	&	CCONJ
ajmri-3088	228	26	moreno	moreno	PROPN
ajmri-3088	228	27	,	,	PUNCT
ajmri-3088	228	28	2023	2023	NUM
ajmri-3088	228	29	)	)	PUNCT
ajmri-3088	228	30	.	.	PUNCT
ajmri-3088	229	1	conclusion	conclusion	NOUN
ajmri-3088	229	2	this	this	DET
ajmri-3088	229	3	study	study	NOUN
ajmri-3088	229	4	showed	show	VERB
ajmri-3088	229	5	a	a	DET
ajmri-3088	229	6	prevalence	prevalence	NOUN
ajmri-3088	229	7	of	of	ADP
ajmri-3088	229	8	8.4	8.4	NUM
ajmri-3088	229	9	%	%	NOUN
ajmri-3088	229	10	hiv	hiv	PROPN
ajmri-3088	229	11	/	/	SYM
ajmri-3088	229	12	hbv	hbv	NOUN
ajmri-3088	229	13	coinfection	coinfection	NOUN
ajmri-3088	229	14	among	among	ADP
ajmri-3088	229	15	clinically	clinically	ADV
ajmri-3088	229	16	diagnosed	diagnose	VERB
ajmri-3088	229	17	hiv-1	hiv-1	PUNCT
ajmri-3088	229	18	positive	positive	ADJ
ajmri-3088	229	19	patients	patient	NOUN
ajmri-3088	229	20	respectively	respectively	ADV
ajmri-3088	229	21	.	.	PUNCT
ajmri-3088	230	1	the	the	DET
ajmri-3088	230	2	study	study	NOUN
ajmri-3088	230	3	also	also	ADV
ajmri-3088	230	4	showed	show	VERB
ajmri-3088	230	5	significant	significant	ADJ
ajmri-3088	230	6	differences	difference	NOUN
ajmri-3088	230	7	in	in	ADP
ajmri-3088	230	8	the	the	DET
ajmri-3088	230	9	immunologic	immunologic	ADJ
ajmri-3088	230	10	and	and	CCONJ
ajmri-3088	230	11	virological	virological	ADJ
ajmri-3088	230	12	responses	response	NOUN
ajmri-3088	230	13	of	of	ADP
ajmri-3088	230	14	patients	patient	NOUN
ajmri-3088	230	15	with	with	ADP
ajmri-3088	230	16	hiv	hiv	PROPN
ajmri-3088	230	17	mono	mono	NOUN
ajmri-3088	230	18	-	-	PUNCT
ajmri-3088	230	19	infections	infection	NOUN
ajmri-3088	230	20	and	and	CCONJ
ajmri-3088	230	21	patients	patient	NOUN
ajmri-3088	230	22	with	with	ADP
ajmri-3088	230	23	hiv	hiv	PROPN
ajmri-3088	230	24	/	/	SYM
ajmri-3088	230	25	hbv	hbv	NOUN
ajmri-3088	230	26	coinfections	coinfection	NOUN
ajmri-3088	230	27	.	.	PUNCT
ajmri-3088	231	1	it	it	PRON
ajmri-3088	231	2	was	be	AUX
ajmri-3088	231	3	seen	see	VERB
ajmri-3088	231	4	that	that	SCONJ
ajmri-3088	231	5	females	female	NOUN
ajmri-3088	231	6	are	be	AUX
ajmri-3088	231	7	more	more	ADV
ajmri-3088	231	8	susceptible	susceptible	ADJ
ajmri-3088	231	9	to	to	ADP
ajmri-3088	231	10	hiv	hiv	PROPN
ajmri-3088	231	11	/	/	SYM
ajmri-3088	231	12	hbv	hbv	NOUN
ajmri-3088	231	13	coinfection	coinfection	NOUN
ajmri-3088	231	14	,	,	PUNCT
ajmri-3088	231	15	and	and	CCONJ
ajmri-3088	231	16	the	the	DET
ajmri-3088	231	17	most	most	ADV
ajmri-3088	231	18	susceptible	susceptible	ADJ
ajmri-3088	231	19	age	age	NOUN
ajmri-3088	231	20	group	group	NOUN
ajmri-3088	231	21	was	be	AUX
ajmri-3088	231	22	found	find	VERB
ajmri-3088	231	23	to	to	PART
ajmri-3088	231	24	be	be	AUX
ajmri-3088	231	25	in	in	ADP
ajmri-3088	231	26	the	the	DET
ajmri-3088	231	27	range	range	NOUN
ajmri-3088	231	28	of	of	ADP
ajmri-3088	231	29	22	22	NUM
ajmri-3088	231	30	-	-	SYM
ajmri-3088	231	31	37	37	NUM
ajmri-3088	231	32	years	year	NOUN
ajmri-3088	231	33	.	.	PUNCT
ajmri-3088	232	1	the	the	DET
ajmri-3088	232	2	t	t	NOUN
ajmri-3088	232	3	-	-	PUNCT
ajmri-3088	232	4	cell	cell	NOUN
ajmri-3088	232	5	depletion	depletion	NOUN
ajmri-3088	232	6	was	be	AUX
ajmri-3088	232	7	seen	see	VERB
ajmri-3088	232	8	to	to	PART
ajmri-3088	232	9	be	be	AUX
ajmri-3088	232	10	double	double	ADJ
ajmri-3088	232	11	in	in	ADP
ajmri-3088	232	12	hbv	hbv	NOUN
ajmri-3088	232	13	and	and	CCONJ
ajmri-3088	232	14	hiv	hiv	PROPN
ajmri-3088	232	15	mono	mono	PROPN
ajmri-3088	232	16	infections	infection	NOUN
ajmri-3088	232	17	.	.	PUNCT
ajmri-3088	233	1	the	the	DET
ajmri-3088	233	2	study	study	NOUN
ajmri-3088	233	3	,	,	PUNCT
ajmri-3088	233	4	therefore	therefore	ADV
ajmri-3088	233	5	,	,	PUNCT
ajmri-3088	233	6	concludes	conclude	VERB
ajmri-3088	233	7	that	that	SCONJ
ajmri-3088	233	8	hiv	hiv	PROPN
ajmri-3088	233	9	/	/	SYM
ajmri-3088	233	10	hbv	hbv	PROPN
ajmri-3088	233	11	coinfections	coinfection	NOUN
ajmri-3088	233	12	significantly	significantly	ADV
ajmri-3088	233	13	affect	affect	VERB
ajmri-3088	233	14	the	the	DET
ajmri-3088	233	15	immunologic	immunologic	ADJ
ajmri-3088	233	16	and	and	CCONJ
ajmri-3088	233	17	virological	virological	ADJ
ajmri-3088	233	18	responses	response	NOUN
ajmri-3088	233	19	of	of	ADP
ajmri-3088	233	20	patients	patient	NOUN
ajmri-3088	233	21	and	and	CCONJ
ajmri-3088	233	22	the	the	DET
ajmri-3088	233	23	t	t	PROPN
ajmri-3088	233	24	-	-	PUNCT
ajmri-3088	233	25	lymphocyte	lymphocyte	ADJ
ajmri-3088	233	26	population	population	NOUN
ajmri-3088	233	27	.	.	PUNCT
ajmri-3088	234	1	limitations	limitation	NOUN
ajmri-3088	234	2	the	the	DET
ajmri-3088	234	3	sample	sample	NOUN
ajmri-3088	234	4	included	include	VERB
ajmri-3088	234	5	in	in	ADP
ajmri-3088	234	6	the	the	DET
ajmri-3088	234	7	study	study	NOUN
ajmri-3088	234	8	may	may	AUX
ajmri-3088	234	9	not	not	PART
ajmri-3088	234	10	be	be	AUX
ajmri-3088	234	11	able	able	ADJ
ajmri-3088	234	12	to	to	PART
ajmri-3088	234	13	represent	represent	VERB
ajmri-3088	234	14	the	the	DET
ajmri-3088	234	15	whole	whole	ADJ
ajmri-3088	234	16	population	population	NOUN
ajmri-3088	234	17	affected	affect	VERB
ajmri-3088	234	18	by	by	ADP
ajmri-3088	234	19	coinfection	coinfection	NOUN
ajmri-3088	234	20	of	of	ADP
ajmri-3088	234	21	hiv	hiv	PROPN
ajmri-3088	234	22	/	/	SYM
ajmri-3088	234	23	hbv	hbv	NOUN
ajmri-3088	234	24	,	,	PUNCT
ajmri-3088	234	25	and	and	CCONJ
ajmri-3088	234	26	so	so	ADV
ajmri-3088	234	27	it	it	PRON
ajmri-3088	234	28	contains	contain	VERB
ajmri-3088	234	29	the	the	DET
ajmri-3088	234	30	potential	potential	NOUN
ajmri-3088	234	31	to	to	PART
ajmri-3088	234	32	be	be	AUX
ajmri-3088	234	33	biased	bias	VERB
ajmri-3088	234	34	.	.	PUNCT
ajmri-3088	235	1	the	the	DET
ajmri-3088	235	2	study	study	NOUN
ajmri-3088	235	3	was	be	AUX
ajmri-3088	235	4	cross	cross	ADJ
ajmri-3088	235	5	-	-	ADJ
ajmri-3088	235	6	sectional	sectional	ADJ
ajmri-3088	235	7	and	and	CCONJ
ajmri-3088	235	8	may	may	AUX
ajmri-3088	235	9	limit	limit	VERB
ajmri-3088	235	10	inferences	inference	NOUN
ajmri-3088	235	11	and	and	CCONJ
ajmri-3088	235	12	social	social	ADJ
ajmri-3088	235	13	stigmas	stigma	NOUN
ajmri-3088	235	14	.	.	PUNCT
ajmri-3088	236	1	due	due	ADP
ajmri-3088	236	2	to	to	ADP
ajmri-3088	236	3	the	the	DET
ajmri-3088	236	4	sensitive	sensitive	ADJ
ajmri-3088	236	5	nature	nature	NOUN
ajmri-3088	236	6	of	of	ADP
ajmri-3088	236	7	the	the	DET
ajmri-3088	236	8	study	study	NOUN
ajmri-3088	236	9	,	,	PUNCT
ajmri-3088	236	10	it	it	PRON
ajmri-3088	236	11	requires	require	VERB
ajmri-3088	236	12	ethical	ethical	ADJ
ajmri-3088	236	13	concern	concern	NOUN
ajmri-3088	236	14	and	and	CCONJ
ajmri-3088	236	15	careful	careful	ADJ
ajmri-3088	236	16	handling	handling	NOUN
ajmri-3088	236	17	of	of	ADP
ajmri-3088	236	18	participants	participant	NOUN
ajmri-3088	236	19	.	.	PUNCT
ajmri-3088	237	1	references	reference	NOUN
ajmri-3088	237	2	armani	armani	NOUN
ajmri-3088	237	3	-	-	PUNCT
ajmri-3088	237	4	tourret	tourret	NOUN
ajmri-3088	237	5	,	,	PUNCT
ajmri-3088	237	6	m.	m.	NOUN
ajmri-3088	237	7	,	,	PUNCT
ajmri-3088	237	8	zhou	zhou	PROPN
ajmri-3088	237	9	,	,	PUNCT
ajmri-3088	237	10	z.	z.	PROPN
ajmri-3088	237	11	,	,	PUNCT
ajmri-3088	237	12	gasser	gasser	PROPN
ajmri-3088	237	13	,	,	PUNCT
ajmri-3088	237	14	r.	r.	PROPN
ajmri-3088	237	15	,	,	PUNCT
ajmri-3088	237	16	staropoli	staropoli	PROPN
ajmri-3088	237	17	,	,	PUNCT
ajmri-3088	237	18	i.	i.	NOUN
ajmri-3088	237	19	,	,	PUNCT
ajmri-3088	237	20	cantaloube	cantaloube	NOUN
ajmri-3088	237	21	-	-	PUNCT
ajmri-3088	237	22	ferrieu	ferrieu	NOUN
ajmri-3088	237	23	,	,	PUNCT
ajmri-3088	237	24	v.	v.	PROPN
ajmri-3088	237	25	,	,	PUNCT
ajmri-3088	237	26	benureau	benureau	NOUN
ajmri-3088	237	27	,	,	PUNCT
ajmri-3088	237	28	y.	y.	PROPN
ajmri-3088	237	29	,	,	PUNCT
ajmri-3088	237	30	garcia	garcia	PROPN
ajmri-3088	237	31	-	-	PUNCT
ajmri-3088	237	32	perez	perez	PROPN
ajmri-3088	237	33	,	,	PUNCT
ajmri-3088	237	34	j.	j.	PROPN
ajmri-3088	237	35	,	,	PUNCT
ajmri-3088	237	36	pérez	pérez	NOUN
ajmri-3088	237	37	-	-	PUNCT
ajmri-3088	237	38	olmeda	olmeda	PROPN
ajmri-3088	237	39	,	,	PUNCT
ajmri-3088	237	40	m.	m.	NOUN
ajmri-3088	237	41	,	,	PUNCT
ajmri-3088	237	42	lorin	lorin	PROPN
ajmri-3088	237	43	,	,	PUNCT
ajmri-3088	237	44	v.	v.	PROPN
ajmri-3088	237	45	,	,	PUNCT
ajmri-3088	237	46	&	&	CCONJ
ajmri-3088	237	47	puissant	puissant	PROPN
ajmri-3088	237	48	-	-	PROPN
ajmri-3088	237	49	lubrano	lubrano	PROPN
ajmri-3088	237	50	,	,	PUNCT
ajmri-3088	237	51	b.	b.	PROPN
ajmri-3088	237	52	(	(	PUNCT
ajmri-3088	237	53	2021	2021	NUM
ajmri-3088	237	54	)	)	PUNCT
ajmri-3088	237	55	.	.	PUNCT
ajmri-3088	238	1	mechanisms	mechanism	NOUN
ajmri-3088	238	2	of	of	ADP
ajmri-3088	238	3	hiv-1	hiv-1	X
ajmri-3088	238	4	evasion	evasion	NOUN
ajmri-3088	238	5	to	to	ADP
ajmri-3088	238	6	the	the	DET
ajmri-3088	238	7	antiviral	antiviral	NOUN
ajmri-3088	238	8	pa	pa	PROPN
ajmri-3088	238	9	ge	ge	PROPN
ajmri-3088	238	10	59	59	NUM
ajmri-3088	239	1	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	239	2	am	am	NOUN
ajmri-3088	239	3	.	.	PUNCT
ajmri-3088	240	1	j.	j.	PROPN
ajmri-3088	240	2	multidis	multidis	PROPN
ajmri-3088	240	3	.	.	PUNCT
ajmri-3088	241	1	res	re	NOUN
ajmri-3088	241	2	.	.	PUNCT
ajmri-3088	242	1	innov	innov	PROPN
ajmri-3088	242	2	.	.	PUNCT
ajmri-3088	243	1	3(5	3(5	NUM
ajmri-3088	243	2	)	)	PUNCT
ajmri-3088	243	3	50	50	NUM
ajmri-3088	243	4	-	-	SYM
ajmri-3088	243	5	60	60	NUM
ajmri-3088	243	6	,	,	PUNCT
ajmri-3088	243	7	2024	2024	NUM
ajmri-3088	243	8	activity	activity	NOUN
ajmri-3088	243	9	of	of	ADP
ajmri-3088	243	10	chemokine	chemokine	ADJ
ajmri-3088	243	11	cxcl12	cxcl12	PROPN
ajmri-3088	243	12	indicate	indicate	VERB
ajmri-3088	243	13	potential	potential	ADJ
ajmri-3088	243	14	links	link	NOUN
ajmri-3088	243	15	with	with	ADP
ajmri-3088	243	16	pathogenesis	pathogenesis	NOUN
ajmri-3088	243	17	.	.	PUNCT
ajmri-3088	244	1	plos	plos	PROPN
ajmri-3088	244	2	pathogens	pathogens	PROPN
ajmri-3088	244	3	,	,	PUNCT
ajmri-3088	244	4	17(4	17(4	NUM
ajmri-3088	244	5	)	)	PUNCT
ajmri-3088	244	6	,	,	PUNCT
ajmri-3088	244	7	e1009526	e1009526	NOUN
ajmri-3088	244	8	.	.	PUNCT
ajmri-3088	245	1	azzam	azzam	PROPN
ajmri-3088	245	2	,	,	PUNCT
ajmri-3088	245	3	a.	a.	PROPN
ajmri-3088	245	4	,	,	PUNCT
ajmri-3088	245	5	khaled	khaled	PROPN
ajmri-3088	245	6	,	,	PUNCT
ajmri-3088	245	7	h.	h.	PROPN
ajmri-3088	245	8	,	,	PUNCT
ajmri-3088	245	9	el	el	PROPN
ajmri-3088	245	10	-	-	PUNCT
ajmri-3088	245	11	kayal	kayal	PROPN
ajmri-3088	245	12	,	,	PUNCT
ajmri-3088	245	13	e.	e.	PROPN
ajmri-3088	245	14	s.	s.	PROPN
ajmri-3088	245	15	,	,	PUNCT
ajmri-3088	245	16	gad	gad	PROPN
ajmri-3088	245	17	,	,	PUNCT
ajmri-3088	245	18	f.	f.	PROPN
ajmri-3088	245	19	a.	a.	PROPN
ajmri-3088	245	20	,	,	PUNCT
ajmri-3088	245	21	&	&	CCONJ
ajmri-3088	245	22	omar	omar	PROPN
ajmri-3088	245	23	,	,	PUNCT
ajmri-3088	245	24	s.	s.	PROPN
ajmri-3088	245	25	(	(	PUNCT
ajmri-3088	245	26	2023	2023	NUM
ajmri-3088	245	27	)	)	PUNCT
ajmri-3088	245	28	.	.	PUNCT
ajmri-3088	246	1	prevalence	prevalence	NOUN
ajmri-3088	246	2	of	of	ADP
ajmri-3088	246	3	occult	occult	NOUN
ajmri-3088	246	4	hepatitis	hepatitis	PROPN
ajmri-3088	246	5	b	b	PROPN
ajmri-3088	246	6	virus	virus	NOUN
ajmri-3088	246	7	infection	infection	NOUN
ajmri-3088	246	8	in	in	ADP
ajmri-3088	246	9	egypt	egypt	PROPN
ajmri-3088	246	10	:	:	PUNCT
ajmri-3088	246	11	a	a	DET
ajmri-3088	246	12	systematic	systematic	ADJ
ajmri-3088	246	13	review	review	NOUN
ajmri-3088	246	14	with	with	ADP
ajmri-3088	246	15	meta	meta	ADJ
ajmri-3088	246	16	-	-	PUNCT
ajmri-3088	246	17	analysis	analysis	NOUN
ajmri-3088	246	18	.	.	PUNCT
ajmri-3088	247	1	journal	journal	NOUN
ajmri-3088	247	2	of	of	ADP
ajmri-3088	247	3	the	the	DET
ajmri-3088	247	4	egyptian	egyptian	ADJ
ajmri-3088	247	5	public	public	PROPN
ajmri-3088	247	6	health	health	PROPN
ajmri-3088	247	7	association	association	PROPN
ajmri-3088	247	8	,	,	PUNCT
ajmri-3088	247	9	98(1	98(1	NOUN
ajmri-3088	247	10	)	)	PUNCT
ajmri-3088	247	11	,	,	PUNCT
ajmri-3088	247	12	13	13	NUM
ajmri-3088	247	13	.	.	PUNCT
ajmri-3088	248	1	barber	barber	NOUN
ajmri-3088	248	2	-	-	PUNCT
ajmri-3088	248	3	axthelm	axthelm	PROPN
ajmri-3088	248	4	,	,	PUNCT
ajmri-3088	248	5	i.	i.	NOUN
ajmri-3088	248	6	m.	m.	PROPN
ajmri-3088	248	7	,	,	PUNCT
ajmri-3088	248	8	kent	kent	PROPN
ajmri-3088	248	9	,	,	PUNCT
ajmri-3088	248	10	s.	s.	PROPN
ajmri-3088	248	11	j.	j.	PROPN
ajmri-3088	248	12	,	,	PUNCT
ajmri-3088	248	13	&	&	CCONJ
ajmri-3088	248	14	juno	juno	PROPN
ajmri-3088	248	15	,	,	PUNCT
ajmri-3088	248	16	j.	j.	PROPN
ajmri-3088	248	17	a.	a.	PROPN
ajmri-3088	248	18	(	(	PUNCT
ajmri-3088	248	19	2020	2020	NUM
ajmri-3088	248	20	)	)	PUNCT
ajmri-3088	248	21	.	.	PUNCT
ajmri-3088	249	1	understanding	understand	VERB
ajmri-3088	249	2	the	the	DET
ajmri-3088	249	3	role	role	NOUN
ajmri-3088	249	4	of	of	ADP
ajmri-3088	249	5	mucosal	mucosal	NOUN
ajmri-3088	249	6	-	-	PUNCT
ajmri-3088	249	7	associated	associate	VERB
ajmri-3088	249	8	invariant	invariant	PROPN
ajmri-3088	249	9	t	t	PROPN
ajmri-3088	249	10	-	-	PUNCT
ajmri-3088	249	11	cells	cell	NOUN
ajmri-3088	249	12	in	in	ADP
ajmri-3088	249	13	non	non	ADJ
ajmri-3088	249	14	-	-	ADJ
ajmri-3088	249	15	human	human	ADJ
ajmri-3088	249	16	primate	primate	NOUN
ajmri-3088	249	17	models	model	NOUN
ajmri-3088	249	18	of	of	ADP
ajmri-3088	249	19	hiv	hiv	PROPN
ajmri-3088	249	20	infection	infection	NOUN
ajmri-3088	249	21	.	.	PUNCT
ajmri-3088	250	1	frontiers	frontier	NOUN
ajmri-3088	250	2	in	in	ADP
ajmri-3088	250	3	immunology	immunology	NOUN
ajmri-3088	250	4	,	,	PUNCT
ajmri-3088	250	5	11	11	NUM
ajmri-3088	250	6	,	,	PUNCT
ajmri-3088	250	7	550347	550347	NUM
ajmri-3088	250	8	.	.	PUNCT
ajmri-3088	251	1	bono	bono	X
ajmri-3088	251	2	,	,	PUNCT
ajmri-3088	251	3	v.	v.	ADV
ajmri-3088	251	4	,	,	PUNCT
ajmri-3088	251	5	augello	augello	PROPN
ajmri-3088	251	6	,	,	PUNCT
ajmri-3088	251	7	m.	m.	NOUN
ajmri-3088	251	8	,	,	PUNCT
ajmri-3088	251	9	tincati	tincati	PROPN
ajmri-3088	251	10	,	,	PUNCT
ajmri-3088	251	11	c.	c.	PROPN
ajmri-3088	251	12	,	,	PUNCT
ajmri-3088	251	13	&	&	CCONJ
ajmri-3088	251	14	marchetti	marchetti	PROPN
ajmri-3088	251	15	,	,	PUNCT
ajmri-3088	251	16	g.	g.	PROPN
ajmri-3088	251	17	(	(	PUNCT
ajmri-3088	251	18	2022	2022	NUM
ajmri-3088	251	19	)	)	PUNCT
ajmri-3088	251	20	.	.	PUNCT
ajmri-3088	252	1	failure	failure	NOUN
ajmri-3088	252	2	of	of	ADP
ajmri-3088	252	3	cd4	cd4	PROPN
ajmri-3088	252	4	+	+	PROPN
ajmri-3088	252	5	t	t	PROPN
ajmri-3088	252	6	-	-	PUNCT
ajmri-3088	252	7	cell	cell	NOUN
ajmri-3088	252	8	recovery	recovery	NOUN
ajmri-3088	252	9	upon	upon	SCONJ
ajmri-3088	252	10	virally	virally	ADV
ajmri-3088	252	11	-	-	PUNCT
ajmri-3088	252	12	effective	effective	ADJ
ajmri-3088	252	13	cart	cart	NOUN
ajmri-3088	252	14	:	:	PUNCT
ajmri-3088	252	15	an	an	DET
ajmri-3088	252	16	enduring	endure	VERB
ajmri-3088	252	17	gap	gap	NOUN
ajmri-3088	252	18	in	in	ADP
ajmri-3088	252	19	the	the	DET
ajmri-3088	252	20	understanding	understanding	NOUN
ajmri-3088	252	21	of	of	ADP
ajmri-3088	252	22	hiv+	hiv+	ADJ
ajmri-3088	252	23	immunological	immunological	ADJ
ajmri-3088	252	24	non	non	NOUN
ajmri-3088	252	25	-	-	NOUN
ajmri-3088	252	26	responders	responder	NOUN
ajmri-3088	252	27	.	.	PUNCT
ajmri-3088	253	1	new	new	ADJ
ajmri-3088	253	2	microbiol	microbiol	NOUN
ajmri-3088	253	3	,	,	PUNCT
ajmri-3088	253	4	45(3	45(3	NUM
ajmri-3088	253	5	)	)	PUNCT
ajmri-3088	253	6	,	,	PUNCT
ajmri-3088	253	7	155	155	NUM
ajmri-3088	253	8	-	-	SYM
ajmri-3088	253	9	172	172	NUM
ajmri-3088	253	10	.	.	PUNCT
ajmri-3088	254	1	breen	breen	PROPN
ajmri-3088	254	2	,	,	PUNCT
ajmri-3088	254	3	r.	r.	PROPN
ajmri-3088	254	4	w.	w.	PROPN
ajmri-3088	254	5	,	,	PUNCT
ajmri-3088	254	6	parmley	parmley	PROPN
ajmri-3088	254	7	,	,	PUNCT
ajmri-3088	254	8	l.	l.	PROPN
ajmri-3088	254	9	e.	e.	PROPN
ajmri-3088	254	10	,	,	PUNCT
ajmri-3088	254	11	mapingure	mapingure	NOUN
ajmri-3088	254	12	,	,	PUNCT
ajmri-3088	254	13	m.	m.	NOUN
ajmri-3088	254	14	p.	p.	PROPN
ajmri-3088	254	15	,	,	PUNCT
ajmri-3088	254	16	chingombe	chingombe	NOUN
ajmri-3088	254	17	,	,	PUNCT
ajmri-3088	254	18	i.	i.	PROPN
ajmri-3088	254	19	,	,	PUNCT
ajmri-3088	254	20	mugurungi	mugurungi	PROPN
ajmri-3088	254	21	,	,	PUNCT
ajmri-3088	254	22	o.	o.	PROPN
ajmri-3088	254	23	,	,	PUNCT
ajmri-3088	254	24	musuka	musuka	PROPN
ajmri-3088	254	25	,	,	PUNCT
ajmri-3088	254	26	g.	g.	PROPN
ajmri-3088	254	27	,	,	PUNCT
ajmri-3088	254	28	hakim	hakim	PROPN
ajmri-3088	254	29	,	,	PUNCT
ajmri-3088	254	30	a.	a.	PROPN
ajmri-3088	254	31	j.	j.	PROPN
ajmri-3088	254	32	,	,	PUNCT
ajmri-3088	254	33	rogers	rogers	PROPN
ajmri-3088	254	34	,	,	PUNCT
ajmri-3088	254	35	j.	j.	PROPN
ajmri-3088	254	36	h.	h.	PROPN
ajmri-3088	254	37	,	,	PUNCT
ajmri-3088	254	38	moyo	moyo	PROPN
ajmri-3088	254	39	,	,	PUNCT
ajmri-3088	254	40	b.	b.	PROPN
ajmri-3088	254	41	,	,	PUNCT
ajmri-3088	254	42	&	&	CCONJ
ajmri-3088	254	43	samba	samba	PROPN
ajmri-3088	254	44	,	,	PUNCT
ajmri-3088	254	45	c.	c.	NOUN
ajmri-3088	254	46	(	(	PUNCT
ajmri-3088	254	47	2024	2024	NUM
ajmri-3088	254	48	)	)	PUNCT
ajmri-3088	254	49	.	.	PUNCT
ajmri-3088	255	1	hepatitis	hepatitis	PROPN
ajmri-3088	255	2	b	b	PROPN
ajmri-3088	255	3	virus	virus	NOUN
ajmri-3088	255	4	infection	infection	NOUN
ajmri-3088	255	5	(	(	PUNCT
ajmri-3088	255	6	hbv	hbv	NOUN
ajmri-3088	255	7	)	)	PUNCT
ajmri-3088	255	8	and	and	CCONJ
ajmri-3088	255	9	hiv	hiv	PROPN
ajmri-3088	255	10	-	-	PUNCT
ajmri-3088	255	11	hbv	hbv	NOUN
ajmri-3088	255	12	coinfection	coinfection	NOUN
ajmri-3088	255	13	among	among	ADP
ajmri-3088	255	14	men	man	NOUN
ajmri-3088	255	15	who	who	PRON
ajmri-3088	255	16	have	have	VERB
ajmri-3088	255	17	sex	sex	NOUN
ajmri-3088	255	18	with	with	ADP
ajmri-3088	255	19	men	man	NOUN
ajmri-3088	255	20	,	,	PUNCT
ajmri-3088	255	21	transgender	transgender	NOUN
ajmri-3088	255	22	women	woman	NOUN
ajmri-3088	255	23	,	,	PUNCT
ajmri-3088	255	24	and	and	CCONJ
ajmri-3088	255	25	genderqueer	genderqueer	NOUN
ajmri-3088	255	26	individuals	individual	NOUN
ajmri-3088	255	27	in	in	ADP
ajmri-3088	255	28	harare	harare	PROPN
ajmri-3088	255	29	and	and	CCONJ
ajmri-3088	255	30	bulawayo	bulawayo	PROPN
ajmri-3088	255	31	zimbabwe	zimbabwe	PROPN
ajmri-3088	255	32	,	,	PUNCT
ajmri-3088	255	33	2019	2019	NUM
ajmri-3088	255	34	.	.	PUNCT
ajmri-3088	256	1	heliyon	heliyon	NOUN
ajmri-3088	256	2	.	.	PUNCT
ajmri-3088	257	1	cai	cai	PROPN
ajmri-3088	257	2	,	,	PUNCT
ajmri-3088	257	3	y.	y.	PROPN
ajmri-3088	257	4	,	,	PUNCT
ajmri-3088	257	5	ji	ji	PROPN
ajmri-3088	257	6	,	,	PUNCT
ajmri-3088	257	7	h.	h.	PROPN
ajmri-3088	257	8	,	,	PUNCT
ajmri-3088	257	9	zhou	zhou	PROPN
ajmri-3088	257	10	,	,	PUNCT
ajmri-3088	257	11	x.	x.	PROPN
ajmri-3088	257	12	,	,	PUNCT
ajmri-3088	257	13	zhao	zhao	PROPN
ajmri-3088	257	14	,	,	PUNCT
ajmri-3088	257	15	k.	k.	PROPN
ajmri-3088	257	16	,	,	PUNCT
ajmri-3088	257	17	zhang	zhang	PROPN
ajmri-3088	257	18	,	,	PUNCT
ajmri-3088	257	19	x.	x.	PROPN
ajmri-3088	257	20	,	,	PUNCT
ajmri-3088	257	21	pan	pan	PROPN
ajmri-3088	257	22	,	,	PUNCT
ajmri-3088	257	23	l.	l.	PROPN
ajmri-3088	257	24	,	,	PUNCT
ajmri-3088	257	25	&	&	CCONJ
ajmri-3088	257	26	shi	shi	PROPN
ajmri-3088	257	27	,	,	PUNCT
ajmri-3088	257	28	r.	r.	PROPN
ajmri-3088	257	29	(	(	PUNCT
ajmri-3088	257	30	2023	2023	NUM
ajmri-3088	257	31	)	)	PUNCT
ajmri-3088	257	32	.	.	PUNCT
ajmri-3088	258	1	interleukin-21	interleukin-21	ADJ
ajmri-3088	258	2	modulates	modulate	NOUN
ajmri-3088	258	3	balance	balance	NOUN
ajmri-3088	258	4	between	between	ADP
ajmri-3088	258	5	regulatory	regulatory	ADJ
ajmri-3088	258	6	t	t	NOUN
ajmri-3088	258	7	cells	cell	NOUN
ajmri-3088	258	8	and	and	CCONJ
ajmri-3088	258	9	t	t	PROPN
ajmri-3088	258	10	-	-	PUNCT
ajmri-3088	258	11	helper	helper	NOUN
ajmri-3088	258	12	17	17	NUM
ajmri-3088	258	13	cells	cell	NOUN
ajmri-3088	258	14	in	in	ADP
ajmri-3088	258	15	chronic	chronic	ADJ
ajmri-3088	258	16	hepatitis	hepatitis	PROPN
ajmri-3088	258	17	b	b	PROPN
ajmri-3088	258	18	virus	virus	NOUN
ajmri-3088	258	19	infection	infection	NOUN
ajmri-3088	258	20	.	.	PUNCT
ajmri-3088	259	1	bmc	bmc	ADJ
ajmri-3088	259	2	infectious	infectious	ADJ
ajmri-3088	259	3	diseases	disease	NOUN
ajmri-3088	259	4	,	,	PUNCT
ajmri-3088	259	5	23(1	23(1	NUM
ajmri-3088	259	6	)	)	PUNCT
ajmri-3088	259	7	,	,	PUNCT
ajmri-3088	259	8	719	719	X
ajmri-3088	259	9	.	.	PUNCT
ajmri-3088	259	10	cao	cao	PROPN
ajmri-3088	259	11	,	,	PUNCT
ajmri-3088	259	12	w.-j	w.-j	PROPN
ajmri-3088	259	13	.	.	PROPN
ajmri-3088	259	14	,	,	PUNCT
ajmri-3088	259	15	zhang	zhang	PROPN
ajmri-3088	259	16	,	,	PUNCT
ajmri-3088	259	17	x.-c	x.-c	PROPN
ajmri-3088	259	18	.	.	PROPN
ajmri-3088	259	19	,	,	PUNCT
ajmri-3088	259	20	wan	wan	PROPN
ajmri-3088	259	21	,	,	PUNCT
ajmri-3088	259	22	l.-y	l.-y	PROPN
ajmri-3088	259	23	.	.	PUNCT
ajmri-3088	259	24	,	,	PUNCT
ajmri-3088	259	25	li	li	PROPN
ajmri-3088	259	26	,	,	PUNCT
ajmri-3088	259	27	q.-y	q.-y	NOUN
ajmri-3088	259	28	.	.	PROPN
ajmri-3088	259	29	,	,	PUNCT
ajmri-3088	259	30	mu	mu	PROPN
ajmri-3088	259	31	,	,	PUNCT
ajmri-3088	259	32	x.-y	x.-y	NOUN
ajmri-3088	259	33	.	.	PUNCT
ajmri-3088	259	34	,	,	PUNCT
ajmri-3088	259	35	guo	guo	PROPN
ajmri-3088	259	36	,	,	PUNCT
ajmri-3088	259	37	a.-l	a.-l	PROPN
ajmri-3088	259	38	.	.	PUNCT
ajmri-3088	260	1	,	,	PUNCT
ajmri-3088	260	2	zhou	zhou	PROPN
ajmri-3088	260	3	,	,	PUNCT
ajmri-3088	260	4	m.-j	m.-j	PROPN
ajmri-3088	260	5	.	.	PUNCT
ajmri-3088	260	6	,	,	PUNCT
ajmri-3088	260	7	shen	shen	PROPN
ajmri-3088	260	8	,	,	PUNCT
ajmri-3088	260	9	l.-l	l.-l	PROPN
ajmri-3088	260	10	.	.	PUNCT
ajmri-3088	260	11	,	,	PUNCT
ajmri-3088	260	12	zhang	zhang	PROPN
ajmri-3088	260	13	,	,	PUNCT
ajmri-3088	260	14	c.	c.	PROPN
ajmri-3088	260	15	,	,	PUNCT
ajmri-3088	260	16	&	&	CCONJ
ajmri-3088	260	17	fan	fan	PROPN
ajmri-3088	260	18	,	,	PUNCT
ajmri-3088	260	19	x.	x.	NOUN
ajmri-3088	260	20	(	(	PUNCT
ajmri-3088	260	21	2022	2022	NUM
ajmri-3088	260	22	)	)	PUNCT
ajmri-3088	260	23	.	.	PUNCT
ajmri-3088	261	1	immune	immune	ADJ
ajmri-3088	261	2	dysfunctions	dysfunction	NOUN
ajmri-3088	261	3	of	of	ADP
ajmri-3088	261	4	cd56neg	cd56neg	PROPN
ajmri-3088	261	5	nk	nk	PROPN
ajmri-3088	261	6	cells	cell	NOUN
ajmri-3088	261	7	are	be	AUX
ajmri-3088	261	8	associated	associate	VERB
ajmri-3088	261	9	with	with	ADP
ajmri-3088	261	10	hiv-1	hiv-1	ADJ
ajmri-3088	261	11	disease	disease	NOUN
ajmri-3088	261	12	progression	progression	NOUN
ajmri-3088	261	13	.	.	PUNCT
ajmri-3088	262	1	frontiers	frontier	NOUN
ajmri-3088	262	2	in	in	ADP
ajmri-3088	262	3	immunology	immunology	NOUN
ajmri-3088	262	4	,	,	PUNCT
ajmri-3088	262	5	12	12	NUM
ajmri-3088	262	6	,	,	PUNCT
ajmri-3088	262	7	811091	811091	NUM
ajmri-3088	262	8	.	.	PUNCT
ajmri-3088	263	1	chaudhary	chaudhary	PROPN
ajmri-3088	263	2	,	,	PUNCT
ajmri-3088	263	3	o.	o.	PROPN
ajmri-3088	263	4	,	,	PUNCT
ajmri-3088	263	5	trotta	trotta	NOUN
ajmri-3088	263	6	,	,	PUNCT
ajmri-3088	263	7	d.	d.	PROPN
ajmri-3088	263	8	,	,	PUNCT
ajmri-3088	263	9	wang	wang	PROPN
ajmri-3088	263	10	,	,	PUNCT
ajmri-3088	263	11	k.	k.	PROPN
ajmri-3088	263	12	,	,	PUNCT
ajmri-3088	263	13	wang	wang	PROPN
ajmri-3088	263	14	,	,	PUNCT
ajmri-3088	263	15	x.	x.	PROPN
ajmri-3088	263	16	,	,	PUNCT
ajmri-3088	263	17	chu	chu	PROPN
ajmri-3088	263	18	,	,	PUNCT
ajmri-3088	263	19	x.	x.	PROPN
ajmri-3088	263	20	,	,	PUNCT
ajmri-3088	263	21	bradley	bradley	PROPN
ajmri-3088	263	22	,	,	PUNCT
ajmri-3088	263	23	c.	c.	PROPN
ajmri-3088	263	24	,	,	PUNCT
ajmri-3088	263	25	okulicz	okulicz	VERB
ajmri-3088	263	26	,	,	PUNCT
ajmri-3088	263	27	j.	j.	PROPN
ajmri-3088	263	28	,	,	PUNCT
ajmri-3088	263	29	maves	mave	NOUN
ajmri-3088	263	30	,	,	PUNCT
ajmri-3088	263	31	r.	r.	PROPN
ajmri-3088	263	32	c.	c.	PROPN
ajmri-3088	263	33	,	,	PUNCT
ajmri-3088	263	34	kronmann	kronmann	PROPN
ajmri-3088	263	35	,	,	PUNCT
ajmri-3088	263	36	k.	k.	PROPN
ajmri-3088	263	37	,	,	PUNCT
ajmri-3088	263	38	&	&	CCONJ
ajmri-3088	263	39	schofield	schofield	PROPN
ajmri-3088	263	40	,	,	PUNCT
ajmri-3088	263	41	c.	c.	PROPN
ajmri-3088	263	42	m.	m.	NOUN
ajmri-3088	263	43	(	(	PUNCT
ajmri-3088	263	44	2022	2022	NUM
ajmri-3088	263	45	)	)	PUNCT
ajmri-3088	263	46	.	.	PUNCT
ajmri-3088	264	1	patients	patient	NOUN
ajmri-3088	264	2	with	with	ADP
ajmri-3088	264	3	hivassociated	hivassociated	ADJ
ajmri-3088	264	4	cancers	cancer	NOUN
ajmri-3088	264	5	have	have	VERB
ajmri-3088	264	6	evidence	evidence	NOUN
ajmri-3088	264	7	of	of	ADP
ajmri-3088	264	8	increased	increase	VERB
ajmri-3088	264	9	t	t	NOUN
ajmri-3088	264	10	cell	cell	NOUN
ajmri-3088	264	11	dysfunction	dysfunction	NOUN
ajmri-3088	264	12	and	and	CCONJ
ajmri-3088	264	13	exhaustion	exhaustion	NOUN
ajmri-3088	264	14	prior	prior	ADV
ajmri-3088	264	15	to	to	ADP
ajmri-3088	264	16	cancer	cancer	NOUN
ajmri-3088	264	17	diagnosis	diagnosis	NOUN
ajmri-3088	264	18	.	.	PUNCT
ajmri-3088	265	1	journal	journal	NOUN
ajmri-3088	265	2	for	for	ADP
ajmri-3088	265	3	immunotherapy	immunotherapy	NOUN
ajmri-3088	265	4	of	of	ADP
ajmri-3088	265	5	cancer	cancer	NOUN
ajmri-3088	265	6	,	,	PUNCT
ajmri-3088	265	7	10(4	10(4	NUM
ajmri-3088	265	8	)	)	PUNCT
ajmri-3088	265	9	.	.	PUNCT
ajmri-3088	266	1	corcorran	corcorran	PROPN
ajmri-3088	266	2	,	,	PUNCT
ajmri-3088	266	3	m.	m.	NOUN
ajmri-3088	266	4	a.	a.	PROPN
ajmri-3088	266	5	,	,	PUNCT
ajmri-3088	266	6	&	&	CCONJ
ajmri-3088	266	7	kim	kim	PROPN
ajmri-3088	266	8	,	,	PUNCT
ajmri-3088	266	9	h.	h.	PROPN
ajmri-3088	266	10	n.	n.	PROPN
ajmri-3088	266	11	(	(	PUNCT
ajmri-3088	266	12	2023	2023	NUM
ajmri-3088	266	13	)	)	PUNCT
ajmri-3088	266	14	.	.	PUNCT
ajmri-3088	267	1	chronic	chronic	ADJ
ajmri-3088	267	2	hepatitis	hepatitis	PROPN
ajmri-3088	267	3	b	b	PROPN
ajmri-3088	267	4	and	and	CCONJ
ajmri-3088	267	5	hiv	hiv	PROPN
ajmri-3088	267	6	coinfection	coinfection	NOUN
ajmri-3088	267	7	.	.	PUNCT
ajmri-3088	268	1	topics	topic	NOUN
ajmri-3088	268	2	in	in	ADP
ajmri-3088	268	3	antiviral	antiviral	ADJ
ajmri-3088	268	4	medicine	medicine	NOUN
ajmri-3088	268	5	,	,	PUNCT
ajmri-3088	268	6	31(1	31(1	NUM
ajmri-3088	268	7	)	)	PUNCT
ajmri-3088	268	8	,	,	PUNCT
ajmri-3088	268	9	14	14	NUM
ajmri-3088	268	10	.	.	PUNCT
ajmri-3088	268	11	de	de	PROPN
ajmri-3088	268	12	gea	gea	PROPN
ajmri-3088	268	13	-	-	PUNCT
ajmri-3088	268	14	grela	grela	PROPN
ajmri-3088	268	15	,	,	PUNCT
ajmri-3088	268	16	a.	a.	NOUN
ajmri-3088	268	17	,	,	PUNCT
ajmri-3088	268	18	&	&	CCONJ
ajmri-3088	268	19	moreno	moreno	PROPN
ajmri-3088	268	20	,	,	PUNCT
ajmri-3088	268	21	s.	s.	PROPN
ajmri-3088	268	22	(	(	PUNCT
ajmri-3088	268	23	2023	2023	NUM
ajmri-3088	268	24	)	)	PUNCT
ajmri-3088	268	25	.	.	PUNCT
ajmri-3088	269	1	controversies	controversy	NOUN
ajmri-3088	269	2	in	in	ADP
ajmri-3088	269	3	the	the	DET
ajmri-3088	269	4	design	design	NOUN
ajmri-3088	269	5	of	of	ADP
ajmri-3088	269	6	strategies	strategy	NOUN
ajmri-3088	269	7	for	for	ADP
ajmri-3088	269	8	the	the	DET
ajmri-3088	269	9	cure	cure	NOUN
ajmri-3088	269	10	of	of	ADP
ajmri-3088	269	11	hiv	hiv	PROPN
ajmri-3088	269	12	infection	infection	NOUN
ajmri-3088	269	13	.	.	PUNCT
ajmri-3088	270	1	pathogens	pathogen	NOUN
ajmri-3088	270	2	,	,	PUNCT
ajmri-3088	270	3	12(2	12(2	NUM
ajmri-3088	270	4	)	)	PUNCT
ajmri-3088	270	5	,	,	PUNCT
ajmri-3088	270	6	322	322	NUM
ajmri-3088	270	7	.	.	PUNCT
ajmri-3088	270	8	dumolard	dumolard	PROPN
ajmri-3088	270	9	,	,	PUNCT
ajmri-3088	270	10	l.	l.	PROPN
ajmri-3088	270	11	,	,	PUNCT
ajmri-3088	270	12	aspord	aspord	PROPN
ajmri-3088	270	13	,	,	PUNCT
ajmri-3088	270	14	c.	c.	PROPN
ajmri-3088	270	15	,	,	PUNCT
ajmri-3088	270	16	marche	marche	NOUN
ajmri-3088	270	17	,	,	PUNCT
ajmri-3088	270	18	p.	p.	PROPN
ajmri-3088	270	19	n.	n.	PROPN
ajmri-3088	270	20	,	,	PUNCT
ajmri-3088	270	21	&	&	CCONJ
ajmri-3088	270	22	macek	macek	PROPN
ajmri-3088	270	23	jilkova	jilkova	PROPN
ajmri-3088	270	24	,	,	PUNCT
ajmri-3088	270	25	z.	z.	PROPN
ajmri-3088	270	26	(	(	PUNCT
ajmri-3088	270	27	2023	2023	NUM
ajmri-3088	270	28	)	)	PUNCT
ajmri-3088	270	29	.	.	PUNCT
ajmri-3088	271	1	immune	immune	ADJ
ajmri-3088	271	2	checkpoints	checkpoint	NOUN
ajmri-3088	271	3	on	on	ADP
ajmri-3088	271	4	t	t	PROPN
ajmri-3088	271	5	and	and	CCONJ
ajmri-3088	271	6	nk	nk	PROPN
ajmri-3088	271	7	cells	cell	NOUN
ajmri-3088	271	8	in	in	ADP
ajmri-3088	271	9	the	the	DET
ajmri-3088	271	10	context	context	NOUN
ajmri-3088	271	11	of	of	ADP
ajmri-3088	271	12	hbv	hbv	NOUN
ajmri-3088	271	13	infection	infection	NOUN
ajmri-3088	271	14	:	:	PUNCT
ajmri-3088	271	15	landscape	landscape	NOUN
ajmri-3088	271	16	,	,	PUNCT
ajmri-3088	271	17	pathophysiology	pathophysiology	NOUN
ajmri-3088	271	18	and	and	CCONJ
ajmri-3088	271	19	therapeutic	therapeutic	ADJ
ajmri-3088	271	20	exploitation	exploitation	NOUN
ajmri-3088	271	21	.	.	PUNCT
ajmri-3088	272	1	frontiers	frontier	NOUN
ajmri-3088	272	2	in	in	ADP
ajmri-3088	272	3	immunology	immunology	NOUN
ajmri-3088	272	4	,	,	PUNCT
ajmri-3088	272	5	14	14	NUM
ajmri-3088	272	6	,	,	PUNCT
ajmri-3088	272	7	1148111	1148111	NUM
ajmri-3088	272	8	.	.	PUNCT
ajmri-3088	273	1	fromentin	fromentin	PROPN
ajmri-3088	273	2	,	,	PUNCT
ajmri-3088	273	3	r.	r.	PROPN
ajmri-3088	273	4	,	,	PUNCT
ajmri-3088	273	5	&	&	CCONJ
ajmri-3088	273	6	chomont	chomont	PROPN
ajmri-3088	273	7	,	,	PUNCT
ajmri-3088	273	8	n.	n.	NOUN
ajmri-3088	273	9	(	(	PUNCT
ajmri-3088	273	10	2021	2021	NUM
ajmri-3088	273	11	)	)	PUNCT
ajmri-3088	273	12	.	.	PUNCT
ajmri-3088	274	1	hiv	hiv	PROPN
ajmri-3088	274	2	persistence	persistence	NOUN
ajmri-3088	274	3	in	in	ADP
ajmri-3088	274	4	subsets	subset	NOUN
ajmri-3088	274	5	of	of	ADP
ajmri-3088	274	6	cd4	cd4	PROPN
ajmri-3088	274	7	+	+	PROPN
ajmri-3088	274	8	t	t	NOUN
ajmri-3088	274	9	cells	cell	NOUN
ajmri-3088	274	10	:	:	PUNCT
ajmri-3088	274	11	50	50	NUM
ajmri-3088	274	12	shades	shade	NOUN
ajmri-3088	274	13	of	of	ADP
ajmri-3088	274	14	reservoirs	reservoir	NOUN
ajmri-3088	274	15	.	.	PUNCT
ajmri-3088	275	1	seminars	seminar	NOUN
ajmri-3088	275	2	in	in	ADP
ajmri-3088	275	3	immunology	immunology	NOUN
ajmri-3088	275	4	.	.	PUNCT
ajmri-3088	276	1	gruszczyńska	gruszczyńska	PROPN
ajmri-3088	276	2	,	,	PUNCT
ajmri-3088	276	3	e.	e.	PROPN
ajmri-3088	276	4	,	,	PUNCT
ajmri-3088	276	5	&	&	CCONJ
ajmri-3088	276	6	rzeszutek	rzeszutek	PROPN
ajmri-3088	276	7	,	,	PUNCT
ajmri-3088	276	8	m.	m.	NOUN
ajmri-3088	276	9	(	(	PUNCT
ajmri-3088	276	10	2023	2023	NUM
ajmri-3088	276	11	)	)	PUNCT
ajmri-3088	276	12	.	.	PUNCT
ajmri-3088	277	1	hiv	hiv	PROPN
ajmri-3088	277	2	/	/	SYM
ajmri-3088	277	3	aids	aids	PROPN
ajmri-3088	277	4	stigma	stigma	NOUN
ajmri-3088	277	5	accumulation	accumulation	NOUN
ajmri-3088	277	6	among	among	ADP
ajmri-3088	277	7	people	people	NOUN
ajmri-3088	277	8	living	live	VERB
ajmri-3088	277	9	with	with	ADP
ajmri-3088	277	10	hiv	hiv	PROPN
ajmri-3088	277	11	:	:	PUNCT
ajmri-3088	277	12	a	a	DET
ajmri-3088	277	13	role	role	NOUN
ajmri-3088	277	14	of	of	ADP
ajmri-3088	277	15	general	general	ADJ
ajmri-3088	277	16	and	and	CCONJ
ajmri-3088	277	17	relative	relative	ADJ
ajmri-3088	277	18	minority	minority	NOUN
ajmri-3088	277	19	status	status	NOUN
ajmri-3088	277	20	.	.	PUNCT
ajmri-3088	278	1	scientific	scientific	ADJ
ajmri-3088	278	2	reports	report	NOUN
ajmri-3088	278	3	,	,	PUNCT
ajmri-3088	278	4	13(1	13(1	NUM
ajmri-3088	278	5	)	)	PUNCT
ajmri-3088	278	6	,	,	PUNCT
ajmri-3088	278	7	10709	10709	NUM
ajmri-3088	278	8	.	.	PUNCT
ajmri-3088	279	1	kirchmair	kirchmair	PROPN
ajmri-3088	279	2	,	,	PUNCT
ajmri-3088	279	3	a.	a.	NOUN
ajmri-3088	279	4	,	,	PUNCT
ajmri-3088	279	5	nemati	nemati	PROPN
ajmri-3088	279	6	,	,	PUNCT
ajmri-3088	279	7	n.	n.	NOUN
ajmri-3088	279	8	,	,	PUNCT
ajmri-3088	279	9	lamberti	lamberti	PROPN
ajmri-3088	279	10	,	,	PUNCT
ajmri-3088	279	11	g.	g.	PROPN
ajmri-3088	279	12	,	,	PUNCT
ajmri-3088	279	13	trefny	trefny	NOUN
ajmri-3088	279	14	,	,	PUNCT
ajmri-3088	279	15	m.	m.	NOUN
ajmri-3088	279	16	,	,	PUNCT
ajmri-3088	279	17	krogsdam	krogsdam	PROPN
ajmri-3088	279	18	,	,	PUNCT
ajmri-3088	279	19	a.	a.	NOUN
ajmri-3088	279	20	,	,	PUNCT
ajmri-3088	279	21	siller	siller	NOUN
ajmri-3088	279	22	,	,	PUNCT
ajmri-3088	279	23	a.	a.	NOUN
ajmri-3088	279	24	,	,	PUNCT
ajmri-3088	279	25	hortnagl	hortnagl	NOUN
ajmri-3088	279	26	,	,	PUNCT
ajmri-3088	279	27	p.	p.	NOUN
ajmri-3088	279	28	,	,	PUNCT
ajmri-3088	279	29	schumacher	schumacher	PROPN
ajmri-3088	279	30	,	,	PUNCT
ajmri-3088	279	31	p.	p.	PROPN
ajmri-3088	279	32	,	,	PUNCT
ajmri-3088	279	33	sopper	sopper	NOUN
ajmri-3088	279	34	,	,	PUNCT
ajmri-3088	279	35	s.	s.	PROPN
ajmri-3088	279	36	,	,	PUNCT
ajmri-3088	279	37	&	&	CCONJ
ajmri-3088	279	38	sandbichler	sandbichler	NOUN
ajmri-3088	279	39	,	,	PUNCT
ajmri-3088	279	40	a.	a.	NOUN
ajmri-3088	279	41	(	(	PUNCT
ajmri-3088	279	42	2023	2023	NUM
ajmri-3088	279	43	)	)	PUNCT
ajmri-3088	279	44	.	.	PUNCT
ajmri-3088	280	1	<	<	X
ajmri-3088	280	2	/sup	/sup	X
ajmri-3088	280	3	>	>	X
ajmri-3088	280	4	13<//	13<//	ADJ
ajmri-3088	280	5	sup	sup	NOUN
ajmri-3088	280	6	>	>	X
ajmri-3088	280	7	c	c	PROPN
ajmri-3088	280	8	tracer	tracer	NOUN
ajmri-3088	280	9	analysis	analysis	NOUN
ajmri-3088	280	10	reveals	reveal	VERB
ajmri-3088	280	11	the	the	DET
ajmri-3088	280	12	landscape	landscape	NOUN
ajmri-3088	280	13	of	of	ADP
ajmri-3088	280	14	metabolic	metabolic	NOUN
ajmri-3088	280	15	checkpoints	checkpoint	NOUN
ajmri-3088	280	16	in	in	ADP
ajmri-3088	280	17	human	human	ADJ
ajmri-3088	280	18	cd8</sup>+<//	cd8</sup>+<//	PROPN
ajmri-3088	280	19	sup	sup	NOUN
ajmri-3088	280	20	>	>	X
ajmri-3088	280	21	t	t	NOUN
ajmri-3088	280	22	cell	cell	NOUN
ajmri-3088	280	23	differentiation	differentiation	NOUN
ajmri-3088	280	24	and	and	CCONJ
ajmri-3088	280	25	exhaustion	exhaustion	NOUN
ajmri-3088	280	26	.	.	PUNCT
ajmri-3088	281	1	frontiers	frontier	NOUN
ajmri-3088	281	2	in	in	ADP
ajmri-3088	281	3	immunology	immunology	NOUN
ajmri-3088	281	4	,	,	PUNCT
ajmri-3088	281	5	14	14	NUM
ajmri-3088	281	6	.	.	PUNCT
ajmri-3088	282	1	kirkoyun	kirkoyun	PROPN
ajmri-3088	282	2	uysal	uysal	PROPN
ajmri-3088	282	3	,	,	PUNCT
ajmri-3088	282	4	h.	h.	PROPN
ajmri-3088	282	5	,	,	PUNCT
ajmri-3088	282	6	koksal	koksal	NOUN
ajmri-3088	282	7	,	,	PUNCT
ajmri-3088	282	8	m.	m.	NOUN
ajmri-3088	282	9	o.	o.	PROPN
ajmri-3088	282	10	,	,	PUNCT
ajmri-3088	282	11	sarsar	sarsar	PROPN
ajmri-3088	282	12	,	,	PUNCT
ajmri-3088	282	13	k.	k.	PROPN
ajmri-3088	282	14	,	,	PUNCT
ajmri-3088	282	15	soguksu	soguksu	ADJ
ajmri-3088	282	16	,	,	PUNCT
ajmri-3088	282	17	p.	p.	PROPN
ajmri-3088	282	18	,	,	PUNCT
ajmri-3088	282	19	erkose	erkose	VERB
ajmri-3088	282	20	genc	genc	PROPN
ajmri-3088	282	21	,	,	PUNCT
ajmri-3088	282	22	g.	g.	PROPN
ajmri-3088	282	23	,	,	PUNCT
ajmri-3088	282	24	yapar	yapar	NOUN
ajmri-3088	282	25	,	,	PUNCT
ajmri-3088	282	26	g.	g.	PROPN
ajmri-3088	282	27	,	,	PUNCT
ajmri-3088	282	28	ozdemir	ozdemir	PROPN
ajmri-3088	282	29	,	,	PUNCT
ajmri-3088	282	30	e.	e.	PROPN
ajmri-3088	282	31	,	,	PUNCT
ajmri-3088	282	32	onel	onel	NOUN
ajmri-3088	282	33	,	,	PUNCT
ajmri-3088	282	34	m.	m.	NOUN
ajmri-3088	282	35	,	,	PUNCT
ajmri-3088	282	36	mese	mese	PROPN
ajmri-3088	282	37	,	,	PUNCT
ajmri-3088	282	38	s.	s.	PROPN
ajmri-3088	282	39	,	,	PUNCT
ajmri-3088	282	40	&	&	CCONJ
ajmri-3088	282	41	demirci	demirci	PROPN
ajmri-3088	282	42	,	,	PUNCT
ajmri-3088	282	43	m.	m.	NOUN
ajmri-3088	282	44	(	(	PUNCT
ajmri-3088	282	45	2023	2023	NUM
ajmri-3088	282	46	)	)	PUNCT
ajmri-3088	282	47	.	.	PUNCT
ajmri-3088	283	1	distribution	distribution	NOUN
ajmri-3088	283	2	of	of	ADP
ajmri-3088	283	3	opportunistic	opportunistic	ADJ
ajmri-3088	283	4	pathogens	pathogen	NOUN
ajmri-3088	283	5	in	in	ADP
ajmri-3088	283	6	people	people	NOUN
ajmri-3088	283	7	living	live	VERB
ajmri-3088	283	8	with	with	ADP
ajmri-3088	283	9	hiv	hiv	PROPN
ajmri-3088	283	10	at	at	ADP
ajmri-3088	283	11	a	a	DET
ajmri-3088	283	12	university	university	NOUN
ajmri-3088	283	13	hospital	hospital	NOUN
ajmri-3088	283	14	in	in	ADP
ajmri-3088	283	15	istanbul	istanbul	PROPN
ajmri-3088	283	16	over	over	ADP
ajmri-3088	283	17	a	a	DET
ajmri-3088	283	18	one	one	NUM
ajmri-3088	283	19	-	-	PUNCT
ajmri-3088	283	20	year	year	NOUN
ajmri-3088	283	21	treatment	treatment	NOUN
ajmri-3088	283	22	period	period	NOUN
ajmri-3088	283	23	and	and	CCONJ
ajmri-3088	283	24	its	its	PRON
ajmri-3088	283	25	association	association	NOUN
ajmri-3088	283	26	with	with	ADP
ajmri-3088	283	27	cd4	cd4	PROPN
ajmri-3088	283	28	t	t	PROPN
ajmri-3088	283	29	cell	cell	NOUN
ajmri-3088	283	30	counts	count	NOUN
ajmri-3088	283	31	.	.	PUNCT
ajmri-3088	284	1	pathogens	pathogen	NOUN
ajmri-3088	284	2	,	,	PUNCT
ajmri-3088	284	3	12(10	12(10	NUM
ajmri-3088	284	4	)	)	PUNCT
ajmri-3088	284	5	,	,	PUNCT
ajmri-3088	284	6	1226	1226	NUM
ajmri-3088	284	7	.	.	PUNCT
ajmri-3088	285	1	lim	lim	PROPN
ajmri-3088	285	2	,	,	PUNCT
ajmri-3088	285	3	s.	s.	PROPN
ajmri-3088	285	4	g.	g.	PROPN
ajmri-3088	285	5	,	,	PUNCT
ajmri-3088	285	6	baumert	baumert	PROPN
ajmri-3088	285	7	,	,	PUNCT
ajmri-3088	285	8	t.	t.	PROPN
ajmri-3088	285	9	f.	f.	PROPN
ajmri-3088	285	10	,	,	PUNCT
ajmri-3088	285	11	boni	boni	PROPN
ajmri-3088	285	12	,	,	PUNCT
ajmri-3088	285	13	c.	c.	NOUN
ajmri-3088	285	14	,	,	PUNCT
ajmri-3088	285	15	gane	gane	NOUN
ajmri-3088	285	16	,	,	PUNCT
ajmri-3088	285	17	e.	e.	PROPN
ajmri-3088	285	18	,	,	PUNCT
ajmri-3088	285	19	levrero	levrero	PROPN
ajmri-3088	285	20	,	,	PUNCT
ajmri-3088	285	21	m.	m.	NOUN
ajmri-3088	285	22	,	,	PUNCT
ajmri-3088	285	23	lok	lok	PROPN
ajmri-3088	285	24	,	,	PUNCT
ajmri-3088	285	25	a.	a.	PROPN
ajmri-3088	285	26	s.	s.	PROPN
ajmri-3088	285	27	,	,	PUNCT
ajmri-3088	285	28	maini	maini	PROPN
ajmri-3088	285	29	,	,	PUNCT
ajmri-3088	285	30	m.	m.	NOUN
ajmri-3088	285	31	k.	k.	PROPN
ajmri-3088	285	32	,	,	PUNCT
ajmri-3088	285	33	terrault	terrault	NOUN
ajmri-3088	285	34	,	,	PUNCT
ajmri-3088	285	35	n.	n.	NOUN
ajmri-3088	285	36	a.	a.	PROPN
ajmri-3088	285	37	,	,	PUNCT
ajmri-3088	285	38	&	&	CCONJ
ajmri-3088	285	39	zoulim	zoulim	PROPN
ajmri-3088	285	40	,	,	PUNCT
ajmri-3088	285	41	f.	f.	PROPN
ajmri-3088	285	42	(	(	PUNCT
ajmri-3088	285	43	2023	2023	NUM
ajmri-3088	285	44	)	)	PUNCT
ajmri-3088	285	45	.	.	PUNCT
ajmri-3088	286	1	the	the	DET
ajmri-3088	286	2	scientific	scientific	ADJ
ajmri-3088	286	3	basis	basis	NOUN
ajmri-3088	286	4	of	of	ADP
ajmri-3088	286	5	combination	combination	NOUN
ajmri-3088	286	6	therapy	therapy	NOUN
ajmri-3088	286	7	for	for	ADP
ajmri-3088	286	8	chronic	chronic	ADJ
ajmri-3088	286	9	hepatitis	hepatitis	NOUN
ajmri-3088	286	10	b	b	NOUN
ajmri-3088	286	11	functional	functional	ADJ
ajmri-3088	286	12	cure	cure	NOUN
ajmri-3088	286	13	.	.	PUNCT
ajmri-3088	287	1	nature	nature	NOUN
ajmri-3088	287	2	reviews	review	VERB
ajmri-3088	287	3	gastroenterology	gastroenterology	NOUN
ajmri-3088	287	4	&	&	CCONJ
ajmri-3088	287	5	hepatology	hepatology	NOUN
ajmri-3088	287	6	,	,	PUNCT
ajmri-3088	287	7	20(4	20(4	NOUN
ajmri-3088	287	8	)	)	PUNCT
ajmri-3088	287	9	,	,	PUNCT
ajmri-3088	287	10	238	238	NUM
ajmri-3088	287	11	-	-	SYM
ajmri-3088	287	12	253	253	NUM
ajmri-3088	287	13	.	.	PUNCT
ajmri-3088	288	1	mukasa	mukasa	PROPN
ajmri-3088	288	2	kafeero	kafeero	PROPN
ajmri-3088	288	3	,	,	PUNCT
ajmri-3088	288	4	h.	h.	PROPN
ajmri-3088	288	5	,	,	PUNCT
ajmri-3088	288	6	ndagire	ndagire	ADJ
ajmri-3088	288	7	,	,	PUNCT
ajmri-3088	288	8	d.	d.	PROPN
ajmri-3088	288	9	,	,	PUNCT
ajmri-3088	288	10	ocama	ocama	NOUN
ajmri-3088	288	11	,	,	PUNCT
ajmri-3088	288	12	p.	p.	PROPN
ajmri-3088	288	13	,	,	PUNCT
ajmri-3088	288	14	walusansa	walusansa	PROPN
ajmri-3088	288	15	,	,	PUNCT
ajmri-3088	288	16	a.	a.	NOUN
ajmri-3088	288	17	,	,	PUNCT
ajmri-3088	288	18	&	&	CCONJ
ajmri-3088	288	19	sendagire	sendagire	PROPN
ajmri-3088	288	20	,	,	PUNCT
ajmri-3088	288	21	h.	h.	PROPN
ajmri-3088	288	22	(	(	PUNCT
ajmri-3088	288	23	2006	2006	NUM
ajmri-3088	288	24	)	)	PUNCT
ajmri-3088	288	25	.	.	PUNCT
ajmri-3088	289	1	sero	sero	NOUN
ajmri-3088	289	2	-	-	PUNCT
ajmri-3088	289	3	prevalence	prevalence	NOUN
ajmri-3088	289	4	of	of	ADP
ajmri-3088	289	5	human	human	ADJ
ajmri-3088	289	6	immunodeficiency	immunodeficiency	NOUN
ajmri-3088	289	7	virus	virus	NOUN
ajmri-3088	289	8	–	–	PUNCT
ajmri-3088	289	9	hepatitis	hepatitis	PROPN
ajmri-3088	289	10	b	b	PROPN
ajmri-3088	289	11	virus	virus	NOUN
ajmri-3088	289	12	(	(	PUNCT
ajmri-3088	289	13	hiv	hiv	NOUN
ajmri-3088	289	14	–	–	PUNCT
ajmri-3088	289	15	hbv	hbv	NOUN
ajmri-3088	289	16	)	)	PUNCT
ajmri-3088	289	17	co	co	NOUN
ajmri-3088	289	18	-	-	NOUN
ajmri-3088	289	19	infection	infection	NOUN
ajmri-3088	289	20	among	among	ADP
ajmri-3088	289	21	pregnant	pregnant	ADJ
ajmri-3088	289	22	women	woman	NOUN
ajmri-3088	289	23	attending	attend	VERB
ajmri-3088	289	24	antenatal	antenatal	ADJ
ajmri-3088	289	25	care	care	NOUN
ajmri-3088	289	26	(	(	PUNCT
ajmri-3088	289	27	anc	anc	PROPN
ajmri-3088	289	28	)	)	PUNCT
ajmri-3088	289	29	in	in	ADP
ajmri-3088	289	30	sub	sub	ADJ
ajmri-3088	289	31	-	-	ADJ
ajmri-3088	289	32	saharan	saharan	ADJ
ajmri-3088	289	33	africa	africa	PROPN
ajmri-3088	289	34	(	(	PUNCT
ajmri-3088	289	35	ssa	ssa	PROPN
ajmri-3088	289	36	)	)	PUNCT
ajmri-3088	289	37	and	and	CCONJ
ajmri-3088	289	38	the	the	DET
ajmri-3088	289	39	associated	associated	ADJ
ajmri-3088	289	40	risk	risk	NOUN
ajmri-3088	289	41	factors	factor	NOUN
ajmri-3088	289	42	:	:	PUNCT
ajmri-3088	289	43	a	a	DET
ajmri-3088	289	44	systematic	systematic	ADJ
ajmri-3088	289	45	review	review	NOUN
ajmri-3088	289	46	and	and	CCONJ
ajmri-3088	289	47	meta	meta	ADJ
ajmri-3088	289	48	-	-	PUNCT
ajmri-3088	289	49	analysis	analysis	NOUN
ajmri-3088	289	50	.	.	PUNCT
ajmri-3088	290	1	nguyen	nguyen	PROPN
ajmri-3088	290	2	,	,	PUNCT
ajmri-3088	290	3	r.	r.	PROPN
ajmri-3088	290	4	n.	n.	PROPN
ajmri-3088	290	5	,	,	PUNCT
ajmri-3088	290	6	ton	ton	PROPN
ajmri-3088	290	7	,	,	PUNCT
ajmri-3088	290	8	q.	q.	PROPN
ajmri-3088	290	9	c.	c.	PROPN
ajmri-3088	290	10	,	,	PUNCT
ajmri-3088	290	11	tran	tran	PROPN
ajmri-3088	290	12	,	,	PUNCT
ajmri-3088	290	13	q.	q.	PROPN
ajmri-3088	290	14	h.	h.	PROPN
ajmri-3088	290	15	,	,	PUNCT
ajmri-3088	290	16	&	&	CCONJ
ajmri-3088	290	17	nguyen	nguyen	PROPN
ajmri-3088	290	18	,	,	PUNCT
ajmri-3088	290	19	t.	t.	PROPN
ajmri-3088	290	20	k.	k.	PROPN
ajmri-3088	290	21	l.	l.	PROPN
ajmri-3088	290	22	(	(	PUNCT
ajmri-3088	290	23	2020	2020	NUM
ajmri-3088	290	24	)	)	PUNCT
ajmri-3088	290	25	.	.	PUNCT
ajmri-3088	291	1	mother	mother	NOUN
ajmri-3088	291	2	-	-	PUNCT
ajmri-3088	291	3	to	to	ADP
ajmri-3088	291	4	-	-	PUNCT
ajmri-3088	291	5	child	child	NOUN
ajmri-3088	291	6	transmission	transmission	NOUN
ajmri-3088	291	7	of	of	ADP
ajmri-3088	291	8	hiv	hiv	PROPN
ajmri-3088	291	9	and	and	CCONJ
ajmri-3088	291	10	its	its	PRON
ajmri-3088	291	11	predictors	predictor	NOUN
ajmri-3088	291	12	among	among	ADP
ajmri-3088	291	13	hiv	hiv	PROPN
ajmri-3088	291	14	-	-	PUNCT
ajmri-3088	291	15	exposed	expose	VERB
ajmri-3088	291	16	infants	infant	NOUN
ajmri-3088	291	17	at	at	ADP
ajmri-3088	291	18	an	an	DET
ajmri-3088	291	19	outpatient	outpatient	NOUN
ajmri-3088	291	20	clinic	clinic	NOUN
ajmri-3088	291	21	for	for	ADP
ajmri-3088	291	22	hiv	hiv	PROPN
ajmri-3088	291	23	/	/	SYM
ajmri-3088	291	24	aids	aids	PROPN
ajmri-3088	291	25	in	in	ADP
ajmri-3088	291	26	vietnam	vietnam	PROPN
ajmri-3088	291	27	.	.	PUNCT
ajmri-3088	292	1	hiv/	hiv/	PROPN
ajmri-3088	292	2	aids	aids	PROPN
ajmri-3088	292	3	-	-	PUNCT
ajmri-3088	292	4	research	research	NOUN
ajmri-3088	292	5	and	and	CCONJ
ajmri-3088	292	6	palliative	palliative	ADJ
ajmri-3088	292	7	care	care	NOUN
ajmri-3088	292	8	,	,	PUNCT
ajmri-3088	292	9	253	253	NUM
ajmri-3088	292	10	-	-	SYM
ajmri-3088	292	11	261	261	NUM
ajmri-3088	292	12	.	.	PUNCT
ajmri-3088	293	1	perez	perez	PROPN
ajmri-3088	293	2	-	-	PUNCT
ajmri-3088	293	3	molina	molina	PROPN
ajmri-3088	293	4	,	,	PUNCT
ajmri-3088	293	5	j.	j.	PROPN
ajmri-3088	293	6	a.	a.	PROPN
ajmri-3088	293	7	,	,	PUNCT
ajmri-3088	293	8	crespillo	crespillo	NOUN
ajmri-3088	293	9	-	-	PUNCT
ajmri-3088	293	10	andújar	andújar	NOUN
ajmri-3088	293	11	,	,	PUNCT
ajmri-3088	293	12	c.	c.	PROPN
ajmri-3088	293	13	,	,	PUNCT
ajmri-3088	293	14	zamora	zamora	PROPN
ajmri-3088	293	15	,	,	PUNCT
ajmri-3088	293	16	j.	j.	PROPN
ajmri-3088	293	17	,	,	PUNCT
ajmri-3088	293	18	fernández	fernández	PROPN
ajmri-3088	293	19	-	-	PUNCT
ajmri-3088	293	20	félix	félix	PROPN
ajmri-3088	293	21	,	,	PUNCT
ajmri-3088	293	22	b.	b.	PROPN
ajmri-3088	293	23	m.	m.	PROPN
ajmri-3088	293	24	,	,	PUNCT
ajmri-3088	293	25	gaetano	gaetano	PROPN
ajmri-3088	293	26	-	-	PUNCT
ajmri-3088	293	27	gil	gil	PROPN
ajmri-3088	293	28	,	,	PUNCT
ajmri-3088	293	29	a.	a.	NOUN
ajmri-3088	293	30	,	,	PUNCT
ajmri-3088	293	31	lopezbernaldo	lopezbernaldo	PROPN
ajmri-3088	293	32	de	de	X
ajmri-3088	293	33	quiros	quiros	PROPN
ajmri-3088	293	34	,	,	PUNCT
ajmri-3088	293	35	j.	j.	PROPN
ajmri-3088	293	36	c.	c.	PROPN
ajmri-3088	293	37	,	,	PUNCT
ajmri-3088	293	38	serrano	serrano	NOUN
ajmri-3088	293	39	-	-	PUNCT
ajmri-3088	293	40	villar	villar	PROPN
ajmri-3088	293	41	,	,	PUNCT
ajmri-3088	293	42	s.	s.	PROPN
ajmri-3088	293	43	,	,	PUNCT
ajmri-3088	293	44	moreno	moreno	PROPN
ajmri-3088	293	45	,	,	PUNCT
ajmri-3088	293	46	s.	s.	PROPN
ajmri-3088	293	47	,	,	PUNCT
ajmri-3088	293	48	álvarez	álvarez	NOUN
ajmri-3088	293	49	-	-	PUNCT
ajmri-3088	293	50	díaz	díaz	NOUN
ajmri-3088	293	51	,	,	PUNCT
ajmri-3088	293	52	n.	n.	NOUN
ajmri-3088	293	53	,	,	PUNCT
ajmri-3088	293	54	&	&	CCONJ
ajmri-3088	293	55	berenguer	berenguer	PROPN
ajmri-3088	293	56	,	,	PUNCT
ajmri-3088	293	57	j.	j.	PROPN
ajmri-3088	293	58	(	(	PUNCT
ajmri-3088	293	59	2023	2023	NUM
ajmri-3088	293	60	)	)	PUNCT
ajmri-3088	293	61	.	.	PUNCT
ajmri-3088	294	1	contribution	contribution	NOUN
ajmri-3088	294	2	of	of	ADP
ajmri-3088	294	3	low	low	ADJ
ajmri-3088	294	4	cd4	cd4	PROPN
ajmri-3088	294	5	cell	cell	NOUN
ajmri-3088	294	6	counts	count	NOUN
ajmri-3088	294	7	and	and	CCONJ
ajmri-3088	294	8	high	high	ADJ
ajmri-3088	294	9	human	human	ADJ
ajmri-3088	294	10	immunodeficiency	immunodeficiency	NOUN
ajmri-3088	294	11	virus	virus	NOUN
ajmri-3088	294	12	(	(	PUNCT
ajmri-3088	294	13	hiv	hiv	PROPN
ajmri-3088	294	14	)	)	PUNCT
ajmri-3088	294	15	viral	viral	ADJ
ajmri-3088	294	16	load	load	NOUN
ajmri-3088	294	17	to	to	ADP
ajmri-3088	294	18	the	the	DET
ajmri-3088	294	19	efficacy	efficacy	NOUN
ajmri-3088	294	20	of	of	ADP
ajmri-3088	294	21	preferred	preferred	ADJ
ajmri-3088	294	22	first	first	ADJ
ajmri-3088	294	23	-	-	PUNCT
ajmri-3088	294	24	line	line	NOUN
ajmri-3088	294	25	antiretroviral	antiretroviral	ADJ
ajmri-3088	294	26	regimens	regimen	NOUN
ajmri-3088	294	27	for	for	ADP
ajmri-3088	294	28	treating	treat	VERB
ajmri-3088	294	29	hiv	hiv	PROPN
ajmri-3088	294	30	infection	infection	NOUN
ajmri-3088	294	31	:	:	PUNCT
ajmri-3088	294	32	a	a	DET
ajmri-3088	294	33	systematic	systematic	ADJ
ajmri-3088	294	34	review	review	NOUN
ajmri-3088	294	35	and	and	CCONJ
ajmri-3088	294	36	meta	meta	ADJ
ajmri-3088	294	37	-	-	PUNCT
ajmri-3088	294	38	analysis	analysis	NOUN
ajmri-3088	294	39	.	.	PUNCT
ajmri-3088	295	1	clinical	clinical	ADJ
ajmri-3088	295	2	infectious	infectious	ADJ
ajmri-3088	295	3	diseases	disease	NOUN
ajmri-3088	295	4	,	,	PUNCT
ajmri-3088	295	5	76(11	76(11	NUM
ajmri-3088	295	6	)	)	PUNCT
ajmri-3088	295	7	,	,	PUNCT
ajmri-3088	295	8	20272037	20272037	NUM
ajmri-3088	295	9	.	.	PUNCT
ajmri-3088	296	1	rahman	rahman	PROPN
ajmri-3088	296	2	,	,	PUNCT
ajmri-3088	296	3	a.	a.	NOUN
ajmri-3088	296	4	n.-u	n.-u	PROPN
ajmri-3088	296	5	.	.	PUNCT
ajmri-3088	296	6	,	,	PUNCT
ajmri-3088	296	7	liu	liu	PROPN
ajmri-3088	296	8	,	,	PUNCT
ajmri-3088	296	9	j.	j.	PROPN
ajmri-3088	296	10	,	,	PUNCT
ajmri-3088	296	11	mujib	mujib	PROPN
ajmri-3088	296	12	,	,	PUNCT
ajmri-3088	296	13	s.	s.	PROPN
ajmri-3088	296	14	,	,	PUNCT
ajmri-3088	296	15	kidane	kidane	PROPN
ajmri-3088	296	16	,	,	PUNCT
ajmri-3088	296	17	s.	s.	PROPN
ajmri-3088	296	18	,	,	PUNCT
ajmri-3088	296	19	ali	ali	PROPN
ajmri-3088	296	20	,	,	PUNCT
ajmri-3088	296	21	a.	a.	PROPN
ajmri-3088	296	22	,	,	PUNCT
ajmri-3088	296	23	szep	szep	PROPN
ajmri-3088	296	24	,	,	PUNCT
ajmri-3088	296	25	s.	s.	PROPN
ajmri-3088	296	26	,	,	PUNCT
ajmri-3088	296	27	han	han	PROPN
ajmri-3088	296	28	,	,	PUNCT
ajmri-3088	296	29	c.	c.	PROPN
ajmri-3088	296	30	,	,	PUNCT
ajmri-3088	296	31	bonner	bonner	PROPN
ajmri-3088	296	32	,	,	PUNCT
ajmri-3088	296	33	p.	p.	NOUN
ajmri-3088	296	34	,	,	PUNCT
ajmri-3088	296	35	parsons	parson	NOUN
ajmri-3088	296	36	,	,	PUNCT
ajmri-3088	296	37	m.	m.	NOUN
ajmri-3088	296	38	,	,	PUNCT
ajmri-3088	296	39	&	&	CCONJ
ajmri-3088	296	40	benko	benko	PROPN
ajmri-3088	296	41	,	,	PUNCT
ajmri-3088	296	42	e.	e.	PROPN
ajmri-3088	296	43	(	(	PUNCT
ajmri-3088	296	44	2021	2021	NUM
ajmri-3088	296	45	)	)	PUNCT
ajmri-3088	296	46	.	.	PUNCT
ajmri-3088	297	1	elevated	elevated	ADJ
ajmri-3088	297	2	glycolysis	glycolysis	NOUN
ajmri-3088	297	3	imparts	impart	VERB
ajmri-3088	297	4	functional	functional	ADJ
ajmri-3088	297	5	ability	ability	NOUN
ajmri-3088	297	6	to	to	PART
ajmri-3088	297	7	cd8	cd8	PROPN
ajmri-3088	297	8	+	+	PROPN
ajmri-3088	297	9	t	t	PROPN
ajmri-3088	297	10	cells	cell	NOUN
ajmri-3088	297	11	in	in	ADP
ajmri-3088	297	12	hiv	hiv	PROPN
ajmri-3088	297	13	infection	infection	NOUN
ajmri-3088	297	14	.	.	PUNCT
ajmri-3088	298	1	life	life	NOUN
ajmri-3088	298	2	science	science	PROPN
ajmri-3088	298	3	alliance	alliance	PROPN
ajmri-3088	298	4	,	,	PUNCT
ajmri-3088	298	5	4(11	4(11	NUM
ajmri-3088	298	6	)	)	PUNCT
ajmri-3088	298	7	.	.	PUNCT
ajmri-3088	299	1	ruta	ruta	PROPN
ajmri-3088	299	2	,	,	PUNCT
ajmri-3088	299	3	s.	s.	PROPN
ajmri-3088	299	4	,	,	PUNCT
ajmri-3088	299	5	grecu	grecu	PROPN
ajmri-3088	299	6	,	,	PUNCT
ajmri-3088	299	7	l.	l.	PROPN
ajmri-3088	299	8	,	,	PUNCT
ajmri-3088	299	9	iacob	iacob	NOUN
ajmri-3088	299	10	,	,	PUNCT
ajmri-3088	299	11	d.	d.	PROPN
ajmri-3088	299	12	,	,	PUNCT
ajmri-3088	299	13	cernescu	cernescu	PROPN
ajmri-3088	299	14	,	,	PUNCT
ajmri-3088	299	15	c.	c.	PROPN
ajmri-3088	299	16	,	,	PUNCT
ajmri-3088	299	17	&	&	CCONJ
ajmri-3088	299	18	sultana	sultana	PROPN
ajmri-3088	299	19	,	,	PUNCT
ajmri-3088	299	20	c.	c.	NOUN
ajmri-3088	299	21	(	(	PUNCT
ajmri-3088	299	22	2023	2023	NUM
ajmri-3088	299	23	)	)	PUNCT
ajmri-3088	299	24	.	.	PUNCT
ajmri-3088	300	1	hiv	hiv	PROPN
ajmri-3088	300	2	-	-	PUNCT
ajmri-3088	300	3	hbv	hbv	NOUN
ajmri-3088	300	4	coinfection	coinfection	NOUN
ajmri-3088	300	5	—	—	PUNCT
ajmri-3088	300	6	current	current	ADJ
ajmri-3088	300	7	challenges	challenge	NOUN
ajmri-3088	300	8	for	for	ADP
ajmri-3088	300	9	virologic	virologic	ADJ
ajmri-3088	300	10	monitoring	monitoring	NOUN
ajmri-3088	300	11	.	.	PUNCT
ajmri-3088	301	1	biomedicines	biomedicine	NOUN
ajmri-3088	301	2	,	,	PUNCT
ajmri-3088	301	3	11(5	11(5	NUM
ajmri-3088	301	4	)	)	PUNCT
ajmri-3088	301	5	,	,	PUNCT
ajmri-3088	301	6	1306	1306	NUM
ajmri-3088	301	7	.	.	PUNCT
ajmri-3088	302	1	serrano	serrano	NOUN
ajmri-3088	302	2	-	-	PUNCT
ajmri-3088	302	3	villar	villar	PROPN
ajmri-3088	302	4	,	,	PUNCT
ajmri-3088	302	5	s.	s.	PROPN
ajmri-3088	302	6	,	,	PUNCT
ajmri-3088	302	7	wu	wu	PROPN
ajmri-3088	302	8	,	,	PUNCT
ajmri-3088	302	9	k.	k.	PROPN
ajmri-3088	302	10	,	,	PUNCT
ajmri-3088	302	11	hunt	hunt	PROPN
ajmri-3088	302	12	,	,	PUNCT
ajmri-3088	302	13	p.	p.	PROPN
ajmri-3088	302	14	w.	w.	PROPN
ajmri-3088	302	15	,	,	PUNCT
ajmri-3088	302	16	lok	lok	PROPN
ajmri-3088	302	17	,	,	PUNCT
ajmri-3088	302	18	j.	j.	PROPN
ajmri-3088	302	19	j.	j.	PROPN
ajmri-3088	302	20	,	,	PUNCT
ajmri-3088	302	21	ron	ron	PROPN
ajmri-3088	302	22	,	,	PUNCT
ajmri-3088	302	23	r.	r.	PROPN
ajmri-3088	302	24	,	,	PUNCT
ajmri-3088	302	25	sainz	sainz	PROPN
ajmri-3088	302	26	,	,	PUNCT
ajmri-3088	302	27	t.	t.	PROPN
ajmri-3088	302	28	,	,	PUNCT
ajmri-3088	302	29	moreno	moreno	PROPN
ajmri-3088	302	30	,	,	PUNCT
ajmri-3088	302	31	s.	s.	PROPN
ajmri-3088	302	32	,	,	PUNCT
ajmri-3088	302	33	deeks	deek	NOUN
ajmri-3088	302	34	,	,	PUNCT
ajmri-3088	302	35	s.	s.	PROPN
ajmri-3088	302	36	g.	g.	PROPN
ajmri-3088	302	37	,	,	PUNCT
ajmri-3088	302	38	&	&	CCONJ
ajmri-3088	302	39	bosch	bosch	PROPN
ajmri-3088	302	40	,	,	PUNCT
ajmri-3088	302	41	r.	r.	PROPN
ajmri-3088	302	42	j.	j.	PROPN
ajmri-3088	302	43	(	(	PUNCT
ajmri-3088	302	44	2022	2022	NUM
ajmri-3088	302	45	)	)	PUNCT
ajmri-3088	302	46	.	.	PUNCT
ajmri-3088	303	1	predictive	predictive	ADJ
ajmri-3088	303	2	value	value	NOUN
ajmri-3088	303	3	of	of	ADP
ajmri-3088	303	4	cd8	cd8	PROPN
ajmri-3088	303	5	+	+	PROPN
ajmri-3088	303	6	t	t	PROPN
ajmri-3088	303	7	cell	cell	NOUN
ajmri-3088	303	8	and	and	CCONJ
ajmri-3088	303	9	cd4/	cd4/	VERB
ajmri-3088	303	10	cd8	cd8	PROPN
ajmri-3088	303	11	ratio	ratio	NOUN
ajmri-3088	303	12	at	at	ADP
ajmri-3088	303	13	two	two	NUM
ajmri-3088	303	14	years	year	NOUN
ajmri-3088	303	15	of	of	ADP
ajmri-3088	303	16	successful	successful	ADJ
ajmri-3088	303	17	art	art	NOUN
ajmri-3088	303	18	in	in	ADP
ajmri-3088	303	19	the	the	DET
ajmri-3088	303	20	risk	risk	NOUN
ajmri-3088	303	21	of	of	ADP
ajmri-3088	303	22	aids	aid	NOUN
ajmri-3088	303	23	and	and	CCONJ
ajmri-3088	303	24	non	non	ADJ
ajmri-3088	303	25	-	-	ADJ
ajmri-3088	303	26	aids	aids	ADJ
ajmri-3088	303	27	events	event	NOUN
ajmri-3088	303	28	.	.	PUNCT
ajmri-3088	304	1	ebiomedicine	ebiomedicine	ADJ
ajmri-3088	304	2	,	,	PUNCT
ajmri-3088	304	3	80	80	NUM
ajmri-3088	304	4	.	.	PUNCT
ajmri-3088	304	5	tang	tang	PROPN
ajmri-3088	304	6	,	,	PUNCT
ajmri-3088	304	7	g.	g.	PROPN
ajmri-3088	304	8	,	,	PUNCT
ajmri-3088	304	9	yuan	yuan	PROPN
ajmri-3088	304	10	,	,	PUNCT
ajmri-3088	304	11	x.	x.	PROPN
ajmri-3088	304	12	,	,	PUNCT
ajmri-3088	304	13	luo	luo	PROPN
ajmri-3088	304	14	,	,	PUNCT
ajmri-3088	304	15	y.	y.	PROPN
ajmri-3088	304	16	,	,	PUNCT
ajmri-3088	304	17	lin	lin	PROPN
ajmri-3088	304	18	,	,	PUNCT
ajmri-3088	304	19	q.	q.	PROPN
ajmri-3088	304	20	,	,	PUNCT
ajmri-3088	304	21	chen	chen	PROPN
ajmri-3088	304	22	,	,	PUNCT
ajmri-3088	304	23	z.	z.	PROPN
ajmri-3088	304	24	,	,	PUNCT
ajmri-3088	304	25	xing	xing	PROPN
ajmri-3088	304	26	,	,	PUNCT
ajmri-3088	304	27	x.	x.	NOUN
ajmri-3088	304	28	,	,	PUNCT
ajmri-3088	304	29	song	song	NOUN
ajmri-3088	304	30	,	,	PUNCT
ajmri-3088	304	31	h.	h.	PROPN
ajmri-3088	304	32	,	,	PUNCT
ajmri-3088	304	33	wu	wu	PROPN
ajmri-3088	304	34	,	,	PUNCT
ajmri-3088	304	35	s.	s.	PROPN
ajmri-3088	304	36	,	,	PUNCT
ajmri-3088	304	37	hou	hou	PROPN
ajmri-3088	304	38	,	,	PUNCT
ajmri-3088	304	39	h.	h.	PROPN
ajmri-3088	304	40	,	,	PUNCT
ajmri-3088	304	41	&	&	CCONJ
ajmri-3088	304	42	yu	yu	PROPN
ajmri-3088	304	43	,	,	PUNCT
ajmri-3088	304	44	j.	j.	PROPN
ajmri-3088	304	45	(	(	PUNCT
ajmri-3088	304	46	2020	2020	NUM
ajmri-3088	304	47	)	)	PUNCT
ajmri-3088	304	48	.	.	PUNCT
ajmri-3088	305	1	establishing	establish	VERB
ajmri-3088	305	2	immune	immune	ADJ
ajmri-3088	305	3	scoring	scoring	NOUN
ajmri-3088	305	4	model	model	NOUN
ajmri-3088	305	5	based	base	VERB
ajmri-3088	305	6	on	on	ADP
ajmri-3088	305	7	combination	combination	NOUN
ajmri-3088	305	8	of	of	ADP
ajmri-3088	305	9	the	the	DET
ajmri-3088	305	10	number	number	NOUN
ajmri-3088	305	11	,	,	PUNCT
ajmri-3088	305	12	function	function	NOUN
ajmri-3088	305	13	,	,	PUNCT
ajmri-3088	305	14	and	and	CCONJ
ajmri-3088	305	15	phenotype	phenotype	NOUN
ajmri-3088	305	16	of	of	ADP
ajmri-3088	305	17	lymphocytes	lymphocyte	NOUN
ajmri-3088	305	18	.	.	PUNCT
ajmri-3088	306	1	aging	age	VERB
ajmri-3088	306	2	(	(	PUNCT
ajmri-3088	306	3	albany	albany	PROPN
ajmri-3088	306	4	ny	ny	PROPN
ajmri-3088	306	5	)	)	PUNCT
ajmri-3088	306	6	,	,	PUNCT
ajmri-3088	306	7	12(10	12(10	NUM
ajmri-3088	306	8	)	)	PUNCT
ajmri-3088	306	9	,	,	PUNCT
ajmri-3088	306	10	9328	9328	NUM
ajmri-3088	306	11	.	.	PUNCT
ajmri-3088	307	1	pa	pa	PROPN
ajmri-3088	307	2	ge	ge	PROPN
ajmri-3088	307	3	60	60	NUM
ajmri-3088	308	1	https://journals.e-palli.com/home/index.php/ajmri	https://journals.e-palli.com/home/index.php/ajmri	PROPN
ajmri-3088	308	2	am	am	NOUN
ajmri-3088	308	3	.	.	PUNCT
ajmri-3088	309	1	j.	j.	PROPN
ajmri-3088	309	2	multidis	multidis	PROPN
ajmri-3088	309	3	.	.	PUNCT
ajmri-3088	310	1	res	re	NOUN
ajmri-3088	310	2	.	.	PUNCT
ajmri-3088	311	1	innov	innov	PROPN
ajmri-3088	311	2	.	.	PUNCT
ajmri-3088	312	1	3(5	3(5	NUM
ajmri-3088	312	2	)	)	PUNCT
ajmri-3088	312	3	50	50	NUM
ajmri-3088	312	4	-	-	SYM
ajmri-3088	312	5	60	60	NUM
ajmri-3088	312	6	,	,	PUNCT
ajmri-3088	312	7	2024	2024	NUM
ajmri-3088	312	8	tortellini	tortellini	NOUN
ajmri-3088	312	9	,	,	PUNCT
ajmri-3088	312	10	e.	e.	PROPN
ajmri-3088	312	11	,	,	PUNCT
ajmri-3088	312	12	fosso	fosso	PROPN
ajmri-3088	312	13	ngangue	ngangue	PROPN
ajmri-3088	312	14	,	,	PUNCT
ajmri-3088	312	15	y.	y.	PROPN
ajmri-3088	312	16	c.	c.	PROPN
ajmri-3088	312	17	,	,	PUNCT
ajmri-3088	312	18	dominelli	dominelli	PROPN
ajmri-3088	312	19	,	,	PUNCT
ajmri-3088	312	20	f.	f.	PROPN
ajmri-3088	312	21	,	,	PUNCT
ajmri-3088	312	22	guardiani	guardiani	PROPN
ajmri-3088	312	23	,	,	PUNCT
ajmri-3088	312	24	m.	m.	NOUN
ajmri-3088	312	25	,	,	PUNCT
ajmri-3088	312	26	falvino	falvino	NOUN
ajmri-3088	312	27	,	,	PUNCT
ajmri-3088	312	28	c.	c.	NOUN
ajmri-3088	312	29	,	,	PUNCT
ajmri-3088	312	30	mengoni	mengoni	NOUN
ajmri-3088	312	31	,	,	PUNCT
ajmri-3088	312	32	f.	f.	PROPN
ajmri-3088	312	33	,	,	PUNCT
ajmri-3088	312	34	carraro	carraro	PROPN
ajmri-3088	312	35	,	,	PUNCT
ajmri-3088	312	36	a.	a.	PROPN
ajmri-3088	312	37	,	,	PUNCT
ajmri-3088	312	38	marocco	marocco	PROPN
ajmri-3088	312	39	,	,	PUNCT
ajmri-3088	312	40	r.	r.	PROPN
ajmri-3088	312	41	,	,	PUNCT
ajmri-3088	312	42	pasculli	pasculli	PROPN
ajmri-3088	312	43	,	,	PUNCT
ajmri-3088	312	44	p.	p.	NOUN
ajmri-3088	312	45	,	,	PUNCT
ajmri-3088	312	46	&	&	CCONJ
ajmri-3088	312	47	mastroianni	mastroianni	PROPN
ajmri-3088	312	48	,	,	PUNCT
ajmri-3088	312	49	c.	c.	PROPN
ajmri-3088	312	50	m.	m.	NOUN
ajmri-3088	312	51	(	(	PUNCT
ajmri-3088	312	52	2023	2023	NUM
ajmri-3088	312	53	)	)	PUNCT
ajmri-3088	312	54	.	.	PUNCT
ajmri-3088	313	1	immunogenicity	immunogenicity	NOUN
ajmri-3088	313	2	and	and	CCONJ
ajmri-3088	313	3	efficacy	efficacy	NOUN
ajmri-3088	313	4	of	of	ADP
ajmri-3088	313	5	vaccination	vaccination	NOUN
ajmri-3088	313	6	in	in	ADP
ajmri-3088	313	7	people	people	NOUN
ajmri-3088	313	8	living	live	VERB
ajmri-3088	313	9	with	with	ADP
ajmri-3088	313	10	human	human	ADJ
ajmri-3088	313	11	immunodeficiency	immunodeficiency	NOUN
ajmri-3088	313	12	virus	virus	NOUN
ajmri-3088	313	13	.	.	PUNCT
ajmri-3088	314	1	viruses	virus	NOUN
ajmri-3088	314	2	,	,	PUNCT
ajmri-3088	314	3	15(9	15(9	NUM
ajmri-3088	314	4	)	)	PUNCT
ajmri-3088	314	5	,	,	PUNCT
ajmri-3088	314	6	1844	1844	NUM
ajmri-3088	314	7	.	.	PUNCT
ajmri-3088	315	1	weldemhret	weldemhret	PROPN
ajmri-3088	315	2	,	,	PUNCT
ajmri-3088	315	3	l.	l.	PROPN
ajmri-3088	315	4	(	(	PUNCT
ajmri-3088	315	5	2021	2021	NUM
ajmri-3088	315	6	)	)	PUNCT
ajmri-3088	315	7	.	.	PUNCT
ajmri-3088	316	1	epidemiology	epidemiology	NOUN
ajmri-3088	316	2	and	and	CCONJ
ajmri-3088	316	3	challenges	challenge	NOUN
ajmri-3088	316	4	of	of	ADP
ajmri-3088	316	5	hbv	hbv	NOUN
ajmri-3088	316	6	/	/	SYM
ajmri-3088	316	7	hiv	hiv	PROPN
ajmri-3088	316	8	co	co	NOUN
ajmri-3088	316	9	-	-	NOUN
ajmri-3088	316	10	infection	infection	NOUN
ajmri-3088	316	11	amongst	amongst	ADP
ajmri-3088	316	12	hiv	hiv	PROPN
ajmri-3088	316	13	-	-	PUNCT
ajmri-3088	316	14	infected	infect	VERB
ajmri-3088	316	15	patients	patient	NOUN
ajmri-3088	316	16	in	in	ADP
ajmri-3088	316	17	endemic	endemic	ADJ
ajmri-3088	316	18	areas	area	NOUN
ajmri-3088	316	19	.	.	PUNCT
ajmri-3088	317	1	hiv	hiv	PROPN
ajmri-3088	317	2	/	/	SYM
ajmri-3088	317	3	aids	aids	PROPN
ajmri-3088	317	4	-	-	PUNCT
ajmri-3088	317	5	research	research	NOUN
ajmri-3088	317	6	and	and	CCONJ
ajmri-3088	317	7	palliative	palliative	ADJ
ajmri-3088	317	8	care	care	NOUN
ajmri-3088	317	9	,	,	PUNCT
ajmri-3088	317	10	485	485	NUM
ajmri-3088	317	11	-	-	SYM
ajmri-3088	317	12	490	490	NUM
ajmri-3088	317	13	.	.	PUNCT
ajmri-3088	317	14	wu	wu	PROPN
ajmri-3088	317	15	,	,	PUNCT
ajmri-3088	317	16	j.	j.	PROPN
ajmri-3088	317	17	,	,	PUNCT
ajmri-3088	317	18	han	han	PROPN
ajmri-3088	317	19	,	,	PUNCT
ajmri-3088	317	20	m.	m.	NOUN
ajmri-3088	317	21	,	,	PUNCT
ajmri-3088	317	22	li	li	PROPN
ajmri-3088	317	23	,	,	PUNCT
ajmri-3088	317	24	j.	j.	PROPN
ajmri-3088	317	25	,	,	PUNCT
ajmri-3088	317	26	yang	yang	PROPN
ajmri-3088	317	27	,	,	PUNCT
ajmri-3088	317	28	x.	x.	PROPN
ajmri-3088	317	29	,	,	PUNCT
ajmri-3088	317	30	&	&	CCONJ
ajmri-3088	317	31	yang	yang	PROPN
ajmri-3088	317	32	,	,	PUNCT
ajmri-3088	317	33	d.	d.	PROPN
ajmri-3088	317	34	(	(	PUNCT
ajmri-3088	317	35	2020	2020	NUM
ajmri-3088	317	36	)	)	PUNCT
ajmri-3088	317	37	.	.	PUNCT
ajmri-3088	318	1	immunopathogenesis	immunopathogenesis	NOUN
ajmri-3088	318	2	of	of	ADP
ajmri-3088	318	3	hbv	hbv	NOUN
ajmri-3088	318	4	infection	infection	NOUN
ajmri-3088	318	5	.	.	PUNCT
ajmri-3088	319	1	in	in	ADP
ajmri-3088	319	2	d.	d.	PROPN
ajmri-3088	319	3	yang	yang	PROPN
ajmri-3088	319	4	(	(	PUNCT
ajmri-3088	319	5	ed	ed	NOUN
ajmri-3088	319	6	.	.	PUNCT
ajmri-3088	319	7	)	)	PUNCT
ajmri-3088	319	8	,	,	PUNCT
ajmri-3088	319	9	hepatitis	hepatitis	PROPN
ajmri-3088	319	10	b	b	PROPN
ajmri-3088	319	11	virus	virus	NOUN
ajmri-3088	319	12	infection	infection	NOUN
ajmri-3088	319	13	:	:	PUNCT
ajmri-3088	319	14	molecular	molecular	ADJ
ajmri-3088	319	15	virology	virology	NOUN
ajmri-3088	319	16	to	to	ADP
ajmri-3088	319	17	antiviral	antiviral	ADJ
ajmri-3088	319	18	drugs	drug	NOUN
ajmri-3088	319	19	(	(	PUNCT
ajmri-3088	319	20	pp	pp	ADJ
ajmri-3088	319	21	.	.	PUNCT
ajmri-3088	320	1	71	71	NUM
ajmri-3088	320	2	-	-	SYM
ajmri-3088	320	3	107	107	NUM
ajmri-3088	320	4	)	)	PUNCT
ajmri-3088	320	5	.	.	PUNCT
ajmri-3088	321	1	youssif	youssif	PROPN
ajmri-3088	321	2	,	,	PUNCT
ajmri-3088	321	3	r.	r.	PROPN
ajmri-3088	321	4	a.	a.	PROPN
ajmri-3088	321	5	,	,	PUNCT
ajmri-3088	321	6	ezzel	ezzel	PROPN
ajmri-3088	321	7	-	-	PUNCT
ajmri-3088	321	8	din	din	PROPN
ajmri-3088	321	9	,	,	PUNCT
ajmri-3088	321	10	a.	a.	NOUN
ajmri-3088	321	11	m.	m.	NOUN
ajmri-3088	321	12	,	,	PUNCT
ajmri-3088	321	13	abd	abd	PROPN
ajmri-3088	321	14	el	el	PROPN
ajmri-3088	321	15	-	-	PUNCT
ajmri-3088	321	16	hafeez	hafeez	PROPN
ajmri-3088	321	17	,	,	PUNCT
ajmri-3088	321	18	h.	h.	PROPN
ajmri-3088	321	19	a.	a.	PROPN
ajmri-3088	321	20	,	,	PUNCT
ajmri-3088	321	21	sayed	say	VERB
ajmri-3088	321	22	,	,	PUNCT
ajmri-3088	321	23	s.	s.	PROPN
ajmri-3088	321	24	k.	k.	PROPN
ajmri-3088	321	25	,	,	PUNCT
ajmri-3088	321	26	shaaban	shaaban	ADJ
ajmri-3088	321	27	,	,	PUNCT
ajmri-3088	321	28	o.	o.	NOUN
ajmri-3088	321	29	m.	m.	NOUN
ajmri-3088	321	30	,	,	PUNCT
ajmri-3088	321	31	&	&	CCONJ
ajmri-3088	321	32	kamal	kamal	PROPN
ajmri-3088	321	33	,	,	PUNCT
ajmri-3088	321	34	d.	d.	PROPN
ajmri-3088	321	35	t.	t.	PROPN
ajmri-3088	321	36	(	(	PUNCT
ajmri-3088	321	37	2023	2023	NUM
ajmri-3088	321	38	)	)	PUNCT
ajmri-3088	321	39	.	.	PUNCT
ajmri-3088	322	1	effect	effect	NOUN
ajmri-3088	322	2	of	of	ADP
ajmri-3088	322	3	obligatory	obligatory	ADJ
ajmri-3088	322	4	hepatitis	hepatitis	NOUN
ajmri-3088	322	5	b	b	PROPN
ajmri-3088	322	6	vaccination	vaccination	NOUN
ajmri-3088	322	7	program	program	NOUN
ajmri-3088	322	8	on	on	ADP
ajmri-3088	322	9	the	the	DET
ajmri-3088	322	10	prevalence	prevalence	NOUN
ajmri-3088	322	11	of	of	ADP
ajmri-3088	322	12	occult	occult	NOUN
ajmri-3088	322	13	hepatitis	hepatitis	PROPN
ajmri-3088	322	14	b	b	PROPN
ajmri-3088	322	15	among	among	ADP
ajmri-3088	322	16	pregnant	pregnant	ADJ
ajmri-3088	322	17	women	woman	NOUN
ajmri-3088	322	18	in	in	ADP
ajmri-3088	322	19	egypt	egypt	PROPN
ajmri-3088	322	20	:	:	PUNCT
ajmri-3088	322	21	a	a	DET
ajmri-3088	322	22	cross	cross	ADJ
ajmri-3088	322	23	sectional	sectional	ADJ
ajmri-3088	322	24	study	study	NOUN
ajmri-3088	322	25	.	.	PUNCT
ajmri-3088	323	1	the	the	DET
ajmri-3088	323	2	egyptian	egyptian	ADJ
ajmri-3088	323	3	journal	journal	PROPN
ajmri-3088	323	4	of	of	ADP
ajmri-3088	323	5	immunology	immunology	NOUN
ajmri-3088	323	6	,	,	PUNCT
ajmri-3088	323	7	30(4	30(4	NUM
ajmri-3088	323	8	)	)	PUNCT
ajmri-3088	323	9	,	,	PUNCT
ajmri-3088	323	10	101	101	NUM
ajmri-3088	323	11	-	-	SYM
ajmri-3088	323	12	110	110	NUM
ajmri-3088	323	13	.	.	PUNCT
ajmri-3088	323	14	yu	yu	PROPN
ajmri-3088	323	15	,	,	PUNCT
ajmri-3088	323	16	x.	x.	PROPN
ajmri-3088	323	17	,	,	PUNCT
ajmri-3088	323	18	zheng	zheng	PROPN
ajmri-3088	323	19	,	,	PUNCT
ajmri-3088	323	20	y.	y.	PROPN
ajmri-3088	323	21	,	,	PUNCT
ajmri-3088	323	22	zeng	zeng	PROPN
ajmri-3088	323	23	,	,	PUNCT
ajmri-3088	323	24	d.	d.	PROPN
ajmri-3088	323	25	,	,	PUNCT
ajmri-3088	323	26	zhou	zhou	PROPN
ajmri-3088	323	27	,	,	PUNCT
ajmri-3088	323	28	y.	y.	PROPN
ajmri-3088	323	29	,	,	PUNCT
ajmri-3088	323	30	sun	sun	PROPN
ajmri-3088	323	31	,	,	PUNCT
ajmri-3088	323	32	j.	j.	PROPN
ajmri-3088	323	33	,	,	PUNCT
ajmri-3088	323	34	su	su	PROPN
ajmri-3088	323	35	,	,	PUNCT
ajmri-3088	323	36	m.	m.	NOUN
ajmri-3088	323	37	,	,	PUNCT
ajmri-3088	323	38	zhang	zhang	PROPN
ajmri-3088	323	39	,	,	PUNCT
ajmri-3088	323	40	h.	h.	PROPN
ajmri-3088	323	41	,	,	PUNCT
ajmri-3088	323	42	zheng	zheng	PROPN
ajmri-3088	323	43	,	,	PUNCT
ajmri-3088	323	44	m.	m.	NOUN
ajmri-3088	323	45	,	,	PUNCT
ajmri-3088	323	46	huang	huang	PROPN
ajmri-3088	323	47	,	,	PUNCT
ajmri-3088	323	48	z.	z.	PROPN
ajmri-3088	323	49	,	,	PUNCT
ajmri-3088	323	50	&	&	CCONJ
ajmri-3088	323	51	lin	lin	PROPN
ajmri-3088	323	52	,	,	PUNCT
ajmri-3088	323	53	w.	w.	PROPN
ajmri-3088	323	54	(	(	PUNCT
ajmri-3088	323	55	2023	2023	NUM
ajmri-3088	323	56	)	)	PUNCT
ajmri-3088	323	57	.	.	PUNCT
ajmri-3088	324	1	decreased	decrease	VERB
ajmri-3088	324	2	frequency	frequency	NOUN
ajmri-3088	324	3	of	of	ADP
ajmri-3088	324	4	a	a	DET
ajmri-3088	324	5	novel	novel	ADJ
ajmri-3088	324	6	t‐lymphocyte	t‐lymphocyte	NUM
ajmri-3088	324	7	subset	subset	NOUN
ajmri-3088	324	8	,	,	PUNCT
ajmri-3088	324	9	cd3	cd3	PROPN
ajmri-3088	324	10	+	+	X
ajmri-3088	324	11	cd4−	cd4−	PROPN
ajmri-3088	324	12	cd7	cd7	PROPN
ajmri-3088	324	13	+	+	PROPN
ajmri-3088	324	14	cd57−	cd57−	PROPN
ajmri-3088	324	15	t	t	NOUN
ajmri-3088	324	16	cells	cell	NOUN
ajmri-3088	324	17	,	,	PUNCT
ajmri-3088	324	18	in	in	SCONJ
ajmri-3088	324	19	hepatitis	hepatitis	PROPN
ajmri-3088	324	20	b	b	PROPN
ajmri-3088	324	21	virus‐related	virus‐relate	VERB
ajmri-3088	324	22	end‐stage	end‐stage	NOUN
ajmri-3088	324	23	liver	liver	NOUN
ajmri-3088	324	24	disease	disease	NOUN
ajmri-3088	324	25	might	might	AUX
ajmri-3088	324	26	contribute	contribute	VERB
ajmri-3088	324	27	to	to	ADP
ajmri-3088	324	28	disease	disease	NOUN
ajmri-3088	324	29	progression	progression	NOUN
ajmri-3088	324	30	.	.	PUNCT
ajmri-3088	325	1	journal	journal	PROPN
ajmri-3088	325	2	of	of	ADP
ajmri-3088	325	3	medical	medical	ADJ
ajmri-3088	325	4	virology	virology	NOUN
ajmri-3088	325	5	,	,	PUNCT
ajmri-3088	325	6	95(1	95(1	NOUN
ajmri-3088	325	7	)	)	PUNCT
ajmri-3088	325	8	,	,	PUNCT
ajmri-3088	325	9	e28129	e28129	PROPN
ajmri-3088	325	10	.	.	PROPN
ajmri-3088	325	11	yuan	yuan	PROPN
ajmri-3088	325	12	,	,	PUNCT
ajmri-3088	325	13	r.	r.	PROPN
ajmri-3088	325	14	,	,	PUNCT
ajmri-3088	325	15	li	li	PROPN
ajmri-3088	325	16	,	,	PUNCT
ajmri-3088	325	17	l.	l.	PROPN
ajmri-3088	325	18	,	,	PUNCT
ajmri-3088	325	19	hu	hu	PROPN
ajmri-3088	325	20	,	,	PUNCT
ajmri-3088	325	21	w.	w.	PROPN
ajmri-3088	325	22	,	,	PUNCT
ajmri-3088	325	23	zhuang	zhuang	PROPN
ajmri-3088	325	24	,	,	PUNCT
ajmri-3088	325	25	k.	k.	PROPN
ajmri-3088	325	26	,	,	PUNCT
ajmri-3088	325	27	zhang	zhang	PROPN
ajmri-3088	325	28	,	,	PUNCT
ajmri-3088	325	29	e.	e.	PROPN
ajmri-3088	325	30	,	,	PUNCT
ajmri-3088	325	31	yan	yan	PROPN
ajmri-3088	325	32	,	,	PUNCT
ajmri-3088	325	33	y.	y.	PROPN
ajmri-3088	325	34	,	,	PUNCT
ajmri-3088	325	35	feng	feng	PROPN
ajmri-3088	325	36	,	,	PUNCT
ajmri-3088	325	37	l.	l.	PROPN
ajmri-3088	325	38	,	,	PUNCT
ajmri-3088	325	39	chen	chen	PROPN
ajmri-3088	325	40	,	,	PUNCT
ajmri-3088	325	41	x.	x.	PROPN
ajmri-3088	325	42	,	,	PUNCT
ajmri-3088	325	43	cao	cao	PROPN
ajmri-3088	325	44	,	,	PUNCT
ajmri-3088	325	45	q.	q.	PROPN
ajmri-3088	325	46	,	,	PUNCT
ajmri-3088	325	47	&	&	CCONJ
ajmri-3088	325	48	ke	ke	PROPN
ajmri-3088	325	49	,	,	PUNCT
ajmri-3088	325	50	h.	h.	PROPN
ajmri-3088	325	51	(	(	PUNCT
ajmri-3088	325	52	2023	2023	NUM
ajmri-3088	325	53	)	)	PUNCT
ajmri-3088	325	54	.	.	PUNCT
ajmri-3088	326	1	characteristics	characteristic	NOUN
ajmri-3088	326	2	of	of	ADP
ajmri-3088	326	3	refined	refined	ADJ
ajmri-3088	326	4	lymphocyte	lymphocyte	ADJ
ajmri-3088	326	5	subsets	subset	NOUN
ajmri-3088	326	6	changes	change	NOUN
ajmri-3088	326	7	in	in	ADP
ajmri-3088	326	8	people	people	NOUN
ajmri-3088	326	9	living	live	VERB
ajmri-3088	326	10	with	with	ADP
ajmri-3088	326	11	hiv	hiv	PROPN
ajmri-3088	326	12	/	/	SYM
ajmri-3088	326	13	aids	aids	PROPN
ajmri-3088	326	14	during	during	ADP
ajmri-3088	326	15	antiretroviral	antiretroviral	ADJ
ajmri-3088	326	16	therapy	therapy	NOUN
ajmri-3088	326	17	period	period	NOUN
ajmri-3088	326	18	:	:	PUNCT
ajmri-3088	326	19	an	an	DET
ajmri-3088	326	20	observation	observation	NOUN
ajmri-3088	326	21	from	from	ADP
ajmri-3088	326	22	wuhan	wuhan	PROPN
ajmri-3088	326	23	,	,	PUNCT
ajmri-3088	326	24	china	china	PROPN
ajmri-3088	326	25	.	.	PUNCT
ajmri-3088	327	1	frontiers	frontier	NOUN
ajmri-3088	327	2	in	in	ADP
ajmri-3088	327	3	immunology	immunology	NOUN
ajmri-3088	327	4	,	,	PUNCT
ajmri-3088	327	5	14	14	NUM
ajmri-3088	327	6	,	,	PUNCT
ajmri-3088	327	7	1089379	1089379	NUM
ajmri-3088	327	8	.	.	PUNCT
ajmri-3088	328	1	zhang	zhang	PROPN
ajmri-3088	328	2	,	,	PUNCT
ajmri-3088	328	3	w.	w.	PROPN
ajmri-3088	328	4	,	,	PUNCT
ajmri-3088	328	5	&	&	CCONJ
ajmri-3088	328	6	ruan	ruan	PROPN
ajmri-3088	328	7	,	,	PUNCT
ajmri-3088	328	8	l.	l.	PROPN
ajmri-3088	328	9	(	(	PUNCT
ajmri-3088	328	10	2023	2023	NUM
ajmri-3088	328	11	)	)	PUNCT
ajmri-3088	328	12	.	.	PUNCT
ajmri-3088	329	1	recent	recent	ADJ
ajmri-3088	329	2	advances	advance	NOUN
ajmri-3088	329	3	in	in	ADP
ajmri-3088	329	4	poor	poor	ADJ
ajmri-3088	329	5	hiv	hiv	PROPN
ajmri-3088	329	6	immune	immune	ADJ
ajmri-3088	329	7	reconstitution	reconstitution	NOUN
ajmri-3088	329	8	:	:	PUNCT
ajmri-3088	329	9	what	what	PRON
ajmri-3088	329	10	will	will	AUX
ajmri-3088	329	11	the	the	DET
ajmri-3088	329	12	future	future	ADJ
ajmri-3088	329	13	look	look	VERB
ajmri-3088	329	14	like	like	ADP
ajmri-3088	329	15	?	?	PUNCT
ajmri-3088	330	1	frontiers	frontier	NOUN
ajmri-3088	330	2	in	in	ADP
ajmri-3088	330	3	microbiology	microbiology	NOUN
ajmri-3088	330	4	,	,	PUNCT
ajmri-3088	330	5	14	14	NUM
ajmri-3088	330	6	,	,	PUNCT
ajmri-3088	330	7	1236460	1236460	NUM
ajmri-3088	330	8	.	.	PUNCT
ajmri-3088	331	1	zhu	zhu	PROPN
ajmri-3088	331	2	,	,	PUNCT
ajmri-3088	331	3	z.	z.	PROPN
ajmri-3088	331	4	,	,	PUNCT
ajmri-3088	331	5	qin	qin	PROPN
ajmri-3088	331	6	,	,	PUNCT
ajmri-3088	331	7	y.	y.	PROPN
ajmri-3088	331	8	,	,	PUNCT
ajmri-3088	331	9	liang	liang	PROPN
ajmri-3088	331	10	,	,	PUNCT
ajmri-3088	331	11	q.	q.	PROPN
ajmri-3088	331	12	,	,	PUNCT
ajmri-3088	331	13	xia	xia	PROPN
ajmri-3088	331	14	,	,	PUNCT
ajmri-3088	331	15	w.	w.	PROPN
ajmri-3088	331	16	,	,	PUNCT
ajmri-3088	331	17	zhang	zhang	PROPN
ajmri-3088	331	18	,	,	PUNCT
ajmri-3088	331	19	t.	t.	PROPN
ajmri-3088	331	20	,	,	PUNCT
ajmri-3088	331	21	wang	wang	PROPN
ajmri-3088	331	22	,	,	PUNCT
ajmri-3088	331	23	w.	w.	PROPN
ajmri-3088	331	24	,	,	PUNCT
ajmri-3088	331	25	zhang	zhang	PROPN
ajmri-3088	331	26	,	,	PUNCT
ajmri-3088	331	27	m.	m.	NOUN
ajmri-3088	331	28	,	,	PUNCT
ajmri-3088	331	29	jiang	jiang	PROPN
ajmri-3088	331	30	,	,	PUNCT
ajmri-3088	331	31	t.	t.	PROPN
ajmri-3088	331	32	,	,	PUNCT
ajmri-3088	331	33	wu	wu	PROPN
ajmri-3088	331	34	,	,	PUNCT
ajmri-3088	331	35	h.	h.	PROPN
ajmri-3088	331	36	,	,	PUNCT
ajmri-3088	331	37	&	&	CCONJ
ajmri-3088	331	38	tian	tian	PROPN
ajmri-3088	331	39	,	,	PUNCT
ajmri-3088	331	40	y.	y.	PROPN
ajmri-3088	331	41	(	(	PUNCT
ajmri-3088	331	42	2022	2022	NUM
ajmri-3088	331	43	)	)	PUNCT
ajmri-3088	331	44	.	.	PUNCT
ajmri-3088	332	1	increased	increase	VERB
ajmri-3088	332	2	hbv	hbv	NOUN
ajmri-3088	332	3	coinfection	coinfection	NOUN
ajmri-3088	332	4	and	and	CCONJ
ajmri-3088	332	5	decreased	decrease	VERB
ajmri-3088	332	6	ifnγ	ifnγ	NOUN
ajmri-3088	332	7	-	-	PUNCT
ajmri-3088	332	8	producing	produce	VERB
ajmri-3088	332	9	hbv	hbv	NOUN
ajmri-3088	332	10	-	-	PUNCT
ajmri-3088	332	11	specific	specific	NOUN
ajmri-3088	332	12	cd8	cd8	PROPN
ajmri-3088	332	13	+	+	PROPN
ajmri-3088	332	14	t	t	NOUN
ajmri-3088	332	15	cell	cell	NOUN
ajmri-3088	332	16	numbers	number	NOUN
ajmri-3088	332	17	during	during	ADP
ajmri-3088	332	18	hiv	hiv	PROPN
ajmri-3088	332	19	disease	disease	NOUN
ajmri-3088	332	20	progression	progression	NOUN
ajmri-3088	332	21	.	.	PUNCT
ajmri-3088	333	1	frontiers	frontier	NOUN
ajmri-3088	333	2	in	in	ADP
ajmri-3088	333	3	immunology	immunology	NOUN
ajmri-3088	333	4	,	,	PUNCT
ajmri-3088	333	5	13	13	NUM
ajmri-3088	333	6	,	,	PUNCT
ajmri-3088	333	7	861804	861804	NUM
ajmri-3088	333	8	.	.	PUNCT